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Abstract 
There is evidence to suggest that dysregulation of the HPA axis might be one of the 
biological pathways linking psychosocial stress with cardiovascular disease (CVD). This 
PhD consisted of three studies that aimed to assess the role of HPA axis dysregulation in 
CVD, and to examine potential biological mechanisms that might be involved in stress-
related HPA axis dysregulation. 
Study 1 assessed the utility of pre-surgical diurnal cortisol rhythm in predicting adverse 
outcomes in advanced heart disease using data from an observational clinical cohort 
study. The results showed that patients with flatter pre-surgical cortisol slopes were at 
increased risk of experiencing an adverse event in the years following coronary 
revascularisation. This finding provides evidence for the clinical relevance of HPA axis 
dysregulation in CVD. 
Study 2 and 3 sought to garner more information about the biological mechanisms 
underlying stress-related HPA axis dysregulation using data from a randomised 
controlled trial involving the administration of pharmacological probes to healthy 
volunteers.  
In Study 2 the effects of six-day administration of beta-blockers and SSRIs on diurnal 
cortisol secretion were examined. Results indicated that women taking SSRIs had 
significantly steeper diurnal cortisol slopes compared to placebo. Mechanistically, these 
results support the notion that the serotonergic system exerts substantial effects on the 
HPA axis, potentially through modulation of the serotonergic or corticosteroid receptors. 
Therapeutically, these results suggest that SSRIs might be a plausible intervention for 
female CHD patients with flatter cortisol slopes 
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In Study 3 the effects of seven-day administration of beta-blockers and SSRIs on cortisol 
stress reactivity and corticosteroid receptor sensitivity in the laboratory were investigated. 
The results indicated that generally, acute stress brought about a decrease in corticosteroid 
receptor sensitivity. SSRIs enhanced this decrease and also blunted the cortisol stress 
response. These results suggest that SSRIs may enhance adaptive stress-related changes 
in HPA axis function, thereby having therapeutic implications for stress-related illness 
such as CVD.  
Together this body of work indicates that alterations in HPA axis function play a role in 
CVD and that the serotonergic system likely plays a role in stress-related dysregulation 
of the HPA axis. 
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Chapter 1 
Literature review: Stress and cardiovascular disease 
1.1 Introduction 
This chapter will describe the literature relating to the role of stress in cardiovascular 
disease (CVD). Firstly, the pathophysiology of CVD will be described. Following this, 
evidence for the role of psychosocial stress in the aetiology of CVD will be provided with 
a particular focus on external stressors, such as work stress, financial stress, and caregiver 
stress; negative emotional disorders, such as depression and anxiety; and acute stress 
triggers, such as natural disasters, war and terrorism, and periods of intense emotion. 
Additionally, this chapter will describe the literature on the effects of psychosocial stress 
on prognosis in those already diagnosed with CVD. The aim of this chapter is to highlight 
the importance of psychosocial stress in CVD progression and prognosis, while 
highlighting some of the limitations of the work to date.  
1.2 Cardiovascular disease: Pathogenesis and prevalence 
CVD is an umbrella term referring to a group of diseases affecting the circulatory system. 
The most common forms of CVD are coronary heart disease (CHD) and stroke. 
Atherosclerosis is the primary pathological process underlying the development of CHD. 
It is a lifelong process whereby fatty deposits lead to the progressive narrowing of the 
coronary arteries due to the formation of atheromatous plaques. The lipid hypothesis of 
atherosclerosis holds that it is primarily a cholesterol storage disease. However, it is now 
understood that atherosclerosis is also an inflammatory disorder which can affect all 
middle- and large-sized blood vessels in the circulatory system (Hansson & Libby, 2006; 
Libby, Ridker, & Hansson, 2011). Atherosclerosis begins in childhood, with 
atherosclerotic change and development occurring during adolescence and young 
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adulthood (McGill et al., 2000; Williams et al., 2002). Across the lifespan, the cumulative 
effect of known cardiovascular risk factors accelerates the progression of atherosclerosis. 
These risk factors include clinical, biological, behavioural, and social factors. The clinical 
factors include hypertension, dyslipidaemia, type 2 diabetes, and overweight/obesity. 
Biological factors include genetic predisposition, older age, and being male. Behavioural 
factors include smoking, sedentary lifestyle, excessive alcohol intake, and poor diet. Low 
socioeconomic status (SES) and low education comprise the social factors. The majority 
of people who develop advanced atherosclerosis will be in an asymptomatic disease state 
for many years.   
The human artery contains three layers (See Figure 1.1, Box 1). The inner layer is called 
the tunica intima and is lined by a layer of endothelial cells. The next layer is the media, 
followed by the adventitia which contains nerve endings, microvessels, mast cells, and 
fibroblasts. Dyslipidaemia, hypertension, and the presence of pro-inflammatory cytokines 
can cause irritation to the endothelial cells lining the tunica intima. These endothelial cells 
then express adhesion molecules which capture leukocytes on their surface, when 
ordinarily white blood cells stream past without attaching. These leukocytes, which are 
primarily monocytes, then migrate into the intima where they mature into macrophages. 
The macrophages become resident in the artery wall and engulf lipoprotein molecules 
thus becoming foam cells (See Figure 1.1, Box 2). They also have a number of pro-
inflammatory functions producing high levels of cytokines such as IL-1β and tumour 
necrosis factor. The development of atheromatous plaques also involves the migration of 
smooth muscle cells (the endogenous cells of the artery wall) from the media into the 
tunica intima where they proliferate forming a complex extracellular matrix through the 
release of macromolecules such as collagen and proteoglycans (See Figure 1.1, Box 3). 
This extracellular matrix forms a fibrous cap that covers the plaque. Underneath this cap, 
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the macrophages in the plaque begin to die via apoptosis thus releasing the lipids they 
have engulfed. The cellular debris and lipid molecules form a lipid-rich centre referred to 
as the necrotic core of the plaque. As cells and lipids accumulate the plaque enlarges and 
bulges into the lumen of the artery. Over time, the fibrous cap becomes thin and can 
fracture. If the plaque ruptures, the necrotic core of the plaque can leak into the lumen 
triggering the development of a thrombus (See Figure 1.1, Box 4).  
 
 
Plaques can cause clinical manifestations of CVD by either bringing about stenoses that 
limit blood flow to certain tissues leading to ischaemia, or by creating thrombi that lodge 
in arteries and interrupt blood flow. These clinical manifestations of CVD include acute 
coronary syndromes (ACS), namely myocardial infarction (MI) and unstable angina, as 
 
 
  
Figure 1.1. The stages of atherosclerosis. Box 1 shows the cell structure of a healthy human artery. Boxes 
2, 3, and 4 show the gradual progression of atherosclerosis culminating in plaque rupture.   
Adapted from Libby, Ridker, & Hansson (2011) 
1 2 
3 4 
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well as stable angina. MI occurs when one of the coronary arteries is occluded by a 
thrombus following the rupture of an atheromatous plaque. The resulting ischaemia can 
lead to damage or death of cardiac tissue. Stable angina is a chronic condition 
characterised by chest pain on exertion caused by a lack of oxygen supply to the heart 
due to stenosis brought about by atherosclerosis. Unstable angina is distinct from stable 
angina in that chest pain occurs more frequently and for longer, and is not necessarily 
triggered by exertion. Unlike stable angina, unstable angina is caused by a thrombus 
partially occluding a coronary artery.  
Recent estimates from the World Health Organisation (WHO) revealed that CVD is the 
leading cause of death worldwide (WHO, 2015). In 2012 an estimated 17.5 million people 
died from CVD, accounting for 31% of all global deaths. Roughly 7.4 million of these 
deaths were caused by CHD and 6.7 million were due to stroke. Recent statistics from the 
UK have revealed that CVD is the second main cause of death after cancer with these 
diseases causing 27% and 29% of all deaths in 2014 respectively (Townsend, Bhatnagar, 
Wilkins, Wickramasinghe, & Rayner, 2015).  In 2014, CVD accounted for around 
155,000 deaths in the UK – approximately 69,000 deaths were due to CHD, and 39,000 
were due to stroke (ibid). This makes CHD the biggest single cause of death in the UK 
accounting for 15% of male and 10% of female deaths (ibid). In the UK, CVD mortality 
rates have been in decline since the 1970s. Recent statistics from the British Heart 
Foundation show that between 1974 and 2013 CHD mortality rates have declined by 73% 
in those dying at any age, and 81% in those dying before 75 years (ibid). This reduction 
in mortality is thought to be attributable to a combination of reductions in major risk 
factors such as smoking, as well as improved hospital treatment and better clinical 
management of hypertension and dyslipidaemia (O’Flaherty, Buchan, & Capewell, 2013; 
Smolina, Wright, Rayner, & Goldacre, 2012).  Despite the reduction in CVD mortality 
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rates, the economic costs of the disease are vast.  In 2013/2014, the CVD healthcare 
expenditure within the UK amounted to approximately £5.9 billion (Townsend et al., 
2015). Moreover, the total cost of CVD to the UK economy was estimated to be £15.2 
billion in 2014 with this figure being attributable to direct healthcare costs, productivity 
losses, and informal care of CVD patients (ibid). A recent report by the Centre for 
Economics and Business Research predicts that the total costs of CVD to the UK will rise 
to £18.7 billion by 2020 (Centre for Economics and Business Research, 2014).   
1.3 Stress and cardiovascular disease: Introduction 
As mentioned in the previous section, there are a number of well-established clinical, 
biological, behavioural, and social risk factors for CVD. Recently, there has been 
emerging interest in psychological risk factors for CVD with a particular focus on 
psychosocial stress. There has been accumulating evidence that psychosocial stress plays 
a role in the pathogenesis of CVD (Dimsdale, 2008; Hjemdahl, Rosengren, & Steptoe, 
2011; Neylon et al., 2013; Steptoe & Kivimäki, 2013). Systematic reviews are in 
agreement that psychosocial stress predicts CVD incidence in initially healthy 
populations independent of standard risk factors (Everson-Rose & Lewis, 2005; Kuper, 
Marmot, & Hemingway, 2005). For the purposes of this literature review, psychosocial 
stress will be divided into three distinct categories: external stressors, negative emotional 
disorders, and acute stress triggers. Additionally, in this literature review I will also 
evaluate the evidence for the role of psychosocial stress in the prognosis of those already 
diagnosed with CVD.  
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1.4 Stress and cardiovascular disease: External stressors 
In this section I will seek to review the literature looking at associations between external 
stressors and CVD risk. Firstly, I will describe studies that have focused on broad 
composite measures of perceived life stress and chronic stress burden. Following this, I 
will describe associations between more specific types of psychosocial stress and CVD 
risk. These include caregiver stress, financial and work stress, and social isolation and 
loneliness. Where possible, results of systematic reviews and meta-analyses will be 
reported.  
 1.4.1 External stressors: Perceived stress and chronic stress burden 
The INTERHEART Study (Yusuf et al., 2004) examined the association between 
psychosocial stress over the previous 12 months and MI incidence in a standardised case-
control study. Psychosocial stress was a composite self-report measure comprising stress 
at work and home, financial stress, the occurrence of major life events, lack of perceived 
control, and depression. This association was assessed in 15,152 MI cases and 14,820 
CHD-free matched controls in 52 countries representing every inhabited continent. 
Results indicated that higher levels of psychosocial stress increased the risk of MI almost 
threefold after controlling for a range of traditional CVD risk factors, as well as 
geographic region. This association was seen in both men and women of all ages in all 
regions of the world.  
Andersen and colleagues (Andersen, Diderichsen, Kornerup, Prescott, & Rod, 2011) 
prospectively examined the association between major life events across the lifespan and 
incident CHD in 8,738 participants from the Copenhagen City Heart Study. There was no 
significant association between major life events and incident CHD. The authors put the 
lack of association down to the measurement of major life events, arguing that it may not 
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be a measure of chronic stress. They also argue that the 16-year follow-up period was too 
wide a timespan for the stress to have a meaningful effect on cardiac health.  
A meta-analysis carried out in 2012 examined the association of perceived stress and 
incident CHD (Richardson et al., 2012). Six (n=118,696) of the 23 potentially relevant 
articles met the criteria for section indicating that many of the studies examining this 
association were not of adequate quality. Meta-analysis revealed that high levels of 
perceived stress were associated with a moderately increased risk of incident CHD. 
However, the studies included in the meta-analysis differed in terms of covariates 
included in the models. All studies controlled for age, blood pressure, smoking, and 
cholesterol. Only three studies controlled for social factors such as SES, and only one 
study controlled for psychological factors such as depression and anxiety.  
A recent study prospectively examined the independent effects of individual-level 
stressors and neighbourhood-level stressors on incident CHD in a large sample from the 
Multi-Ethnic Study of Atherosclerosis with a 10.2 year follow-up period (Kershaw et al., 
2015). Individual-level stressors included financial, work, relationship, and health-related 
stress. Neighbourhood-level stressors included neighbourhood safety and violence, social 
cohesion, and aesthetic quality. Higher individual-level stressors were linearly associated 
with incident CHD (n=6678). However, neighbourhood-level stressors were non-linearly 
associated with incident CHD, with medium levels of neighbourhood stress having a 
higher CHD risk (49%) than high levels of neighbourhood stress (27%). The authors find 
this result difficult to interpret and put it down to a stress measurement issue.  
Associations specifically between psychosocial stress and stroke incidence have also been 
described. Truelsen and colleagues (Truelsen, Nielsen, Boysen, & Grønbaek, 2003) 
prospectively examined associations between self-reported stress and stroke incidence 
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and fatality 13 years later in 12,574 men and women from the Copenhagen City Heart 
Study. Self-reported stress was measured in terms of stress intensity and frequency 
pertaining to feelings of tension, nervousness, impatience, anxiety, or sleeplessness. 
Results indicated that high stress frequency and intensity were associated with almost a 
doubled risk of fatal stroke compared to low stress after controlling for a number of 
traditional risk factors. But, self-reported stress was not associated with non-fatal stroke 
after adjustment for these covariates. The authors posit that the lack of significant 
association between stress and non-fatal stroke may be in part due to differences in CVD 
risk profiles amongst participants.  
A number of studies have also examined associations between psychosocial stress and 
both CHD and stroke incidence combined. Iso and colleagues looked at associations 
between perceived stress measured at baseline and stroke and CHD mortality in 73,424 
initially disease-free Japanese men and women, with a follow-up of 580,378 person-years 
(Iso et al., 2002). Japanese women with high levels of perceived stress had a two-fold 
higher risk of death from stroke and CHD compared to those who reported low stress 
after adjusting for known cardiovascular risk factors. However, the same association was 
not observed in Japanese men.  
Stressful life events and social strain were measured at baseline in 82,000 women from 
the Women’s Health Initiative (Kershaw et al., 2014). After a follow-up period of 18 
years, higher levels of stressful life events and social strain were associated with higher 
incident CHD and stroke. These associations were attenuated and became non-significant 
after adjustment for behavioural (e.g. smoking, dietary intake) and biological (e.g. 
hypertension, diabetes) CVD risk factors. The lack of association reported here lends 
support to the argument put forward by Andersen and colleagues (2011) that there was 
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too wide a timespan (18 years) between the stress exposure and the cardiovascular event 
for stress to have a meaningful effect on cardiovascular health.  
In the Hispanic Community Health Study, chronic stress burden, but not perceived or 
traumatic stress, was associated with a higher prevalence of CHD and stroke prevalence 
in 5313 men and women of mixed Hispanic/Latino ethnic backgrounds (Gallo et al., 
2014). Additionally, chronic stress burden was associated with a higher prevalence of 
known CVD risk factors such as type 2 diabetes and hypertension in those free from CVD. 
Associations between stress and subclinical CVD have also been reported. Life stress (a 
composite measure of childhood trauma, negative life events, daily hassles, and job 
strain) was found to be associated with increased arterial stiffness, but not carotid 
atherosclerosis, in 650 participants from the Netherlands Study of Depression and 
Anxiety after controlling for many cardiovascular risk factors (Bomhof-Roordink et al., 
2015).  
The studies outlined above focused on associations between broad composite measures 
of stress or perceived stress and CVD risk. Strengths of these studies include large sample 
sizes, with a number of studies being carried out across different cultures and ethnicities. 
On the whole these studies controlled for a large number of biological and behavioural 
cardiovascular risk factors. Overall, the evidence from these studies suggests that 
psychosocial stress is a significant risk factor for CVD incidence and mortality. However, 
a number of studies did not find such associations. How stress was conceptualised in these 
studies may be partially responsible for the lack of significant findings. The two studies 
that reported non-significant associations measured stress in terms of stressful or major 
life events (Andersen et al., 2011; Kershaw et al., 2014) whereas the other studies used 
either measures of perceived stress, or composite measures of a number of stress factors. 
What both these studies also have in common is the long follow-up length. Andersen and 
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colleagues (2011) argue that major life events may have a short-term effect on CVD risk, 
and if the life events occurred many years before the cardiovascular event this would 
explain why there is only a very weak association reported.  
 1.4.2 External stressors: Caregiver stress 
I will now describe research which has focused on specific types of external chronic 
stressors and their associations with cardiovascular risk. The chronic stress of caregiving 
for an elderly, ill, or disabled loved-one has been found to be associated with poor health 
and premature mortality (Schulz & Beach, 1999). Lee and colleagues examined 54,412 
CVD-free women from the Nurse’s Health Study (Lee, Colditz, Berkman, & Kawachi, 
2003). Information about caregiver stress was measured at baseline, and reports of 
incident CHD were collected throughout the four year follow-up period. Caregiving for 
an ill or disabled spouse for ≥ 9 hours per day was associated with an increased risk of 
incident CHD after adjusting for numerous cardiovascular risk factors. Interestingly, 
caregiving for an ill parent or other relative was not associated with higher CHD risk. 
This indicates that the high level of care required when taking care of a spouse may be 
more of a stressor and therefore increase CHD risk in women.  
Another study examining the effects of spousal caregiving strain on CVD risk found that 
high strain was associated with a 23% higher covariate-adjusted Framingham stroke risk 
score in both male and female caregivers (n=716) (Haley, Roth, Howard, & Safford, 
2010). However, there was no association between caregiving strain and Framingham 
CHD risk scores (n=607). Capistrant and colleagues (Capistrant, Moon, Berkman, & 
Glymour, 2012) examined the association between spousal caregiving stress and CVD 
risk in 8,472 CVD-free participants from the Health and Retirement Study. Long-term 
spousal caregiving, defined as ≥14 hours of care per week measured in two consecutive 
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biennial questionnaires, was associated with a two-fold risk (hazard ratio=1.95) of CVD 
onset, but only in white individuals.  
Caregiving stress has also been associated with known CVD risk factors. Roepke and 
colleagues (Roepke et al., 2012) found that the duration of care in caregivers of those with 
Alzheimer’s disease was associated with increased carotid intima-media thickness 
independent of risk factors. This indicates that caregiving stress may increase CVD risk 
through atherosclerotic burden. Dementia caregivers have also been found to have higher 
levels of plasma IL-6 and D-dimer compared to sex-matched non-caregiving controls 
(von Känel et al., 2006). 
In terms of caregiving stress, the evidence does suggest that this type of chronic stress 
increases overall CVD risk, as well as levels of known CVD risk factors. Research 
indicates that the spousal caregiving is linked with increased CVD risk suggesting that 
caring for a spouse is a larger stressor than caring for another relative with a disability or 
illness. Studies in this area have largely focused on spousal caregiving. Further research 
should focus on CVD risk in other types of caregiver stress, such as CVD risk in 
carers/parents of sick children, or caregiver burden in mental illness. Interestingly, 
research in this area also indicates that ethnicity is an important factor in the association 
between caregiving stress and CVD risk, and therefore should be adjusted for in studies 
of this kind. Duration of care also appears to be important, indicating a cumulative effect 
of this type of chronic stress on CVD risk. 
 1.4.3 External stressors: Work stress, financial stress, and social isolation 
Work stress is the most widely studied external stressor. The work stress literature has 
been largely dominated by the ‘demand-control’ or ‘job strain’ model in which a 
combination of highly demanding work and low control conditions elicits stress in the 
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workplace (Karasek & Theorell, 1990). A systematic review examining work-related 
psychosocial factors and development of CHD found that there was moderate evidence 
that high demand, and a combination of high job strain and low social support at work 
(iso-strain), were associated with increased CHD risk in men (Eller et al., 2009). This 
finding was in men only as studies involving women were too few at the time to draw any 
meaningful conclusion. Pejtersen and colleagues (Pejtersen, Burr, Hannerz, Fishta, & 
Hurwitz Eller, 2015) updated this systematic review and meta-analysis with the results of 
11 new studies examining work-related psychosocial factors and the development of 
CHD. The main result of this meta-analysis was that the ‘control’ element of job strain 
explained excess risk for MI amongst the selected studies (44 studies in total). However, 
results also revealed that a large amount of the selected studies (42/44) lacked sufficient 
power to detect a meaningful excess risk of MI. The authors also posit that the 
overwhelming focus on psychosocial stress models such as the job strain model make it 
difficult to paint a clear picture of what psychosocial factors at work are affecting CVD 
risk. A recent overview of systematic reviews carried out in this field confirmed the 
overwhelming focus on the job strain model in psychosocial stress research. Based on the 
evidence to date, the authors of this overview concluded that there is modest to moderate 
evidence for an association between psychosocial work stress and CVD risk in men 
(Fishta & Backé, 2015).  
The most compelling evidence for an association between work stress and CVD risk 
comes from a recent systematic review of the evidence from 27 studies from Europe, 
Asia, and the United States (n= >600,000) (Kivimäki & Kawachi, 2015). Results from 
this review found that work stress, with a focus on job strain and long working hours, was 
associated with a 10-40% excess risk of incident CHD and stroke, independent of 
conventional risk factors such as age, sex, and SES. They also reported associations 
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between work stress and type 2 diabetes, but not with cancer or chronic pulmonary 
obstructive disorder, which suggests outcome specificity in terms of work stress effects 
on health. A recent meta-analysis of the same magnitude (25 studies, n= >600,000) found 
that long working hours (≥55 hours per week) compared to standard working hours (35-
40 hours per week) were associated with an increased risk of CHD and stroke incidence 
(Kivimäki et al., 2015), after controlling for age, sex, and SES. The association between 
longer working hours and stroke was stronger than the association between working hours 
and CHD and demonstrated a dose-response association.  
Although distinct from work stress, financial stress has also been associated with CVD 
risk. A Swedish study reported that men without a cash margin (i.e. the ability to raise 
approximately £1000 in one week if an unexpected situation were to occur) had an 
increased risk of incident CVD after adjusting for relevant covariates (Carlsson et al., 
2014). This link between financial strain and incident CVD was not present for women.  
Thus, we see that there is evidence suggesting that both work and financial stress are 
associated with increased CVD risk. However, these associations have been largely 
reported in men. Further research is needed in female samples to elucidate the effects 
work stress in this population. Also, overuse of the job strain model in studies assessing 
associations between work stress and CVD risk may be hampering our ability to assess 
what other elements of work stress are important. Future research should include other 
work-related variables, such as long working hours.  
Social isolation is another external stressor that has been associated with CVD 
progression. A meta-analysis of nine prospective cohort studies in CHD-free populations 
revealed that social isolation and loneliness were associated with a 50% excess risk of 
CHD on average (Steptoe & Kivimäki, 2012). A more recent meta-analysis of 11 
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longitudinal CHD and eight longitudinal stroke studies found that poor social 
relationships, defined as social isolation or loneliness, were associated with a 29% 
increase in the risk of incident CHD and a 32% increase in the risk of stroke (Valtorta, 
Kanaan, Gilbody, Ronzi, & Hanratty, 2016). 
 1.4.4 External stressors: Summary 
In sum, many external stressors have been associated with increased CVD risk, incident 
CVD, and CVD mortality. However, there are a number of issues to consider when 
interpreting the evidence. There are differences in the way stress is conceptualised across 
studies which potentially affect the associations reported with CVD. For example, 
measuring stressful life events rather than measuring broad composite measures of stress, 
or focusing on the job strain model rather than taking a wider approach to work stress, 
seems to attenuate the association between stress and CVD. Additionally, the timing 
between measurement of stress and measurement of cardiovascular health appears to be 
of importance to results. Studies with longer durations between these measurements have 
reported null findings (Andersen et al., 2011; Kershaw et al., 2014). In support of this, 
Nielsen and colleagues (Nielsen et al., 2006) reported that significant associations 
between high levels of perceived stress and CHD were attenuated as follow-up continued. 
This implies that psychosocial stress may have a relatively short-term effect on CVD 
incidence. Another prevalent issue in studies measuring associations between 
psychosocial stress and CVD is choice of covariates included in analyses. Most studies 
tend to adjust for well-established cardiovascular risk factors such as age sex, smoking, 
cholesterol, hypertension, etc. However, some fail to adjust for known social and 
behavioural cardiovascular risk factors. Therefore, the extent to which the stress-CVD 
link is associated with different behavioural, clinical, and social risk factors is difficult to 
interpret. Despite the problems listed above, most studies examining the associations 
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between external stressors and CVD tend to report at least modest to moderate 
associations after controlling for traditional risk factors, providing support for the role of 
these types of stressors in the development of CVD.  
1.5 Stress and cardiovascular disease: Negative emotional disorders 
In this section I will review the literature examining associations between negative 
emotional disorders and CVD risk. Firstly, I will describe studies that have focused on 
psychological distress as measured by the 12-item General Health Questionnaire (GHQ) 
(Goldberg, 1992). The GHQ provides quite a comprehensive measure of psychological 
distress consisting of items that capture depressive symptoms, anxiety, social 
dysfunction, and loss of confidence. Following this, I will describe studies that have 
focused specifically on associations between depressive symptoms and CVD risk. Studies 
examining associations between anxiety and CVD risk will then be outlined.  
 1.5.1 Negative emotional disorders: Psychological distress 
Hamer and colleagues (Hamer, Molloy, & Stamatakis, 2008) examined data from 6,576 
healthy men and women from the Scottish Health Study and revealed associations 
between baseline psychological distress and CVD events 7.2 years later. However, this 
association was only significant when adjusting for age and sex and did not survive the 
addition of behavioural cardiovascular risk factors including smoking, alcohol intake, and 
physical activity. A meta-analysis of 10 large prospective cohort studies from the Health 
Survey for England revealed an association between psychological distress and CVD 
mortality in 68,222 people who were initially disease-free (Russ et al., 2012). This 
association remained after adjustment for a number of relevant covariates including SES, 
body mass index (BMI), smoking status, alcohol intake, physical activity, blood pressure, 
and diabetes status. Another study using data from the Health Survey for England 
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examined associations between psychological distress and CVD mortality in 66,500 
initially disease-free men and women and found that a one category increase in GHQ 
scores predicted increased stroke mortality (hazard ratio=1.18) and CHD mortality 
(hazard ratio=1.24) at a median follow-up time of 7.9 years (Lazzarino, Hamer, 
Stamatakis, & Steptoe, 2013). These associations were found to be strongest in the lowest 
SES categories. Similar covariates were adjusted for as in the meta-analysis carried out 
by Russ and colleagues (2012), with the absence of certain behavioural factors such as 
physical activity and alcohol intake.  
 1.5.2 Negative emotional disorders: Depression and anxiety 
There are a number of well-conducted systematic reviews and meta-analyses that show 
that depression is an independent risk factor for CVD (Dhar & Barton, 2016), and 
evidence suggests that as depressive symptoms worsen risk of developing CHD increases 
(Glassman & Shapiro, 1998). Nicholson and colleagues (Nicholson, Kuper, & 
Hemingway, 2006) carried out a meta-analysis of 21 aetiological studies examining 
associations between depression and future CVD. Together, these 21 studies comprised 
124,509 participants and 416 cardiac events. Over a mean follow-up period of 10.8 years, 
results revealed an 80% higher risk of developing or dying from CHD in those with 
depression at baseline. Adjusting for other cardiovascular risk factors resulted in marginal 
reductions in relative risk. 
A later meta-analysis examining 28 studies confirmed the findings of Nicholson and 
colleagues (Van der Kooy et al., 2007). Sixteen of these studies examined CVD-free 
populations at baseline and found an increased risk of CVD in those who reported 
depressive symptoms at baseline (risk estimate = 1.57). The authors reported that 
clinically diagnosed major depression showed the greatest risk for the development of 
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CVD, equalling the risk of smoking and diabetes. A recent meta-analysis of 30 
prospective cohort studies (n=893,850) revealed a pooled relative risk of 1.30 for both 
CHD and MI incidence in those with depression (Gan et al., 2014). Interestingly, the 
pooled relative risk for both CHD and MI was stronger with a follow-up period of less 
than 15 years (relative risk = 1.36) compared with follow-up periods of 15 years or longer 
(relative risk = 1.09).  
The most recent studies examining the role of depression in the aetiology of heart disease 
are in agreement with results from previous meta-analyses.  In a study of 3572 men and 
women who had experienced an acute MI, 48% of the women and 25% of the men 
reported a lifetime history of depression (Smolderen et al., 2015). In a recent study using 
data from the Netherlands Study of Depression and Anxiety, there was a significant 
association between depression and new-onset CVD over a six year period in 2,510 
initially CVD-free participants (Seldenrijk et al., 2015). Cox regression models revealed 
that having depression more than doubled the risk of developing new onset CVD (hazard 
ratio = 2.30).  
Anxiety has also been found to be an independent risk factor for CHD. Roest and 
colleagues carried out a meta-analysis of 20 studies reporting on anxiety and incident 
CHD over a mean follow-up period of 11.2 years in 249,846 individuals (Roest, Martens, 
de Jonge, & Denollet, 2010). The authors found people high in anxiety were at an 
increased risk of CHD (hazard ratio = 1.26) and cardiac death (hazard ratio = 1.48) 
independent of biological, social, and behavioural cardiovascular risk factors. There was 
no association between anxiety and nonfatal MI. A recent large meta-analysis of 37 
studies (n=1,565,699) examining associations between anxiety and new onset CVD found 
that anxiety was associated with a 52% increase in risk of CVD (Batelaan, Seldenrijk, 
Bot, van Balkom, & Penninx, 2016). Anxiety was also associated with an increased risk 
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of MI of 38%, and a 74% increased risk for stroke. Adjustment for publication bias 
reduced the strength of all the reported associations. Although they remained significant 
the authors do not provide the attenuated hazard ratios. Therefore, results of this meta-
analysis should be interpreted with that in mind.  
The latest meta-analysis examining anxiety and CVD risk included 46 cohort studies 
(n=2,017,276) and found that anxiety was associated with an increased risk of CVD 
mortality (41%), CHD (41%), stroke (71%), and heart failure (35%) (Emdin et al., 2016). 
However, in concurrence with Roest and colleagues (2010), anxiety was not associated 
with MI. The most recent study examining the role of anxiety in new onset CVD has 
reported that anxiety is a unique risk factor for stroke and MI in older primary care 
patients initially CVD-free (Stewart, Hawkins, Khambaty, Perkins, & Callahan, 2016). 
The authors examined the predictive value of anxiety and depression screening in 2,041 
older primary care patients with a follow-up of eight years. Cox proportional hazards 
models revealed that a positive anxiety screen at baseline, but not a positive depression 
screen, was associated with a 54% increased risk of a CVD event in the first three years 
of follow up, after controlling for demographic and biological cardiovascular risk factors. 
However, after three years of follow-up this association disappeared. Conversely, a recent 
study found that depression, and comorbid depression and anxiety, was associated with 
new onset CVD, but anxiety alone was not (Seldenrijk et al., 2015). This indicates that 
inclusion of depressive symptoms as a covariate in research examining associations 
between anxiety and CVD is important.  
 1.5.3 Negative emotional disorders: Summary 
In sum, the evidence does seem to suggest that negative emotional disorders are 
associated with increased CVD risk, incidence, and mortality. However, as with research 
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on external stressors, some studies failed to adjust for known behavioural, social, and 
clinical risk factors. Failure to include some of these well-established risk factors could 
inflate the magnitude of associations reported between negative emotional disorders and 
CVD and this should be taken in to account when interpreting results. Interestingly, as 
seen with some external stressor types, the duration of follow-up in studies examining 
associations between depression and anxiety and CVD risk seems to be of importance to 
results. The relative risk of CVD in those with depression was 27% higher with a follow-
up period of less than 15 years (Gan et al., 2014), and association between anxiety and 
CVD risk disappeared after three years of follow-up (Stewart et al., 2016). These findings 
support the notion that psychosocial stress may have a relatively short-term effect on 
CVD risk.  
1.6 Stress and cardiovascular disease: Acute stress triggers 
Episodes of acute emotional stress have been shown to trigger adverse cardiovascular 
events in individuals with underlying CVD. In this section I will describe the literature 
examining associations between these acute stress triggers and cardiac events. Evidence 
for emotional triggering of cardiac events comes from both population-based studies and 
patient studies.  
Population-based studies have revealed that major events such as natural disaster, war, 
terrorist attacks, and major sporting events can trigger cardiac events in those with 
underlying CHD (Steptoe & Brydon, 2009). Natural disasters such as large-scale 
earthquakes, tsunamis, and hurricanes are recognised as acute stressors. A number of 
studies have described associations between natural disasters and increased rates of 
cardiac events and cardiac mortality. In the week following the Northridge Earthquake in 
California in 1994, hospital admissions for acute MI in the surrounding areas increased 
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by 35% (Leor & Kloner, 1996). This same earthquake was also found to increase rates of 
sudden cardiac death from the normal daily average of 4.6 (2.1) to 24 on the day of the 
earthquake (Leor, Poole, & Kloner, 1996). The Hanshin-Awaji earthquake in 1995 
resulted in a 3.5 fold increase in hospital admissions for acute MI in the four weeks 
following the earthquake (Suzuki et al., 1997). Hospital admissions for ACS also 
increased in the three week period following the Great Eastern Japan Earthquake and 
tsunami in 2011 (Nozaki et al., 2013). Additionally, the incidence of sudden cardiac and 
unexpected deaths doubled in the four week period following this earthquake (Niiyama 
et al., 2014). The authors also reported significant associations between the rates of 
sudden death and seismic activity following the earthquake, indicating that the acute 
stress associated with fear of a repeated earthquake may have been a causal factor in these 
sudden deaths.  
Taken together, the studies provide evidence that acute stress brought about by an 
earthquake can trigger cardiac events. However, following the Loma Prieta earthquake in 
San Francisco in 1989, there was no increase in hospital admission for ACS (Brown, 
1999). Steptoe and Brydon (2009) suggest that the timing of the earthquakes may provide 
an explanation for this disparity in findings. The Hanshin-Awaji and Northridge 
earthquakes struck in the early morning in winter, whereas the Loma Prieta earthquake 
occurred on an afternoon in the autumn. Susceptibility to acute MI is known to be raised 
in winter months, and in the early mornings (Elliott, 2001). The Great Eastern Japan 
Earthquake occurred on a spring afternoon, which is not in line with this argument. The 
subsequent occurrence of a large-scale tsunami and nuclear emergency may be the reason 
for this disparity.  
Large-scale natural disasters have also been shown to affect long-term cardiac health. In 
the three years following the Hanshin-Awaji earthquake, mortality from acute MI 
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increased by 14% (Nakagawa et al., 2009). In the six years following Hurricane Katrina, 
there was a more than three-fold increase in admissions for acute MI (Peters et al., 2014). 
Together, these studies suggest that as well as being acute stress triggers, natural disasters 
can result in chronic stress that affects the cardiovascular risk profile. This chronic stress 
may be to do with fear of recurrence of the disaster, bereavement, financial loss, forced 
migration, and general social upheaval.  
Research into acute stress triggers for cardiac events have also focused on the effects of 
war and terrorist attacks. During the Gulf War in 1991 incidences of acute MI and sudden 
cardiac death increased in response to Iraqi missile attacks in an area of Israel that was 
not hit by missiles, but was within hearing range of the explosions (Meisel et al., 1991). 
A number of studies have examined the cardiovascular effects of the terrorist attacks on 
the World Trade Centre in New York in 2001 (9/11). In the 60 days following these 
attacks, hospital admissions for acute MI increased by 49% in 16 New Jersey hospitals 
(Allegra, Mostashari, Rothman, Milano, & Cochrane, 2005), and increases in MI 
admissions were also observed in a Brooklyn hospital (Feng, Lenihanx, Johnson, Karri, 
& Reddy, 2006). However, a study of eight New York City hospitals found no acute 
increases in hospitalisation for cardiac events in the week following 9/11 (Chi, Speakman, 
Poole, Kandefer, & Kloner, 2003). Examining mortality data also found that there was no 
significant increase in cardiac deaths in New York in the months following the 9/11 
attacks (Chi, Poole, Kandefer, & Kloner, 2003). These results are rather mixed. Holman 
and colleagues found that people who made subjective reports of high acute stress 
responses to the 9/11 attacks had a 53% increased incidence of cardiovascular events over 
the following three years, indicating that the degree to which the person found 9/11 
stressful may account for the varying results across studies (Holman et al., 2008). 
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Although nowhere near as severe or traumatic as natural disasters or terrorist attacks, 
sporting events have also been found to have acute effects on cardiac health. During the 
1998 World Cup, hospital admissions for acute MI increased by 25% in England on the 
day the English team lost to Argentina in a penalty shoot-out (Carroll, Ebrahim, Tilling, 
Macleod, & Smith, 2002). This effect extended to two days after the football match. A 
retrospective study examining the effects of football matches in England from 1994 to 
1998 found that acute MI and stroke mortality was significantly increased (relative risk = 
1.28) in men when the local football team lost at home (Kirkup & Merrick, 2003). Similar 
results have been reported in Germany with the incidence of acute cardiovascular 
emergencies increasing 2.66 times on World Cup match days involving the German team 
(Wilbert-Lampen et al., 2008). More specifically, research has shown that cardiovascular 
risk is increased in football fans only when the team in question loses. When Los Angeles 
played in the Superbowl and lost, deaths from CHD and acute MIs increased significantly 
(Kloner, McDonald, Leeka, & Poole, 2009). However, when Los Angeles played in the 
Superbowl and won all-cause mortality rates were reduced (ibid).    
Patient studies in acute stress trigger research have revealed that acute periods of intense, 
anger, stress, depression, and sadness can trigger coronary events (Steptoe & Brydon, 
2009). A meta-analysis of five case-crossover studies (the gold standard of research in 
this area) revealed that the pooled relative risk of an ACS being preceded by a period of 
anger, sadness, or stress was 2.48 (Steptoe & Kivimäki, 2013). A recent meta-analysis 
examined nine independent case-crossover studies looking at associations between 
periods of intense anger and adverse cardiac outcomes. The authors concluded that there 
was an elevated risk of ACS, ischaemic and haemorrhagic stroke, and arrhythmia in the 
two hour period following an outburst of intense anger (Mostofsky, Penner, & Mittleman, 
2014). However, these findings were more pronounced in people with higher underlying 
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cardiovascular risk who experienced frequent outbursts of anger in general. The most 
recent study examining the effects of anger on cardiac events is in keeping with the results 
of Mostofsky and colleague’s (2014) meta-analysis. Buckley and colleagues (Buckley et 
al., 2015) report results of a case-crossover study that revealed an increased relative risk 
(8.6) of experiencing an MI within 2 hours of experiencing very intense anger. Acute 
grief has also been shown to elevate risk of cardiac events. In a UK-based matched cohort 
study, the rate of MI and stroke in older adults who had recently lost their partners was 
increased almost two-fold, but only in the 30 days following the bereavement (Carey et 
al., 2014). 
In sum, the evidence supports the idea that intense emotional stress brought about by 
large-scale events or personal emotional experience can increase rates of cardiac events, 
in particular acute MI. But, as Steptoe and Brydon (2009) point out in their review, it is 
difficult to rule out alternative explanations for cardiac events following large-scale 
natural disasters, acts of terrorism, and sporting events. It is quite possible that disruption 
of health services at the time, or perhaps physical trauma or exertion, or even drinking 
too heavily at a football match, could have brought about the cardiac events in question. 
Although the evidence from patient studies indicates that intense emotions can trigger 
cardiac events, it is also possible that other factors are involved.  
1.7 Stress and cardiovascular disease: Prognosis in those already affected 
As well as playing a role in the aetiology of CVD and the triggering of acute cardiac 
events, psychosocial stress can also worsen prognosis in those who already have CVD. 
In this section I will first describe literature examining the role of external stressors in 
CVD prognosis, with a particular focus on perceived stress, work stress, and the role of 
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social support. I will then discuss the role of negative emotional disorders in disease 
progression.  
 1.7.1 The role of external stressors in CVD prognosis 
In a large study of 4,204 acute MI patients, levels of perceived stress over the month 
preceding the MI were measured during hospitalisation. Patients with moderate to high 
perceived stress had increased 2-year all-cause mortality (hazard ratio = 1.42) compared 
with patients low in perceived stress after adjusting for conventional risk factors (Arnold, 
Smolderen, Buchanan, Li, & Spertus, 2012). Furthermore, patients with high/moderate 
perceived stress levels also had worse angina-specific quality of life one year after their 
initial MI. Similarly, high perceived stress scores measured during hospitalisation in 
3,572 acute MI patients were associated with worse angina-related quality of life one 
month after the MI (Xu et al., 2015). The role of perceived stress in heart failure prognosis 
has also been examined but the authors reported that it was not significantly associated 
with event free survival in 81 heart failure patients (Alhurani et al., 2014). 
A recent systematic review and meta-analysis identified five papers derived from four 
different prospective cohort studies that examined associations between work stress and 
recurrent events in patients following their first cardiac event (Li, Zhang, Loerbroks, 
Angerer, & Siegrist, 2014). Meta-analysis (n=2,578) revealed that work stress increased 
the risk of future cardiac events by 65%. One of the studies included in the meta-analysis 
failed to find a significant association between work stress and further cardiac events in 
292 female ACS patients in Sweden (Orth-Gomér et al., 2000). Interestingly, in these 
women marital stress was associated with a 2.9 fold increase in future cardiac events, 
even after adjusting for a large number of known cardiovascular risk factors. This may be 
because about a third of the sample was not in employment when baseline data were 
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collected. The authors also posit that women generally perceive spousal relationships as 
less supportive than men which may explain why marital stress, rather than work stress, 
was a predictor of future cardiac events in this study. Financial strain has also been 
associated with poor CHD prognosis. Financial strain over the previous year was 
measured in women who had been hospitalised for an ACS and was found to be associated 
with an almost threefold (hazard ratio = 2.76) risk of recurrent cardiac events after 
controlling for numerous potential confounders (Georgiades, Janszky, Blom, László, & 
Ahnve, 2009).  
Social support appears to have a protective role when it comes to CVD prognosis. Barth 
and colleagues carried out a systematic review and identified 20 prognostic papers 
examining associations between social support and CVD mortality suitable for inclusion 
in a meta-analysis (Barth, Schneider, & von Känel, 2010). Results indicated that patients 
with low functional support had an increased risk of both cardiac and non-cardiac 
mortality after adjustment for relevant risk factors (pooled hazard ratio = 1.59). High 
social support and strong social relationships have also been associated with better 
cardiovascular prognosis (Holt-Lunstad, Smith, & Layton, 2010).  
Thus, we see that as well as playing a role in CVD risk, external stressors play a role in 
CVD prognosis. However, this body of prognostic research is beset by similar issues seen 
in the CVD risk literature. Firstly, the way stress is conceptualised may be problematic – 
particularly in the prognostic literature relating to work stress. All the studies included in 
Li et al.’s (2014) meta-analysis conceptualised stress using the job strain model which 
means other psychosocial factors pertaining to work stress, and specifically the stress of 
returning to work after a cardiac event, were not considered. Secondly, the effects of some 
external stressors on CVD prognosis have not been examined. For example, the role of 
caregiver stress in CVD sufferers is yet to be explored. Associations between both marital 
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stress and financial strain and poor cardiovascular prognosis have been reported only in 
women, meaning that the relevance of these types of external stressors in men is as of yet 
unknown. Thirdly, studies measuring associations between external psychosocial 
stressors and CVD prognosis differ in terms of covariates adjusted for. A number of 
studies failed to control for important clinical and biological variables. Therefore, the 
extent to which stress affects prognosis may have been inflated in these studies. 
 1.7.2 The role of negative emotional disorders in CVD prognosis 
Negative emotional disorders have been associated with worse prognosis in CVD 
patients. Depression is prevalent and persistent in CHD patients and a comprehensive 
review has shown that 19.8% of acute MI survivors meet the criteria for major depression, 
while approximately 30% have mild-to-moderate depressive symptoms (Thombs et al., 
2006). A number of meta-analyses have provided evidence for the link between 
depressive symptoms and worse prognosis in CVD patients. Van Melle and colleagues 
included 22 papers examining associations between depressives symptoms in acute MI 
patients and long-term cardiovascular prognosis in a meta-analysis (n=6,367) (Van Melle 
et al., 2004). The results indicated that MI patients with depression had more than a 2.5-
fold increase in cardiac mortality, and an almost two-fold risk for new cardiovascular 
events. Interestingly, neither follow-up duration nor method of measuring depression 
significantly affected the association between depression and mortality. A meta-analysis 
of 29 papers published in the same year also reported a two-fold increase of mortality in 
depressed patients in the two years after initial assessment (Barth, Schumacher, & 
Herrmann-Lingen, 2004). This association weakened after two years, but remained 
significant long-term.  
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In a 2006 meta-analysis of 34 prognostic studies, the pooled relative risk of all-cause or 
CHD mortality associated with depression was 1.80 (Nicholson et al., 2006). 
Interestingly, left ventricular function was only adjusted for in a small number of studies 
and inclusion of this covariate attenuated the relative risk by 48%. Although depression 
plays a role in CVD prognosis, this led the authors to suggest that depression was not yet 
an established independent risk factor for poor CHD prognosis as many studies failed to 
adjust for relevant risk factors. Meijer and colleagues identified 29 studies for inclusion 
in a meta-analysis examining the relationship between depression following the 
occurrence of an MI and cardiac prognosis (n=16,889) (Meijer et al., 2011). Similar to 
both meta-analyses carried out in 2004, the authors reported a 2.7-fold increased risk of 
cardiac mortality and a 1.6-fold increased risk of cardiac events in patients with post-MI 
depression. However, the strength of the association between depression and cardiac 
events decreased as follow-up duration increased – a finding also reported in Barth et al.’s 
(2004) meta-analysis. A recent meta-analysis sought to ascertain whether the 
cognitive/affective or somatic/affective symptoms of depression were more relevant for 
cardiovascular prognosis (de Miranda Azevedo, Roest, Hoen, & de Jonge, 2014). 
Thirteen prospective studies of 11,128 participants were included in the meta-analysis. In 
the fully adjusted analysis, somatic/affective depression symptoms, but not 
cognitive/affective symptoms, were associated with poor prognosis in CVD patients 
(hazard ratio = 1.19). 
There is evidence that anxiety is also associated with poorer prognosis in CVD patients. 
A 2010 meta-analysis of 12 studies comprising 5,750 MI patients reported associations 
between anxiety and cardiac mortality as well as new cardiac events independent of 
clinical variables, including depression (Roest, Martens, Denollet, & de Jonge, 2010). 
Roest and colleagues followed up this meta-analysis with a study examining associations 
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between generalised anxiety disorder (GAD) and adverse cardiac outcomes in MI patients 
with a 7-10 year follow-up period (Roest, Zuidersma, & de Jonge, 2012). Results from 
simple age and sex adjusted models showed that GAD was associated with an almost 
twofold risk of adverse events. Adjustment for various other clinical factors, including 
depression, did not affect the magnitude of the association greatly. However, the authors 
did not adjust for any social or behavioural factors.  
 A systematic review of studies examining the role of worry and GAD in cardiovascular 
health found that three studies had reported associations between GAD and poorer 
prognosis in CHD patients, even after adjusting for depression (Tully, Cosh, & Baune, 
2013). However, a year later Tully and colleagues carried out a meta-analysis on five 
studies examining the role of GAD in CHD patients and reported no significant 
associations (Tully, Cosh, & Baumeister, 2014). The latest meta-analysis in the area of 
anxiety and CVD prognosis included 44 articles examining prospective associations 
between anxiety and mortality in CHD patients (n=30,527) (Celano et al., 2015).  After 
adjusting for a number of covariates, anxiety was not associated with mortality or poorer 
outcomes in CHD patients. The authors performed sensitivity analyses and found that 
when they separated the samples into post-ACS patients and stable CHD patients, the risk 
of poorer outcomes in anxious stable CHD patients was significantly elevated after 
adjusting for a number of relevant covariates. There were no significant increases in 
outcome risk in anxious post-ACS patients.  
In summary, the evidence suggests that negative emotional disorders play a role in 
prognosis in those already with CVD. Three meta-analyses to date have reported 2 to 2.5-
fold increases in risk of future cardiac events and mortality in CHD patients with 
depression (Barth et al., 2004; Meijer et al., 2011; Van Melle et al., 2004). However, the 
largest meta-analysis carried out so far (Nicholson et al., 2006) found that many studies 
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failed to adjust for relevant risk factors such as smoking and BMI, leading to inflated 
associations between depression and prognosis in CVD patients. More than 50% of 
patients suffering from depression or anxiety will also suffer from a comorbid depressive 
or anxiety disorder (Hirschfeld, 2001). Therefore, failure to adjust for symptoms of 
anxiety in many of these studies could also lead to inflated risk estimates. Adjusting for 
symptoms of depression seems to be more commonplace in prognostic studies measuring 
anxiety in CHD patients. This may be why the results of meta-analyses in this field are a 
little more mixed. Another reason for the mixed results seen in the prognostic meta-
analyses related to anxiety may be failure to define samples correctly, i.e. separate stable 
CHD patients from post-ACS patients who are likely more symptomatic (Celano et al., 
2015). Nevertheless, the literature suggests that both depression and anxiety play a 
significant role in CVD prognosis, but more work is needed with both well-adjusted 
statistical models and well-defined patient samples.      
1.8 Chapter summary  
Overall the evidence suggests that psychosocial stress contributes significantly to the 
aetiology of CVD, CVD mortality, and CVD prognosis in those already affected. External 
life stressors, depression and anxiety, and intense periods of acute stress all seem to play 
a role in cardiovascular health. However, all studies in this area of research have been 
either cross-sectional or longitudinal prospective observational studies, meaning that 
these studies provide evidence for associations between stress and CVD, but are not able 
to establish causality.  
Results in this research area have been mixed and this is probably due to a number of 
methodological factors. On the whole, studies in this field tend to be well-powered and 
well-designed. But, there are issues with how stress is conceptualised and measured that 
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may affect the results of these studies. As mentioned earlier in this literature review, 
measuring life events rather than how people perceive life events as stressful, or focusing 
on the ‘job strain’ model rather than taking a wider approach to measuring work stress 
has likely affected results in the external stressor literature. Additionally, failure to adjust 
for covariates relevant to the development of CVD may have resulted in inflated 
associations between psychosocial stress and CVD outcomes. In general, most studies 
tend to adjust for traditional risk factors. But, health behaviours, social, and psychological 
factors known to be relevant to cardiovascular risk are often not controlled for. 
One interesting issue that emerges from the stress-CVD literature is duration of time 
between measurement of stress and cardiovascular event. Longer follow-up durations 
seem to weaken associations between psychosocial stress and cardiovascular risk and this 
is seen in external stressor research (Andersen et al., 2011; Kershaw et al., 2014), and 
both depression (Barth et al., 2004; Gan et al., 2014; Meijer et al., 2011) and anxiety 
(Stewart et al., 2016) research. What this suggests is that psychosocial stress likely has 
cumulative effects that lead to biological alterations that increase CVD risk over time, 
and that stress needs to be sustained in order to have a long-term effect. The lack of 
significant findings in the studies with long follow-up durations implies that perhaps the 
stress had dissipated (i.e. major life events), or the depression or anxiety symptoms had 
been dealt with or had waned.  
Nevertheless, this body of research does support the role of psychosocial stress in 
cardiovascular disease. The next step is to increase our understanding of the underlying 
biological mechanisms and pathways that link psychosocial stress with CVD. Then we 
may be able to devise targeted interventions to prevent psychosocial stress from 
developing into disease. In the next chapter I will discuss the role of a specific biological 
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pathway, the hypothalamic-pituitary-adrenal axis, in the link between psychosocial stress 
and CVD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
49 
 
Chapter 2 
Literature review: The role of the hypothalamic-pituitary-adrenal axis and the 
corticosteroid receptors 
2.1 Introduction 
In this chapter I will define and describe the hypothalamic-pituitary-adrenal (HPA) axis 
and its role in the stress response. I will then provide evidence for associations between 
chronic stress and dysregulation of the HPA axis, and associations between dysregulation 
of the HPA axis and CVD risk and prognosis. By doing this, I hope to show how 
dysregulation of the HPA axis might be one of the biological pathways linking 
psychosocial stress and CVD. I will then introduce the corticosteroid receptors and define 
and describe their role in the stress response. I will argue that stress-related modulation 
of these receptors, resulting in reduced glucocorticoid sensitivity, might be one 
mechanism through which HPA axis dysregulation is brought about. Thus, the aim of this 
chapter is to highlight the role of stress-related HPA axis dysregulation in CVD, and to 
provide evidence for the role of the corticosteroid receptor in HPA axis dysregulation.  
2.2 Potential pathways linking psychosocial stress and CVD 
There are a number of pathways through which psychosocial stress may contribute to the 
pathophysiology of CVD. One possibility is that the relationship between stress and CVD 
may be mediated through behavioural pathways. Psychosocial stress can influence CVD 
risk indirectly by increasing more adverse health behaviours (Steptoe & Kivimäki, 2012). 
A prospective cohort study (n=7,066) examining stress-related changes in health 
behaviours found that individuals with high levels of perceived stress were less likely to 
quit smoking over time, more likely to be sedentary, and less likely to keep alcohol 
consumption within the recommended limits (Rod et al., 2010). Psychosocial stress and 
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particularly depression has been associated with poorer adherence to medication in CHD 
patients (Gehi, Haas, Pipkin, & Whooley, 2005). Additionally, psychological distress has 
been associated with poor cardiac rehabilitation attendance in CHD patients (Glazer, 
Emery, Frid, & Banyasz, 2002).  
There is substantial evidence from both observational and laboratory studies suggesting 
that there are direct pathophysiological links between psychosocial stress and CVD. 
Psychosocial stress factors have been associated with increases in autonomic and 
endothelial dysfunction, increased systemic inflammation, upregulated cellular adhesion, 
and also promotion of a pro-thrombotic state (von Känel, 2012). Of particular relevance 
to this PhD is the association between psychosocial stress and alterations in HPA axis 
activity. The HPA axis is the major neuroendocrine system in humans that is activated 
during times of stress and incorporates a major part of the stress response. Before 
describing associations between psychosocial stress, alterations in HPA axis function, 
and the development of CVD, I will provide a brief overview of the stress system and the 
stress response.  
2.3 The stress system and the stress response 
When homeostasis is threatened, or perceived to be so, the stress response is initiated. 
The stress response is an adaptive response that brings about changes in the sympatho-
adrenal-medullary (SAM) system and the HPA axis which then go onto induce 
cardiovascular, metabolic, and immune changes that serve to protect the body from stress 
(Brotman, Golden, & Wittstein, 2007). The neural circuitry that initiates the stress 
response is mainly located in the hypothalamus and the brain stem. This circuitry includes 
corticotropin releasing hormone (CRH) neurons of the paraventricular nucleus of the 
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hypothalamus, and the locus coeruleus-norepinephrine (LC-NE) system in the pons and 
medulla (Tsigos & Chrousos, 2002).  
The SAM system is comprised of the sympathetic nervous system (SNS) and the adrenal 
medulla. During times of stress, the SAM system is activated by the LC-NE system. 
Firstly, the LC-NE system releases epinephrine into the brain which results in heightened 
alertness and a decrease in functions such as sleeping and eating (Brotman et al., 2007). 
This system also stimulates the hypothalamus which activates the SNS and results in the 
secretion of epinephrine and norepinephrine from the adrenal medulla. The release of 
these catecholamines results in increased heart rate, blood pressure, blood viscosity, and 
inflammation (Brotman et al., 2007). That is, in times of acute stress the SAM system is 
responsible for initiating the ‘fight or flight’ response, readying the body for any injury 
that may occur.  
During times of stress (see Figure 2.1), the HPA axis is activated by CRH from the 
paraventricular nucleus of the hypothalamus, which then leads to the release of 
adrenocorticotropic hormone (ACTH) from the anterior pituitary gland. ACTH then 
stimulates the release of glucocorticoids from the adrenal cortices, as well as some 
mineralocorticoids and androgens. Cortisol is the neuroendocrine end-point of the HPA 
axis and is the main circulating glucocorticoid in humans. Cortisol is a pleiotropic 
hormone. It has central energy-conserving effects as well as regulatory effects on the 
metabolism of protein, glucose, and fat for energy release. Cortisol exerts an 
immunomodulatory effect inhibiting the stress-related release of a number of 
inflammatory cytokines such as interleukin (IL) -6, IL-1, and tumour necrosis factor-α 
(TNF-α) (Kaltsas, Zannas, & Chrousos, 2012). Cortisol also increases blood pressure in 
times of stress via vasoconstriction (Girod & Brotman, 2004). In addition, cortisol exerts 
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a regulatory effect on itself suppressing the release of its biological precursors (CRH and 
ACTH) thus forming a negative feedback loop.  
 
 
 
During times of stress, there is a lot of cross-talk between the SAM system and the HPA 
axis. For example, while catecholamines released by the adrenal medulla serve to 
stimulate secretion of IL-6 (März et al., 1998), the HPA axis serves to inhibit the release 
of pro-inflammatory cytokines (Kaltsas et al., 2012). Moreover, IL-6 has also been found 
to stimulate activation of the HPA axis independent of CRH release (Bethin, Vogt, & 
Muglia, 2000). In sum, both systems serve to regulate each other, and a number of 
inflammatory mediators. However, when these systems become dysregulated, there can 
be adverse cardiovascular consequences.  
Although both systems are interrelated, this PhD will predominantly focus on the causes 
of HPA axis dysregulation and its implications for cardiovascular health.  
 
Figure 2.1. The hypothalamic-pituitary-adrenal axis 
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2.4 Stress-related HPA axis activity 
HPA axis activity increases in response to stress, resulting in increased levels of cortisol 
in humans, in order to exert the metabolic, cardiovascular, and anti-inflammatory effects 
required to maintain what Sterling and Eyer referred to as ‘allostasis’ (Sterling & Eyer, 
1988). Allostasis is the process of achieving stability through a number of short-term 
adaptive physiological changes (McEwen & Wingfield, 2003). Alterations in HPA axis 
activity in response to stress is just one example of allostasis. Other examples include 
alterations in catecholamine levels, cytokine levels, heart rate, and blood pressure 
(McEwen & Wingfield, 2010). When allostasis is called upon too often, or is not managed 
efficiently, the demand of all these adaptive processes on the body can take its toll. This 
is referred to as ‘allostatic load’ or ‘allostatic overload’ (McEwen, 2000). Allostatic load 
can be interpreted as the ‘wear and tear’ of certain biological systems when faced with 
either too much stress, or failure to adapt to stress biologically, i.e. not ‘turning off’ the 
stress response when it is no longer required (McEwen, 2007). As the stress response is 
sustained over time, the biological ‘wear and tear’ on the body and brain can lead to the 
development of pathology and illness (McEwen, 2008).  
Figure 2.2 illustrates four different conditions that lead to allostatic load (McEwen, 1998). 
For the purposes of this PhD the ‘physiological response’ referred to in the figure 
represents the cortisol stress response. Box (1) illustrates the normal cortisol response to 
stress, where cortisol increases, the increase is sustained for an appropriate amount of 
time in order for cortisol to exert its effects, and then the response is turned off. Box (2) 
represents repeated stress ‘hits’ from different stressors meaning that the cortisol stress 
response is frequently being triggered. Box (3) represents repeated stress hits from the 
same type of stressor and failure to habituate to that stressor. Box (4) represents a 
prolonged cortisol response to stress due to a delayed or failed shut down of the stress 
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response. Finally, Box (5) represents an inadequate or blunted cortisol response to stress. 
The prolonged (Box 4) and inadequate (Box 5) cortisol responses are likely what occurs 
after many repeated stress ‘hits’ (Box 2), or failure to adapt to stress (Box 3). A prolonged 
increase in cortisol after stress indicates that the hormone is unable to exert its self-
regulatory function. An inadequate cortisol response to stress means that cortisol cannot 
exert its regulatory effects on inflammation, metabolism, and the cardiovascular system, 
potentially leading to hyperactivity of other stress-related mechanisms (e.g. increased 
inflammation).  
 
Figure 2.2. Four types of allostatic load. Box (1) represents the normal cortisol stress response. Box (2) represents 
cortisol responses to repeated different stress hits. Box (3) represents lack of adaptation of cortisol to a similar  
stressor. Box (4) represents a prolonged cortisol response due to a delayed shutdown. Box (5) represents an 
inadequate cortisol stress response.  
Adapted from McEwen (1998). 
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2.5 Diurnal HPA axis activity 
Under basal, unstressed conditions, the HPA axis shows marked diurnal patterning and 
levels vary substantially throughout the day (Figure 2.3). These patterns can be observed 
with repeated plasma samples, but are more commonly assessed noninvasively with 
assays of free cortisol in saliva. The circadian rhythm of the HPA axis is regulated by the 
suprachiasmatic nucleus in the hypothalamus, which responds to levels of light in the 
environment, and then goes on to stimulate the release of CRH from the neurons in the 
paraventricular nucleus (Spiga, Walker, Terry, & Lightman, 2014). Cortisol is at high 
levels on waking, followed by a rise that reaches a peak approximately 30 minutes after 
waking. This is referred to as the cortisol awakening response (CAR). There is then a 
subsequent decline across the day (the cortisol slope), with cortisol reaching its nadir at 
around midnight (Adam & Kumari, 2009).  
 
 
 
 
Figure 2.3. The diurnal nature of HPA axis function. Under basal (unstressed) 
conditions, cortisol secretion is characterised by a circadian rhythm. The decline 
of cortisol across the day is referred to as the cortisol ‘slope’. 
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As well as dysregulation of the HPA axis manifesting as prolonged or inadequate cortisol 
responses to stress, dysregulation also occurs at the basal, unstressed level. Dysregulation 
of basal HPA axis function can cause alterations in the diurnal cortisol rhythm that take 
the form of blunted or heightened CARs, as well as flatter or steeper cortisol slopes 
(Adam & Kumari, 2009). These flatter cortisol slopes can be driven by lower waking 
cortisol levels, higher evening cortisol levels, or both. Another proxy for HPA axis 
dysregulation is area under the curve (AUC) which is an estimate of average cortisol 
exposure across the day (Adam & Kumari, 2009).  
2.6 Psychosocial stress and dysregulation of diurnal HPA axis function 
A growing body of evidence suggests an association between psychosocial stress and 
dysregulation of diurnal HPA axis function. A number of different types of psychosocial 
stress have been shown to be associated with alterations in diurnal HPA axis indices to 
date including acute psychosocial stress, a number of types of chronic stress, as well as 
stress-related disorders such as depression (Collomp et al., 2016). 
 2.6.1 Psychosocial stress and the CAR 
The CAR can be determined by either calculating simple change scores between cortisol 
levels at waking and levels at 20-45 minutes after waking, or by calculating the AUC, or 
the overall volume, of cortisol released over this waking period (Clow, Thorn, Evans, & 
Hucklebridge, 2004). Chida and Steptoe carried out a meta-analysis of 62 studies that 
examined associations between different psychosocial stress factors and the CAR (Chida 
& Steptoe, 2009). These psychosocial stress factors included job stress, general life stress 
(including perceived stress), depression, anxiety, posttraumatic stress disorder (PTSD), 
fatigue or burnout, as well as positive psychological factors such as positive affect and 
optimism. The authors separated studies into those that examined the CAR calculated 
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using simple change scores (CARi) and those that examined the CAR by calculating the 
AUC over the waking period (CARAUC).  
Meta-analysis revealed that the CARi was positively associated with levels of job stress 
and general life stress. Interestingly there were negative associations between the CARi 
and fatigue or burnout. Similarly, the CARAUC was found to be associated with higher 
general life stress. When the authors limited the meta-analysis to include only studies 
with high methodological quality scores, the positive association between the CARAUC 
and general life stress remained, but a negative association between the CARAUC and 
PTSD also emerged. These results indicate that different psychosocial stress factors have 
differing effects on the CAR. More recent research has replicated the negative 
associations between the CAR and people with burnout. Oosterholt and colleagues 
reported a blunted CAR in clinical and non-clinical burnout patient groups compared to 
healthy controls (Oosterholt, Maes, Van der Linden, Verbraak, & Kompier, 2015). 
Negative associations between the CAR and PTSD have also been replicated with a 
blunted CAR being reported in 24 adolescent girls with diagnoses of PTSD (Keeshin, 
Strawn, Out, Granger, & Putnam, 2014).  
Although Chida and Steptoe’s meta-analysis reported associations between enhanced 
CAR and general life and job stress, some research carried out since the meta-analysis 
reports contradictory associations. Academic stress was found to be associated with a 
reduced CAR in 42 healthy young men compared to 21 age-matched men not undergoing 
examinations (Duan et al., 2013). These reductions in CAR were negatively correlated 
with perceived stress and anxiety levels. Cropley and colleagues reported blunted CAR 
in school teachers with high levels of work-related rumination compared to teachers with 
low levels (Cropley, Rydstedt, Devereux, & Middleton, 2015). High levels of perceived 
stress have also been associated with blunted CAR in 64 healthy men and women 
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(Gartland, O’Connor, Lawton, & Bristow, 2014). Conversely, enhanced CAR has been 
reported in 24 healthy adults who had experienced early life trauma (Lu et al., 2013). This 
finding was later replicated in 58 people who had experienced childhood trauma (Lu, 
Gao, Huang, Li, & Xu, 2016).  
Collectively, what these results indicate is that different types of stress potentially have 
differing effects on the CAR. Other factors may come into play such participant age, sex, 
or clinical status. Additionally, the timing and duration of the type of stress is probably 
important. Whether or not participants were going through a particularly stressful period 
at the time of data collection may have affected results. Acute anticipatory stress has been 
shown to result in an increase in cortisol levels after awakening (Wetherell, Lovell, & 
Smith, 2015). Working mothers reporting high job strain and high parenting stress have 
been found to have enhanced CAR increases on workdays compared with non-workdays 
(Hibel, Mercado, & Trumbell, 2012). What these results suggest is that stress-related 
situational factors affect the CAR. Therefore, future studies should seek to measure and 
adjust for these factors. 
Interestingly, depression has also been found to have a varying association with the CAR. 
There has been a large amount of research carried out on CAR profiles in depression. A 
recent systematic review of the literature concluded that depression is associated with 
both a heightened and a blunted CAR (Dedovic & Ngiam, 2015). The authors suggest 
that this discrepancy might be related to depression severity. In fact, one study examining 
basal HPA axis function in depression described an inverted U-shaped association 
between depression and CARAUC (Veen et al., 2011). This non-linear association has been 
replicated in a much larger sample from the Netherlands Study of Depression and Anxiety 
(Wardenaar et al., 2011). It is possible that this non-linear association was the reason why 
there was no association between depression and the CAR in Chida and Steptoe’s (2009) 
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meta-analysis. However, a recent case-controlled study examining associations between 
depression and morning cortisol in older adults did not observe this U-shaped association 
between morning HPA axis function and depression (Rhebergen et al., 2015).   
 2.6.2 Psychosocial stress and the cortisol slope 
The cortisol slope is a measure of cortisol decline across the day and can be calculated in 
a number of ways. Typically, where a number of cortisol samples have been provided 
across the day a line of best fit is applied to each individuals’ data points using linear 
regression and the slope of this line is used as an estimate of the cortisol slope across the 
day (Adam & Kumari, 2009). The CAR sample (waking +30 minutes) is generally not 
included in these calculations and the slope is based on the first sample of the day taken 
upon waking.  
Flatter cortisol slopes have been associated with a number of different stressors and 
negative emotional disorders. In a 2007 meta-analysis, Miller and colleagues examined 
the effects of chronic stress on a number of diurnal cortisol parameters (Miller, Chen, & 
Zhou, 2007). They identified 119 papers (n=8,521) studying a number of different types 
of chronic stress including combat/war experience, abuse/assault, bereavement, 
caregiving stress, natural disasters, and job loss. Meta-analysis revealed that exposure to 
chronic stress was significantly associated with a flatter diurnal rhythm, as well as 
significantly lower morning cortisol levels and higher afternoon/evening levels which 
were likely resulting in the flattened slope.  
Research carried out in this area since this meta-analysis has largely corroborated this 
result. In a large study (n=1,694) of men and women from the National Study of Daily 
Experiences, a greater frequency of daily stressors was associated with a flatter diurnal 
cortisol slope (Stawski, Cichy, Piazza, & Almeida, 2013). This association remained 
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robust after adjustment for negative affect, and clinical factors also. Perceived stress in 
the home has also been associated with a flatter cortisol slope in men, but not in women 
(Sjörs, Ljung, & Jonsdottir, 2014). Work stress has been associated with flatter cortisol 
slopes. In a large occupational cohort (n=2,126), effort-reward imbalance was found to 
be related to flatter cortisol rhythm throughout the day (Liao, Brunner, & Kumari, 2013). 
However, this association was modest after adjustment for a number of demographic 
factors. Family-to-work spillover, i.e. the extent to which work infringes on your family 
life, has also been associated with flatter cortisol slopes (Zilioli, Imami, & Slatcher, 
2016).  
In a study of 98 older adults from the Brain Health Substudy of the Baltimore Experience 
Corps Trial, those deemed as socioeconomically disadvantaged had flatter cortisol slopes 
across the day (Agbedia et al., 2011). Early life adversity has also been associated with 
flattened diurnal cortisol rhythms in children and adolescents (Koss, Mliner, Donzella, & 
Gunnar, 2016; McLachlan et al., 2016). However, a previous study reported no difference 
in cortisol slope between women who had experienced early life adversity and matched 
controls who had not (Gonzalez, Jenkins, Steiner, & Fleming, 2009).  
Negative emotional disorders, in particular depression, have also been associated with 
aberrant cortisol rhythm throughout the day. In a sample of 257 Swedish men and women, 
depression was found to be associated with flatter diurnal cortisol slopes (Sjögren, 
Leanderson, & Kristenson, 2006). Flatter cortisol slopes have also been reported in 
women with major depressive disorder (Jarcho, Slavich, Tylova-Stein, Wolkowitz, & 
Burke, 2013), as well as in adolescents who have had recent episodes of major depressive 
disorder (Doane et al., 2013). Negative emotions such as sadness, loneliness, and high 
reports of general distress were also associated with flattened rhythms in this adolescent 
sample (ibid). More severe depressive symptoms have also been associated with more 
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pronounced flattening of the cortisol slope (Hsiao et al., 2010). In disagreement with 
previous research, a recent study reported no difference in cortisol slope between 
depressed and non-depressed individuals (Booij et al., 2015). It is possible that this study 
may have been underpowered to detect significant differences between groups (n=15 per 
group).  
Conversely, associations between positive psychosocial factors and steeper cortisol 
declines across the day have been reported, lending support for the associations between 
negative stress factors and flatter cortisol slopes. Social support and positive coping styles 
were associated with steeper cortisol rhythms across the day (Sjögren et al., 2006). There 
have also been associations reported between high levels of positive affect, such as 
feelings of alertness and activeness, and steeper diurnal cortisol slopes (Hoyt, Craske, 
Mineka, & Adam, 2015). 
 2.6.3 Psychosocial stress and cortisol AUC 
The cortisol AUC is not a measure of the circadian variation of cortisol but instead reflects 
the average levels of cortisol secreted throughout the day (Adam & Kumari, 2009). 
Nevertheless, associations between cortisol AUC and psychosocial stress factors have 
also been reported. As with research looking at the CAR, results from AUC research have 
been varied. Miller and colleagues (2007) meta-analysis cited earlier also elicited 
significant associations between exposure to chronic stress and a higher daily volume of 
cortisol output. However, more recent research has produced mixed results. Examination 
stress has been linked with reduced cortisol AUC in healthy young men (Duan et al., 
2013). Job strain has also been linked with altered cortisol AUC. In 104 healthy adults, 
higher job strain was associated with higher cortisol AUC (Maina, Bovenzi, Palmas, & 
Filon, 2009). Conversely, a more recent study reported lower total cortisol AUC in older 
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adults with higher levels of job strain from the Multi-Ethnic Study of Atherosclerosis 
Stress Study (Rudolph et al., 2016). The authors posit that the age of the participants may 
be the reason for the discrepancy between these two studies. Interestingly in a sample of 
68 healthy younger adults there was no association between job strain and cortisol AUC 
(Maina, Palmas, & Filon, 2007). However the cortisol AUC was significantly higher on 
working days compared with non-working days. This indicates that, like the CAR, 
situational factors have influence on the AUC. Temporality may also be an issue affecting 
results in these studies. In their meta-analysis, Miller and colleagues (2007) showed that 
as time since the stress exposure increased the strength of the association between stress 
and cortisol AUC decreased.  
Alterations in cortisol AUC have also been reported in depression. In 45 female 
caregivers of stroke survivors, higher levels of depressive symptoms were associated with 
lower cortisol levels across the day (Saban, Mathews, Bryant, O’Brien, & Janusek, 2012). 
In a study of 401 men and women in Canada, lower cortisol concentrations across the day 
were associated with symptoms of depression, psychological distress, and burnout 
(Marchand, Durand, Juster, & Lupien, 2014). Conversely, elevated cortisol AUC has 
been reported in 57 depressed individuals compared to healthy controls (Dienes, Hazel, 
& Hammen, 2013).  In a meta-analysis of 20 studies examining salivary cortisol in 
depression, the results suggested that salivary cortisol levels are generally increased in 
patients with a depressive disorder (Knorr, Vinberg, Kessing, & Wetterslev, 2010). 
However, using meta-regression the authors found that the difference in salivary cortisol 
levels observed was probably associated with age and intra-assay variability of the 
cortisol kits, rather than depression scores. Low social support has been associated with 
higher cortisol AUC in healthy students (Heaney, Phillips, & Carroll, 2010), whereas in 
older adults low social support was associated with a reduced cortisol AUC (Piazza, 
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Charles, Stawski, & Almeida, 2013).In this same older sample, higher levels of negative 
affect were positively associated with cortisol AUC. What these results suggest is that, 
like CAR, alterations in cortisol AUC related to depression are mixed and are possibly 
related to other factors like age, temporality, and other psychosocial factors such as social 
support and affect.  
2.7 Psychosocial stress and dysregulation of stress-related HPA axis activity 
Acute psychosocial stress induced in the laboratory leads to activation of the HPA axis 
and a subsequent increase in cortisol levels (Dickerson & Kemeny, 2004). There is a body 
of evidence suggesting that exposure to chronic stressors can bring about alterations in 
the magnitude of cortisol responses to acute stress.  
 2.7.1 Exposure to chronic stress and early life adversity 
The most comprehensive meta-analysis to date examining the effects of chronic 
psychosocial factors on cortisol responses to acute stress in the laboratory revealed that 
positive psychological traits, i.e. openness, spirituality, self-esteem, and positive coping 
style, were associated with reduced cortisol stress reactivity in the laboratory (Chida & 
Hamer, 2008). However, there were no significant associations between negative stress-
related factors and laboratory-induced cortisol stress responses due to inconsistency 
between studies. This lack of association may have been down to the nature of the chronic 
stressor or the duration between stress exposure and acute stress testing (Miller et al., 
2007). Perhaps the positive psychological factors were associated with cortisol responses 
in the laboratory because they are stable traits rather than transient stress factors that can 
dissipate over time.  
Much of the research looking at the effects of chronic stress exposure on acute cortisol 
stress reactivity has focused on early life adversity. In healthy adults with no 
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psychopathology, those with a history of moderate to severe childhood maltreatment 
exhibited blunted cortisol responses to psychosocial stress in the laboratory compared to 
those with no experience of maltreatment (Carpenter et al., 2007). In a follow-up study 
the authors replicated these findings in a non-clinical sample of women and found that 
those who had experienced childhood physical abuse had blunted cortisol responses to 
laboratory stress compared to those who had not (Carpenter, Shattuck, Tyrka, Geracioti, 
& Price, 2010). Similarly, in a study of 80 healthy men and women exposed to a 
psychosocial laboratory stress, those who had high exposure to adverse childhood events 
(n=33) had significantly blunted cortisol responses to the stress tasks compared to those 
with no exposure to adverse events (Elzinga et al., 2008). Pre-stress cortisol values did 
not differ between groups.  
In a highly cited study, Heim and colleagues compared four different groups of women 
(n=49) on cortisol and ACTH responses to acute psychosocial stress in the laboratory 
(Heim, Ehlert, & Hellhammer, 2000). One group had current major depression and had 
experienced childhood abuse, one group was free from depression but had experienced 
childhood abuse, one group had current major depression and had not experienced 
childhood abuse, and the control group had experienced neither depression nor abuse in 
childhood. The results indicated that after the acute stress protocol, abused women with 
current major depression exhibited significantly higher cortisol responses to stress 
compared with the other three groups. In terms of ACTH responses, both groups of 
abused women, regardless of depression status exhibited significant increases compared 
to non-abused depressed women and controls. These findings are in contrast with those 
of Suzuki and colleagues who found that cortisol responses to stress were blunted in those 
who had experienced childhood trauma, regardless of depressive status (Suzuki, Poon, 
Papadopoulos, Kumari, & Cleare, 2014).  
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Goldman-Mellor and colleagues compared three different groups of healthy men and 
women from the Whitehall II cohort (n=543) (Goldman-Mellor, Hamer, & Steptoe, 
2012). Two of the groups had experienced early life stress whereas one had not (control 
group). Of the early life stress groups, one had a history of recurrent psychological 
distress over the previous 20 years, whereas the other group did not. Following an acute 
stress laboratory protocol, those who had experienced both early life stress and recurrent 
psychological distress had blunted cortisol responses to stress compared with the control 
group. Conversely, similar to the findings of Heim and colleagues, those who had 
experienced early life stress with little or no history of ongoing distress had elevated 
baseline cortisol levels and prolonged cortisol responses to stress compared to the control 
group. These results differ from the earlier studies mentioned above. This may be because 
in these earlier studies the ‘healthy’ participants who had experienced early childhood 
adversity may have had underlying depressive symptomatology or psychological distress 
that was not taken into account. The discrepancies between results in this area could also 
have to do with the way early childhood adversity is defined. Stress involving threat to 
the physical self or trauma are known to elicit different HPA axis responses compared to 
stress that threatens the social self (Miller et al., 2007).  
 2.7.2 The effects of depression 
Cortisol stress reactivity has been found to be dysregulated in depression. In a small meta-
analysis of seven studies (n=196), those with major depressive disorder were found to 
have prolonged cortisol responses compared to non-depressed individuals indicating 
delayed shutdown of the stress response (Burke, Davis, Otte, & Mohr, 2005). However, 
within this meta-analysis, older patients and more severely depressed patients were found 
to have blunted cortisol reactivity to acute stress, particularly when the laboratory session 
was in the afternoon. The results of a more recent study partially mirror those of this meta-
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analysis. Amongst 351 adolescents from the TRAILS cohort, Booij and colleagues found 
that adolescents with recent-onset major depressive problems had prolonged responses to 
a laboratory-based stress protocol (Booij, Bouma, de Jonge, Ormel, & Oldehinkel, 2013). 
However, those who had persistent or recurrent depression throughout adolescence had 
blunted cortisol responses to the same stress protocol. These results suggest that initially, 
depressive symptoms might enhance (prolong) the cortisol stress response, but over time 
responsivity diminishes possibly due to repeated stress hits. This may be why blunted 
cortisol responses to stress were seen in older and more severely depressed patients in 
Burke et al.’s (2005) meta-analysis.  
Amongst a sample of older people (n=68, >55y) with elevated cardiovascular risk, those 
who were clinically depressed were found to have blunted cortisol responses to acute 
laboratory stress compared to their non-depressed counterparts (Taylor et al., 2006). 
Similarly, a recent study showed that in a large older sample (n=725, 50-65y) from the 
Dutch Famine Birth Cohort Study, higher symptoms of depression and anxiety were 
associated with blunted cortisol stress reactivity in the laboratory (de Rooij, 2013). This 
finding is in support of the notion that older age, and therefore perhaps longer exposure 
to depression and anxiety throughout the lifespan, results in diminished cortisol reactivity 
to stress. A recent study examining cortisol stress reactivity in youth depression (n=115, 
9–16y) found that depressive symptoms were associated with higher cortisol responses to 
a socially evaluated cold-pressor test, but only in boys (Lopez-Duran et al., 2015). This 
lends further support that age, and exposure to depression, plays a role in the association 
between depression and cortisol stress reactivity.   
Overall, the evidence suggests that psychosocial stress factors and negative emotional 
disorders are associated with dysregulation of both basal and stress-related HPA axis 
function. Different stress types seem to exert different effects on the direction of 
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dysregulation of the HPA axis. For example, both heightened and blunted CARs have 
been reported across different types of stress. This also applies to cortisol AUC as well 
as cortisol stress reactivity. Factors that appear to influence the direction of dysregulation 
are age, temporal issues, and also the severity of the stressor. However, in terms of cortisol 
slope, flatter cortisol slopes seem to be uniformly associated with stress-related factors.  
As mentioned previously, cortisol is a pleiotropic hormone that exerts regulatory effects 
on energy release, cardiovascular function, and the release of a number of pro-
inflammatory cytokines, as well as regulating its own release via a negative feedback 
loop. Stress-related dysregulation of the HPA axis may then have further reaching 
biological implications that could promote the development of a number of diseases, 
including CVD. In the next section I will provide evidence for the role of HPA axis 
dysregulation in CVD.  
2.8 HPA axis dysregulation and CVD 
In a comprehensive review, Girod and Brotman lay out the ways in which the HPA axis 
is important for cardiovascular function and reduction of CVD risk (Girod & Brotman, 
2004). Firstly, they note that a normally functioning HPA axis ‘primes’ the body for stress 
by preparing the metabolic, cardiovascular, haemostatic and autonomic components of 
the stress response required for the experience of everyday stress. Secondly, they outline 
the ‘suppressive’ role of cortisol in that it prevents inflammation and tissue repair 
processes from exceeding required levels and resulting in damage to the self. Thirdly, 
cortisol is known to play a role in insulin sensitivity, lipid production, and fat 
accumulation (Peckett, Wright, & Riddell, 2011). Based on these three roles of the HPA 
axis outlined above, dysregulation of the axis and abnormal cortisol secretion could 
therefore negatively alter cardiovascular risk (Girod & Brotman, 2004). 
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 2.8.1 Diurnal HPA axis function in CVD 
Standard observational methods have revealed associations between dysregulation of 
basal diurnal HPA axis activity and progression of CVD. High levels of cortisol reactivity 
in the hour after waking have been found to be positively associated with intima media 
thickness of the artery carotis communis in women (Eller, Netterstrøm, & Allerup, 2005; 
Eller, Netterstrøm, & Hansen, 2001). Morning levels of cortisol have been found to be 
elevated in men who have moderate to severe coronary atherosclerosis (Troxler, Sprague, 
Albanese, Fuchs, & Thompson, 1977). In the CARDIA study, there was a significant 
cross-sectional association between a flatter cortisol slope across the day and higher levels 
of coronary artery calcification in 718 healthy middle-aged adults (Matthews, Schwartz, 
Cohen, & Seeman, 2006). In the Multi-Ethnic Study of Atherosclerosis Stress Study, a 
unit increase in coronary calcium was associated with a 1.77% flatter decline in cortisol 
in 464 older men and women (Hajat et al., 2013). In 1,866 healthy participants from the 
Rotterdam Study, higher cortisol AUC values were associated with an increased number 
of atherosclerotic plaques in the carotid arteries (Dekker et al., 2008).  
Dysregulated diurnal HPA axis function has been reported in clinical cohorts also. 
Patients with CHD have been found to have flatter diurnal cortisol slopes compared to 
healthy controls (Nijm, Kristenson, Olsson, & Jonasson, 2007). However, this finding 
was not replicated by Bhattacharyya and colleagues who examined cortisol slopes in 
patients with CAD compared to those without (Bhattacharyya, Molloy, & Steptoe, 2008). 
The CAR has also been found to be blunted in CVD patients (Vreeburg et al., 2009). 
Interestingly, dysregulation of the CAR seems to vary according to disease severity. CHD 
patients who had a history of MI had a more blunted CAR compared to CHD patients 
who had no previous MI (Merswolken, Deter, Siebenhuener, Orth-Gomér, & Weber, 
2013).  
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Thus, the evidence suggests that dysregulation of basal HPA axis function is associated 
with markers of cardiovascular risk, as well as being characteristic of CHD itself. This 
implies that HPA axis dysregulation may be one of the biological pathways through which 
psychosocial stress causes the development of CVD. The impact of stress on the 
pathophysiology of CVD is also likely to be mediated in part by mild chronic systemic 
inflammation (Steptoe & Kivimäki, 2013). The role of inflammation in atherosclerosis is 
well established (Hansson & Hermansson, 2011) and markers of low grade inflammation 
have been associated with higher risk of CVD (Danesh et al., 2004). Seeing as 
glucocorticoids serve to regulate inflammation, it is likely that dysregulation of the HPA 
axis contributes to chronic systemic inflammation characteristic of CVD. In fact, in the 
cross-sectional study where Nijm and colleagues showed that flatter cortisol slopes were 
seen in CHD patients compared to healthy controls, they also reported that levels of 
evening cortisol (which were the driving force behind the flattened cortisol rhythm) were 
strongly correlated with serum levels of IL-6 and C-reactive protein (CRP) (Nijm et al., 
2007).  
An important study has shown that dysregulation of the HPA axis not only plays a role in 
the development of CVD, but is also associated with cardiovascular mortality. Kumari 
and colleagues examined diurnal cortisol patterns in 4,047 civil servants from the 
Whitehall II cohort and assessed mortality data over a follow-up period of 6.1 years 
(Kumari, Shipley, Stafford, & Kivimaki, 2011). The results showed that flatter cortisol 
slopes were associated with increased risk of all-cause mortality, but that this association 
was mainly driven by an increased risk of cardiovascular death. These results indicate 
that dysregulation of diurnal cortisol secretion is related to CVD mortality in originally 
disease-free individuals. To date, no one has examined the role of diurnal HPA axis 
dysregulation in the prognosis of those who already have advanced CVD.  
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Therefore, the first study of this PhD presented in Chapter 3 will examine whether 
pre-surgical diurnal cortisol profiles can predict adverse clinical outcomes in 
patients with advanced heart disease.  
 2.8.2 Cortisol stress reactivity in CVD 
Evidence for the role of HPA axis dysfunction in CVD also comes from laboratory studies 
of cortisol stress reactivity. Dysregulated cortisol responses to stress have been associated 
with elevated CVD risk factors. As mentioned before, the role of systemic inflammation 
in atherosclerosis is well established. Inflammation increases in response to acute stress 
challenges (Steptoe, Hamer, & Chida, 2007). In a laboratory-based acute stress study 
healthy middle-aged participants were divided into cortisol responders and cortisol non-
responders. Following the stress protocol, cortisol non-responders had higher levels of 
plasma IL-6 and a greater IL-1 receptor antagonist (IL-1Ra) response to stress compared 
with cortisol responders (Kunz-Ebrecht, Mohamed-Ali, Feldman, Kirschbaum, & 
Steptoe, 2003). This suggests that an adequate cortisol response to stress is required to 
regulate the inflammatory stress response. Those with blunted cortisol stress reactivity 
(i.e. the non-responders) had both increased systemic inflammation (IL-6), an increased 
inflammatory stress response (IL-1Ra), as well as lower heart rate variability, which are 
all factors associated with the development of CVD (Kunz-Ebrecht et al., 2003).  
Interestingly, cortisol responders to acute laboratory stress have been found cross-
sectionally to have increased levels of significant coronary artery calcification (Agatston 
score ≥100) after adjustment for a number of traditional risk factors (Hamer, O’Donnell, 
Lahiri, & Steptoe, 2010). Since interpretation of causality in cross-sectional data can be 
problematic, the authors decided to carry out a prospective follow-up of this study. They 
examined coronary artery calcification progression over the three year follow-up period 
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and found an association between higher, or more prolonged, cortisol stress reactivity and 
rate of calcification progression (Hamer, Endrighi, Venuraju, Lahiri, & Steptoe, 2012). 
In older initially healthy men and women, cortisol stress reactivity in the laboratory was 
found to be associated with higher incident hypertension at three year follow-up after 
adjusting for a number of clinical factors (Hamer & Steptoe, 2012).  
The results of the four aforementioned studies provide conflicting results. On the one 
hand blunted cortisol stress reactivity is associated with a number of CVD risk factors, 
and on the other, heightened cortisol stress reactivity is associated with increased 
coronary artery calcification (a sub-clinical marker of atherosclerosis), and incident 
hypertension. It is possible that age is a factor in the discrepancy between these results. 
In the earlier study by Kunz-Ebrecht and colleagues, the sample was comprised of healthy 
middle-aged participants. In the studies carried out by Hamer and colleagues, the samples 
were comprised of healthy older adults. Age is known to be a strong regulatory factor of 
cortisol secretion (Veldhuis, Sharma, & Roelfsema, 2013). Nevertheless, the results of 
these studies provide evidence that dysregulation of the cortisol stress response, 
regardless of direction, is associated with adverse cardiovascular and atherosclerotic 
factors.  
Cortisol responses to acute laboratory stress have also been measured in CHD patients. 
Thirty patients who had recently experienced a first-time ACS underwent a psychosocial 
stress protocol comprising anger recall and arithmetic. Compared with age-matched 
healthy controls, the CHD patients had blunted cortisol responses to stress, even after 
adjusting for confounding factors such as smoking or medication use (Nijm et al., 2007). 
A very recent study has replicated these findings. In 91 participants who underwent the 
Trier Social Stress Test (TSST) in the laboratory, those who had CHD (n=46) had blunted 
cortisol stress reactivity compared to those who were CHD-free (Waller et al., 2016). This 
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group difference remained significant even after adjustment for cardiovascular 
medication use. These findings are in line with the results of a population based study 
which showed that Lithuanian men had significantly lower cortisol responses to acute 
psychosocial stress in the laboratory compared to men from Sweden (Kristenson et al., 
1998). Men from Lithuania have been shown to have a four-fold risk for CHD mortality, 
more atherosclerotic plaques, increased intima-media thickness, and higher levels of 
carotid artery stiffness compared to men from Sweden (Kristenson et al., 2000).  
Taken together, these observational and laboratory-based studies suggest that 
dysregulation of the HPA axis, through changes in both the diurnal cortisol profile and 
cortisol stress reactivity, may increase CVD risk and progression. The evidence suggests 
that psychosocial stress factors and negative emotional disorders can bring about 
dysregulation of the HPA axis. Therefore, it is possible that dysregulation of the HPA 
axis may be one of the biological pathways through which psychosocial stress ‘gets under 
the skin’ and affects the pathophysiology of CVD. It is therefore important that we 
establish how psychosocial stress might bring about sustained changes in HPA axis 
function. One possible course is via changes in the sensitivity of the corticosteroid 
receptors.  
2.9 The role of the corticosteroid receptors 
Cortisol exerts its effects by binding to its receptors – the glucocorticoid receptor (GR) 
and the mineralocorticoid receptor (MR). GRs are ubiquitously expressed around the 
body, whereas MRs are expressed only in selected tissues such as the kidney, colon, heart, 
and central nervous system (CNS). In their inactivated state, both receptors reside within 
the cell cytoplasm anchored in place by chaperone molecules. Once bound to cortisol, the 
receptor sheds its chaperone molecules and translocates into the cell nucleus (see Figure 
73 
 
2.4). Within the cell nucleus there are two distinct mechanisms of action through which 
the ‘activated’ receptor exerts effects on gene transcription. Firstly, the ligand-receptor 
complex can directly bind to glucocorticoid response elements (GREs) in target genes in 
order to enhance gene transcription. The activated receptor can also bind with negative 
GREs in order to inhibit gene transcription. Binding to GREs represents the classic model 
of corticosteroid receptor action (Bamberger, Schulte, & Chrousos, 1996) and allows 
cortisol to exert its regulatory effects. The second mechanism of action is largely of 
relevance to the anti-inflammatory effects of cortisol. A number of immune genes (e.g. 
IL-6, IL-2) do not have GREs yet their expression is suppressed by cortisol (Bamberger 
et al., 1996). This is because cortisol can also exert its effects by binding directly with 
transcription factors within the cell nucleus, such as Nuclear factor-κb (NF-κB) or 
activator protein-1 (AP-1), in order to down-regulate inflammatory gene transcription 
(Girod & Brotman, 2004).  
The MRs are referred to as Type I receptors. They have a high affinity for endogenous 
glucocorticoids (i.e. cortisol in humans, corticosterone in rats) and aldosterone (salt and 
water regulation) and are therefore thought to regulate basal activity of the HPA axis as 
well as the onset of the stress response (de Kloet, 1998). The GRs are referred to as Type 
II receptors. They have a high affinity for dexamethasone (a synthetic glucocorticoid) but 
a low affinity for endogenous glucocorticoids. Therefore, they are thought to be important 
in the regulation of the stress response when levels of endogenous glucocorticoids are 
high, and the subsequent shutdown of the cortisol stress response via the negative 
feedback loop of the HPA axis (Carvalho & Pariante, 2008). One explanation of HPA 
axis dysregulation may be diminished sensitivity of the corticosteroid receptors. With 
reduced receptor sensitivity, cortisol is no longer able to exert its regulatory effects 
successfully leading to a breakdown in the HPA axis negative feedback loop, and an 
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increase in the intensity of the inflammatory response (Cohen et al., 2012). An increase 
in the intensity or duration of the inflammatory response has consequences for the 
development and progression of chronic inflammatory diseases such as CVD (Danesh et 
al., 2004).  
2.9.1 What causes modulation of corticosteroid receptor sensitivity? 
There is a substantial amount of difference between individuals in corticosteroid receptor 
sensitivity (Quax et al., 2013) and there are a number of factors that modulate this 
sensitivity. Firstly, the extracellular and intracellular bioavailability of glucocorticoids 
will affect sensitivity of the corticosteroid receptors. For example, patients on long term 
exogenous treatment with synthetic glucocorticoids will quite often develop tissue-
Figure 2.4. Translocation of the corticosteroid receptor into the cell nucleus. Once a glucocorticoid 
binds to its receptor, the receptor sheds its chaperone molecules (HSP90, p23) and translocates into 
the cell nucleus where it binds to GREs on target genes, or directly with transcription factors, in order 
to activate or repress gene transcription.  
HSP90: heat shock protein 90; p23: protein 23; GRE: glucocorticoid response element 
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specific glucocorticoid resistance (Oakley & Cidlowski, 2013). Circulating levels of 
corticosteroid-binding globulin (CBG) may influence the bioavailability of 
glucocorticoids (Bamberger et al., 1996). CBG is the major transporter protein for 
glucocorticoids and binds to approximately 80-90% of all circulating cortisol. The 
remaining 20% is comprised of albumin-bound and free cortisol. Only cortisol not bound 
to CBG is biologically active (Lewis, Bagley, Elder, Bachmann, & Torpy, 2005). 
Therefore, the amount of CBG in circulation will influence the amount of cortisol 
available to act on intracellular corticosteroid receptors. CBG levels are under complex 
regulatory control and exposure to inflammatory cytokines such as IL-6 and IL-1β have 
been shown to influence CBG secretion and messenger RNA (mRNA) levels (Emptoz-
Bonneton, Crave, LeJeune, Brébant, & Pugeat, 1997). CBG release is also known to be 
affected by psychosocial stress (Kumsta, Entringer, Hellhammer, & Wüst, 2007). 
Variations in the levels of 11β-hydroxysteroid dehydrogenase (11β-HSD) may also affect 
receptor sensitivity. 11β-HSD is an enzyme that can convert cortisol both to its active and 
inactive forms. 11β-HSD-1 converts cortisone, which is biologically inactive, to cortisol. 
11β-HSD-2 oxidises cortisol into the inactive metabolite cortisone. Changes in the levels 
of these enzymes within the cell exert effects on the bioavailability of cortisol, thereby 
affecting corticosteroid receptor sensitivity (Oakley & Cidlowski, 2013). Increased levels 
of 11β-HSD-1 have been associated with an increase in GR sensitivity (Whorwood, 
Donovan, Wood, & Phillips, 2001). Interestingly, increased levels of 11β-HSD-2 have 
been found in the offspring of maternal Holocaust survivors who underwent severe 
trauma (Bierer et al., 2014).  
Corticosteroid receptor sensitivity may also be affected by the number of receptors in the 
cell, or the ‘hormone binding capacity’ of the cell (Bamberger et al., 1996). Lower cell 
receptor concentrations have been found in patients with depression (Pariante & Miller, 
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2001), and depression has been associated with decreased glucocorticoid senstivity (Pace, 
Hu, & Miller, 2007). Glucocorticoids themselves have been shown to bring about 
significant downregulation of corticosteroid receptors (Bamberger et al., 1996). This may 
be an adaptive function preventing tissue damage from overexposure to glucocorticoids, 
which may over time become maladaptive. The hormone binding affinity of the receptors 
also likely plays an important role in modulation of receptor sensitivity.  Every receptor 
has a ligand-binding domain which is the area to which glucocorticoids bind. Co-
incubation with IL-2 and IL-4 has brought about alterations in the ligand-binding domains 
of human lymphocytes leading to reduced hormone binding affinity of the GR (Kam, 
Szefler, Surs, Sher, & Leung, 1993). What this indicates is that increased inflammation 
may bring about reduced corticosteroid receptor sensitivity through reducing hormone 
binding affinity.  
Differing ratios of splice variants of the corticosteroid receptors may also affect receptor 
sensitivity. The GR gene NR3C1 consists of nine exons which are subject to splicing, 
which gives rise to a number of splice variants of the gene, two of which are the GRα and 
GRβ isoforms (Quax et al., 2013). In isolation, GRα facilitates the action of 
glucocorticoids, whereas GRβ is inactive. However, when GRβ is co-expressed with 
GRα, GRβ inhibits the action of GRα which suggests that a higher GRβ:GRα ratio may 
lead to glucocorticoid resistance (Oakley & Cidlowski, 2013). The GRβ isoform is 
present in many cells, but is usually found in lower levels than the GRα isoform. 
However, cytokines have been found to influence the expression of GR splice variants. 
IL-2 and IL-4 were found to increase the expression of GRβ isoforms in peripheral blood 
mononuclear cells (PBMCs) by more than 100% (Leung et al., 1997). The pro-
inflammatory cytokines TNF-α and IL-1β were shown to increase GRα expression by 
150% while increasing GRβ by 350% in HeLA cells which express both isoforms 
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endogenously (Webster, Oakley, Jewell, & Cidlowski, 2001). The results of these studies 
indicate that inflammatory cytokines could bring about a decrease in corticosteroid 
receptor sensitivity through upregulation of the GRβ splice variant of the receptor. 
Individual variation in GR sensitivity may also be influenced by genetic difference. 
Functional polymorphisms of the GR gene have been shown to influence the effects of 
glucocorticoids. Individuals with the ER22/23EK polymorphism of the GR gene have 
been found to demonstrate glucocorticoid resistance, whereas individuals with the N363S 
single nucleotide polymorphism (SNP) have demonstrated enhanced GR sensitivity 
(Manenschijn, Van Den Akker, Lamberts, & Van Rossum, 2009).  
 2.9.2 How do we measure corticosteroid receptor sensitivity? 
Corticosteroid receptor sensitivity can be indirectly assessed both in vivo and in vitro. 
Assessment involves measuring associations between a specific input (e.g. different 
concentrations of synthetic glucocorticoids) and suppression of a specific output, such as 
ACTH or cortisol production, mitogen-induced lymphocyte proliferation, or 
lipopolysaccharide (LPS)–induced inflammatory cytokine production (Rohleder, Wolf, 
& Kirschbaum, 2003). These associations allow us to examine glucocorticoid sensitivity 
in peripheral blood cells thus providing us with a proxy measure of corticosteroid receptor 
sensitivity. Note that from now on the terms ‘glucocorticoid sensitivity’ and 
‘corticosteroid receptor sensitivity’ will be used interchangeably.  
In vivo, the most widely used method to examine glucocorticoid sensitivity is the 
dexamethasone suppression test (DST) (Rohleder et al., 2003). This test involves 
peripheral administration (usually oral) of a low dose of the synthetic glucocorticoid 
dexamethasone which in theory should then suppress the release of ACTH from the 
pituitary via negative feedback. In turn, the release of cortisol should also be suppressed. 
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The results of the DST can be interpreted as an index of glucocorticoid sensitivity with 
non-suppression of cortisol release being indicative of diminished GR sensitivity (Ebrecht 
et al., 2000).  
In vitro assays have also been developed in order to examine glucocorticoid resistance 
within immune cells. In this assay the effect of dexamethasone on lymphocyte 
proliferation or production of inflammatory cytokines, both of which should be inhibited 
by glucocorticoids, is used as an index of GR sensitivity (Carvalho & Pariante, 2008; 
Rohleder et al., 2003). The most common assay used today was developed by DeRijk and 
colleagues who use LPS to stimulate the release of inflammatory cytokines in whole 
blood, or PBMCs isolated from whole blood, (DeRijk, Petrides, Deuster, Gold, & 
Sternberg, 1996). LPS is an endotoxin produced by gram-negative bacteria known to 
induce an inflammatory immune response from cells (Raetz & Whitfield, 2002). The 
inhibition of LPS-stimulated secretion of inflammatory cytokines by different 
concentrations of dexamethasone is used as an index of glucocorticoid sensitivity. Failure 
to inhibit, or partial inhibition, indicates reduced in vivo GR sensitivity and non-
suppression in the DST has been correlated with reduced dexamethasone-induced 
inhibition of lymphocyte proliferation in vitro (Carvalho & Pariante, 2008). Within this 
thesis, these in vitro assays will be referred to as glucocorticoid sensitivity assays.    
As dexamethasone has a high binding affinity for the GR, the DST and glucocorticoid 
sensitivity assays outlined above only provide a proxy measure of sensitivity of this 
specific receptor. The prednisolone suppression test (PST) has been developed which 
allows the evaluation of both the GR and the MR. Prednisolone is a synthetic 
glucocorticoid which is more similar than dexamethasone to cortisol and therefore binds 
to both the GR and the MR (Pariante et al., 2002). Thus, the inhibition of LPS-stimulated 
secretion of inflammatory cytokines by different concentrations of prednisolone provides 
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an indirect measure of GR and MR sensitivity. Prednisolone can also be used in vitro in 
glucocorticoid sensitivity assays. 
In vitro glucocorticoid sensitivity assays are usually performed using whole blood or 
using PBMCs isolated from whole blood. Whole blood allows for rapid measurement of 
peripheral glucocorticoid sensitivity in white blood cells. However, it does not account 
for differences in cell population ratios within the white blood cells which could influence 
variability within the sample being measured (Burnsides et al., 2012). Therefore, it is 
preferable to carry out these assays using specific isolated PBMCs such as lymphocytes 
or monocytes.  
One flaw of glucocorticoid sensitivity assays is that they are not tissue specific. These 
assays are carried out using whole blood or PBMCs meaning that the results give an 
indication of peripheral corticosteroid receptor sensitivity and cannot be extended to other 
tissues of interest, such as cardiac or brain tissue (Carvalho & Pariante, 2008). Also, 
measuring a small number of specific outcomes, such as LPS-induced IL-6 or TNF-α 
levels, means we are not examining all the wider effects of glucocorticoids (Quax et al., 
2013). Therefore results of these assays should be interpreted with these issues in mind.  
There are other in vitro methods used to measure corticosteroid receptor sensitivity and 
receptor function. The number of receptors within cells and the hormone binding affinity 
of the receptors can be measured directly using a glucocorticoid binding assay (Chriguer 
et al., 2005). Corticosteroid receptor mRNA expression can be assessed in PBMCs and 
receptor protein levels can be measured directly using Western blot techniques and 
indirectly using cytosol binding (Carvalho & Pariante, 2008). This provides an indication 
of the number of receptors within the cells. Measuring the number of corticosteroid 
receptors is an indicator of glucocorticoid sensitivity, but does not provide information 
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about the biological effectiveness of the receptor (Quax et al., 2013). Examining the rate 
of translocation of the corticosteroid receptors into cell nuclei also provides another proxy 
of receptor function.  
 2.10 Psychosocial stress and the corticosteroid receptors 
To date, a number of studies have examined the effects of both chronic and acute stress 
on corticosteroid receptor sensitivity. Before describing this body of literature it is worth 
noting that the majority of research has focused on the sensitivity of the GR, with very 
little attention paid to the MR. I will first describe studies that have looked at associations 
between chronic stress and corticosteroid receptor sensitivity, and then move on to 
describe studies of the effects of acute stress on receptor sensitivity in the laboratory. 
 2.10.1 Chronic stress and corticosteroid receptor sensitivity 
Many types of chronic stressors, including negative emotional disorders, have been found 
to affect the sensitivity of GRs (See Table 2.1). Associations between job strain and 
glucocorticoid resistance have been reported. In a study measuring vital exhaustion in 
male industrial employees, those who were highly exhausted had reduced GR sensitivity 
compared to non-exhausted employees (Wirtz et al., 2003). Highly exhausted employees 
also had elevated levels of CRP. However, a recent study reported increased GR 
sensitivity and function in 12 men suffering from job-related exhaustion compared to 12 
matched healthy controls (Menke et al., 2014). In 46 healthy school teachers, those who 
reported high levels of effort-reward imbalance at work had reduced GR sensitivity 
compared to those with low effort-reward imbalance (Bellingrath, Rohleder, & Kudielka, 
2013). In a study assessing the effects of academic stress on glucocorticoid resistance in 
11 healthy students, the authors compared glucocorticoid sensitivity in lymphocytes one 
hour before an examination and also on a control day during a holiday period (Sauer et 
81 
 
al., 1995). They found that academic stress resulted in a decrease in cortisol inhibition of 
lymphocyte IL-2 production, implying reduced lymphocyte sensitivity to cortisol. The 
authors posit that exposure of lymphocytes to increased cortisol levels during the pre-
exam stress period may have resulted in a loss of GR sensitivity. This reduction in 
sensitivity could be an adaptive response to short-term hypercortisolism. However, the 
small sample size means that results should be interpreted with caution.  
Reduced lymphocyte sensitivity to cortisol has also been reported in elderly caregivers of 
dementia patients compared to elderly non-caregivers (Bauer et al., 2000). Miller and 
colleagues reported decreased dexamethasone suppression of LPS-induced IL-6 
production in whole blood of parents of children with cancer compared to parents of 
healthy children, indicating reduced GR sensitivity to dexamethasone (Miller, Cohen, & 
Kim, 2002). These same parents also reported high levels of psychological distress, and 
had flatter cortisol slopes across the day. However, in a recent study there were no 
significant differences in GR protein levels or hydrocortisone suppression of LPS-
induced IL-6 production from monocytes in adult caregivers of family members with 
glioblastoma compared with controls whose lives were free of major stressors (Miller et 
al., 2014).  The authors posit that hydrocortisone could be acting on the MR which may 
be why there were no significant differences in the caregiver sample.  
Reduced GR sensitivity has also been reported in those suffering from emotional 
disorders. Women with major depressive disorder were shown to have diminished GR 
sensitivity compared to healthy controls, and this diminished sensitivity was associated 
with flatter diurnal cortisol slopes (Jarcho et al., 2013). A systematic review of 34 studies 
examining associations between early life stress, depression, and GR and MR sensitivity 
found that early life stress leads to reduced inhibitory feedback of the HPA axis via  
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Table 2.1. Studies examining the effects of chronic stress on corticosteroid receptor function 
Author/date Sample Study design 
Chronic stress type GR/MR measurement 
protocol 
Statistical test and 
covariates 
Main findings 
Sauer et al. (1995) 11 healthy students (6 
female), mean age 19y 
Differences in 
glucocorticoid 
sensitivity during 
examination period 
and holiday period 
Academic stress  Cortisol suppression of 
PHA-induced lymphocyte 
proliferation in isolated 
PBMCs 
Spearman’s rank 
correlations; no 
covariates 
Academic stress was associated 
with reduced glucocorticoid 
sensitivity, implying reduced 
sensitivity of the corticosteroid 
receptors. 
Bauer et al. (2000) 49 spousal caregivers 
of dementia patients 
(24 female), mean age 
72y, 67 matched non-
caregiver controls 
Differences in 
glucocorticoid 
sensitivity between 
elderly caregivers and 
non-caregivers 
Caregiver stress DEX and cortisol 
suppression of PHA-
induced lymphocyte 
proliferation in isolated 
PBMCs 
ANOVA; no 
covariates 
Caregivers had reduced 
glucocorticoid sensitivity 
compared to non-caregivers, 
implying reduced sensitivity of 
the corticosteroid receptors.  
Miller et al. (2002) 25 parents of children 
undergoing cancer 
treatment (mean age 
36y), 25 matched 
controls with healthy 
children 
Differences in 
glucocorticoid 
sensitivity between 
both groups of parents 
Chronic psychological 
stress of having a child 
who is undergoing 
treatment for cancer 
DEX suppression of LPS-
induced IL-6, IL-1β, and 
TNF-α production in 
whole blood 
ANOVA; baseline 
cytokine values 
Parents of children with cancer 
had reduced GR sensitivity 
compared to parents of 
medically healthy children. 
They also had flatter cortisol 
slopes. 
Wirtz et al. (2003) 325 healthy adults (280 
male), mean age 40y 
Difference in 
glucocorticoid 
sensitivity between 
those who are non-
exhausted, and highly 
exhausted 
Vital exhaustion in 
industrial employees 
DEX suppression of LPS-
induced IL-6 production 
in whole blood 
ANOVA; no 
covariates 
Men who were highly 
exhausted had reduced GR 
sensitivity compared to those 
who were non-exhausted, but 
not those who were moderately 
exhausted.  
DEX = dexamethasone; DST = dexamethasone suppression test; ERI = effort-reward-imbalance; GLM= general linear model; GR = glucocorticoid receptor; IL-1β = interleukin-1β; IL-6 = 
interleukin-6; LPS = lipopolysaccharide; PHA = phytohaemagglutinin (stimulates lymphocyte proliferation); PBMC = peripheral blood mononuclear cell; TNF-α = tumour necrosis factor 
– α; TSST = Trier Social Stress Test; WC = waist circumference. 
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Table 2.1 (continued) Studies examining the effects of chronic stress on corticosteroid receptor function 
Author/date Sample Study design 
Chronic stress type GR/MR measurement 
protocol 
Statistical test and 
covariates 
Main findings 
Bellingrath et al. 
(2013)* 
46 healthy adults (29 
female), mean age 50y. 
Associations between 
chronic stress and GR 
responses to the TSST 
in the lab 
ERI at work and the 
TSST 
DEX suppression of LPS-
induced IL-6 production 
in whole blood 
ANCOVA; gender, 
BMI, depression 
scores 
High levels of ERI were 
associated with decreased GR 
sensitivity both before and 
after acute stress, compared to 
low levels of ERI.  
Menke et al. 
(2014) 
12 men suffering from 
job-related exhaustion 
(mean age 45y), and 12 
matched healthy 
controls 
Difference in GR 
sensitivity and function 
between exhausted and 
non-exhausted men 
Job-related exhaustion GR sensitivity: DST in 
vivo, GR function: DEX 
induced gene expression 
GLM, linear 
regression; age, 
BMI 
Enhanced GR sensitivity and 
function in those suffering 
from exhaustion. 
Miller et al. (2014) 33 caregivers of 
relatives with cancer 
(21 female, mean age 
54y) and 47 non-
caregiving matched 
controls 
Difference in GR 
sensitivity between 
caregivers and non-
caregivers 
Caregiver stress GR sensitivity: 
hydrocortisone 
suppression of LPS-
induced IL-6 production 
in monocytes; monocyte 
expression of GR protein 
levels measured using 
flow cytometry 
Generalised 
estimating 
equations; age, sex, 
ethnicity, education, 
smoking, alcohol 
intake, physical 
activity, WC.  
Both groups had similar levels 
GR protein levels.  
 
No difference in GR sensitivity 
between groups.  
DEX = dexamethasone; DST = dexamethasone suppression test; ERI = effort-reward-imbalance; GLM= general linear model; GR = glucocorticoid receptor; IL-1β = interleukin-1β; IL-6 = 
interleukin-6; LPS = lipopolysaccharide; PHA = phytohaemagglutinin (stimulates lymphocyte proliferation); PBMC = peripheral blood mononuclear cell; TNF-α = tumour necrosis factor 
– α; TSST = Trier Social Stress Test; WC = waist circumference. 
*Although study includes an acute psychosocial stress measure, the relevant associations are between a measure of chronic stress and GR sensitivity 
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changes in GR and MR sensitivity, and the subsequent development of depression  (von 
Werne Baes, de Carvalho Tofoli, Martins, & Juruena, 2012). However, within this review 
there was large methodological variation between studies which may have affected the 
conclusions drawn. Instead of measuring sensitivity of receptors, some studies have 
examined the number of corticosteroid receptors within each cell as a proxy for their 
sensitivity. Calfa and colleagues found that depressed patients had reduced GR numbers 
in PBMCs compared to healthy controls (Calfa et al., 2003). 
Together, this body of research indicates that chronic stress, including depression, results 
in decreased sensitivity of the GR. Pariante and colleagues posit that this diminished GR 
sensitivity brings about impaired feedback inhibition of the HPA axis, thus explaining the 
enhanced cortisol stress reactivity seen in major depression (Pariante, Thomas, 
Lovestone, Makoff, & Kerwin, 2004). As well as shutting down the cortisol stress 
response, the GR are also responsible for regulating the magnitude of the response. This 
means that diminished GR sensitivity could also explain the blunted cortisol stress 
reactivity observed in older and more severely depressed patients (Burke et al., 2005; 
Taylor et al., 2006). Interestingly, the MR appears to be slightly oversensitive in 
depressed patients (Young, Lopez, Murphy-Weinberg, Watson, & Akil, 2003). As the 
MR regulates basal activity of the HPA axis, altered MR sensitivity may have 
implications for the dysregulation of diurnal HPA axis activity brought about by 
depression. It is therefore likely that depression is characterised by an imbalance of both 
GR and MR sensitivity (de Kloet, DeRijk, & Meijer, 2007). This imbalance in sensitivity 
likely has consequences for levels of inflammation in the body also. In support of this, a 
number of the studies outlined above reported higher levels of inflammation and signs of 
HPA axis dysregulation (i.e. flatter diurnal cortisol slopes) within samples experiencing 
stress-related loss in GR sensitivity. This all lends support to the notion that over time, 
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chronic stress brings about dysregulation of the HPA axis and increased systemic 
inflammation via diminished sensitivity of the corticosteroid receptors.  
 2.10.2 Acute stress and corticosteroid receptor sensitivity 
Looking at the effects of acute stress on GR and MR sensitivity may shed some light on 
how stress-related loss of receptor sensitivity comes about. The effects of acute stress on 
corticosteroid receptor function have been examined in a number of studies. 
 2.10.2.1 Acute exercise stress and GR sensitivity 
Most of the early studies used exercise paradigms to examine acute stress-induced 
changes in receptor sensitivity to cortisol. DeRijk and colleagues examined the effects of 
dexamethasone on LPS-induced production of IL-6 in whole blood in healthy men 
exposed to graded exercise on a treadmill (DeRijk et al., 1996). Following exercise, more 
dexamethasone was required to inhibit the LPS-induced release of IL-6 indicating a 
reduction in GR sensitivity. The effects of dexamethasone on LPS-induced release of IL-
6, TNF-α, IL-10 and interferon (IFN)-γ in whole blood were examined in nine well-
trained oarsmen who underwent strenuous exercise for a 15-20 minute period (Smits, 
Grünberg, Derijk, Sterk, & Hiemstra, 1998). Similar to the results of DeRijk and 
colleagues, following exercise, the inhibitory effect of dexamethasone on IL-6 and TNF-
α secretion was reduced indicating reduced GR sensitivity. However, dexamethasone 
effects on IL-10 and IFN-γ release were not altered by exercise.  
In contrast to the results of these studies, Duclos and colleagues looked at the effects of 
an acute bout of exercise on sensitivity to cortisol in the isolated cultured monocytes of 
endurance-trained men (n=6) and found an exercise-induced increase in GR sensitivity 
(Duclos et al., 1999). Similarly, in a more recent study, an acute resistance exercise 
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protocol in resistance-trained men and women (n=15) brought about increased GR 
expression in lymphocytes (Fragala et al., 2011). The reason for the discrepancy in results 
between exercise studies may be the use of different culture conditions across studies 
(Rohleder et al., 2003). As mentioned previously, performing glucocorticoid sensitivity 
assays in whole blood, as opposed to isolated PBMCs, does not take into account 
individual variability in white blood cell population ratios. 
 2.10.2.2 Acute psychosocial stress and GR sensitivity: Murine studies 
The effects of acute psychosocial stress on GR sensitivity have largely been investigated 
in animals. Sheridan and colleagues subjected mice to social reorganisation (SRO) and 
measured GR sensitivity using a synthetic glucocorticoid suppression test on proliferation 
of splenocytes (Sheridan, Stark, Avitsur, & Padgett, 2000). SRO stress involves randomly 
housing groups of male mice separately for two weeks in order for stable social 
hierarchies to form. The dominant mouse from each group is then transferred to a different 
cage where it is perceived as an aggressive intruder. This is stressful for both the resident 
mice and the intruder. The authors found that proliferation of splenocytes was inhibited 
in a dose-dependent manner by glucocorticoids in control mice, whereas proliferation of 
splenocytes in the SRO mice was resistant to glucocorticoid suppression. This indicates 
reduced GR sensitivity in the SRO mice brought about by acute psychosocial stress.  
Similarly, Stark and colleagues demonstrated that the splenocytes of SRO mice were 
resistant to the antiproliferative effects of corticosterone compared to control mice, 
suggesting a decrease in GR sensitivity following bouts of acute psychosocial stress 
(Stark et al., 2001). SRO exposure in mice has also been shown to downregulate the 
expression of GR mRNA (Quan et al., 2001). In all studies, resistance to glucocorticoids 
developed following repeat, but not acute, exposures to SRO, and the resistance persisted 
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for 10 days after the stress exposure ended (Avitsur, Stark, Dhabhar, Padgett, & Sheridan, 
2002). Similarly, Bauer and colleagues showed that repeated exposure to restraint stress 
induced a slight increase in glucocorticoid resistance, i.e. decreased GR sensitivity 
(Bauer, Perks, Lightman, & Shanks, 2001). However, acute exposure did not induce any 
significant changes in GR sensitivity.  
 2.10.2.3 Acute psychosocial stress and corticosteroid receptor sensitivity: 
 Human studies 
To date, five studies have assessed the effects of acute psychosocial stress on 
corticosteroid receptor sensitivity in humans. In these studies, participants were exposed 
to a number of behavioural tasks known to induce activation of the HPA axis stress 
response. In all studies (see Table 2.2) receptor sensitivity was measured using 
dexamethasone suppression of LPS-induced cytokine production in whole blood (see 
Section 6.8.2 for a more detailed description of this procedure). The first study measured 
sex differences in GR sensitivity following acute psychosocial stress in healthy young 
men and women (Rohleder, Schommer, Hellhammer, Engel, & Kirschbaum, 2001). 
Twenty-seven men and 18 women in the luteal phase of their menstrual cycle were 
exposed to the TSST (Kirschbaum, Pirke, & Hellhammer, 1993). Men and women did 
not differ in their salivary cortisol responses to acute stress. However, GR sensitivity 
showed marked gender differences. Examination of the inhibitory concentration 50% 
(IC50) of dexamethasone revealed that one hour after stress GR sensitivity had 
significantly increased in men, whereas sensitivity had decreased in women, although this 
change failed to achieve statistical significance. In agreement with these findings, the 
authors report that IL-6 levels one hour post-stress had significantly decreased in men but 
remained unchanged in women.  
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The second study measured age and sex-steroid related differences in GR sensitivity 
following acute psychosocial stress in healthy elder men (n=14), healthy young men 
(n=14), and healthy elder men who had received a testosterone injection five days prior 
to testing (n=12) (Rohleder, Kudielka, Hellhammer, Wolf, & Kirschbaum, 2002). All 
participants underwent the TSST. An hour after the stress protocol there were no 
differences between groups in terms of stress-induced increases in cortisol. However, GR 
sensitivity as indexed by the IC50 of dexamethasone was significantly increased in the 
younger men, and significantly decreased in the older men. Interestingly, testosterone-
treated older men showed the same significant increase in GR sensitivity as the healthy 
younger men. These findings provide further evidence that acute stress modulates GR 
sensitivity. Furthermore, they indicate that GR sensitivity in response to stress changes 
with age and that these changes are associated with the presence of sex steroids.  
The third study examined the effects of oral contraception on GR sensitivity after acute 
psychosocial stress (Rohleder, Wolf, Piel, & Kirschbaum, 2003). Previous research has 
shown that women taking oral contraceptives have blunted cortisol responses to stress 
(Kirschbaum, Kudielka, Gaab, Schommer, & Hellhammer, 1999). HPA axis activation 
and GR sensitivity were measured in 14 women using oral contraception and 11 women 
in the luteal phase of the menstrual cycle that underwent the TSST. Following stress, 
luteal phase women showed an increase in cortisol whereas the contraceptive users 
showed blunted cortisol stress responses. Luteal phase women exhibited a non-significant 
decrease in GR sensitivity. Women taking oral contraceptives displayed an increase in 
GR sensitivity following acute stress. The authors posit that this increase in GR sensitivity 
is an adaptive response to the blunting of the cortisol stress reactivity which may protect 
women using oral contraceptives from the inflammatory stress response.  
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Table 2.2. Studies examining the effects of acute stress on corticosteroid receptor function 
Author/date Sample Study design 
Stress 
paradigm 
GR/MR measurement 
protocol 
Statistical test and 
covariates 
Main findings 
 
Rohleder et al.  
(2001) 
 
45 healthy adults (18 
women), mean age 25y   
 
Difference between 
men and women in GR 
sensitivity following 
acute stress 
 
TSST 
 
DEX suppression of LPS-
induced IL-6 and TNF-α 
production in whole blood 
 
ANOVA; no 
covariates 
 
Basal GR sensitivity lower in men. 
Increase in GR sensitivity in men, and a 
non-sig decrease in women 60 mins after 
acute stress 
Rohleder et al. 
(2002) 
40 healthy men, 14 young 
(mean age 25y), 14 elderly 
(mean age 67y), 12 elderly 
+ testosterone treatment 
(mean age 68y) 
Difference between 
young men, elderly 
men, and elderly men + 
testosterone in GR 
sensitivity following 
acute stress 
TSST DEX suppression of LPS-
induced IL-6 and TNF-α 
production in whole blood 
ANOVA; no 
covariates 
Basal GR sensitivity lower in younger 
men. 
Increase in GR sensitivity in young and 
testosterone-treated elderly men, non-sig 
decrease in elderly men, 60 mins after 
acute stress.  
Rohleder et al. 
(2003) 
25 healthy women , 14 
taking OC (mean age 22y), 
11 OC-free (mean age 
25y)  
Difference between 
women taking OC, and 
women not, in GR 
sensitivity following 
acute stress  
TSST DEX suppression of LPS-
induced IL-6 and TNF-α 
production in whole blood 
ANOVA; no 
covariates 
No difference in basal GR sensitivity 
Increase of GR sensitivity in OC users, no 
sig. change in women not taking OC.  
DEX = dexamethasone; GLM= general linear model;  GR = glucocorticoid receptor; IL-6 = interleukin-6; LPS = lipopolysaccharide; MR = mineralocorticoid receptor; OC = oral 
contraception; PRED = prednisolone; TNF-α = tumour necrosis factor – α; TSST = Trier Social Stress Test.  
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Table 2.2. (Continued) Studies examining the effects of acute stress on corticosteroid receptor function 
Wirtz et al. 
(2008) 
42 healthy men (mean age 
43y) 
Association between 
BMI and GR 
sensitivity following 
acute stress 
TSST DEX suppression of LPS-
induced TNF-α production 
in whole blood 
ANCOVA, GLM; 
baseline GR 
sensitivity, age, 
mean arterial 
pressure 
Basal GR sensitivity not associated with 
BMI. 
Higher BMI associated with decrease in 
GR sensitivity after acute stress 
Carvalho et al. 
(2015) 
74 older adults, 37 with 
T2DM (mean age 64y), 32 
healthy controls (mean age 
67y) 
 
Difference between 
adults with T2DM and 
healthy controls in GR 
and MR sensitivity 
following acute stress 
2x 5 min 
behavioural 
tasks 
DEX and PRED 
suppression of LPS-
induced IL-6 production in 
whole blood 
GLM; BMI, time of 
session 
T2DM group had higher GR sensitivity at 
baseline, but not MR sensitivity. 
Decrease in GR and MR sensitivity in 
healthy controls, no change on T2DM 
DEX = dexamethasone; GLM= general linear model;  GR = glucocorticoid receptor; IL-6 = interleukin-6; LPS = lipopolysaccharide; MR = mineralocorticoid receptor; OC = oral 
contraception; PRED = prednisolone; T2DM = type 2 diabetes; TNF-α = tumour necrosis factor – α; TSST = Trier Social Stress Test.  
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The fourth study investigated whether BMI affected changes in GR sensitivity following 
acute psychosocial stress (Wirtz, Ehlert, Emini, & Suter, 2008). Forty-two men 
underwent the TSST. BMI was not associated with either diurnal or stress-induced 
cortisol secretion. However, results indicated that a higher BMI was associated with a 
more pronounced loss of GR sensitivity following acute stress. The authors suggest that 
this could be a pathway through which BMI might alter the stress response in ways that 
are detrimental to cardiovascular health.  
The fifth study carried out by our group examined both GR and MR sensitivity to acute 
stress in 37 people with type 2 diabetes and 37 healthy controls (Carvalho et al., 2015). 
People with type 2 diabetes have an increased risk of CVD as well as impairments of the 
HPA axis (Bruehl et al., 2007; Hackett, Steptoe, & Kumari, 2014). MR sensitivity was 
measured using prednisolone suppression of LPS-induced cytokine production in whole 
blood (see Section 6.8.2 for a full description of the procedure). Prednisolone is a 
synthetic glucocorticoid that binds to both the GR and the MR. Mental stress was induced 
using two 5-minute behavioural tasks.  Following stress, the healthy controls (mean age 
= 67.5 years) exhibited a decrease in both GR and MR sensitivity, which is in line with 
the previous finding that GR sensitivity decreases in healthy older men (Rohleder et al., 
2002). However, there was no change in GR or MR sensitivity in those with type 2 
diabetes. The diabetic patients also had blunted stress responses in terms of systolic blood 
pressure, heart rate, and levels of IL-6. The authors suggest that the impaired stress 
responsivity in type 2 diabetes is in part due to a lack of stress-induced alterations in GR 
and MR sensitivity. 
Apart from this fifth study, very little work has been done examining the effects of acute 
stress on the MR. Studies have shown that MR antagonists such as spironolactone result 
in increased basal cortisol levels and increased cortisol responses to exercise stress 
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(Heuser, Deuschle, Weber, Stalla, & Holsboer, 2000; Wellhoener, Born, Fehm, & Dodt, 
2004). A common polymorphism in the MR gene has been associated with higher cortisol 
responses to acute stress (DeRijk et al., 2006). As the MR and GR work in concert to 
regulate the cortisol and inflammatory stress response, future stress research should 
examine both GR and MR sensitivity in order to gain further understanding of the link 
between stress and CVD.  
Therefore, the third study of this PhD presented in Chapter 6 will examine the 
effects of an acute psychosocial stress paradigm on both GR and MR sensitivity in 
healthy volunteers.  
To summarise, results from studies examining the effects of acute stress on corticosteroid 
receptor sensitivity have been mixed. Murine studies suggest that acute stress brings 
about a decrease in GR sensitivity. However, it could be argued that these studies adopt 
a sub-chronic stress paradigm as the effects on GR sensitivity are only seen after repeated 
exposures to the stressor. Human studies have provided varied data on the effects of both 
exercise and psychosocial stress on GR sensitivity. The main conclusion that can be 
drawn from results so far is that acute stress modulates GR sensitivity. There is rather 
large variability in corticosteroid receptor sensitivity in humans with regards to sex, age, 
sex steroid hormone status, BMI, as well as diabetes status.  
2.11 Chapter summary 
Although the direction of results is mixed, psychosocial stress factors and negative 
emotional disorders appear to be associated with dysregulation of both basal and stress-
related HPA axis function. Dysregulation of both basal and stress-related HPA axis 
function has been associated with markers of cardiovascular risk and have been seen in 
CVD patients. This evidence suggests that dysregulation of the HPA axis is likely one of 
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the biological pathways through which psychosocial stress contributes to the 
pathophysiology of CVD.  
The evidence also suggests that alterations in the sensitivity of the corticosteroid receptors 
may be one of the mechanisms through which psychosocial stress brings about sustained 
changes in HPA axis function. The studies cited in the previous sections provide support 
for the notion that stress modulates corticosteroid sensitivity. Reduced GR sensitivity has 
been reported in depression. Chronic life stressors, such as job stress and caregiver stress, 
have been shown to reduce GR sensitivity also. Repeated stress ‘hits’ over time may result 
in a loss of receptor sensitivity, thereby leading to dysregulated cortisol secretion, and 
increased systemic inflammation. For example, in CHD patients, 24-hour cortisol 
secretion is higher than healthy controls and this is accompanied by higher levels of CRP 
and IL-6 (Nijm et al., 2007). This implies diminished corticosteroid receptor sensitivity 
in these patients. 
Data from studies assessing the effects of acute stress on corticosteroid receptor 
sensitivity are more mixed. There is a large amount of variability in GR sensitivity 
following stress in humans with regards to sex, age, and BMI. Moreover, work examining 
the effects of acute stress on MR sensitivity is scarce. Nevertheless, results of these 
studies show that acute stress does modulate corticosteroid receptor sensitivity. Taken 
together, the evidence suggests that dysregulation of the HPA axis, via stress-related 
modulation of the corticosteroid receptors, is one of the biological pathways linking 
psychosocial stress and CVD.  
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Chapter 3 
Study 1 - Diurnal cortisol rhythm and adverse clinical outcomes in patients with  
       advanced CVD: The ARCS Study 
3.1 The Adjustment and Recovery after Cardiac Surgery (ARCS) Study 
Coronary artery bypass graft (CABG) surgery is used to relieve symptoms and improve 
life-expectancy in those suffering from advanced coronary heart disease. The ARCS 
Study was designed to investigate the causes and consequences of poor physical and 
emotional wellbeing following CABG surgery, and the implications for patient quality of 
life and physical recovery. Five sets of factors potentially relevant to emotional and 
physical quality of life post-CABG surgery were the focus of the study: (1) clinical 
factors, e.g. existing heart problems and illness as well as factors pertaining to the surgery 
itself, (2) cognitive factors, e.g. cognitive function as well as the patients’ ability to 
understand health information, (3) social factors, e.g. social support, (4) emotional 
factors, e.g. depression and anxiety, (5) biological factors, e.g. inflammatory markers 
measured in the blood and salivary cortisol measured across the day.  
The ARCS Study used a prospective longitudinal design with a number of assessment 
periods spanning up to 2.68 years after the CABG procedure. Patients were recruited at 
their surgical pre-assessment clinic and were assessed approximately one month prior to 
their surgery (T1), 4-5 days after their surgery while still in hospital care (T2), 8-10 weeks 
after surgery (T3), and 12 months after surgery (T4). At each time point, participants were 
asked to complete a questionnaire pack and provide saliva samples across the day for 
measurement of diurnal cortisol profiles (saliva was not provided at the visit 4-5 days 
after surgery). Blood measures were taken prior to surgery and in the days following 
surgery in order to measure markers of inflammation. Approximately 2.5 years following 
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the procedure, long term clinical outcomes for each patient were collected from electronic 
and paper medical records (T5). This included mortality data, development of post-
surgical infections, any cardiac or non-cardiac related hospital readmissions, adverse 
cardiac events, occurrence of other cardiac procedures or tests (e.g. angiogram, 
percutaneous coronary intervention), occurrence of new onset depression or anxiety, and 
diagnoses of any other major illnesses.  
3.2 My contribution to the ARCS Study 
As part of a team of several ARCS Study researchers, I was involved in study recruitment 
and data collection at all time-points. I recruited a large number of patients at their 
surgical pre-assessment. As well as explaining the study to the patient and obtaining 
informed consent, this also involved administering a short cognitive examination and 
health literacy test, as well as organising blood sample collections for each patient. In 
terms of data collection, I carried out a large number of on-ward structured interviews 
with patients approximately 4-5 days after surgery. I also sent questionnaire and saliva-
collection packs to patients at the 8-10 week and 12 month follow-up points. Additionally, 
I was responsible for prompting patients over the telephone who may have forgotten to 
return their questionnaire packs in the post.  
My largest contribution to the ARCS Study was the collection of the long-term clinical 
outcomes which I was responsible for. In the early stages of my PhD, I spent a number of 
months on site at St. George’s hospital collecting long-term clinical outcome data for each 
individual patient from electronic and paper medical records.  
Additionally, I was largely involved in ARCS Study data entry as well as maintenance of 
the dataset. Furthermore, I have been involved in data analysis. To date, I have produced 
two first-author publications using ARCS data, and have contributed to several other 
96 
 
ARCS Study publications. (Kidd et al., 2014; Kidd, Poole, Leigh, et al., 2016; Kidd, 
Poole, Ronaldson, et al., 2016; Poole et al., 2015; Poole, Kidd, et al., 2014a, 2014b, 2016; 
Poole, Leigh, et al., 2014; Poole, Ronaldson, et al., 2016; Ronaldson et al., 2014, 2015; 
Steptoe et al., 2015).  
3.3 Differentiating my PhD from the ARCS Study 
The ARCS Study is a multidisciplinary study involving several researchers. This study 
has produced a rich dataset containing information pertaining to the five sets of factors 
outlined previously. Accordingly, many issues have been and will be investigated that are 
beyond the scope of my PhD. In my PhD, I used pre-surgical data from T1 of the ARCS 
Study to examine the association between pre-surgical diurnal cortisol rhythm and major 
adverse cardiac events (MACE) and death (T5 data) in patients with advanced heart 
disease undergoing CABG surgery. I also used T1 data to cross-sectionally explore what 
psychosocial stress factors may be affecting diurnal HPA axis function. Results from this 
study have been published in the Journal of Clinical Endocrinology & Metabolism 
(Ronaldson et al., 2015). 
3.4 Introduction 
As mentioned previously in this thesis, there is growing evidence that the HPA axis plays 
a role in the progression of CVD. Elevated 24h urinary cortisol has been found to predict 
cardiovascular death in older people both with and without CVD (Vogelzangs et al., 
2010). Higher serum cortisol has also been associated with cardiovascular mortality in a 
cohort of patients with mood disorder (Jokinen & Nordström, 2009). However, the role 
of the HPA axis in patients with advanced CVD is less clear. Higher serum cortisol levels 
have been found to predict both mortality risk and risk of future cardiac events in chronic 
heart failure (Güder et al., 2007; Yamaji et al., 2009) and ischaemic stroke (Barugh, Gray, 
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Shenkin, MacLullich, & Mead, 2014). However, results from studies of cortisol in acute 
coronary syndrome have been less consistent (Jutla, Yuyun, Quinn, & Ng, 2014; 
Reynolds et al., 2010).  
One difficulty in interpreting this evidence is that cortisol is typically measured with a 
single serum sample. Inconsistencies in associations between cortisol and CVD may be 
because the diurnal nature of cortisol is not being taken into account. More detailed 
measurement of the diurnal cortisol profile would allow for a more in depth investigation 
of the associations between cortisol and clinical endpoints in CVD patients. 
Dysregulation of the HPA axis can result in a reduction in the amplitude of the diurnal 
pattern, or a flatter slope across the day. As mentioned earlier in Chapter 2, flatter cortisol 
slopes have been associated with higher levels of coronary artery calcification (Hajat et 
al., 2013; Matthews et al., 2006), and increased cardiovascular mortality in nonclinical 
populations (Kumari et al., 2011). 
There is a paucity of studies examining the effects of variations in diurnal cortisol rhythms 
on future cardiac events and mortality in patients with established CVD. This study 
therefore sought to examine the relationship between pre-surgical diurnal cortisol and 
clinical outcomes in patients undergoing CABG surgery.  
 3.4.1 Hypotheses 
Based on previous research, I hypothesised that a flatter diurnal cortisol slope before 
surgery would be associated with higher rates of future cardiac events and mortality in 
the years following CABG. I also examined associations between the cortisol awakening 
response (CAR) and total cortisol output across the day, and adverse clinical outcomes. 
However, in keeping with previous research I did not expect to find significant 
associations with these cortisol parameters (Kumari et al., 2011; Matthews et al., 2006). 
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As a flatter diurnal slope could reflect a negative psychosocial stress profile I carried out 
exploratory analyses examining cross-sectional associations between pre-surgical cortisol 
slopes and psychosocial stress variables, namely stressful life events, depression, anxiety, 
and social support, in order to garner information about stress-related factors that may 
bring about dysregulation of the HPA axis. I hypothesised that flatter cortisol slopes 
would be associated with more depressive symptoms, higher levels of anxiety, more 
stressful life events, and low social support.  
3.5 Materials and methods 
 3.5.1 Participants 
The data we used in this analysis were collected as part of the ARCS Study, involving 
patients undergoing first-time elective CABG surgery or CABG plus valve replacement. 
CABG surgery in a single centre (Steptoe et al., 2015) included both on-pump and off-
pump procedures. All procedures were carried out with written informed consent of the 
participants. Ethical approval was obtained from the National Research Ethics Service.  
Participants were 262 prospective CABG patients who were recruited from a pre-surgical 
assessment clinic at St. George’s Hospital, London. Eligible participants had to be at least 
18 years of age and had to be able to complete questionnaires in English. Long term 
recovery outcomes were collected from electronic and paper patient records on average 
2.68 years (SD = 0.40) after surgery. We carried out analyses on 250 patients with 
complete data on clinical outcomes and cortisol slope. There were no significant 
associations between the use of steroid medications and cortisol output, outcome 
variables or covariates (all p values > 0.05). Therefore patients taking steroid medications 
(n = 8) were included in the analyses.  
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There were no significant differences between patients included in and excluded from the 
analyses in terms of age, sex, BMI, smoking status, length of hospital stay, the occurrence 
of major adverse cardiac events (MACE), chronic disease burden, diabetes status, or 
whether or not the person had on-pump surgery (all p values < 0.05). However, European 
System for Cardiac Operative Risk Evaluation (EuroSCORE) was higher in the 12 
patients without cortisol data (F(2, 345) = 5.23, p = 0.006) indicating poorer prognosis 
on average. Patients included in the analyses did not differ from those excluded in terms 
of any of the psychosocial stress variables (all p values < 0.05). 
 3.5.2 Biological and clinical measures 
Diurnal salivary cortisol 
At the pre-surgical assessment clinic (T1) participants received a saliva collection kit and 
were given instructions for collection at home. The kit included seven pre-labelled 
‘salivette’ collection tubes (Sarstedt, Leicester, UK) and a cortisol diary. The cortisol 
diary contained instructions on how and when to give samples (Appendix A). These 
diaries were also used to record information on factors likely to introduce variation in 
cortisol samples such as mood, exercise, and daily stressors. Participants were instructed 
to choose one day prior to surgery on which to provide seven saliva samples at set time 
points: on waking, 30 minutes after waking (30+), 10am, 12pm, 4pm, 8pm, and bedtime. 
Participants stored their samples in the refrigerator before returning them to the clinic. 
The samples were obtained an average 30.6 days (SD = 36.9) prior to surgery and were 
stored at -20°C for analysis at a later date. Cortisol levels were assessed from saliva using 
a time resolved immunoassay with fluorescence detection at the University of Dresden, 
Germany. The intra- and inter-assay coefficients of variation were less than 4%. 
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We computed three different cortisol measures. Total cortisol output over the day was 
assessed by calculating the cortisol AUC with respect to ground (Pruessner, Kirschbaum, 
Meinlschmid, & Hellhammer, 2003). The CAR was calculated by measuring the 
difference between the sample taken on waking and the 30+ sample. In line with other 
work produced by Steptoe’s group, participants who reported giving their first sample 
more than 15 minutes after waking were excluded from the analyses. Previous research 
has shown that a long delay between waking and providing the ‘waking’ sample can 
produce misleading CAR results, but a delay of less than 15 minutes between waking and 
providing the sample does not seem problematic (Dockray, Bhattacharyya, Molloy, & 
Steptoe, 2008). An expert panel recently recommended that CAR data should be excluded 
if the waking sample is provided with a delay of 5 minutes or more. However, the same 
expert panel also stated that this tight accuracy margin would result in substantial data 
loss (26-46%) and therefore researchers need to choose between scientific precision and 
practical feasibility (Stalder et al., 2016). A number of previous studies have selected an 
accuracy margin of <15 minutes (DeSantis, Adam, Mendelsohn, & Doane, 2010; 
Dockray et al., 2008; Okun et al., 2010). In order to see if the accuracy margin would 
affect results obtained, CAR was also calculated using an accuracy margin of <5 minutes. 
The implications of selecting these accuracy margins for the current study will be 
addressed in the Discussion (Section 3.7). The cortisol slope was calculated in nmol/l/h 
by regressing cortisol on sample collection time, with 30+ excluded (Messerli-Bürgy et 
al., 2012); higher values indicate a steeper decrease in cortisol over the day. Waking and 
evening (the average of 8pm and bedtime) values were also calculated.  
Participants were to be excluded from analysis if any cortisol value exceeded 70 nmol/L. 
No participants had cortisol values that exceeded this limit. Cortisol slope was calculated 
if the participant had at least four available cortisol measures (excluding the 30+ morning 
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sample). 250 patients provided sufficient saliva samples for the calculation of cortisol 
slope. The CAR was calculated for 179 patients as 70 patients reported providing their 
waking sample more than 15 minutes after waking, and one patient failed to provide a 
waking sample. Cortisol AUC was calculated only for those who provided all seven saliva 
samples. Therefore, cortisol AUC was calculated for 220 patients as 30 failed to provide 
all samples.  
Long term clinical outcomes 
Long term clinical outcomes included in this study were occurrence of a MACE and death 
(all-cause mortality) and were collected up to 2.68 years after surgery (T5). Post-operative 
MACE included admissions for myocardial infarction, unstable angina, stroke, and/or 
heart failure. Occurrence of MACE was treated as a binary variable where either no 
MACE occurred or ≥1 MACE occurred. Mortality and MACE data were gathered by 
reviewing in-hospital electronic and paper patient records.   
3.5.3 Psychosocial stress variables 
A number of measures from the ARCS study were selected for use in this thesis in order 
to assess cross-sectional associations between pre-surgical psychosocial stress variables 
and pre-surgical diurnal salivary cortisol. The stress variables included in the analyses 
were depressive symptoms, anxiety, stressful life events, and social support. These 
measures were completed an average 29.1 (SD = 29.7) days prior to surgery.  
Depressive symptoms 
Depressive symptoms were measured using the Beck Depression Inventory (BDI) (Beck, 
Steer, & Carbin, 1988). The BDI can be used to measure depressive symptoms in both 
psychiatric and non-psychiatric healthy individuals, and has been found to be preferable 
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to the Hospital Anxiety and Depression Scale (HADS) for measuring depressive 
symptoms in cardiac patients (Thombs et al., 2006). It comprises 21 items that are scored 
on a scale ranging from 0-3, with total scores ranging from 0-63. Higher scores indicate 
greater emotional disturbance. Respondents are asked to provide answers that best 
describe the way they have been feeling over the past two weeks.  The Cronbach’s alpha 
for the BDI in this sample was 0.85. 
Figure 3.1. Flow diagram of participant recruitment and attrition from the ARCS Study  
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Anxiety 
Anxiety was measured using the seven-item anxiety subscale of the HADS (Zigmond & 
Snaith, 1983). This subscale was favoured over other anxiety questionnaires due to its 
brevity. Each item is scored on a scale ranging from 0-3, with total scores ranging from 
0-21. Items are summed to generate a total score, with reverse coding on item 4 (‘I can 
sit at ease and feel relaxed’). The anxiety subscale of the HADS has been shown to be 
suitable for use in cardiac patients (Roberts, Bonnici, Mackinnon, & Worcester, 2001). 
The Cronbach’s alpha for the HADS anxiety subscale in this sample was 0.88. 
Stressful life events 
A modified version of the chronic burden scale used in the Multi-Ethnic Study of 
Atherosclerosis was used to measure stressful life events in the current sample (Diez Roux 
et al., 2006). The chronic burden scale comprises five items that ask respondents to report 
ongoing difficulties or stress in five areas of life: health of self, health of others, job or 
ability to work, financial strain, and relationships. In the ARCS study two extra items 
were added in order to measure ongoing difficulties relating to grief or bereavement, and 
living conditions. Patients were coded as having difficulty or stress in one of the areas of 
life if they reported a moderately stressful or severely stressful ongoing problem that had 
been present for six months or more. The stressful life events score was the number of 
items a patient reported having difficulty with (range 0-7). Associations between pre-
surgical cortisol and individual items pertaining to each area of life were also examined.  
Social support 
Social support was measured using the ENRICHD Social Support Instrument (ESSI). The 
ESSI is a validated seven-item scale used to assess the quality of social support and was 
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developed specifically for use in the ENRICHD study of cardiac patients (Mitchell et al., 
2003). The items relate to structural (partner), instrumental (tangible), and emotional 
(caring) support. Items are scored on a five-point Likert scale ranging from 1 ‘None of 
the time’ to 5 ‘All of the time’. Responses to item 7 (‘Are you currently married or living 
with a partner?’) were scored 4 ‘Yes’ or 2 ‘No’ in accordance with scoring guidelines. 
Total scores range from 8-34 with higher scores indicating greater social support. The 
Cronbach’s alpha for this sample was 0.93. 
 3.5.4 Covariates: clinical and sociodemographic factors 
Cardiovascular history and clinical factors during admission and management (length of 
hospital stay, whether the patient had on-pump surgery) were obtained from clinical 
notes. Clinical risk was assessed using the EuroSCORE (Roques, Michel, Goldstone, & 
Nashef, 2003). EuroSCORE is a combined measure of procedural mortality risk based on 
17 factors comprising patient-related factors (e.g. age, sex), cardiac-related factors (e.g. 
unstable angina, recent MI), and surgery-related factors (e.g. surgery on thoracic aorta). 
Items were scored in accordance with the ‘logistic EuroSCORE’ method to generate a 
percentage mortality risk estimate; further details of the scoring method can be found on 
the EuroSCORE website (www.euroscore.org/logisticEuroSCORE.htm). In addition, we 
recorded whether a patient underwent cardiopulmonary bypass. History of diabetes was 
taken from medical notes, categorising patients as diabetic or non-diabetic. 
Participants were asked to report any longstanding illnesses apart from heart disease prior 
to surgery (e.g. cancer, thyroid disorder); responses were summed to compute a chronic 
illness burden variable. Smoking was measured as a binary variable (current smoker/non-
smoker). BMI was assessed at the pre-operative clinic appointment and calculated using 
the standard formula (kg/m2).   
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 3.5.5 Statistical analyses 
A composite outcome was created combining MACE and mortality. Cox proportional 
hazards models were used to determine relationships between cortisol before surgery and 
clinical outcome; when a patient experienced more than one MACE, the earliest time 
interval from baseline was analysed. Separate models were fitted for the cortisol slope 
over the day, cortisol AUC, CAR, and waking and evening cortisol values.  
Because of the low number of clinical events (n = 18), only three covariates were included 
in the Cox regression models in order to avoid over-fitting. Therefore we included those 
covariates deemed most clinically relevant: EuroSCORE, whether the patient underwent 
cardiopulmonary bypass, and chronic illness burden. Age and sex were not adjusted for 
separately in the Cox regression models as both age and sex are included in the 
EuroSCORE. 
In order to garner information about psychosocial factors which may influence diurnal 
cortisol measures, cross-sectional associations between pre-surgical psychosocial stress 
variables and cortisol were examined using Pearson’s correlations. Statistically 
significant correlations were then entered into simple age and sex-adjusted linear 
regression models, with the psychosocial variable acting as the predictor and the cortisol 
variable as the outcome.  
Associations between pre-surgical cortisol and covariates were examined using Pearson’s 
correlations for continuous data and independent t-tests for categorical variables. 
Differences between mean cortisol values between patients who died or experienced a 
MACE and patients who experienced no event were examined using independent t-tests.  
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The significance level was set to p < 0.05 for all analyses, with precise p values reported 
for all test results. All statistical analyses were performed using SPSS version 22.0 (SPSS 
Inc., Chicago, Illinois, USA). 
3.6 Results 
Table 3.1 summarises the characteristics of the patients. The sample had an age range of 
44-90 years, was predominantly male (86.4%), and overweight (BMI>25 = 81.6%). Just 
under a quarter of the patients were diabetic (24%). The majority had on-pump 
cardiopulmonary bypass surgery (79.2%). In the years following surgery (M = 2.68 years, 
SD = 0.40) nine patients (3.6%) experienced a MACE and 10 patients (4%) died, with 
one individual experiencing both outcomes. 
 
Table 3.1. Demographic, cortisol, and clinical characteristics of the sample (n=250) 
 Characteristic Mean ± SD or n(%) 
Age (years) 68.1±8.9 
Female 34(13.6) 
BMI (kg/m2) 28.8±4.4 
Smoker 20(8.0) 
Ethnicity (white) 219(87.6) 
Co-morbidities  
Diabetes 60(24.0) 
Chronic illness burden   
              No other chronic illness 156(62.4) 
              1 other chronic illness 74(29.6) 
              2 other chronic illnesses 20(8.0) 
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Table 3.1. (continued) Demographic, cortisol, and clinical characteristics of the sample (n=250) 
 Characteristic Mean ± SD or N(%) 
Pre-surgical measures of cortisol  
Slope (nmol/L/hr) 1.67±1.31 
Area under the curve (nmol/L.hr) 147.9±46.2 
Waking cortisol (nmol/L) 19.4±8.7 
Time of waking (hh:mm) 06:56±01:12 
Average evening cortisol (nmol/L) 4.37±3.81 
Clinical factors  
Logistic EuroSCORE (%) 4.49±3.06 
Number of grafts 2.97±1.13 
On-pump 198(79.2) 
Long-term recovery  
Major adverse cardiac event 9(3.6) 
Deceased 10(4.0) 
Psychosocial stress variables  
Depressive symptoms 8.54±6.55 
Anxiety 5.87±4.33 
Stressful life events 1.32±1.27 
Social support 28.7±5.7 
 
 
Figure 3.2 depicts the mean cortisol profiles across the day of patients who either died or 
experienced a MACE, and patients who experienced no events in the years following 
bypass surgery. Cortisol slope, cortisol AUC, CAR, and waking cortisol levels were not 
significantly associated with EuroSCORE, cardiopulmonary bypass, or chronic illness 
burden. Evening cortisol levels were associated with EuroSCORE (r = 0.14, p = 0.030) 
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but not with cardiopulmonary bypass or chronic illness burden. Occurrence of death or 
MACE following surgery was associated with EuroSCORE (r = 0.24, p < 0.001), and 
chronic illness burden (r = 0.19, p = 0.003).    
In terms of psychosocial stress variables, patients scored relatively low on measures of 
depression and anxiety and had experienced roughly one stressful life event in the 
previous six months (Table 3.1). Social support as measured by the ESSI appeared to be 
relatively high in this sample (M =28.7, SD = 5.7). 
 3.6.1 Pre-surgical cortisol and clinical outcomes 
Diurnal cortisol slope predicted the occurrence of death or MACE following CABG 
surgery (hazard ratio = 0.73, 95% CI = 0.56 – 0.96, p = 0.023) (see Table 3.2). Patients 
with a steeper cortisol decline over the day were at reduced risk of experiencing adverse 
clinical outcomes (Table 3.2). More specifically, these results indicate that for every 1 
nmol/l/h  increase in cortisol slope the risk of death or MACE fell by 27%. Chronic illness 
burden (p = 0.035) and EuroSCORE (p = 0.002) also predicted death or MACE following 
surgery. 
These results indicate that higher illness burden and a worse EuroSCORE were associated 
with negative outcomes in the years following surgery. These analyses were repeated 
after excluding immediate events (3 events) that occurred in the 5 day post-operative 
period. A steeper pre-surgical cortisol slope remained predictive of reduced risk of 
adverse clinical outcomes (hazard ratio = 0.70, 95% CI = 0.52 – 0.94, p = 0.017).  For 
every nmol/l/hr increase in cortisol slope, the risk of death or MACE after the 5-day post- 
operative period fell by 30%. These survival analyses were carried out treating cortisol 
slope as a continuous variable, but for descriptive purposes participants were split into 
two equal groups based on cortisol slope using a median split. Cortisol changes over the 
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day ≤1.68 nmol/l/h were considered indicative of ‘flatter’ slopes. Kaplan-Meier survival 
plots of the two groups are shown in Figure 3.3. This plot reveals that divergence in 
survival/occurrence of MACE as a function of cortisol slope emerges very soon after 
CABG surgery. 
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Table 3.2. Results of Cox regression analysis; showing predictive effects of cortisol slope and covariates 
on the occurrence of MACE and/or death in the years following CABG surgery* 
Variable Coefficient (B) SE Wald χ2  p  HR 95% CI 
Cortisol slope -0.31 0.14 5.16 .023 0.73 0.56–0.96 
Chronic illness burden 0.67 0.32 4.46 .035 1.96 1.05-3.65 
EuroSCORE 0.18 0.06 9.27 .002 1.20 1.07-1.35 
Bypassa -0.28 0.67 0.18 .670 0.75 0.20-2.79 
*This model includes MACE/mortality cases that occurred within the 5 day post-operative period 
aWhether the patient underwent cardiopulmonary bypass (on pump/off pump) 
Figure 3.2. Mean salivary cortisol values sampled on waking, waking+30mins, in the morning (10am), 
at noon, in the afternoon (4pm), evening (8pm), and at bedtime, in patients who experienced death or 
MACE in the years following surgery (pink line) and in patients who experienced no events (blue line). 
Error bars represent SEM. 
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A flatter cortisol slope across the day can be due to low cortisol output on waking and/or 
higher evening cortisol values. We therefore examined associations between both waking 
and evening cortisol and clinical outcome. Waking cortisol was inversely associated with 
clinical outcome (hazard ratio = 0.93, 95% CI = 0.88 – 0.98, p = 0.011) suggesting that 
higher cortisol output on waking is linked to event-free survival. Evening cortisol levels 
were also significantly associated with clinical outcome (hazard ratio = 1.09, 95% CI = 
1.01 – 1.17, p = 0.019) indicating that higher evening cortisol is linked to MACE or death 
in the years following surgery. So the relationship between cardiac morbidity and flatter 
slope appeared to result both from lower cortisol on waking and higher cortisol in the 
evening.  
 
 
Figure 3.3. Kaplan-Meier survival curves for patients split into two equal groups at the median 
diurnal cortisol slope. This median split was performed only for illustrative purposes.  
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We also examined the association between cortisol AUC and adverse clinical outcomes 
(Table 3.3). Pre-surgical AUC did not predict survival or the occurrence of a MACE in  
 
Table 3.3. Results of Cox regression analysis, showing predictive effects of cortisol AUC and covariates 
on the occurrence of MACE and/or death in the years following CABG surgery* 
Variable Coefficient (B) SE Wald χ2 p HR 95% CI 
Cortisol AUC 0.00 0.00 0.32 .575 1.00 1.00-1.00 
Chronic illness burden 0.49 0.36 1.90 .169 1.63 0.81-3.29 
EuroSCORE 0.18 0.06 7.47 .006 1.19 1.05-1.35 
Bypassa -0.04 0.80 0.00 .962 0.96 0.20-4.58 
*This model includes MACE/mortality cases that occurred within the 5 day post-operative period 
a Whether the patient underwent cardiopulmonary bypass (on pump/off pump) 
 
 
Table 3.4. Results of Cox regression analysis, showing predictive effects of CAR and covariates on the 
occurrence of MACE and/or death in the years following CABG surgery* 
Variable Coefficient (B) SE Wald χ2 p HR 95% CI 
CAR (<15m delay) -0.01 0.03 0.03 .871 0.99 0.94-1.05 
CAR (<5m delay) -0.01 0.04 0.06 .813 0.99 0.91-1.07 
Chronic illness burden 0.48 0.42 1.33 .249 1.62 0.71-3.69 
EuroSCORE 0.18 0.08 5.03 .025 1.53 1.02-1.39 
Bypass 0.43 1.07 0.16 .690 1.19 0.19-12.6 
*This model includes MACE/mortality cases that occurred within the 5 day post-operative period 
 
 
the years following bypass surgery (p = 0.27). Excluding death or MACE that occurred 
in the 5 day post-operative period did not change these results.  Similarly, pre-surgical 
CAR did not predict survival or MACE occurrence in the years following bypass surgery 
regardless of the accuracy margin used (<15 min delay: p = 0.87, <5 min delay: p = 0.81) 
(Table 3.4). This association also remained non-significant after excluding death or 
MACE that occurred in the 5 day post-operative period. 
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As mentioned in Section 3.5.5 age and sex were not adjusted for separately in the Cox 
regression models as both age and sex are accounted for in the EuroSCORE. However, 
exploratory analysis revealed that after simple adjustment for age and sex, cortisol slope 
no longer significantly predicted survival or MACE occurence (p = 0.07), whereas sex 
did (hazard ratio = 3.91, 95% CI = 1.47 – 10.4, p = 0.006). This will be discussed as a 
limitation in Section 3.7. 
 3.6.2 Pre-surgical cortisol slope and psychosocial stress variables 
 
Since pre-surgical cortisol slope was associated with the occurrence of death or MACE, 
one possibility is that it reflects a negative psychosocial stress profile, and that this in turn 
might be related to cardiovascular morbidity. I therefore computed cross-sectional 
associations between pre-surgical cortisol slope and psychosocial stress variables; I 
hypothesised that steeper cortisol slopes would be related to fewer depressive symptoms, 
lower anxiety, fewer stressful life events, and greater social support. These results are 
summarised in Table 3.5. Interestingly, cortisol slope was not associated with any of the 
 
Table 3.5. Cross-sectional associations between pre-surgical cortisol slope, and waking and evening 
levels, and psychosocial stress variables 
  Depressive 
symptoms 
Anxiety Stressful life 
events 
Social support 
 r p r p r p r p 
Cortisol slope -0.83 .193 -0.01 .822 -0.09 .131 0.04 .555 
Waking cortisol -0.13 .040 -0.03 .638 -0.09 .170 0.10 .113 
Evening cortisol 0.04 .523 0.02 .751 0.01 .863 -0.03 .646 
 
psychosocial stress variables (all p values > 0.05). We also examined associations 
between waking and evening cortisol, and the psychosocial stress variables. Waking 
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cortisol was not correlated with anxiety symptoms (r = -0.05, p = 0.64), stressful life 
events (r = -0.09, p = 0.17), or social support (r = 0.10, p = 0.11). However, there was a 
significant correlation between depressive symptoms and waking cortisol (r = -0.13, p = 
0.040). This indicates that higher levels of waking cortisol were associated with lower 
depressive symptoms. As mentioned previously, higher waking cortisol levels were also 
linked to event-free survival. However, the association between depressive symptoms and 
waking cortisol levels became non-significant in a simple age- and sex-adjusted linear 
regression (p = 0.13). There were no significant associations between evening cortisol 
levels and any of the psychosocial stress variables (all p > 0.05). 
3.7 Discussion 
 3.7.1 Summary of results 
As hypothesised, the results of the study suggest that a flatter diurnal cortisol slope prior 
to surgery predicts the occurrence of MACE or mortality in CABG patients. Cortisol was 
sampled a month before surgery, so does not reflect acute anticipatory stress responses 
prior to surgery. Our findings suggest that a flatter cortisol slope is related to poorer long-
term outcomes in a patient sample with advanced CVD following bypass surgery, and 
that this association is being driven by alterations in both waking and evening cortisol. 
These associations were independent of EuroSCORE, whether or not the patient 
underwent cardiopulmonary bypass, and chronic illness burden. There was no association 
between pre-surgical CAR or cortisol AUC and adverse clinical outcomes in the years 
following surgery. Contrary to expectation, there were no significant relationships 
between cortisol slope and depressive symptoms, anxiety, stressful life events, or social 
support. Higher waking cortisol was associated with lower depression scores. However, 
this association did not survive a simple age- and sex-adjusted linear regression.  
114 
 
 3.7.2 Comparison to previous research 
To my knowledge, this is the first study to examine the association between diurnal 
cortisol and the occurrence of MACE or mortality in the years following CABG surgery. 
These findings are in line with research which has reported associations between flatter 
diurnal slopes and adverse clinical events in other serious illnesses. For example, a flatter 
cortisol slope has been found to predict worse prognosis and mortality in metastatic breast 
cancer, lung cancer, and epithelial ovarian cancer (Schrepf et al., 2015; Sephton et al., 
2013; Sephton, Sapolsky, Kraemer, & Spiegel, 2000). Patients with heart disease have 
been found to have a flatter cortisol rhythm compared with healthy controls (Nijm, 
Kristenson, Olsson, & Jonasson, 2007). However, as mentioned previously 
Bhattacharyya and colleagues found no significant difference in cortisol slope between 
patients with CAD and healthy controls (Bhattacharyya et al., 2008). What the authors 
did find was that cortisol slopes were flatter in CAD patients who were depressed (ibid). 
In the current study we found no association between depressive symptoms and cortisol 
slope. Therefore, the association between cortisol rhythm and mortality and adverse 
events in the current sample indicates that HPA axis dysregulation may increase with 
disease progression.    
Our results indicate that both waking and evening cortisol levels predicted adverse 
outcomes for CABG patients, so the adverse effects of flatter profiles are not the result 
only of reduced waking concentration or elevated evening values. Kumari and colleagues 
found that an association between flatter cortisol slope and CVD mortality in a nonclinical 
sample was driven primarily by changes in evening levels of cortisol only (Kumari et al., 
2011). One reason for this discrepancy may be that HPA axis dysregulation has 
progressed further in individuals with advanced CVD. Fatigue and vital exhaustion are 
associated with cortisol output, as well as being risk factors for the occurrence of adverse 
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cardiac events over time (Nicolson & van Diest, 2000; Williams et al., 2010). 
Associations between lower levels of waking cortisol and fatigue have been reported in 
older adults and coronary artery disease patients (Bunevicius et al., 2012; Kumari et al., 
2009). Breast cancer survivors suffering from fatigue have been found to have flatter 
diurnal cortisol slopes than survivors without fatigue (Bower et al., 2005). It is possible 
that fatigue or exhaustion may be a factor influencing the association between lower 
waking cortisol and adverse outcomes in the current study.  
3.7.3 Potential mechanisms explaining the link between diurnal cortisol rhythm 
and adverse outcomes 
It is likely that one of the factors contributing to the link between cortisol rhythm and 
MACE/mortality in these patients is inflammation. As mentioned before, cortisol exerts 
an immunomodulatory effect on inhibiting the release of pro-inflammatory cytokines. 
Therefore, dysregulation of the HPA axis in these patients may lead to sustained high 
levels of inflammation (Nijm & Jonasson, 2009). A flattened cortisol slope has been 
associated with higher levels of circulating of IL-6 in CHD (Nijm et al., 2007), epithelial 
ovarian cancer (Schrepf et al., 2015) and metastatic colorectal cancer (Rich et al., 2005).  
CABG surgery leads to substantial increases in cortisol concentration that decline over 
the post-operative period, and is coupled with alterations in sensitivity to ACTH 
(Gibbison et al., 2015). Mechanistically, dysregulation of the HPA axis in these patients 
was likely caused in part by diminished sensitivity of the GR and MR. Diminished GR 
sensitivity has been associated with a flatter diurnal cortisol slope (Jarcho et al., 2013). It 
is possible that the association between diurnal cortisol slope and MACE observed in the 
current study reflects reduced sensitivity of the corticosteroid receptors. Future research 
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should simultaneously assess both diurnal cortisol rhythm and GR and MR function in 
CVD patients. 
 3.7.4 CAR: Lack of association 
In this study I found no association between the CAR and the overall cortisol output 
(AUC) and MACE or mortality following CABG surgery. One possibility regarding the 
CAR is that the chosen accuracy margin of <15 minutes between waking and providing 
the waking sample was too wide which went on to attenuate CAR estimates (Stalder et 
al., 2016). However, using a smaller accuracy margin of <5 minutes also produced non-
significant results. This indicates that the CAR was not associated with adverse clinical 
outcomes in this patient sample. Interestingly, there is evidence that the CAR is under a 
regulatory cycle distinct from the other diurnal cortisol parameters (Clow et al., 2004) 
which may in part explain why associations were seen between cortisol slope and adverse 
outcomes, but not the CAR. A previous study examining associations between diurnal 
cortisol rhythm and cardiovascular mortality in a non-clinical sample also found no 
significant associations with the CAR (Kumari et al., 2011). Similarly, cortisol AUC also 
was not associated with coronary artery calcification in a non-clinical population 
(Matthews et al., 2006).  A study of lung cancer survival also found that cortisol AUC 
had no predictive value in terms of mortality (Sephton et al., 2013). This adds support to 
the notion that measuring cortisol slope across the day is likely to be a more useful 
prognostic tool than the awakening response or total cortisol output. Inflammatory 
cytokines exhibit distinct diurnal patterns that are inversely related to the diurnal rhythm 
of cortisol (Petrovsky, McNair, & Harrison, 1998). Diurnal cortisol rhythm may then be 
a more useful prognostic tool as it reflects dysregulation of inflammation, whereas the 
CAR or total cortisol output does not.  
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 3.7.5 Psychosocial stress: Lack of association 
Flatter diurnal cortisol rhythms have been associated with a number of psychosocial stress 
factors, such as depression, chronic stress, and work stress (Bhattacharyya et al., 2008; 
Liao et al., 2013; Miller et al., 2007). Many of these factors are associated with CHD 
incidence (Steptoe & Kivimäki, 2012), and also contribute to recurrent events and 
mortality in patients with advanced CVD (Meijer et al., 2011). However, in the current 
study we found no associations between flatter cortisol slopes and any of the psychosocial 
stress variables measured. When examining waking and evening levels of cortisol 
separately, we did find that depressive symptoms were negatively correlated with levels 
of waking cortisol. In the current study, higher waking cortisol levels were also linked to 
event-free survival, meaning that depressive symptoms may play a role in this link. 
However, the correlation did not survive a simple age- and sex-adjusted regression 
indicating that the association between depressive symptoms and cortisol profiles in these 
patients is tenuous at best. Previous research has shown that waking cortisol levels are 
increased in depressed individuals and in people at risk of depression (Bhagwagar, Hafizi, 
& Cowen, 2005; Mannie, Harmer, & Cowen, 2007) which may be why the association 
reported in the current study disappeared after adjustment for age and sex.  
One of the reasons why we may not have found cross-sectional associations between the 
psychosocial stress variables and diurnal cortisol rhythm in this study is that our patient 
sample was relatively unstressed. That is, they had a rather low number of stressful life 
events, low depression and anxiety scores, and high levels of social support. It may be 
that the association between stress and diurnal cortisol profiles in the current study were 
too weak to detect. Future research of this kind should seek to include more stress-related 
measures such as early childhood adversity, and measures of perceived stress. Another 
possibility is that because patients all had advanced coronary artery disease, cortisol was 
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driven more by the physiological dysregulation associated with the disease itself rather 
than psychosocial factors. 
 3.7.6 Strengths and limitations 
A strength of this study is that cortisol was measured repeatedly across a day several 
weeks before surgery. The pattern of output may therefore represent habitual profiles 
rather than being affected by acute anticipation of hospitalisation. Had cortisol been 
measured the day before surgery, for example, there may have been alterations in the 
normal diurnal cortisol profiles of the patients. Anticipation of a stressful event has been 
shown to result in an elevated CAR (Wetherell et al., 2015) and acute stress has also been 
found to affect cortisol slope and evening levels (Hulme, French, & Agrawal, 2011).  
The study had a prospective design and attrition was low, with ascertainment of clinical 
outcomes in more than 95% of participants. However, the sample size was relatively 
small, with MACE and death occurring in only 18 participants (19 events). The ARCS 
study was not specifically designed to investigate cortisol and cardiac outcomes, and this 
limited statistical power and reduced the number of covariates that could be included in 
the analyses. Larger studies of patients with advanced cardiac disease are needed to 
establish the robustness of the findings. Our sample was largely composed of white men 
of European origin. Additionally, this sample also appeared to be particularly well-
adjusted in terms of psychosocial stress factors. Thus, the results may not be readily 
generalizable to other groups. We were unable to access information about specific causes 
of death for all patients who died. Therefore, specific associations between dysregulation 
of the HPA axis and CVD mortality could not be assessed. It is possible that a number of 
these patients died from non-cardiac causes. Nevertheless, since all these patients had 
advanced CHD, this is likely to have been the cause of the majority of deaths.  
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Another issue is that cortisol was measured over a single day meaning that the diurnal 
rhythm may have been affected by situational factors related to that particular day, rather 
than long-term factors. Measurement over several days might provide a more robust 
estimate of stable individual differences in the diurnal cortisol profile.  Previous research 
has shown that measurement of CAR and AUC data over a single day is affected more 
by situational rather than trait factors (Hellhammer et al., 2007). However, these same 
authors argue that measures of CAR and AUC are predominantly affected by trait factors 
on weekdays, and situational factors on weekend days. In the current study, cortisol was 
measured over the course of a weekday which may help counteract the effects of single-
day sampling. Furthermore, previous studies of the stability of cortisol across days have 
been predominantly based on younger people (students or working adults) in which 
factors related to demands on different days are accentuated. Our sample had an average 
age of 68 years, and most patients were retired. Their habits may be less variable across 
days, meaning that a single day could be more representative than in younger people. 
Nonetheless, these measurement issues should be borne in mind while interpreting these 
results. Another factor which may have influenced cortisol secretion in this sample was 
the inclusion of patients who use steroid medications. Synthetic corticosteroids are known 
to affect the negative feedback regulation of the HPA axis and also potentially affect the 
immunoassays used to measure cortisol (Granger, Hibel, Fortunato, & Kapelewski, 
2009). Consequently inclusion of these patients may have influenced the results of this 
study. However, the use of steroid medications was not associated with any of the cortisol 
parameters. Therefore these participants were included in the analysis in order to increase 
statistical power.  
Additionally, night-time cortisol was not measured so it was not possible to assess total 
24 hour cortisol exposure. Cortisol levels reach their nadir at about midnight (Adam & 
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Kumari, 2009) and increase slowly throughout the night remaining at low levels at 
waking. In the current study there was an association between low levels of waking 
cortisol and adverse long-term clinical outcomes. Therefore, examining the gradual night-
time increase in these patients would have been of interest. Sleep complaints have been 
shown to play a role in adverse recovery following CABG surgery (Poole, Kidd, et al., 
2014b) indicating that poor sleep quality in these patients may be a relevant factor in their 
night-time/waking cortisol profiles.  
Furthermore, these data do not provide direct evidence of a causal connection between 
diurnal cortisol slope and MACE or mortality in these patients; although we included 
important clinical covariates, there might be unmeasured factors influencing diurnal 
cortisol rhythms that also increased risk of adverse outcomes. For example, both BMI 
(Champaneri et al., 2013) and smoking (Badrick, Kirschbaum, & Kumari, 2007) have 
been shown to affect diurnal cortisol profiles, as well as adverse clinical outcomes in 
CVD patients (Critchley & Capewell, 2003). However, I was unable to control for these 
factors in the main analysis due to the relatively low number of events in the study. 
Additional exploratory analyses were carried out in order to see if other factors might 
influence adverse clinical outcomes in these patients. Adding BMI, smoking, sleep 
disturbance, depression, or anxiety to the model did not affect the association between 
cortisol slope and adverse clinical outcomes. Furthermore, none of these factors were 
significantly associated with adverse outcomes in these patients.  
However, additional exploratory analysis revealed that after simple adjustment for age 
and sex, cortisol slope was no longer significantly associated with MACE or mortality, 
whereas sex was. This may be because women who undergo coronary revascularisation 
generally experience greater complications and mortality post-surgically (Kim, Redberg, 
Pavlic, & Eagle, 2007) due to older age at diagnosis, increased thrombotic complications, 
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and anatomical mechanisms such as smaller coronary arteries compared to men 
(Swaminathan et al., 2016). Future research in CABG patients should seek to have a more 
balanced gender ratio.  
 3.7.7 Conclusion 
In conclusion, these results indicate that a flatter diurnal cortisol slope prior to surgery is 
associated with poorer long-term outcomes in patients undergoing coronary 
revascularisation. They provide evidence for a possible role of HPA axis dysregulation in 
CVD and indicate that more pronounced dysregulation may be a marker of more 
advanced disease progression in CVD patients. On the other hand, the results tell us little 
about what brings about HPA axis dysregulation in these patients. In the following 
chapter I will introduce the Stress Pathways Study which was designed to examine the 
effects of pharmacological blockade on a number of stress-related biological factors 
including HPA axis function. The results of the Stress Pathways Study may tell us more 
about how dysregulation of HPA axis functioning comes about.  
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Chapter 4 
The Stress Pathways Study: Introduction and methods 
4.1 The Stress Pathways Study  
As outlined in Chapter 2, to date, evidence for the role of HPA axis dysregulation in the 
stress-CVD link has been provided by both observational studies and 
psychophysiological laboratory stress testing. One way in which more in-depth 
information about stress-related biological pathways can be derived is through the use of 
pharmacological blockade experiments. In these experiments, putative pathways are 
pharmacologically blocked and effects on stress-related biological systems are measured.  
The Stress Pathways Study was set up in order to investigate the psychobiological 
mechanisms through which psychosocial stress is thought to contribute to the 
development of CVD. This study was a randomised controlled trial (RCT) which assessed 
the effects of pharmacological blockade on a number of biological and psychological 
responses to acute laboratory stress. More specifically, healthy volunteers were 
randomised to receive short-term doses of escitalopram (a selective serotonin reuptake 
inhibitor (SSRI)), propranolol (a beta-blocker), or placebo, and the effects of these drugs 
on responses to acute psychosocial stress in the laboratory were measured.  
The Stress Pathways Study was primarily designed to assess the effects of 
pharmacological intervention on inflammatory responses to acute stress. SSRIs and beta-
blockers were selected mainly due to their relevance to inflammation. In principle, the 
inflammatory stress response may be partially regulated by processes at two levels – the 
central and peripheral. SSRIs induce changes in central neurotransmitter function. In 
addition to their ability to alter the reuptake of serotonin, SSRIs exert anti-inflammatory 
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actions and it is thought that this is one of the ways in which they impact upon depressed 
mood (Walker, 2013). Therefore, SSRIs were selected for inclusion in the study as it is 
plausible that SSRI-induced changes in the CNS may attenuate the inflammatory stress 
response. Beta-blockers were chosen in order to assess effects of changes in the peripheral 
nervous system, and the impact of sympathetic activation on the inflammatory stress 
response. Both short- and long-term administration of beta-blockade have been shown to 
reduce basal levels of inflammatory cytokines in murine models (Nguyen et al., 2008), as 
well as in CHD, heart failure, and cardiomyopathy patients (Aronson & Burger, 2001; 
Jenkins, Keevil, Hutchinson, & Brooks, 2002; Ohtsuka et al., 2001). Therefore, beta-
blockade may plausibly reduce inflammatory responses to acute stress.  
The inflammatory markers measured in the Stress Pathways Study included IL-6, IL-1Ra, 
and monocyte chemotactic protein 1 (MCP-1). Markers of endothelial dysfunction were 
also analysed. Secondary aims of the study also included assessment of the effects of 
pharmacological interventions on cardiovascular parameters, neuroendocrine parameters, 
and a number of psychosocial factors. Cardiovascular parameters included blood 
pressure, heart rate, and cardiac index. Neuroendocrine parameters included cortisol 
stress reactivity and corticosteroid receptor function. The effects of the pharmacological 
probes on diurnal cortisol profiles were also assessed prior to the stress laboratory visit. 
A number of psychosocial factors were measured via self-report. These included 
depressive symptoms, anxiety, perceived stress, affect, sleep quality, optimism, and a 
number of health behaviours including smoking, alcohol intake, and physical activity.  
4.2 Differentiating my PhD from the Stress Pathways Study  
The Stress Pathways Study was a multidisciplinary study involving several researchers 
that produced a rich dataset containing information about a number of stress-related 
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biological and psychological parameters. As mentioned above, the primary focus of the 
Stress Pathways Study was to assess the effects of SSRIs and beta-blockers on 
inflammatory responses to acute psychosocial stress in a laboratory setting. My PhD 
study was an extension of this larger study that had related but different aims. Primarily, 
I sought to use the Stress Pathways Study as an opportunity to investigate the impact of 
acute psychosocial stress on corticosteroid receptor sensitivity and cortisol stress 
reactivity. I also sought to assess the effects of the pharmacological probes on both 
corticosteroid receptor sensitivity and cortisol stress reactivity in order to gain insight into 
some of the biological mechanisms involved. Additionally, I also examined the effects of 
SSRIs and beta-blockers on diurnal cortisol rhythm outside of the laboratory in order to 
learn more about what might bring about dysregulation of the HPA axis. The focus of the 
following chapters (Chapters 5 and 6) will be on the effects of the study medications on 
these three aspects of HPA axis function. Detailed reviews of the literature examining the 
effects of beta-blockers and SSRIs on basal/diurnal HPA axis function, and cortisol stress 
reactivity and corticosteroid receptor function will be provided in Chapters 5 and 6 
respectively.   
4.3 The pharmacological probes 
We chose to assess the effects of seven-day administration of SSRIs and beta-blockers on 
biological responses to acute psychophysiological stress. Originally these drug types were 
chosen to further explore their known effects on inflammatory aspects of the stress 
response. Therefore, these pharmacological interventions may not be the most suited to 
eliciting information about the biological pathways involved in dysregulation of the HPA 
axis, and the link with CVD. The effects of these drugs on certain aspects of HPA axis 
function have been investigated previously and detailed literature reviews will be 
provided in Chapters 5 and 6. However, overall the effects of these drugs on stress-related 
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and basal HPA axis function are not very well-known and therefore relatively exploratory. 
The implications of these drug choices for this PhD thesis will be dealt with in detail in 
the final Discussion chapter (Chapter 7).  
Specifically, we chose to assess the effects of the beta blocker propranolol and the SSRI 
escitalopram in the Stress Pathways Study for reasons outlined below.    
 4.3.1 Beta-blocker: Propranolol 
The SNS is one of the major systems activated during the stress response. Its effectors 
epinephrine and norepinephrine are released from the adrenal glands via stimulation from 
the brain stem during times of stress. These catecholamines serve to initiate the ‘fight or 
flight’ response resulting in increased heart rate, respiratory rate, as well as energy 
mobilisation within cells throughout the body. Beta-blockers are antihypertensive agents 
also used to treat tremors and anxiety. Their mechanism of action is believed to be through 
blocking the effects of catecholamines on β-adrenoreceptors, thereby reducing cardiac 
output, and attenuating the pressor response to catecholamines during times of stress and 
anxiety (Ripley & Saseen, 2014).  
Beta-blockers are widely prescribed in the treatment of hypertension and have a wide 
survival benefit for those with CHD and heart failure (Gorre & Vandekerckhove, 2010). 
Beta-blockers may partially exert their therapeutic effect by altering the biological stress 
response in a way that is beneficial for cardiac health. As mentioned previously, beta-
blockers have been shown to reduce basal levels of inflammation in CHD patients 
(Jenkins et al., 2002). Beta-blockers also attenuate cardiovascular responses to acute 
stress (Mills & Dimsdale, 1991), and have been shown to mitigate the natural killer cell 
stress response (Benschop et al., 1994). The release of natural killer cells is activated by 
a number of pro-inflammatory cytokines. A decrease in natural killer cell release 
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following stress indicates that beta-blockade may be attenuating the release of these 
cytokines. For these reasons we chose to incorporate beta-blockade into the study. 
Additionally, there is evidence to suggest that using beta-blockers to attenuate 
sympathetic activation will have effects on HPA axis function, and corticosteroid receptor 
function. This evidence will be described in detail in Chapters 5 and 6. 
Specifically, we chose to use the beta-blocker propranolol in the Stress Pathways Study. 
Propranolol was chosen as it is a widely prescribed non-selective beta-blocker. This 
means that it blocks the effects of catecholamines at both β1- and β2-adrenoceptors, rather 
than selectively binding to one or the other. This is useful as both of these receptors are 
involved in the biological stress response (β1 – cardiac output; β2 – ‘fight or flight’). 
Propranolol was also chosen as it does not bind to the α-adrenoceptors. This means that 
any observed effects of propranolol on biological responses to stress in the Stress 
Pathways Study can be ascribed to blockade of the β-adrenoceptors only.  
As propranolol is rapidly metabolised with a plasma elimination half-life of 
approximately 4 hours it normally has to be administered 2-4 times per day (Leahey, 
Neill, Varma, & Shanks, 1980). Therefore, in order to reduce burden we gave participants 
80mg of sustained-release propranolol once a day after breakfast. Participants took this 
every morning for seven days. The 80mg dosage was decided on by a clinical research 
fellow involved in the development of the Stress Pathways Study. This dosage is the 
minimum recommended clinical dosage and therefore was chosen for use in a sample of 
healthy volunteers in order to minimise the likelihood of possible side effects. The seven 
day duration period was chosen to keep participant burden to a minimum.  
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 4.3.2 SSRI: Escitalopram 
Serotonin is a neurotransmitter that is synthesised from its chemical precursor the 
essential amino acid tryptophan in the raphe nuclei of the brain. From these nuclei, 
serotonergic neurons spread to almost all parts of the CNS making the serotonergic 
system one of the most diffuse neurochemical systems in the body (Lanfumey, Mongeau, 
Cohen-Salmon, & Hamon, 2008). A wide variety of functions are controlled in part by 
serotonin such as cardiovascular function and endocrine regulation. SSRIs are the most 
widely prescribed antidepressant drug type. They serve to block the reuptake of serotonin 
resulting in an increase in neurotransmitter availability at the synaptic cleft (Stahl, 1998). 
Depression is one of the most common stress-related disorders, and depression is a known 
independent risk factor for CHD (Nicholson et al., 2006; Van der Kooy et al., 2007). CVD 
patients are also known to have higher levels of depression compared to the general 
population (Hare, Toukhsati, Johansson, & Jaarsma, 2014).   
Seeing as SSRIs are the treatment of choice for depression, and many patients with 
comorbid CVD and depression take SSRIs (Shapiro, 2015), we chose to include this 
medication type in the Stress Pathways Study in order to assess its effects on biological 
responses to stress. These effects on the stress response may be clinically relevant for 
CVD patients. SSRIs also have known influences on cardiovascular responses to stress 
as mentioned in Section 4.1 (Golding et al., 2005; Hanson, Outhred, Brunoni, Malhi, & Kemp, 
2013).  It has been proposed that SSRIs may exert their therapeutic effect via reduction in 
levels of inflammatory cytokines (Hannestad, DellaGioia, & Bloch, 2011). Additionally, 
there is evidence that SSRIs alter HPA axis function in ways that are relevant to the 
therapeutic action of the medication (Pariante, Thomas, et al., 2004). This evidence will 
be described in more detail in both Chapter 5 and 6. Seeing as SSRIs appear to affect a 
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number of the systems involved in the stress response we decided to include this type of 
medication in the study.  
Specifically, we chose to use the SSRI escitalopram in the Stress Pathways Study. 
Escitalopram was chosen based on results from a study which showed that this particular 
SSRI significantly reduced mental stress-induced myocardial ischaemia in patients with 
stable CHD, as well as reducing blood pressure and heart rate responses to stress (Jiang, 
Velazquez, Kuchibhatla et al., 2013).  
Additionally, escitalopram was chosen as it is a fast-acting antidepressant with a rapid 
onset of action compared to other SSRIs (Kasper, Spadone, Verpillat, & Angst, 2006). 
Steady-state concentrations of this medication are achieved within seven days of 
administration (Rao, 2007) which fits with the Stress Pathways Study protocol. In adults 
the dosage for escitalopram may vary from 5 to 20mg once daily. We gave participants 
10mg escitalopram once daily to take after breakfast. We chose this dose for a number of 
reasons. Firstly, previous research where escitalopram has been administered to healthy 
participants have prescribed a 10mg dose (Arce, Simmons, Lovero, Stein, & Paulus, 
2008; Bui et al., 2013; Knorr et al., 2012). Secondly, clinically meaningful effects of 
10mg escitalopram have been seen after one week in patients with major depressive 
disorder (Burke, Gergel, & Bose, 2002; Montgomery, Loft, Sánchez, Reines, & Papp, 
2001; Nierenberg et al., 2007). Thirdly, as we were administering these drugs to non-
depressed healthy volunteers we chose the 10mg dosage to minimise the chance of 
adverse drug effects. 
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4.4 Method 
 4.4.1 Study design 
The Stress Pathways Study was a randomised, double-blind, placebo-controlled, parallel-
groups trial. Participants were randomised to receive 10mg/day escitalopram, 80mg/day 
propranolol, or placebo, for seven days in a double-blind manner using simple random 
allocation. This was carried out using a random number generator and was stratified by 
sex to ensure an equal amount of men and women in each condition. The allocation 
sequence was generated using computer software by a member of departmental staff not 
involved in the Stress Pathways Study. On the sixth day of medication, participants 
provided seven saliva samples across the day for measurement of diurnal cortisol 
secretion. On the seventh day of medication, participants underwent psychophysiological 
stress testing in the laboratory. 
 4.4.2 Sample size 
To date, no study has assessed the effects of SSRIs on inflammatory responses to acute 
mental stress. Therefore, the sample size for the Stress Pathways Study was calculated 
with reference to a previous study looking at the efficacy of aspirin and propranolol in 
attenuating the inflammatory response (IL-6) to stress (von Känel, Kudielka, Metzenthin, 
et al., 2008). In this previous study, propranolol had a small effect size of 0.2 (n = 17 in 
the propranolol group). Due to time and laboratory constraints, the Stress Pathways Study 
aimed to have a sample of 90 participants (n=30 per medication group). We performed 
statistical power analyses using G*Power software which revealed that with a sample of 
90 participants we would have >65% power to detect the effects of propranolol on levels 
of the inflammatory cytokine IL-6. As no previous studies have reported effect sizes for 
associations between beta-blockers, SSRIs and cortisol stress reactivity in the laboratory, 
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power calculations directly relevant to neuroendocrine parameters, and therefore this 
PhD, could not be carried out. 
 4.4.3 Participants 
As mentioned in the previous section, we planned to recruit a sample of 90 participants 
(n=30 per medication group). Participants were recruited in and around UCL campus via 
email and poster advertisements. Participants were then contacted via telephone to screen 
them based upon the inclusion and exclusion criteria detailed below. Participants had to 
be generally healthy, aged between 18-65 years and not taking any medications regularly 
(excluding the contraceptive pill). Specific exclusion criteria included any 
haematological, pulmonary, liver, renal, gastrointestinal, heart, cerebrovascular, and 
psychiatric disease; any history of thromboembolism, and any current infection. 
Participants who suffered from asthma, who had known allergies to any of the study 
medications, previous gastrointestinal bleedings, or who were currently pregnant or 
breastfeeding were excluded. Only patients with blood pressure in the normal range were 
included (90/60mmHg to 140/90mmHg).  Recruitment began in October 2014 and was 
completed in August 2015.  
We recruited 104 healthy men and women in total. Eight participants were excluded 
leaving 96 remaining participants with either complete or partial data.  Out of these eight 
participants, four dropped out due to side effects potentially related to the study 
medications, two failed to turn up to their second study appointment, one participant lost 
their medications, and one participant took cold medication while taking the study 
medication and therefore had to be excluded from the trial. Of the remaining 96 
participants, 94 provided saliva samples for the measurement of diurnal cortisol rhythm, 
91 provided saliva samples in the laboratory for measurement of cortisol stress reactivity, 
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and 85 provided full or partial blood samples in the stress laboratory for the analysis of 
corticosteroid receptor sensitivity, inflammatory cytokines, and markers of endothelial 
dysfunction. Full or partial cardiovascular data from the stress laboratory was gathered 
for 90 participants. A more detailed flow diagram of participant data collection and 
attrition is provided in Figure 4.1. All data were collected with the written informed 
consent of the participants. Ethical approval for the Stress Pathways Study was obtained 
from the UCL Research Ethics Committee. 
 4.4.4 Study protocol 
Day 1: Participants came to UCL for a short session where they provided consent to take 
part in the study and had the opportunity to ask any questions. Following this, body 
composition was measured (weight, height, waist circumference, waist-to-hip ratio, 
Bodystat®) and blood pressure was measured to ensure it was within the normal range. 
Female participants were asked whether or not they were taking oral contraception and 
were also asked to provide the date of the first day of their last period. Participants were 
asked to fill out a questionnaire containing demographic information and measures of 
depression, anxiety, affect, perceived stress, sleep quality, optimism, and health 
behaviours. Following this, participants received a bottle containing 12 capsules of the 
study medication (five extra in case the participant needed to reschedule the stress testing 
appointment unexpectedly). All capsules were identical to ensure the protocol was 
double-blind. Participants were instructed to take one capsule every morning after 
breakfast for seven days, the last one on the day of stress testing. Participants were advised 
not to take any other form of medication or herbal remedy while taking the study 
medications, and to avoid alcohol and vigorous physical activity. Participants were also 
provided with a saliva sampling kit with instructions for collection at home.   
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Figure 4.1. Flow diagram of participant data collection and attrition from the Stress Pathways Study 
1Two participants failed to provide diurnal cortisol samples. One failed to provide the samples due to exams. One 
forgot to provide the samples on the required day. 
2Five participants failed to provide cortisol samples during the laboratory session. Two participants fainted during 
the session and were excluded. One participant smoked an e-cigarette during the session and was excluded. One 
participant missed the last dose of their medication and did not undergo the laboratory session as a result. One 
participant was unable to attend the laboratory session. 
3Eleven participants failed to provide blood samples.  The reasons why five participants could not provide blood 
samples are outlined in footnote 2. Of the six remaining, four of the participants were unable to have a cannula 
inserted, and a phlebotomist was unavailable to take blood samples from two participants. Of the 85 people who 
provided blood samples, six of these provided partial blood samples: five participants provided blood at baseline 
and +45m. One participant provided blood at baseline, immediately post-stress, and +75m. 
4 Six participants failed to provide cardiovascular data in the laboratory. The reasons why five participants could not 
provide cardiovascular data are outlined in footnote 2. One other participant failed to provide cardiovascular data as 
the Finometer failed to calibrate correctly.   
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Day 2: Participants began taking the study medication.  
Day 7: Saliva sampling for the measurement of diurnal cortisol secretion took place on 
the day six of the medication. Participants were recruited in a manner which ensured 
saliva sampling always took place on a weekday. Participants used the saliva sampling 
kit they were provided with on Day 1. The kit included seven pre-labelled ‘salivette’ 
collection tubes (Sarstedt, Leicester, UK) and a cortisol sampling diary (Appendix F). 
The cortisol diary contained instructions on how and when to give samples. These diaries 
were also used to record information on factors likely to introduce variation in cortisol 
samples such as mood, exercise, and daily stressors. Participants provided seven saliva 
samples over the course of a week day, on waking, 30 minutes after waking (30+), 10am, 
12pm, 4pm, 8pm, and bedtime. Participants stored their samples in the refrigerator before 
returning them to the researcher at their stress laboratory appointment the following day.  
Day 8: Participants returned to the psychobiology laboratory at UCL to undergo 
psychophysiological stress testing either in the morning (9am-12pm) or the afternoon 
(1.30-4.30pm). They were instructed to refrain from engaging in any physical exercise 
prior to the session, from drinking any alcohol the night before the testing session, and 
from consuming any caffeine on the morning of the testing day. They were told to eat a 
light breakfast and/or lunch. Participants returned the remaining medication to the 
experimenter at this laboratory session and the experimenter then performed a pill count 
in order to ensure adherence to the protocol. 
The laboratory protocol: On arrival at the laboratory participants completed a physical 
symptoms form in order to check health status. The experimenter noted the content and 
time of the participant’s last meal and noted if anything unusual happened to them on 
their way to the testing session. The schedule for the stress testing session is summarised 
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in Figure 4.2. A questionnaire was given to the participant measuring depression, anxiety, 
sleep quality, affect, and any adverse effects from the study medications. The participant 
gave the initial practice saliva sample (S1) using a ‘salivette’ (Sarstedt, Leicester, UK). 
They were then brought to the stress protocol laboratory where they were fitted with an 
intravenous cannula and given 25 minutes to relax before a baseline blood sample (B1; 
approximately 35ml) and a baseline saliva sample (S2) were taken. The participant was 
attached to a Finometer in order to measure cardiovascular parameters (e.g. heart rate, 
blood pressure) continually throughout the testing session. Once the baseline blood and 
saliva samples were taken, the Finometer had been correctly calibrated, and the 
participant had completed a baseline subjective stress questionnaire (Appendix G) the 
psychophysiological stress protocol began. 
 
 
A modified version of the TSST (Kirschbaum et al., 1993) was used in this study in order 
to facilitate data collection. This modified version comprised three tasks.  
1. Socially evaluative public speaking task: The participant sat facing a video camera. 
They were told that they should speak to the video camera as if it was a person and that 
all images recorded would be analysed and rated for content. The experimenter then read 
out a difficult interpersonal scenario to the participant who was told that after a 2-minute 
preparation period they would be given a free speech period of 3 minutes in which to 
tackle this interpersonal scenario. Each participant had to tackle the same interpersonal 
Figure 4.2. Study protocol: blood and saliva sampling 
135 
 
scenario which involved being falsely accused of pickpocketing. The experimenter 
remained in the room for the duration of the task. If the participant stopped speaking 
within the free speech period the experimenter prompted them to continue by saying aloud 
the time remaining.  
2. Mirror tracing task: The participant traced around a copper star with a metal stylus 
while only being allowed to see the mirror image of the star. Going off the star outline 
produced a loud error sound. Participants were instructed to trace around the star as many 
times as possible in 5 minutes while making as few errors as possible.  
3. Arithmetic Task: The participant was asked to serially subtract the number 13 from 
1,022 as fast and as accurately as possible for 5 minutes (Kirschbaum et al., 1993). On 
every failure the participant had to restart at 1,022 with the experimenter interfering ‘Stop, 
1,022’.  
Between each individual stress task participants were given a moment to complete a task 
impact questionnaire in order to measure subjective stress ratings (Appendix G). Mean 
subjective stress ratings for each task were calculated from a single item on each 
questionnaire. This item asks participants to rate how stressed they felt during the task on 
a scale ranging from 1 ‘Not at all’ to 5 ‘Very’. Subjective stress ratings were also 
measured prior to the stress protocol (resting), and 20 minutes after the protocol 
(recovery). Mean subjective stress ratings for each task and for the resting and recovery 
periods are provided in Figure 4.3. Following completion of all three tasks, the participant 
provided a saliva sample (S3 – immediately after stress) and a blood sample (B2). The 
experimenter left the room for 10 minutes to allow the participant to relax with some 
neutral reading material. At 10 minutes post-task the participant provided another saliva 
sample (S4) and again at 20 minutes post-task (S5). They were then allowed to relax for 
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25 minutes. At 45 minutes post-task the participant provided a saliva sample (S6) and 
blood sample (B3). This was also repeated at 75 minutes post-task (S7 and B4). Following 
the protocol, the cannula was removed from the participant’s arm and they were detached 
from the Finometer. The experimenter debriefed the participant about the goal of the 
study and informed them that no video analysis of the speech task would be performed. 
 
 
  
4.4.5 Psychosocial measures 
We chose to include a number of stress-related psychosocial measures in the Stress 
Pathways Study. At baseline we measured depression, anxiety, perceived stress, and 
positive affect. At follow-up (Day 8: testing session) we measured depression, anxiety, 
and positive affect. This was in order to examine whether the study medications affected 
any of these stress-related psychosocial factors. All questionnaire measures were 
researched and selected based on several criteria. First, measures that had been validated 
in healthy non-clinical populations were given preference. Second, validated brief or 
shortened versions were chosen over full versions to reduce response burden. Third, 
where measures were being administered twice, measures that have been shown to be 
valid over repeated time-points were chosen. Details of the individual measures used are 
Figure 4.3. Flow diagram of the stress protocol with mean subjective stress ratings. Ratings were 
provided before the tasks, immediately after each task, and 20 minutes after the stress protocol had 
been completed.  
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provided below and full versions of the study questionnaires are provided in Appendix D 
and E. 
Demographic information 
Demographic information was gathered from all participants. This included age, sex, 
marital status, ethnicity, employment status, level of education, and level of both mother’s 
and father’s education. As the majority of participants were students, parental education 
was used as an indicator of SES. The highest educational qualification of either parent 
was chosen as the SES indicator and based upon this participants were classified as having 
a high, medium, or low SES. Low SES was categorised as those who had less than a high 
school education, medium SES was categorised as those who had a high school education, 
and high SES included those who had an  undergraduate university degree, or higher. 
Participants were asked to specify their marital status by selecting from the following 
options: single, married, living as married, separated, divorced, widowed, other. They 
were also asked to specify their ethnicity by choosing from the following options: white, 
black or black British, mixed, Chinese, Asian or Asian British, other ethnic group. As the 
majority of participants were white (62%) we subsequently created a binary ethnicity 
variable where participants were classified as ‘white’ or ‘non-white’. Employment status 
was measured with the following options: employed full-time, employed part-time, self-
employed, student, unemployed, volunteer, disabled. Participants were asked to provide 
their own level of education as well as the level of both their mother and father using the 
following options: school certificate, GCSEs/O-levels/CSEs, A-levels, undergraduate 
degree, postgraduate degree, none, don’t know, other.  
Smoking status was measured as a binary variable (current smoker/non-smoker). If 
participants were current smokers they were asked to indicate how many cigarettes they 
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smoked per day and also how long they had been a smoker for in years and months. If 
participants were non-smokers they were asked if they had ever been a smoker in the past. 
If they responded yes to this participants were asked when they quit smoking and also if 
they were currently taking any nicotine replacement therapy.  
Depression 
Depressive symptoms were measured using the BDI-II (Beck, Steer, & Brown, 1996). 
The BDI-II has demonstrated high internal reliability and high test-retest reliability 
among both clinical and non-clinical populations, and adequate validity has been 
established (Dozois, Dobson, & Ahnberg, 1998; Wang, & Gorenstein, 2013). The BDI-
II comprises 21 items that are scored on a scale ranging from 0-3, with total scores ranging 
from 0-63. Participants are asked to provide answers that best describe the way they have 
been feeling during the past two weeks. However, due to the Stress Pathways Study 
duration we amended this to avoid confusion and asked participants to describe the way 
they have been feeling over the past week. A psychometric evaluation of the BDI-II 
recommended the use of the following cut-off criteria which we adopted in the current 
study: 0-12, non-depressed; 13-19, dysphoric; 20-63, dysphoric or depressed (Dozois et 
al., 1998). Participants were asked prior to recruitment if they had ever received a clinical 
diagnosis of depression. If not, they were recruited into the study. The Cronbach’s alpha 
for the BDI-II in this sample (n=104) at baseline was 0.87. The Cronbach’s alpha at 
follow-up (n=92) was 0.88. 
Anxiety 
Symptoms of anxiety were measured using the seven-item anxiety subscale of the HADS 
(Zigmond & Snaith, 1983). This subscale was favoured over others due to its brevity. The 
HADS anxiety subscale has also been found to be sensitive to changes across time in 
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response to therapeutic intervention and has performed well in the assessment of anxiety 
symptoms in the general population as well as patient groups (Bjelland, Dahl, Haug, & 
Neckelmann, 2002).  
The seven items of the HADS anxiety subscale are answered on a Likert scale ranging 
from 0 to 3, to indicate the extent to which the symptom has been experienced over the 
past two weeks. We amended this duration to one week to reflect the Stress Pathways 
Study protocol. Items are summed to generate a total score (0-21), with reverse coding 
on item 4 (I can sit at ease and feel relaxed). The recognised cut-off for moderate anxiety 
is a score of  ≥ 11 with higher scores indicating higher anxiety (Snaith, 2003).  Participants 
were asked prior to recruitment if they had ever received a clinical diagnosis of anxiety. 
If not, they were recruited into the study. The Cronbach’s alpha for the HADS anxiety 
subscale in this sample (n=104) at baseline was 0.83. The Cronbach’s alpha at follow-up 
(n=92) was 0.86.  
Perceived stress 
Perceived stress was measured using the Perceived Stress Scale (PSS) (Cohen, Kamarck, 
& Mermelstein, 1983). We chose to use the PSS in this study as it poses an advantage 
over life events scales that are usually used to measure stressful experiences. Life events 
scales usually measure the number of life events and the difficulty adjusting to these 
events without taking into account the personal and contextual factors that influence the 
degree to which a person perceives a situation as stressful. The PSS measures the extent 
to which an individual appraises aspects of one’s life as stressful. The PSS has been found 
to be a reliable and valid self-report measure of perceived stress in a non-clinical student 
sample (Roberti, Harrington, & Storch, 2006) and a psychiatric sample (Hewitt, Flett, & 
Mosher, 1992). The 10-item PSS is scored on a five-point Likert scale ranging from 0 
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‘Never’ to 4 ‘Very often’ and includes items such as ‘In the last month, how often have 
you felt nervous and stressed?’ and ‘In the last month how often have you felt that you 
were unable to control the important things in your life?’. Participants are asked to 
indicate to what extent they have felt or thought a certain way in the past month. Items 
are summed to generate a total score (0-40) with higher scores indicative of greater 
perceived stress. Items 4, 5, 7, and 8 are reverse scored. The Cronbach’s alpha for the 
PSS in this sample (n=104) was 0.86. 
Affect 
Affect was measured using the 10-item positive subscale of the Positive and Negative 
Affect Scale (PANAS) (Watson, Clark, & Tellegen, 1988). Only the positive affect 
subscale was included as both the BDI-II and HADS anxiety subscale provide adequate 
information about negative mood states. There is a great deal of evidence to suggest that 
positive affect and negative affect as conceptualised in the PANAS are distinct constructs 
(Watson, Wiese, Vaidya, & Tellegen, 1999). Therefore, independent inclusion of the 
positive affect subscale is acceptable. The positive affect subscale was chosen for its 
brevity. Also, this subscale is used to measure aspects of positive activation such as high 
energy, enthusiasm, and alertness. These are factors likely to be affected by 
administration of the medications in this study. Both PANAS scales have been shown to 
demonstrate adequate psychometric properties in non-clinical populations (Crawford & 
Henry, 2004) and have also been shown to be sensitive to change over time (Watson, 
1988). 
The 10 items of the positive affect subscale are as follows: interested, excited, strong, 
enthusiastic, proud, alert, inspired, determined, attentive, and active. Participants are 
asked to indicate what extent they have felt this way in the past week. A number of 
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different time-frames have been used with the PANAS in previous research, but ‘in the 
past week’ was chosen for the purposes of the Stress Pathways Study. Each item of the 
positive affect subscale is scored on a scale ranging from 1 ‘Never’ to 5 ‘Always’. Scores 
range from 10-50 with higher scores indicating higher positive affect. The Cronbach’s 
alpha for the positive affect subscale in this sample (n=104) was 0.83. The Cronbach’s 
alpha at follow-up (n=92) was 0.90.  
 4.4.6 Adverse events and drug effects 
We included the following open-ended questions at the end of the questionnaire the 
participants completed at the laboratory session (Day 8): ‘Did you have any significant 
symptoms or medical problems since the last study visit?’, ‘Would you say that any 
medical problem experienced in the last week was due to the study medication?’, and ‘If 
you can, please indicate below which medication you think you have been taking for the 
last 7 days’. Space was provided after all of these questions for participants to provide 
any extra details or information about their responses.  
 4.4.7 Biological measures 
Cortisol sampling 
In the Stress Pathways Study we measured both diurnal cortisol secretion (Day 7), and 
salivary cortisol stress reactivity in the laboratory (Day 8). Cortisol can be assessed in a 
number of biological specimens including saliva, blood, urine, and hair. We chose to 
measure salivary cortisol for a number of reasons. Salivary cortisol provides a reliable 
measure of unbound or ‘free’ cortisol, that is the biologically active cortisol in the body, 
and there are generally high correlations between salivary cortisol levels and levels of 
unbound cortisol in plasma and serum (Hellhammer, Wüst, & Kudielka, 2009; 
142 
 
Kirschbaum & Hellhammer, 2000). Salivary cortisol also has advantages over measuring 
cortisol in blood or urine in terms of ease of measurement. Saliva sampling is a non-
invasive, relatively inexpensive way of measuring cortisol and is especially ideal for 
ambulatory assessment in naturalistic settings where participants are responsible for 
collecting their own samples (Kirschbaum & Hellhammer, 2000). Therefore, we chose to 
measure salivary cortisol, rather than serum or plasma levels, in order to ensure 
consistency between diurnal ambulatory measures and measures taken in the laboratory 
during stress testing. Additionally, cortisol is stable in saliva and is therefore unaffected 
by storage conditions and transport for analysis.    
All saliva samples were collected using ‘salivettes’ (Sarstedt, Leicester, UK). On Day 1 
participants were provided with a cortisol sampling kit for collection of saliva samples at 
home on Day 7, and were shown how to provide a saliva sample. The sampling protocol 
is detailed earlier in this chapter in Section 4.4.4. Once the samples were returned they 
were stored at -20°C for analysis at a later date. Salivary cortisol levels were measured 
using a time-resolved immunoassay with fluorescence detection at the University of 
Dresden. Inter- and intra-assay variability was below 4%. Following analysis, the cortisol 
data were cleaned and four different indices of HPA axis function were computed: CAR, 
total cortisol output (AUC), cortisol slope across the day, and the difference between 
waking and bedtime values. A more detailed account of how these indices were computed 
will be provided in Section 5.5 of this thesis.  
During the laboratory session on Day 8 participants provided seven saliva samples across 
the session. Details of the timings of these samples are provided earlier in this chapter in 
Section 4.4.4. These samples were also stored at -20°C for analysis at a later time. 
Following analysis at the University of Dresden, the cortisol data was cleaned and a 
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number of indices were computed relating to cortisol stress reactivity. A more detailed 
account of these computations will be provided in Section 6.8.1 of this thesis.  
Corticosteroid receptor sensitivity 
GR and MR sensitivity was measured by lipopolysaccharide (LPS) stimulation of whole 
blood cultures co-incubated with different concentrations of glucocorticoids and 
subsequent determination of IL-6 production. IL-6 production was measured using a 
commercially available Luminex technology kit for IL-6 from Bio-RAD®. GR and MR 
sensitivity was measured at each blood-collection time point, i.e. pre-stress, immediately 
post-stress, +45m, and +75m. A more detailed description of the corticosteroid sensitivity 
assay protocol will be provided in Section 6.8.2 of this thesis. 
Cardiovascular measures 
Blood pressure (BP), heart rate, and cardiac output were continuously measured during 
the laboratory session on Day 8 using a Finometer® PRO (Finapres Medical Systems, 
Amsterdam, the Netherlands). The Finometer® PRO uses the Modelflow approach 
developed by Wesseling et al. (Wesseling, Jansen, Settels, & Schreuder, 1993) in order 
to estimate cardiac output. Modelflow estimates stroke volume via a three-element model 
using arterial compliance, aortic flow, and systemic vascular resistance (Shibasaki et al., 
2011). All cardiovascular measures were averaged into mean readings taken from five-
minute intervals. There was a five-minute baseline interval (pre-stress), as well as two 
five-minute recovery period intervals (+40-45m, and +70-75m). Cardiovascular measures 
during the stress protocol were averaged across tasks. Cardiac index (L/min/m2) was 
calculated by dividing cardiac output (L/min) by the body surface area (m2).  
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4.5 Data storage 
All Stress Pathways Study data were collected and stored in line with UCL policy and 
adhered to strict ethical guidelines. The project was registered with the UCL Data 
Protection Office. All data were treated as strictly confidential and were anonymised 
using unique study IDs. Participant consent forms and personal details were stored 
separately from all questionnaire and biological data; all paper data was stored in a locked 
filing cabinet in locked offices at UCL. All electronic data were stored in password-
protected computer files on password-protected computers. Prior to analyses, all 
biological samples collected were stored in a secure code-protected laboratory within the 
Department of Epidemiology & Public Health. All saliva samples were recoded to ensure 
anonymity before being transported to the University of Dresden for analysis via secure 
international courier. Following analysis, these samples were destroyed in Dresden. The 
results of the saliva analyses were returned to UCL electronically in password-protected 
spreadsheets and are currently stored in password-protected computer files. Blood 
samples from each participant are currently being securely stored in -80°C freezers in a 
code-protected laboratory. All data from the Stress Pathways Study may be kept in the 
secure manner described above for up to 20 years prior to being destroyed.  
4.6 Statistical analyses 
All statistical analyses were performed using SPSS version 22.0 software (SPSS Inc., 
Chicago, Illinois, USA). The significance level was set to p < 0.05 for all analyses. 
Specific details of statistical analyses carried out are included in chapters 5 and 6 which 
deal with diurnal cortisol, cortisol stress reactivity, and corticosteroid receptor function.  
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4.7 My contribution to the Stress Pathways Study   
I was directly involved in the development, design, organisation, and running of the Stress 
Pathways Study, under guidance from my supervisors Professor Andrew Steptoe and Dr 
Livia Carvalho. I was responsible for drafting the application for ethical approval for the 
study. In February 2014 I obtained ethical approval for the Stress Pathways Study from 
the UCL Research Ethics Committee. I helped select and compile the measures included 
in the study questionnaires and was very involved with the design of the study. I was 
responsible for the development and creation of all the study materials and was solely 
responsible for study recruitment. Due to a slight delay with the manufacture of the study 
medications, study recruitment began in October 2014. From October 2014 – August 
2015 I conducted the Stress Pathways Study with the assistance of a research nurse and 
research assistant from the department. I ran all 104 laboratory stress sessions and was 
solely responsible for saliva sampling and collection. I also carried out corticosteroid 
receptor sensitivity assays on the blood samples of all 85 participants who were 
successfully cannulated during the laboratory session. I was responsible for the recoding 
of all the saliva samples collected (both diurnal and laboratory) and organised their 
transport to the University of Dresden for cortisol analysis. I created the dataset for the 
study and undertook all of the data entry. I conducted all the statistical analyses myself, 
with help from my PhD supervisors.  
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Chapter 5 
Study 2 – The Stress Pathways Study results: The effect of pharmacological 
blockade on diurnal cortisol secretion in healthy volunteers 
5.1 Introduction 
The results of Study 1 in Chapter 3 of this thesis provided support for the role of 
dysregulation of basal HPA axis function in CVD. However, the results told us very little 
about what brought about this dysregulation. In this chapter I will present results from the 
Stress Pathways Study concerning the effects of beta-blockade and SSRIs on diurnal 
cortisol secretion in healthy volunteers. These results may tell us more about the 
mechanisms and different biological systems involved in dysregulation of diurnal HPA 
axis functioning. Furthermore, these results may highlight potential therapeutic 
interventions for impaired diurnal cortisol rhythms.  
5.2 Literature Review: Beta-blockers and basal HPA axis function 
In Chapter 2 of this thesis I described both the HPA axis and the SAM system and how 
these systems are connected. As well as interacting with each other, these systems are 
also anatomically linked. Within the CNS, there are fibres linking norepinephrine 
releasing neurons in the brainstem with CRH releasing neurons in the hypothalamus 
(Ulrich-Lai & Herman, 2009). Norepinephrine levels have been shown to stimulate the 
release of CRH from the hypothalamus, thereby affecting the regulation of the HPA axis 
(Pacak, 2000; Pacak, Palkovits, Kopin, & Goldstein, 1995). As mentioned in Chapter 4, 
beta-blockers exert their anti-hypertensive and anxiolytic effects by reducing cardiac 
output via antagonism of the β-receptors, reducing norepinephrine release, and 
attenuating the pressor response to catecholamines (Ripley & Saseen, 2014).  
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 5.2.1 Acute administration of beta-blockers 
Due to the interplay between the HPA axis and SAM system, the effects of beta-blockade 
on basal unstressed cortisol secretion have been investigated. However, these studies have 
largely focused on assessing the effects of acute doses of beta-blockers on single plasma 
measures of cortisol. Results of these studies have been mixed, with some reporting acute 
increases in circulating cortisol levels and some reporting no significant changes. In an 
early study, an acute 80mg dose of propranolol given to seven healthy men resulted in 
significant increases in levels of circulating plasma cortisol measured throughout the 
night (Lewis, Groom, Barber, & Henderson, 1981). Using a placebo-controlled crossover 
design, administration of acute doses of metoprolol (100mg) or propranolol (80mg) to six 
men and women with insulin-dependent diabetes resulted in an increase in plasma cortisol 
levels for up to four hours after receiving the medication (Popp, Tse, Shah, Clutter, & 
Cryer, 1984). A single dose of 30mg pindolol did not bring about any significant changes 
in cortisol levels in twelve healthy men (Meltzer & Maes, 1994). However, this same 
dose administered to 23 healthy men was found to increase circulating cortisol levels over 
the next three hours (Meltzer et al., 1994).  
More recently, Kizildere and colleagues administered either 10mg propranolol or placebo 
to 28 healthy men and women (Kizildere, Glück, Zietz, Schölmerich, & Straub, 2003). 
Both groups then underwent a CRH test designed to stimulate cortisol secretion. The 
group that received the acute propranolol dose prior to the CRH test had significantly 
higher levels of serum cortisol between 40 and 120 minutes after the test compared to the 
placebo group.  However, Nonell and colleagues found that intravenous administration 
of propranolol (13μg/minute) to 10 healthy young men over five hours resulted in no 
significant changes in plasma levels of cortisol measured over the same time period 
(Nonell et al., 2004). 
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 5.2.2 Long-term administration of beta-blockers 
The effects of more long-term beta-blockade on basal levels of cortisol have also been 
examined. Dart and colleagues examined the effects of six week treatment with 80mg 
propranolol twice daily on night time cortisol secretion in eight healthy male volunteers.  
They found that propranolol brought about increases in plasma cortisol levels in the first 
six hours of the night (9pm-3am), but subsequently decreased cortisol levels in the second 
period (3am-9am). The authors interpreted this as an alteration in the ‘diurnal variation’ 
of plasma cortisol levels brought about by beta-blockade (Dart, Lewis, Groom, Meek, & 
Henderson, 1981). In the same year, Golub and colleagues found that one month of 
treatment with propranolol (120-240mg/day) in eight patients with essential hypertension 
did not affect plasma cortisol secretion significantly (Golub, Tuck, & Fittingoff, 1981).  
Similarly, a study examining the effects of seven-day treatment with beta-blockers on 
sexual function in 30 healthy male volunteers found that none of the administered drugs 
(atenolol, metoprolol, pindolol, and propranolol) had any significant effects on morning 
serum cortisol levels (Rosen, Kostis, & Jekelis, 1988). More recently, Ahmed and 
colleagues sought to assess the effects of four weeks administration of atenolol 
(50mg/day) on cortisol secretion in 21 healthy men (Ahmed et al., 2010). Compared to 
baseline measures, plasma levels of cortisol after drug treatment were significantly 
lowered. 
Taken together, these studies examining effects of acute beta-blockade on basal HPA axis 
function suggest that acute suppression of the SNS, via its β-adrenergic receptors, seems 
to enhance cortisol secretion. The effects of long-term administration have been more 
mixed. However, the heterogeneity between studies means that this suggestion is made 
with caution. Samples differed widely in terms of sample size, sex, and also health status, 
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with some studies assessing clinical samples (hypertension, diabetes). The studies also 
differed widely in terms of drug type (selective versus non-selective beta blocker), 
dosage, treatment duration, and also route of administration. Additionally, in some cases 
the drugs were co-administered with other substances (e.g. insulin) so it is difficult to 
tease apart the actual effects of beta-blockade. Additionally, in one study a CRH test was 
used to enhance cortisol secretion making the comparison of the results of this study with 
others difficult (Kizildere et al., 2003). All these methodological differences across 
studies likely account for the mixed results, and prevent us from making any reasonable 
assertions about the effects of beta-blockade on basal HPA axis function. 
Probably the biggest difficulty in interpreting evidence from these studies is that cortisol 
is measured either using a single plasma sample taken at different times, or a number of 
plasma samples taken over a short period. The diurnal nature of cortisol secretion is not 
being taken into account. In 1997, Gudbjörnsdóttir and colleagues assessed effects of 
long-term administration of beta-blockers on ‘diurnal’ plasma cortisol levels in seven 
mildly hypertensive men and women (Gudbjörnsdóttir et al., 1997). Participants were 
randomised to receive six weeks treatment with metoprolol (100mg twice daily) or 
placebo in a double-blind crossover trial. Levels of plasma cortisol were measured using 
continuous blood sampling over a 24 hour period at the end of the six weeks. Plasma 
concentrations of cortisol remained unchanged by metoprolol treatment. However, 
although the authors measured cortisol output across the day, they failed to take into 
account its unique diurnal patterning and did not calculate the CAR, AUC, or slope across 
the day.   
In sum, evidence from acute studies, and some long-term studies, suggests that beta-
blockers do exert effects on cortisol secretion. Despite the heterogeneity across studies 
and the problems surrounding cortisol measurement, the evidence to date suggests that 
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SNS suppression by beta-blockade enhances HPA axis activation. Therefore, beta-
blockade likely has consequences for diurnal cortisol secretion. 
5.3 Literature Review: SSRIs and basal HPA axis function 
Depression is one of the most common stress-related disorders. As mentioned in Chapter 
1, depression is a known independent risk factor for CVD (Nicholson et al., 2006; Van 
der Kooy et al., 2007) and also affects prognosis in those already with CVD (Meijer et 
al., 2011). The neurobiology of depression is defined by a deficit in serotonergic activity 
(Owens & Nemeroff, 1994). Hyperactivity of the HPA axis has also been widely reported 
in major depression (Pariante & Lightman, 2008). There is evidence that the 
abnormalities of the serotonergic system and the HPA axis are linked and this interaction 
may be an important mechanism involved in the development of depression, particularly 
at the level of the serotonergic receptors 5-HT1A and 5-HT2A (Porter, Gallagher, 
Watson, & Young, 2004). 
 5.3.1 Acute administration of SSRIs 
Evidence for interactions between the serotonergic system and the HPA axis come from 
studies assessing effects of both acute and chronic administration of SSRIs on basal HPA 
axis function in healthy volunteers and depressed patients. Acute administration of SSRIs 
to healthy participants appears to result overall in an increase in basal levels of cortisol. 
The majority of research in this field has used the SSRI citalopram as a neuroendocrine 
probe. Seifritz and colleagues administered an intravenous infusion of 20mg citalopram 
over a 30 minute period to nine healthy men (Seifritz et al., 1996). The citalopram 
infusion resulted in an increase in plasma cortisol levels which reached a peak 
approximately an hour after administration. The same dose administered orally induced 
increases in plasma cortisol levels about two hours after intake in 48 healthy men 
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(Henning & Netter, 2002). At lower doses citalopram has also been found to induce 
increases in basal cortisol levels. Twelve healthy men and women received 10mg 
citalopram via intravenous infusion which brought about increases in plasma cortisol 
levels in the 150 minute period following infusion (Bhagwagar, Hafizi, & Cowen, 2002). 
Lotrich and colleagues examined the acute effects of four separate IV doses of citalopram 
(10mg, 20mg, 40mg, and 0.33mg/kg) and placebo on cortisol output in 75 healthy 
subjects (Lotrich et al., 2005). Citalopram produced a dose-dependent increase in basal 
cortisol levels. Increases in plasma cortisol levels have also been brought about by oral 
administration of 40mg citalopram in healthy men (Hawken, Owen, Van Vugt, & Delva, 
2006; Mattos, Franco, Noel, Segenreich, & Gonçalves, 2006). Berardelli and colleagues 
found that two hour intravenous infusion of 20mg citalopram brought about increases in 
levels of both ACTH and cortisol, suggesting that increases in serotonin stimulate activity 
of the HPA axis at the pre-pituitary level (Berardelli et al., 2010). These increases were 
found to be more pronounced in middle-aged and elderly men compared to young adults 
suggesting that the influence of serotonin on the HPA axis becomes more pronounced 
with age. 
More recent research has examined acute effects of the SSRI escitalopram on 
neuroendocrine function. A single 10mg dose of escitalopram increased basal levels of 
salivary and plasma cortisol in 15 healthy men and women in a randomised placebo-
controlled cross-over study (Nadeem, Attenburrow, & Cowen, 2004). Single 10mg and 
20mg oral doses of escitalopram have also brought about increases in salivary cortisol in 
healthy men and women (Kuepper, Bausch, Iffland, Reuter, & Hennig, 2006). 
Interestingly, women tended to show significantly more pronounced increases in salivary 
cortisol compared to men, regardless of menstrual cycle phase. Using a repeated measures 
counter-balanced design, Hawken and colleagues found that single oral doses of 20mg 
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escitalopram given to eight healthy men resulted in significant increases in plasma 
cortisol levels in the 240 minutes following drug administration (Hawken, Owen, 
Hudson, & Delva, 2009). 
The SSRI paroxetine has also been found to induce increases in basal cortisol secretion. 
In twenty healthy participants 20mg of paroxetine brought about significant increases in 
ACTH and cortisol levels (Kojima et al., 2003). Five of these participants also received a 
4mg dose of cyproheptadine which is a 5-HT2A receptor antagonist. These participants 
had attenuated cortisol responses to paroxetine which indicates that the neuroendocrine 
response to paroxetine is mediated in some way by the 5-HT2A receptors. However, 
cyproheptadine failed to attenuate the increase in cortisol levels brought about by an acute 
dose of citalopram, suggesting that cortisol response to citalopram are not mediated by 
these receptors (Attenburrow, Mitter, Whale, Terao, & Cowen, 2001).   
 5.3.2 Long-term administration of SSRIs 
The evidence unanimously suggests that acute administration of SSRIs brings about 
increases in HPA axis function in healthy volunteers, albeit with differences between men 
and women in some studies. However, the results from studies assessing longer-term 
administration of SSRIs are more difficult to interpret. Most of these studies have been 
carried out in patient samples with depression. As mentioned previously, hyperactivity of 
the HPA axis has been widely reported in major depression. A number of studies have 
shown that SSRI treatment decreases basal cortisol levels, suggesting ‘normalisation’ of 
HPA axis function. Inder and colleagues gave 27 patients with depression six weeks 
treatment with fluoxetine, which brought about significant reductions in plasma ACTH, 
but not cortisol (Inder, Prickett, Mulder, Donald, & Joyce, 2001). The authors interpret 
this as evidence for SSRI-induced restoration of glucocorticoid negative feedback on 
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ACTH levels. Seven months treatment with fluoxetine brought about reductions in 
urinary free cortisol in 22 depressed patients, but it did not affect basal plasma cortisol 
levels (Vythilingam et al., 2004). However, eight weeks treatment with fluoxetine 
(20mg/day) brought about significant decreases in plasma cortisol levels in 14 men and 
women with major depressive disorder (Jazayeri et al., 2010).  
Escitalopram has also been shown to bring about reductions in cortisol secretion. Ahmed 
and colleagues gave 26 depressed male patients six week treatment with escitalopram 
(Ahmed et al., 2011). Following treatment, basal plasma cortisol concentrations were 
significantly lower, as were depression scores. The authors also measured cortisol in 
single fasting urine samples, but found no significant reduction in urinary cortisol. In a 
recent study, 51 patients with major depressive disorder were given four weeks treatment 
with escitalopram (10-20mg/day) (Park, Lee, Jeong, Han, & Jeon, 2015). Regardless of 
depression scores following treatment, both responders and non-responders had 
significant reductions in basal plasma cortisol levels.  
Dziurkowska and colleagues examined the collective effects of a number of different 
SSRIs on cortisol secretion in 40 depressed men and women (Dziurkowska, Wesolowski, 
& Dziurkowski, 2013). The results showed that SSRIs brought about overall reductions 
in salivary cortisol levels. Similarly, Hernandez and colleagues assessed the collective 
effects of SSRIs (fluoxetine, paroxetine, sertraline) on urinary cortisol levels in 31 
patients with major depressive disorder (Hernandez et al., 2013). After 52 weeks 
treatment, urinary cortisol levels were significantly reduced compared to baseline values. 
Wedekind and colleagues examined the effects of 10 weeks treatment with paroxetine 
(20-40mg/day) on urinary cortisol levels in men and women with panic disorder 
(Wedekind et al., 2008). Paroxetine treatment had no significant effects on urinary 
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cortisol. However, when analysed separately, men receiving paroxetine displayed a trend 
towards lower basal HPA axis function after the treatment period.  
The results of these studies provide support for the notion that SSRIs may exert their 
therapeutic effect via ‘normalisation’ of HPA axis function. However, a number of studies 
have also found that long-term treatment with SSRIs brings about no significant changes 
in basal plasma cortisol (Kauffman, Castracane, White, Baldock, & Owens, 2005; Mück-
Seler, Pivac, Sagud, Jakovljević, & Mihaljević-Peles, 2002) or salivary cortisol values 
(Deuschle et al., 2003). One study has even found that treatment with SSRIs brings about 
increases in basal cortisol values in depressed patients. Four weeks treatment with 
sertraline (42.5mg/day) increased plasma cortisol levels in 15 female patients with major 
depression (Sagud et al., 2002). Increases in cortisol values following SSRI treatment 
have also been reported in healthy men. Ljung and colleagues examined the effects of six 
months treatment with citalopram (10-20mg/day) on basal HPA axis function in 16 
healthy men with moderate abdominal obesity (Ljung et al., 2001). Prior to beginning 
treatment, morning cortisol levels were low in these men indicating dysregulation of the 
HPA axis. Following treatment with citalopram, there was a significant increase in 
morning cortisol levels. However, urinary cortisol levels remained unchanged.  
Taken together, the evidence suggests that acute administration of SSRIs increases 
cortisol secretion. Longer-term administration appears to reduce cortisol secretion in 
depressed patients indicating ‘normalisation’ of HPA axis function brought about by 
increased serotonergic activity. However, the results of these studies have been mixed. 
This is largely to do with methodological heterogeneity between studies. The majority of 
studies examined the effects of SSRIs in depressed individuals, meaning that the 
decreases in cortisol secretion may have been to do with symptom remission rather than 
the direct biological effects of SSRIs on the HPA axis. In fact, in healthy individuals 
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longer-term SSRIs brought about increased basal cortisol levels. Studies also differ in 
terms of specimen used to measure cortisol. Some studies reported alterations in plasma 
cortisol levels and no change in urinary cortisol levels, whereas some studies reported the 
opposite pattern. As with the beta-blocker studies, the biggest difficulty in interpreting 
the evidence from these SSRI studies is that cortisol is measured using single plasma, 
salivary or urinary cortisol samples. These samples are taken at different times across 
studies also making it very difficult to compare results. The diurnal nature of cortisol 
secretion is not being taken into account which makes it difficult to make inferences about 
the effects of SSRIs on HPA axis function. 
 5.3.3 SSRIs and diurnal HPA axis function 
To date, a number of studies have assessed the effects of SSRIs on diurnal cortisol 
secretion. The majority of these studies have been on depressed patients and have yielded 
mixed results. Rota and colleagues assessed the effects of six week treatment with 
fluvoxamine (200mg/day) on circadian cortisol rhythm in 20 patients with major 
depressive disorder (Rota et al., 2005). The authors measured circadian cortisol rhythm 
by calculating the ratio between salivary cortisol measured at 8pm and salivary cortisol 
measured at 8am. They found at baseline, patients with major depression had increased 
ratios compared to controls, which was indicative of a flattened cortisol rhythm. By day 
14 of fluvoxamine treatment the patients had significantly decreased cortisol ratios, 
implying a correction in the circadian rhythm, or a steepening of the slope.  
Three week treatment with escitalopram (10-20mg/day) in major depressive disorder 
patients (n=52) was found to significantly reduce cortisol AUC calculated from four 
salivary cortisol measures taken over the course of a day (Hinkelmann et al., 2012). By 
the end of treatment cortisol AUC in the patient group was reduced to the levels of age 
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and gender matched healthy controls.  Furthermore, reduction in cortisol AUC in the 
patient group correlated with improvements in depressive symptoms.  
Similarly, 12 week treatment with paroxetine (varying dosages) brought about significant 
decreases in cortisol AUC in 70 patients with depression (Ruhé et al., 2015). Moreover, 
over the treatment course, waking cortisol levels decreased and the CAR was significantly 
increased in patients who experienced symptom remission. Reduced cortisol AUC and 
reduced waking cortisol levels have also been reported in eight healthy first degree 
relatives of depressed patients who received four weeks treatment with escitalopram 
(10mg/day) (Knorr et al., 2012). In a large-scale study the association between 
antidepressant use and diurnal cortisol secretion was investigated in 1526 participants 
from the Netherlands Study of Depression and Anxiety (Manthey et al., 2011). Those 
who took SSRIs (n=309) were found to have significantly higher evening cortisol levels 
compared to non-users.  However, one study examining the effects of ten weeks open-
labelled treatment with paroxetine (10mg/day) in patients with depression reported no 
changes in diurnal cortisol rhythm (Tucker et al., 2004). Similarly, long-term treatment 
with SSRIs (sertraline, escitalopram) did not alter cortisol rhythm across the day in 
children with problem behaviour (Hibel, Granger, Cicchetti, & Rogosch, 2007). 
However, only eight children were taking SSRIs meaning that the study may have been 
underpowered to detect effects. 
Lenze and colleagues administered 12 weeks treatment with escitalopram (10-20mg/day) 
or placebo to 60 adults with GAD (Lenze et al., 2011). Similar to results seen in depressed 
patients, treatment significantly reduced cortisol AUC and decreased anxiety levels. 
Furthermore, treatment with escitalopram also reduced the CAR. Diurnal cortisol 
parameters were calculated using salivary cortisol measures taken at six daily time points 
for two consecutive days. However, the authors did not report data on the cortisol slope.  
157 
 
Overall, these results indicate that SSRI treatment does affect diurnal cortisol secretion. 
Despite differences across studies in terms of drug type, duration of treatment, and 
dosage, a number of studies reported reduced cortisol AUC and reduced waking levels of 
cortisol. However, results are mixed regarding the CAR and diurnal cortisol rhythm. 
There is also a paucity of studies assessing the effects of SSRIs on diurnal cortisol 
secretion in healthy volunteers. This means that we cannot distinguish whether observed 
changes in cortisol secretion are due to symptom remission or direct biological effects of 
serotonergic alterations on HPA axis function. More work is needed examining the effects 
of SSRIs on diurnal cortisol parameters in healthy volunteers in order to find out more 
about how serotonergic activity may affect diurnal HPA axis function. 
5.4 Aims and hypotheses 
The aim of this study was to assess the effects of six-day administration of beta-blockers 
and SSRIs on diurnal cortisol parameters using data from the Stress Pathways Study. As 
detailed in previous chapters, research suggests that dysregulation of these diurnal cortisol 
parameters are associated with chronic stress, negative emotional disorders, heightened 
cardiovascular risk, and poor prognosis in those who have CVD. Examining the effects 
of these pharmacological probes on diurnal cortisol secretion may tell us more about what 
biological systems are involved in this dysregulation, and also may identify potential 
therapeutic interventions for ‘normalisation’ of HPA axis function.  
It should be emphasised that although participants were randomised into three groups, 
this was done as an efficient way to compare beta-blockers with placebo, and SSRIs with 
placebo. No hypotheses were generated concerning the differences between beta-blocker 
and SSRI groups, and the data were analysed as two parallel comparisons: beta-blockade 
versus placebo, and SSRIs versus placebo. 
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Acute doses of beta-blockers appear to enhance cortisol secretion, whereas the results of 
studies looking at more long-term administration of these drugs are mixed. To date, no 
study has assessed the effects of beta-blockers on specific diurnal cortisol parameters, i.e. 
the CAR, the cortisol slope, waking cortisol levels, evening cortisol levels, and cortisol 
AUC. Therefore, based upon the increases in cortisol levels brought about by acute beta-
blockade, and based on the notion that SNS suppression brings about increased HPA axis 
activation, I hypothesise that beta-blockers will increase diurnal cortisol secretion, 
i.e. the CAR and AUC will be larger, leading to flatter cortisol slopes.  
Quite a number of studies have assessed the effects of SSRIs on diurnal cortisol secretion 
and the results suggest that SSRIs do affect cortisol across the day. Four studies to date 
have reported reduced cortisol AUC in those taking SSRIs. Three studies also report 
either reduced waking levels or reduced CAR. Therefore, I hypothesise that six-day 
administration of escitalopram will reduce the cortisol AUC and reduce the CAR. 
In line with these reductions, I also hypothesise that SSRIs bring about steeper 
cortisol slopes.  
Daily cortisol secretion is known to be affected by sex (Veldhuis et al., 2013). Sex has 
also been shown to influence cortisol responses to SSRI administration (Kuepper et al., 
2006; Wedekind et al., 2008). Therefore, in this study we will also examine how sex 
influences the effects of the study drugs on diurnal HPA axis function.   
5.5 Calculation of diurnal cortisol parameters 
A detailed description of the cortisol sampling procedure is provided in Chapter 4 of this 
thesis. Four different indices of HPA axis function were calculated for each participant: 
CAR, cortisol AUC, cortisol slope across the day, and the difference between waking and 
bedtime values. The CAR was calculated by subtracting the waking from the waking + 
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30 min values. When calculating the CAR, we omitted individuals who reported a delay 
of >15 min between waking and taking the ‘waking’ sample leaving a sample of 73. As 
mentioned in Chapter 3, a long delay between waking and providing the ‘waking’ sample 
can produce misleading CAR results, but a delay of less than 15 minutes does not seem 
problematic (Dockray et al., 2008). The cortisol AUC over the day was computed 
according to the methods described by Pruessner and colleagues (Pruessner et al., 2003). 
The slope of decline in cortisol across the day was estimated using two methods. First, 
we regressed the samples across the day against time. Second, the difference between 
waking and bedtime values was computed and divided by the time elapsed between the 
two samples. Both are expressed in nmol/L/min. The two slope values correlate 0.91, so 
reflect very similar processes. The average evening cortisol concentration was also 
calculated (mean of 8pm and bedtime values). The exact number of participants available 
for each analysis is detailed in Table 5.2. 
Participants were to be excluded from the analysis if any of the cortisol values exceeded 
70 nmol/L. Of the 94 participants in the study, there were some missing cortisol samples 
as follows: two on waking, one on waking+30 min, three at 10am, and one at 4pm. 
Cortisol slope was calculated if the participant had at least four available cortisol 
measures (excluding the 30+ morning sample). 92 patients had sufficient data for the 
calculation of cortisol slope (two participants provided less than four samples). The CAR 
was calculated for 73 participants as 16 participants reported providing their waking 
sample more than 15 minutes after waking, two participants failed to provide waking 
samples, one participant failed to provide one waking+30 min, and two had cortisol 
sample values that exceeded 70 nmol/L. Cortisol AUC was calculated only for those who 
provided all seven saliva samples. Therefore, cortisol AUC was calculated for the 87 
participants who provided all saliva samples successfully.  
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5.6 Statistical Analyses 
All data were analysed as two parallel comparisons: beta-blockers versus placebo, and 
SSRIs versus placebo.  
Kolmogorov-Smirnov tests were performed in order to test for normality of the 
distribution in diurnal cortisol parameters. These normality tests revealed that all diurnal 
cortisol parameters were normally distributed (all p values > 0.05) apart from bedtime 
cortisol levels, and average evening cortisol levels. However, parametric tests were 
performed on the data as they are the preferred method of analysing data from randomised 
trials (Vickers, 2005). Two-way ANOVAs and chi-square tests were used to compare the 
study medication groups on all demographic characteristics. Where possible, sex was 
included as a between-person factor alongside experimental condition. Changes in stress-
related psychological factors were assessed using two-way ANOVAs, with experimental 
condition (propranolol versus placebo and escitalopram versus placebo) and sex being 
included as the main fixed factors.  
The diurnal cortisol parameters were also analysed using two separate pairwise analyses; 
propranolol versus placebo, and escitalopram versus placebo. Differences between the 
two conditions were analysed using two-way ANOVAs, with experimental condition and 
sex being included as the main fixed factors. We examined the main effects of 
experimental condition as well as the interactive effect of sex. Where there were 
significant interaction effects of sex on diurnal cortisol parameters, we split the data by 
sex and ran one-way ANOVAs in order to determine the effects of the experimental 
condition in men and women separately. Where there were significant differences 
between experimental conditions on any of the demographic characteristics, ANCOVAs 
were run where the demographic variable of interest was included as a covariate.  
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The significance level was set to p < 0.05 for all analyses, with precise p values reported 
for all test results. All statistical analyses were performed using SPSS version 22.0 (SPSS 
Inc., Chicago, Illinois, USA). 
5.7 Results 
 5.7.1 Participants 
Of the 94 participants who provided saliva samples, 32 were taking escitalopram, 30 were 
taking propranolol, and 32 were taking placebo. Table 5.1 summarises the characteristics 
of the participants. The sample had an age range of 18-48 years, were almost two-thirds 
women (62.8%), and were mostly normal weight (79.8% BMI<25). Over half of the 
sample were white (58.5%) and the majority of participants had a high SES based upon 
parental education (81.9%).  
Scores on the BDI-II at baseline ranged from 0-31 indicating the presence of depression 
in some participants. Frequency analysis revealed that two participants had BDI-II scores 
greater than 19 indicating the presence of clinical depression. Scores on the HADS 
anxiety subscale at baseline ranged from 0-15 indicating the presence of anxiety in some 
participants. Frequency analysis revealed that nine participants had scores of 11 or greater 
indicating the presence of anxiety. Sensitivity analyses were carried out with these 
participants removed (n=10). Exclusion of these participants did not affect results 
obtained. Scores on the PSS ranged from 2-31, indicating a good level of variability in 
perceived stress within the sample.  
The propranolol group did not differ significantly from the placebo group in terms of age 
(F(1, 58) = 2.18, p = 0.15), sex (χ2 = 0.52, df = 1 , p = 0.47), BMI (F(1, 58) = 1.33, p = 
0.25), smoking status (χ2 = 0.10, df = 1, p = 0.76), ethnicity (χ2 = 3.66, df = 4, p = 0.45), 
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or SES (χ2 = 0.60, df = 2, p = 0.74). There were also no significant differences between 
groups in baseline depression scores (F(1, 58) = 0.04, p = 0.85), anxiety scores (F(1, 58) 
= 0.01, p = 0.96), perceived stress scores (F(1, 58) = 0.26, p = 0.53), or positive affect 
scores (F(1, 58) = 0.17, p = 0.68). Amongst female participants there was no significant 
difference between drug groups in terms of hormonal contraception use (χ2 = 3.33, df = 
3, p = 0.34). 
The escitalopram group did not differ significantly from the placebo group in terms of 
age (F(1, 60) = 0.16, p = 0.69). However, there was a significant interaction between 
experimental group and sex with respect to age (F(1, 60) = 5.60, p = 0.021). There was a 
significant difference in age between the two groups in men (F(1, 22) = 5.34, p = 0.031) 
but not women (p = 0.15). Men in the escitalopram group were younger (M = 20.1 years, 
SD = 0.6 years) than men receiving placebo (M = 22.4 years, SD = 0.8 years).  The 
escitalopram group did not differ significantly from the placebo group in terms of sex 
distribution (χ2 = 2.40, df = 1, p = 0.12), BMI (F(1, 60) = 0.10, p = 0.76), smoking status 
(χ2 =2.41, df = 1, p = 0.12), ethnicity (χ2 = 0.67, df = 4, p = 0.96), or SES (χ2 = 0.32, df = 
2, p = 0.85). There were also no significant differences between groups in baseline 
depression scores (F(1, 60) = 0.17, p = 0.69), anxiety scores (F(1, 60) = 0.11, p = 0.74), 
perceived stress scores (F(1, 60) = 1.14, p = 0.29), or positive affect scores (F(1, 60) = 
0.36, p = 0.55). Amongst female participants there was no significant difference between 
experimental conditions in terms of hormonal contraception use (χ2 = 3.63, df = 3, p = 
0.30). 
5.7.2 Study medication effects on stress-related psychological factors 
We investigated the effects of the study medications on depression scores, anxiety scores, 
and positive affect on Day 7 of administration. This was in order to clarify that any 
163 
 
Table 5.1. Demographic characteristics of the sample (n = 94)  
 Propranolol (n=30) 
 
Escitalopram (n=32) 
 
Placebo (n=32) 
 
Propranolol vs. placebo  
 
Escitalopram vs. placebo  
 
Characteristic Mean ± SD or N(%) Mean ± SD or N(%) Mean ± SD or N(%) 
Group  
p value 
Group*sex  
p value 
Group  
p value 
Group*sex  
p value 
Age (years) 24.5±6.35 22.1±3.9 22.2±3.0 0.145 0.552 0.692 0.021* 
Female 19(63.3) 17(53.1) 23(71.9) 0.472 - 0.121 - 
BMI (kg/m2)  22.5±2.3 23.3±4.2 23.2±4.0 0.254 0.506 0.757 0.267 
Smoker 3(10.0) 9(28.1) 4(12.5) 0.756 - 0.120 - 
Ethnicity (White) 21(70.0) 17(53.1) 17(53.1) 0.454 - 0.955 - 
SES (n=93)    0.741 - 0.853 - 
         Low 4(13.3) 3(9.4) 3(9.4) - - - - 
        Medium 3(10.0) 1(3.1) 2(6.3) - - - - 
        High 23(76.7) 27(84.4) 27(84.4) - - - - 
Hormonal Contraception  (n=59) 6(31.6) 7(41.2) 5(21.7) 0.343 - 0.304 - 
Depressive symptoms  7.03±6.40 5.91±6.59 6.41±5.07 0.845 0.504 0.685 0.463 
Anxiety symptoms 4.97±4.21 4.75±2.81 5.28±4.03 0.963 0.595 0.739 0.945 
Perceived stress 14.2±6.8 13.2±5.6 15.4±7.2 0.611 0.879 0.290 0.407 
Positive Affect 33.7±5.6 35.2±5.7 35.0±4.8 0.648 0.244 0.548 0.128 
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differences in diurnal cortisol parameters between drug groups on Day 6 were not caused 
by changes in stress- or mood-related factors. The propranolol group did not differ from 
the placebo group in depression scores (F(1, 56) = 0.81, p = 0.37), anxiety scores (F(1, 
56) = 0.32, p = 0.57), or positive affect (F(1, 56) = 0.65, p = 0.42). The escitalopram 
group did not differ from the placebo group in depression scores (F(1, 57) = 0.01, p = 
0.93), anxiety scores (F(1, 57) = 3.11, p = 0.08), or positive affect (F(1, 57) = 0.04, p = 
0.85) There were also no main or interactive effects of sex on any of these factors (all p 
values > 0.05).  
 5.7.3 Study medication effects on diurnal cortisol parameters 
Propranolol versus placebo 
The analyses of cortisol over the day in relation to experimental condition are summarised 
in Table 5.2. A graphical representation of mean cortisol values across the day in both the 
propranolol and placebo groups is provided in Figure 5.1. In terms of cortisol AUC, there 
was no main effect of experimental condition (F(1, 54) = 0.57, p = 0.46) and no main (p 
= 0.31) or interactive effects of sex (p = 0.65). Similarly, the CAR was unaffected by 
experimental condition (F(1, 43)= 0.07, p = 0.79) and there was no interactive effect of 
sex (F(1, 43) = 0.63, p = 0.43). However, there was a main effect of sex on the CAR (F(1, 
43) = 4.73, p = 0.035). The means indicate that female participants had a more pronounced 
CAR than male participants, regardless of experimental condition (Women: M = 15.9, SD 
= 2.6; Men: M = 6.5, SD =3.5) (see Figure 5.2). Regarding cortisol slope, there was no 
main effect of experimental condition (F(1, 57) = 0.94, p = 0.34) and no main (p = 0.42) 
or interactive effect of sex (p = 0.98). Similar findings emerged relating to the difference 
between waking and bedtime values. There was no main effect of experimental condition 
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(F(1, 55) = 0.72, p  = 0.40) and no main (p = 0.31) or interactive effect of sex (p = 0.63) 
on wake-bedtime difference. 
 
  
 
 
 
Propranolol and placebo groups (n=59) Escitalopram and placebo groups (n=61) 
  
Figure 5.2. Sex differences in the CAR across groups in both sets of pairwise analyses. Blue line = male 
CAR; Pink line = female CAR. Error bars represent SEM.  
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Figure 5.1.  Propranolol versus placebo: Mean salivary cortisol values across the day 
averaged across men and women. Saliva samples were taken on waking, 
waking+30mins, 10am, noon, 4pm, 8pm, and at bedtime in healthy volunteers who 
received six day treatment with propranolol (pink line), or placebo (grey line). Error 
bars represent SEM.  
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Table 5.2. Mean cortisol parameter values and p values from ANOVAs comparing the effects of escitalopram and propranolol to placebo  
 Propranolol 
(n=30) 
Escitalopram 
(n=32) 
Placebo(n=32) Propranolol vs. placebo  Escitalopram vs. placebo  
Diurnal cortisol parameters Mean ± SD Mean ± SD Mean ± SD Group 
p value 
Group*sex  
p value 
Group  
p value 
Group*sex  
p value 
Waking cortisol (nmol/L) (n=90) 19.5±10.7 25.2±12.8 18.7±13.3 0.719 0.585 0.071 0.104 
Mean difference±SE 0.8±3.1 6.5±3.4      
Bedtime cortisol (nmol/L) (n=92) 3.91±2.79 5.99±9.68 6.31±8.76 0.332 0.428 0.836 0.092 
Mean difference±SE -2.40±1.65 -0.32±2.34      
Average evening cortisol (nmol/L) (n=92) 4.92±2.83 6.41±5.87 6.58±5.29 0.184 0.962 0.904 0.085 
Mean difference±SE -1.66±1.08 -0.17±1.42      
Cortisol AUC (nmol/L.hr) (n=87)  170.5±55.8 209.6±82.5 188.3±71.8 0.455 0.652 0.225 0.676 
Mean difference±SE -17.9±16.8 21.3±20.2      
CAR (nmol/L) (n=73) 12.5±14.2 7.6±12.3 13.1±14.9 0.790 0.432 0.440 0.221 
Mean difference±SE 0.2±3.9 -3.9±3.8      
Cortisol slope (nmol/L/min) (n=92) 0.0209±0.0157 0.0219±0.0239 0.0153±0.0224 0.338 0.976 0.378 0.023* 
Mean difference±SE 0.0056±0.0274 0.0066±0.0328      
Cortisol slope (wake/bedtime)(nmol/L/min) (n=90) 0.0152±0.0124 0.0193±0.0153 0.0123±0.0137 0.401 0.312 0.089 0.024* 
Mean difference±SE 0.0029±0.0185 0.0070±0.0205      
Mean difference is calculated by subtracting placebo values from each experimental condition. The SE of the mean difference was calculated as the square root of the sum of the squares of 
the SE for each group.   
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Escitalopram versus placebo 
There was no main effect of experimental condition (F(1, 55) = 1.51, p = 0.23) and no 
main (p =0.40) or interactive effect of sex (p = 0.68) on cortisol AUC. There was also no 
main effect of experimental condition (F(1, 48) = 0.61, p = 0.44) or interactive effect of 
sex (p = 0.22) on the CAR. However, there was a main effect of sex on the CAR (F(1, 
48) = 4.62, p = 0.037). The means indicate that women had more pronounced CARs than 
men, regardless of experimental condition (Women: M = 13.2, SE = 2.4; Men: M = 5.0, 
SE = 3.0) (see Figure 5.2).  
There was no main effect of experimental condition (F(1, 58) = 0.79, p = 0.38) or sex (p 
= 0.12) on cortisol slope. However, the ANOVA revealed a significant condition by sex 
interaction effect on cortisol slope (F(1, 58) = 5.49, p = 0.023) (see Figure 5.3). Splitting 
the file by sex revealed no effect of experimental condition on cortisol slope in men (F(1, 
22) = 0.75, p = 0.40). However, there was an effect of experimental condition in women 
(F(1, 36) = 7.54, p = 0.009). The means indicate that women taking escitalopram had 
steeper cortisol slopes (M = 0.0331, SD = 0.0173) compared with women receiving 
placebo (M = 0.0140, SD = 0.0233).  
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Figure 5.3. The interactive effect of sex on cortisol slope (wake-bedtime difference) 
within participants receiving escitalopram. Error bars represent SEM.  
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Similar findings emerged relating to the difference between waking and bedtime values. 
There was no main effect of experimental condition (F(1, 57) = 2.99, p = 0.09) or sex (p 
= 0.08) on wake-bedtime difference. There was a significant condition by sex interaction 
effect on wake-bedtime difference (F(1, 57) = 5.38, p = 0.024). Splitting the file by sex 
revealed no effect of experimental condition in men (F(1, 24) = 0.12, p = 0.75), but did 
reveal a main effect of condition in women (F(1, 35) = 13.5, p = 0.001).  Examining the 
means revealed that women taking escitalopram had a greater wake-bedtime difference 
(M = 0.0267, SD = 0.0106) compared to women taking placebo (M = 0.0118, SD = 
0.0133). These results indicated that women taking escitalopram had a steeper rate of 
cortisol decline across the day compared to those taking placebo. See Figure 5.4 for a 
graphical representation of salivary cortisol profiles across the day in men and women 
receiving escitalopram compared to placebo.  
Alterations in cortisol slope can be driven by levels of cortisol at waking and in the 
evening. Therefore, due to its effects on cortisol slope in women, we examined the effect 
of escitalopram on waking and evening cortisol levels in female participants. There was 
a significant main effect of drug on cortisol waking values (F(1, 35) = 9.21, p =0.005). 
Looking to the mean waking cortisol values indicates that levels were higher in female 
participants taking escitalopram (M = 30.4, SD = 9.4) compared to placebo (M = 18.6, SD 
= 13.3). There was no main effect of drug on cortisol evening values (F(1, 36) = 2.47, p 
= 0.13). I also examined the effects of the drugs on cortisol values at 10am, 12pm, and 
4pm. However, there were no significant main effects of drug, sex, or interactive effects 
of sex on any of these cortisol values (all p values > 0.05). What these findings suggest is 
that the alterations in cortisol slope seen in the female escitalopram group were being 
driven by increases in waking cortisol levels.  
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Seeing as men receiving escitalopram were significantly younger than men receiving 
placebo, sensitivity analyses were carried out with age included as a covariate in the male-
only analyses. ANCOVA revealed no significant main effects of drug on any of the 
cortisol parameters (all p values > 0.05).  
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Figure 5.4. Escitalopram versus placebo: Mean salivary cortisol values across the day 
in (A) men and (B) women. Saliva samples were taken on waking, waking+30mins, 
10am, noon, 4pm, 8pm, and at bedtime in healthy volunteers  who received six day 
treatment with escitalopram (blue line), or placebo (grey line). Error bars represent 
SEM.  
(A) 
(B) 
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5.8 Discussion 
 5.8.1 Summary of results 
The aim of this study was to assess the effects of six-day administration of beta-blockers 
and SSRIs on several different indices of diurnal HPA axis function. We hypothesised 
that both drugs would bring about changes in diurnal cortisol secretion. More specifically, 
we hypothesised that beta-blockers would increase diurnal cortisol secretion, in that the 
CAR and cortisol AUC would be enhanced leading to flatter cortisol slopes. We 
hypothesised that SSRIs would lead to reduced cortisol output with lower waking cortisol 
levels, a reduced CAR and cortisol AUC, and steeper cortisol slopes.  We also postulated 
that sex would play a role in the effects of the study drugs on cortisol secretion over the 
day. The results of this study provide limited support for these hypotheses. There were 
no effects of beta-blockade on cortisol dynamics. Compared with placebo, women taking 
SSRIs had significantly steeper cortisol slopes across the day. This observed difference 
in cortisol slope was independent of any differences in stress- or mood-related factors, 
suggesting that the observed results were due to direct biological effects of SSRIs on HPA 
axis function. The group taking SSRIs did not differ significantly on any other cortisol 
parameter.  
 5.8.2 Comparison to previous research 
Our results are in line with those of Rota et al. (2005) who found that 14 days 
administration of fluvoxamine to 20 depressed individuals resulted in a steepening of the 
cortisol slope. However, our findings are not in line with those of Hibel and colleagues 
and Tucker and colleagues who found that SSRIs had no significant effect on cortisol 
rhythm across the day in children with problem behaviour and depressed patients 
respectively (Hibel et al., 2007; Tucker et al., 2004).  
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It is difficult to compare the results of our study to others. This is largely because previous 
research has assessed effects of SSRIs on HPA axis function in clinical samples. As 
outlined previously, long-term treatment with SSRIs has been shown to reduce the 
cortisol AUC, as well as reduce waking levels of cortisol in patient samples with 
depression and generalised anxiety disorder (Hinkelmann et al., 2012; Knorr et al., 2012; 
Lenze et al., 2011; Ruhé et al., 2015). Cortisol AUC is known to be altered in depression 
and anxiety (Heaney et al., 2010; Marchand et al., 2014). Therefore, the effects of SSRI 
treatment on cortisol AUC may be more pronounced in those who have these stress-
related illnesses. We examined the effects of SSRIs in healthy volunteers which may 
explain why we did not observe any significant effects on overall daily cortisol output. 
In the current study, we found that women taking escitalopram had higher waking levels 
of cortisol compared to women taking placebo. This alteration in morning cortisol likely 
drove the significant changes in cortisol slope in this group. This finding is in line with 
that of Harmer and colleagues who found that six days administration of citalopram 
(20mg/day) brought about significant increases in waking cortisol in healthy volunteers 
(Harmer, Bhagwagar, Shelley, & Cowen, 2003). Conversely, in depressed patients, SSRIs 
have been found to lower levels of waking cortisol (Knorr et al., 2012; Ruhé et al., 2015). 
Waking levels of cortisol have been found to be increased in depression (Bhagwagar et 
al., 2005; Mannie et al., 2007). Therefore, the direction of the effect of SSRIs on waking 
cortisol may be related to mental health status – in depressed patients SSRIs ‘normalise’ 
elevated levels of waking cortisol, and in healthy individuals SSRIs increase waking 
levels. More research is needed to confirm this.  
It is possible that SSRI dosage (10mg/day) used in the current study was not sufficient to 
elicit changes in certain diurnal cortisol parameters in healthy volunteers (i.e. cortisol 
AUC, CAR, evening cortisol levels). Previous studies assessing the effects of 
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escitalopram initially prescribed 10mg per day to participants but then titrated up to 20mg 
as the study progressed (Hinkelmann et al., 2012; Park et al., 2015). Up-titration was not 
practicable in the current study due to the study duration. Perhaps if we had increased the 
dosage we would have observed significant effects of escitalopram on other diurnal 
cortisol parameter also. Additionally, we may have observed significant effects if we 
increased the duration of treatment.  
Previous studies have shown that 12 weeks treatment with paroxetine and escitalopram 
have significantly reduced the CAR in patients with major depressive disorder and 
generalised anxiety disorder respectively (Lenze et al., 2011; Ruhé et al., 2015). In this 
study SSRIs had no effect on the CAR. This may be for reasons to do with using a healthy 
sample as the CAR has been shown to be altered in depression and anxiety (Dedovic & 
Ngiam, 2015; Veen et al., 2011; Wardenaar et al., 2011), or it may be a power issue. As 
mentioned in Chapter 3, the accuracy margin of <15 minutes which we chose for the 
calculation of the CAR may have attenuated CAR estimates (Stalder et al., 2016). Another 
factor that may account for the lack of effect of SSRIs on the CAR is that the CAR may 
be under a regulatory cycle distinct from the cortisol slope (Clow et al., 2004). 
 5.8.3 Potential mechanisms explaining SSRI effects on the HPA axis 
Mechanistically, there are a number of ways in which escitalopram could have altered 
HPA axis function in women in the current study. As mentioned previously, the 
serotonergic system and HPA axis are reciprocally linked (Porter et al., 2004). The 
serotonergic system has been found to exert substantial effects on HPA axis function. 5-
HT1A receptors agonists are known to induce cortisol secretion in healthy volunteers 
(Pitchot, Wauthy, Legros, & Ansseau, 2004). Escitalopram administration leads to rapid 
desensitisation of the 5-HT1A receptor (Zhong, Haddjeri, & Sánchez, 2012). Therefore, 
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six day administration of escitalopram could lead to changes in 5-HT1A receptor 
sensitivity, therefore leading to changes in cortisol secretion. In fact, 
immunohistochemical studies have shown that 5-HT1A receptors are present on the 
paraventricular nucleus of the hypothalamus which is responsible for the release of CRH 
– the initial effector of the HPA axis (Lanfumey et al., 2008).  
As well as changes at the level of the serotonergic receptors, escitalopram may have 
exerted non-serotonergic effects on HPA axis function. A growing body of research 
suggests that SSRIs may exert effects on the HPA axis via modulation of the 
corticosteroid receptors. Four days treatment with citalopram has been shown to increase 
both GR and MR sensitivity in healthy humans (Pariante et al., 2012; Pariante, 
Papadopoulos, et al., 2004). Flatter cortisol slopes have been associated with reduced GR 
sensitivity (Jarcho et al., 2013). It is possible that the steeper cortisol slope seen in women 
taking escitalopram in the current study is a result of increased sensitivity of the 
corticosteroid receptors. I will investigate this in the next chapter of this thesis. SSRIs are 
also known to inhibit P-glycoprotein which is a protein that expels glucocorticoids from 
cells (Ruhé et al., 2015). Therefore, SSRIs may result in increases in levels of intracellular 
cortisol. As mentioned in Chapter 2, intracellular bioavailability of cortisol affects 
corticosteroid receptor sensitivity (Oakley & Cidlowski, 2013). However, escitalopram 
has little effect on the inhibition of P-glycoprotein (Zhong et al., 2012) so it is unlikely 
that this particular mechanism is of relevance to the results of the current study.    
 5.8.4 Sex differences in SSRI effects and HPA axis function 
Steeper slopes were only observed in women taking escitalopram. There are a number of 
reasons why this might be. Firstly, there are known sex differences in HPA axis function. 
Women have been shown to have increased diurnal cortisol secretion (Carpenter, 
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Grecian, & Reynolds, 2015), and higher oestrogen levels have also been associated with 
higher morning cortisol peaks (Wolfram, Bellingrath, & Kudielka, 2011). This may be 
why we observed higher CARs in women compared to men in the current study, 
independent of the effects of the study medications. Male steroidal sex hormones also 
appear to play a role in cortisol secretion. For example, testosterone is known to decrease 
corticosterone in rats (Panagiotakopoulos & Neigh, 2014).  
Secondly, the sex difference observed in the current study may be related to the 5-HT1A 
receptor. As mentioned earlier, stimulation of the 5-HT1A receptor increases cortisol 
secretion. It may be that the female HPA axis response is more responsive to increased 
levels of serotonin due to more enhanced stimulation of these receptors. According to 
Goel and colleagues, oestrogen potentiates 5-HT1A receptor stimulation of the HPA axis, 
whereas testosterone decreases it (Goel, Workman, Lee, Innala, & Viau, 2014). In further 
support of this, research has shown that the level of 5-HT1A receptor mRNA in the 
pituitary gland is almost seven times higher in women (Goel & Bale, 2010). This notion 
is also backed up by studies outlined earlier in this chapter where acute oral doses of 
SSRIs brought about significantly higher cortisol increases in women compared to men 
(Kuepper et al., 2006), and long-term doses brought about lower levels of basal cortisol 
secretion in men (Wedekind et al., 2008). 
Thirdly, and on a more general level, women with depression are known to have better 
responses to SSRIs compared to men. A review of 15 RCTs (n=332) revealed that female 
depressed patients on the whole are more responsive to SSRI treatment than male patients 
in terms of symptom remission (Khan, Brodhead, Schwartz, Kolts, & Brown, 2005). A 
more recent review provides evidence that oestrogen likely plays a role in the sex 
differences seen in therapeutic responses to SSRIs (Damoiseaux, Proost, Jiawan, & 
Melgert, 2014).  
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 5.8.5 Therapeutic implications 
Flatter slopes are characteristic of depression (Doane et al., 2013; Jarcho et al., 2013; 
Sjögren et al., 2006). Although no changes in stress or mood factors were observed in the 
current study, the steeper cortisol rhythm observed in women taking SSRIs may be one 
of the mechanisms through which these drugs exert their therapeutic effects. Flatter slopes 
are also characteristic of CHD (Nijm et al., 2007). In Chapter 3 of this thesis I showed 
how flatter cortisol rhythms, and lower waking cortisol levels, were associated with 
adverse outcomes in patients with advanced CHD (Ronaldson et al., 2015). The results 
of the current study suggest that SSRIs may be a potential therapeutic intervention for 
female CHD patients with flattened diurnal cortisol slopes, seeing as they steepen the 
cortisol slope and increase waking cortisol levels. Many patients with comorbid 
depression and CVD take SSRIs (Shapiro, 2015). In 1834 patients (female n = 849) with 
comorbid CHD and depression, SSRI use was associated with a significantly lower risk 
of death or recurrent cardiac event in the 29 months following the occurrence of an MI 
(Taylor, Youngblood, Catellier, et al., 2005). It is possible that alterations in HPA axis 
function may be one of the ways in which SSRIs exert their protective effects in CHD 
patients. However, a recent study examining the effect of 18 months treatment with 
escitalopram on all-cause mortality in heart failure patients with depression found that 
escitalopram did not significantly reduce mortality or hospitalisation rates compared to 
placebo (Angermann, Gelbrich, Störk, et al., 2016). Only a quarter of the sample was 
comprised of women which may be why no effects were detected. Another reason for this 
lack of effect might be age. Age has been shown to influence the effectiveness of SSRIs 
(Olivier, Blom, Arentsen, & Homberg, 2011) with older people (>50 years) having poorer 
responses to SSRIs (Thase, Entsuah, Cantillon, & Kornstein, 2005). The current study 
was carried out in a relatively young sample, meaning that the results may not be 
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replicable in older patient sample, like in those with CVD. This area warrants further 
investigation, and future studies should take age and sex differences into consideration.  
 5.8.6 Beta-blockers: Lack of effect 
In the current study, beta-blockers had no significant effect on any of the diurnal cortisol 
parameters. This is in line with previous findings where long-term administration of beta-
blockers brought about no changes in plasma cortisol levels, although these studies did 
not assess diurnal cortisol patterns (Golub et al., 1981; Rosen et al., 1988). As mentioned 
in Chapter 2, the SAM system and the HPA axis are the major biological systems involved 
in the stress response, and these systems interact during times of stress. There is also 
evidence to suggest that these two systems interact under basal, unstressed conditions. In 
both healthy and depressed patients diurnal variations cerebrospinal fluid levels of 
norepinephrine and plasma cortisol levels are very highly correlated (Wong et al., 2000). 
Therefore it is puzzling that under unstressed conditions beta-blockade did not bring 
about alterations in diurnal cortisol secretion in this study.  
It is possible that the propranolol dosage used in the current study was not sufficient to 
elicit changes in diurnal cortisol parameters in healthy volunteers. An 80mg dose failed 
to bring about changes in the current study. However, 80mg of propranolol was found to 
be sufficient to induce change in basal plasma levels of night-time cortisol in healthy men 
(Dart et al., 1981). These alterations in night-time cortisol levels were observed after six-
week administration of propranolol. It is possible that the treatment duration of the current 
study (six days) was not sufficient to elicit changes in indices of diurnal HPA axis 
function. Although, administration of acute doses of propranolol (ranging from 10-80mg) 
have brought about increases in circulating cortisol levels in healthy and diabetic 
volunteers (Kizildere et al., 2003; Lewis et al., 1981; Popp et al., 1984). Propranolol is a 
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rapidly metabolised drug that exerts effects on the β-adrenergic receptors quickly (Leahey 
et al., 1980). Propranolol has a half-life of about three to four hours and there is large 
variability in bioavailability across individuals due to rapid metabolism of propranolol in 
the liver (Gomeni, Bianchetti, Sega, & Morselli, 1977). In the current study, participants 
were instructed to take propranolol every morning after their breakfast. However, there 
is no guarantee participants took the drug at the same time every day, or with food which 
is known to affect its bioavailability (Liedholm, Wåhlin-Boll, & Melander, 1990). 
Therefore, although participants received sustained-release propranolol, it is possible that 
there may have been a high rate of variability between participants in the current study 
regarding the bioavailability of propranolol. This may be why there were no significant 
effects on diurnal HPA axis function. Future studies should determine blood 
concentrations of propranolol at the end of the treatment period in order to adjust for this 
factor.   
As mentioned in Chapter 4, propranolol was chosen to assess the effects of changes in the 
peripheral nervous system on HPA axis function. However, as well as exerting effects on 
the beta-adrenergic receptors, there is evidence that propranolol also might act as an 
antagonist of the serotonin receptors 5-HT1A and 5-HT1B (Davids & Lesch, 1996; Hoyer 
et al., 1994). Therefore, propranolol may not have been the most appropriate 
pharmacological probe for assessing the effects of sympathetic activation on HPA axis 
function. Future research should seek to use beta-blockers that do not act on serotonin 
receptors, such as the selective beta-blocker metoprolol.    
 5.8.7 Strengths and limitations 
A strength of this study is that it was a randomised placebo-controlled double-blind trial. 
We adopted a parallel group design meaning that participants receiving placebo acted as 
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the control comparison group for both experimental medications. The three groups in the 
study did not differ significantly in demographic or stress-related factors. As we did not 
employ a crossover design it is possible that the treatment groups were unbalanced on 
some covariates that were not measured in the study. However, adopting a parallel groups 
design allowed us to avoid problems relating to order and carry-over effects to do with 
the study medications. It also meant that participants were unable to become habituated 
to the stress protocol. 
This study had a retention rate of 88.5% with 94 participants providing usable data on 
some parameters of diurnal cortisol secretion. However, it is possible that this study was 
underpowered to detect certain effects. There were also more women than men in the 
current study, meaning that we may have lacked sufficient statistical power to detect drug 
effects in men. Additionally, our sample was largely composed of healthy university 
students from high socioeconomic backgrounds. Therefore the results may not be readily 
generalizable to other groups, or to clinical groups with depression or CVD.  
Cortisol was measured over a single day meaning that the diurnal secretion may have 
been affected by situational factors rather than long-term factors. As mentioned 
previously in Chapter 3 of this PhD, diurnal indices of HPA axis function are 
predominantly affected by trait factors on weekdays as most people have established 
weekday routines (Hellhammer et al., 2007). In the Stress Pathways Study we measured 
cortisol over the course of a weekday which may help counteract the effects of single-day 
sampling. However, the majority of participants were students meaning that routine may 
have been quite variable across weekdays. Therefore the diurnal cortisol profiles of 
participants may have reflected state-like properties rather than trait-like influences. This 
measurement issue should be borne in mind while interpreting results. 
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One further limitation of this study was the use of multiple testing. Within each 
comparison group the effects of experimental condition on seven different cortisol 
parameters were measured simultaneously. This means that the probability of observing 
a significant result due to chance was increased. Use of the Bonferroni correction would 
have set the significance cut-off at p < 0.007, thereby rendering the effects of SSRIs on 
cortisol in females non-significant. However, the Bonferroni correction has a tendency to 
be too conservative (Narum, 2006), and the replication of the significant effects of SSRIs 
in both cortisol slope and wake/bedtime difference in women implies that this result was 
not down to chance.  
 5.8.8 Conclusion 
In conclusion, the results of this study indicate that six day treatment with the SSRI 
escitalopram may bring about a steepening of cortisol slopes in healthy women, via 
increases in waking cortisol levels. Flattened cortisol rhythms have been associated with 
chronic stress, depression, and CHD. This finding suggests that flattening of the cortisol 
slope in women may be related to alterations in the serotonergic system. It also implies 
that SSRIs may exert their therapeutic effects in women via correction of a flattened 
diurnal cortisol rhythm. However, due to the various methodological limitations of this 
study future research is needed to replicate this result. In the following chapter I will 
examine the effects of these study medications on cortisol stress reactivity, corticosteroid 
receptor sensitivity, and other stress-related factors which may help to further explain the 
results of the current study. 
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Chapter 6 
Study 3 – The Stress Pathways Study results: The effect of pharmacological 
blockade on cortisol stress reactivity and corticosteroid receptor sensitivity in 
healthy volunteers 
6.1 Introduction 
In this chapter I will present results from the Stress Pathways Study concerning the effects 
of beta-blockade and SSRIs on cortisol secretion in response to acute psychosocial stress. 
I will also present results regarding the effects of acute psychosocial stress on 
corticosteroid receptor sensitivity. Moreover, I will examine the effects of the study 
medications on baseline corticosteroid receptor sensitivity, and changes in receptor 
sensitivity after acute stress.  
In order to paint a broader picture of how the study medications are affecting the 
biological stress response, I will examine the effects of the medications on cardiovascular 
stress reactivity.  
Together with the results from Chapter 5 of this thesis, these results may shed light on the 
biological mechanisms involved in dysregulation of HPA axis, and highlight medications 
that might be suitable for the treatment of impaired HPA axis function.  
6.2 Literature review: Beta-blockers and cortisol stress reactivity 
In Chapter 5 I described how the HPA axis and the SAM system are anatomically linked 
and how they interact with each other in order to regulate a number of stress-related 
functions, including the release of pro-inflammatory cytokines. However, under basal, 
unstressed conditions I found that six-day treatment with propranolol brought about no 
significant changes in diurnal HPA axis function. It is possible that propranolol may affect 
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stress-related cortisol levels. A number of studies have investigated the effects of beta-
blockade on cortisol responses to a number of types of stress which will be outlined 
below.  
 6.2.1 Acute administration of beta-blockers 
Early investigations in to the effects of beta-blockade on stress-related HPA axis function 
examined cortisol responses to exercise. MacDonald and colleagues administered either 
a single dose of metoprolol (100mg), propranolol (80mg), or placebo in a crossover 
design to 10 men with essential hypertension (Macdonald, Bennett, Brown, Wilcox, & 
Skene, 1984). The men then underwent a prolonged exercise protocol. The single dose of 
propranolol, but not metoprolol, brought about significant increases in plasma cortisol 
and adrenaline levels during exercise compared to placebo. Similar increases in cortisol 
responses to submaximal exercise have been observed in healthy untrained men receiving 
acute intravenous pre-treatment with propranolol (Jezová, Vigas, Klimes, & Jurcovicová, 
1983). In agreement with these earlier studies, a more recent study reported increases in 
plasma cortisol levels in ten healthy men undergoing maximal exercise to exhaustion after 
a dose of 80mg propranolol compared to placebo (Viru et al., 2007). However, single 
doses of 150mg metoprolol and 120mg propranolol brought about no significant changes 
in cortisol secretion following exercise (30m cycle) in seven healthy men compared to 
placebo (Uusitupa et al., 1982). 
Acute effects of beta-blockers on cortisol reactivity to psychosocial stress have also been 
examined. Andrews and Pruessner, in what they called the ‘propranolol suppression test’ 
administered a single dose of propranolol (80mg) or placebo to 30 healthy men (n=15 in 
each group) (Andrews & Pruessner, 2013). Following this, participants underwent the 
TSST. Results showed that those who received propranolol had significantly increased 
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cortisol responses to acute stress alongside significantly decreased heart rate responses, 
compared to the placebo group. A single 80mg dose of propranolol given to 14 healthy 
men who underwent a psychosocial stress protocol resulted in higher salivary cortisol 
stress responses compared to placebo-treated men (Maheu, Joober, & Lupien, 2005). In 
six young Type A men, a single dose of propranolol attenuated heart rate responses and 
increased cortisol responses to mental arithmetic stress (Williams, Lane, Kuhn, Knopes, 
& Schanberg, 1988). However, Dreifus and colleagues administered 60mg propranolol 
or placebo to 48 healthy women prior to undergoing the TSST and found that both groups 
experienced stress-induced cortisol increases that did not differ significantly (Dreifus, 
Engler, & Kissler, 2014). It is possible that the 60mg dose administered by Dreifus and 
colleagues (2014) was not adequate to bring about changes in stress-related HPA axis 
function, seeing as the majority of studies reporting cortisol increases administered 80mg 
propranolol. 
More novel stress paradigms have been used to investigate the effects of acute beta-
blockade on stress-related HPA axis function. Benschop and colleagues report that 160mg 
(4x40mg doses) propranolol administered over 1.5 days to 16 healthy men undergoing 
their first-time parachute jump elicited no effects in cortisol stress reactivity compared to 
placebo (Benschop et al., 1996). However, the men receiving propranolol did have more 
pronounced ACTH responses to the jump than those receiving placebo (Oberbeck et al., 
1998).  Cortisol responses to cold water immersion stress were also increased by a 40mg 
dose of propranolol in eight healthy young men (Šimečková, Janskỳ, Lesna, Vybiral, & 
Šrámek, 2000). Khan and colleagues examined the effects of an acute intravenous dose 
of propranolol (0.2mg/kg) on cortisol responses to pentagastrin administration in 16 
healthy men and women (Khan, Liberzon, & Abelson, 2004). Pentagastrin is a substance 
that produces symptoms of anxiety and panic, and brings about strong activation of the 
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HPA axis. Compared to placebo, those who received propranolol had a delayed but 
enhanced cortisol response to pentagastrin. ACTH and adrenaline responses were also 
enhanced in the propranolol group. The heart rate acceleration usually brought about by 
pentagastrin was virtually eliminated by propranolol also. 
Together, what these results suggest is that acute beta-blockade brings about enhanced 
cortisol stress reactivity. At the same time, beta-blockade also attenuates heart rate 
responses to stress. This implies an inverse relationship between the HPA axis and the 
SAM system in that suppression of the SNS stress response by beta-blockade brings about 
an increase in HPA axis function. In support of this, a study that combined the DST with 
the TSST found that those who had received dexamethasone the night before stress testing 
had lower cortisol stress responses in combination with an elevated heart rate compared 
to the placebo group (Andrews, D’Aguiar, & Pruessner, 2012).  
 6.2.2 Long-term administration of beta-blockers 
The effects of more long-term administration of beta-blockers on cortisol stress reactivity 
have also been examined, but to a lesser extent than acute administration. Two early 
studies examined the effects of long-term beta-blockade on cortisol responses to exercise. 
In the first study, 10 men with essential hypertension received 28 day treatment with 
propranolol (80mg/day), metoprolol (100mg/day), and placebo in a crossover design 
(Macdonald et al., 1984). Following this, the men underwent a prolonged exercise 
protocol. Both the propranolol and metoprolol treatment brought about increased cortisol 
responses to exercise compared to placebo. Similarly, in 18 healthy young men 100mg 
metoprolol (twice daily) and 10mg timolol (twice daily) for five days resulted in 
significantly increased cortisol responses to exercise compared to placebo (Gullestad, 
Dolva, Kjeldsen, Eide, & Kjekshus, 1989).  
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To date, only one study has examined the effects of prolonged beta-blockade on cortisol 
responses to psychosocial stress. Kudielka and colleagues administered propranolol 
(80mg/day) to 19 healthy men and women for five days (Kudielka et al., 2007). 
Participants then underwent the TSST. Neither pre-stress cortisol levels nor cortisol 
responses to the TSST in the propranolol group differed significantly from placebo. 
Similar null findings have been reported in 20 healthy male volunteers undergoing a 
bungee jump who received three day pre-treatment with propranolol (3 x 40mg/day) (van 
Westerloo et al., 2011). 
 6.2.3 Summary 
Taken together, the studies examining effects of acute beta-blockade on cortisol stress 
reactivity suggest that acute suppression of the SNS via beta-blockade seems to enhance 
HPA axis stress reactivity. This effect appears to hold despite heterogeneity between 
studies in terms of sample size, stress paradigm, route of drug administration, and 
biological specimen used for cortisol measurement (saliva/plasma). However, results 
from studies examining more long-term effects of beta-blockade on cortisol stress 
reactivity have been mixed. Five-day and 28-day administration of beta-blockers appear 
to increase cortisol secretion following exercise paradigms. However, using a 
psychosocial stress paradigm and a more novel bungee jump paradigm has produced null 
findings. This is peculiar considering acute doses appear to bring about enhanced cortisol 
responses to the TSST. Interestingly, the studies that report these enhanced responses do 
so only in male samples (Andrews & Pruessner, 2013; Maheu et al., 2005; Williams et 
al., 1988). Dreifus and colleagues reported null findings following the TSST in a sample 
comprised of women (Dreifus et al., 2014). The inclusion of women in the sample may 
have been one of the reasons Kudielka and colleagues (2007) report null findings 
following longer-term administration of propranolol. Neither study include the use of 
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contraceptive pill as a covariate – something that is known to affect cortisol stress 
reactivity (Rohleder, Wolf, Piel, & Kirschbaum, 2003). This may also have affected 
results obtained.  
In sum, the results of this body of work suggest that suppression of the SNS brings about 
increases in stress-related HPA axis function. However, further work is needed examining 
effects of longer-term beta-blocker administration.  
6.3 Literature review: SSRIs and cortisol stress reactivity 
In Chapter 5 I reported results from the Stress Pathways Study showing that SSRIs 
brought about steeper diurnal cortisol rhythms in women. Flatter slopes are known to be 
characteristic of depression (Doane et al., 2013; Jarcho et al., 2013; Sjögren et al., 2006) 
and the results from the Stress Pathways Study suggest that SSRI treatment may 
normalise the diurnal cortisol rhythm in women. Cortisol stress reactivity is also known 
to be dysregulated in depression with both enhanced and blunted cortisol responses to 
stress being reported depending on the severity and duration of depressive symptoms. It 
is possible that SSRIs may affect the cortisol stress response also. A number of studies 
have examined these effects. 
6.3.1 Acute administration of SSRIs 
Using a crossover design, Ahrens and colleagues administered single doses of either the 
SSRI sertraline (100mg) or placebo to 12 healthy men (Ahrens, Frankhauser, Lederbogen, 
& Deuschle, 2007). They then examined neuroendocrine responses to exercise stress. 
Baseline pre-exercise cortisol levels in the sertraline group were higher, and the cortisol 
responses to exercise stress were enhanced in this group also. The effects of acute SSRI 
administration on cortisol response to psychosocial stress have also been examined. 
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Healthy men were randomised to receive single doses of 10mg escitalopram (n=17), 
20mg escitalopram (n=14), or placebo (n=12) (Garcia-Leal, Del-Ben, Leal, Graeff, & 
Guimarães, 2010). Following this, they underwent a simulated public speaking protocol, 
similar to the public speaking component of the TSST. Escitalopram did not bring about 
any significant alterations in cortisol stress reactivity compared to placebo. However, this 
is probably because the public speaking protocol did not elicit a cortisol stress response 
in either group.  
 6.3.2 Long-term administration of SSRIs 
A number of studies have examined the effects of longer-term SSRI administration on 
cortisol stress reactivity, with mixed results. Ljung and colleagues administered six 
months treatment with citalopram (20-40mg/day) or placebo to 16 healthy men with 
moderate abdominal obesity in a crossover trial (Ljung et al., 2001). Following the 
treatment period, the men underwent an arithmetic stress test. Citalopram brought about 
increases in baseline morning cortisol values, and following stress cortisol secretion was 
enhanced in the citalopram group. Duncko and colleagues examined the effects of SSRIs 
in an all-male sample also. Thirty-one healthy men were randomised to receive either 
tianeptine (37.5mg/day), citalopram (20mg/day), or placebo for six days. Following this, 
the men underwent a stress protocol comprised of a short intelligence test and the Stroop 
colour interference test. The antidepressant drugs brought about no changes in cortisol 
stress reactivity compared to placebo. However, after seven days administration, 
antidepressant treatment in the same male sample brought about enhanced ACTH 
responses to insulin-induced hypoglycaemia compared to placebo (Jezová & Duncko, 
2002). Cortisol remained unaffected.  
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Kotlyar and colleagues have investigated the effects of SSRIs on cortisol stress reactivity 
in a mixed healthy sample. Using a crossover design, 62 men and women received one 
month treatment with paroxetine (10-20mg/day) and placebo (Kotlyar et al., 2013). 
Following treatment participants underwent a modified version of the TSST. Paroxetine 
brought about a significant overall increase in cortisol levels. However, there was no 
significant difference in the cortisol stress response between the conditions.  
Cortisol stress reactivity in depressed patients undergoing treatment with SSRIs has also 
been examined. Patients with major depression who had been treated with bupropion 
(200-450mg/day, n=17), or paroxetine (10-50mg/day, n=17) for at least two months were 
compared to 15 non-depressed controls (Straneva-Meuse, Light, Allen, Golding, & 
Girdler, 2004). All participants underwent a modified version of the TSST. Those taking 
bupropion and paroxetine had blunted cortisol stress reactivity compared to healthy 
controls.  
 6.3.3 Summary 
Only one study to date has assessed the effects of acute SSRI treatment on cortisol 
responses to psychosocial stress (Garcia-Leal et al., 2010). The pharmacological effects 
of SSRIs are known to be delayed (Frazer & Benmansour, 2002) meaning that longer-
term administration may be required to see the effects of SSRIs on cortisol stress 
reactivity. However, the results from these longer-term studies have been mixed. As with 
the longer-term beta-blocker studies, SSRIs only seem to enhance stress-related 
neuroendocrine activity in all-male samples (Jezová & Duncko, 2002; Ljung et al., 2001). 
Healthy and depressed samples report null findings or blunted cortisol reactivity 
respectively (Kotlyar et al., 2013; Straneva-Meuse et al., 2004). To date, there have been 
too few studies carried out on the effects of SSRIs on the cortisol stress response, and 
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amongst the studies that do exist there has been much variability in terms of sample 
characteristics (e.g. healthy versus depressed versus abdominally obese), treatment 
duration, and stress protocol used. The evidence suggests that SSRIs affect basal/diurnal 
cortisol secretion, and that they likely also affect secretion during times of stress. More 
work is needed to clarify these effects.  
6.4 Cortisol stress reactivity: Aims and hypotheses 
The aim of this study was to examine the effects of seven-day administration of beta-
blockers and SSRIs on cortisol stress reactivity in the laboratory using data from the 
Stress Pathways Study. As discussed in Chapter 2, chronic stress and depression are 
associated with changes in the cortisol stress response. Altered cortisol stress reactivity 
has also been associated with cardiovascular risk factors, and has been seen in CHD 
patients. Looking at how beta-blockers and SSRIs might alter cortisol secretion after 
acute laboratory stress in healthy volunteers may provide information about the biological 
systems involved in stress-related HPA axis dysregulation and may also identify potential 
therapeutic interventions.  
Beta-blockers 
Based on results from studies outlined above, I hypothesise that seven-day treatment with 
propranolol will bring about increased cortisol stress reactivity in the laboratory.  
SSRIs 
Based on results from studies outlined above in healthy volunteers free from depression, 
I hypothesise that seven-day treatment with escitalopram will bring about increases in 
cortisol stress reactivity in the laboratory. 
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Moreover, in studies examining longer-term administration of beta-blockers and SSRIs 
on cortisol stress reactivity, significant enhancement of cortisol secretion has only been 
reported in all-male samples. Therefore, I will also examine how sex influences the effects 
of the study medications. 
6.5 Literature review: Beta-blockers and corticosteroid receptor sensitivity 
As mentioned previously, studies using beta-blockers have provided evidence for the 
notion that suppression of the SNS brings about increased HPA axis activity. It is possible 
that beta-blockade may modulate HPA axis activity via the corticosteroid receptors. For 
example, epinephrine and norepinephrine have been shown to affect GR transactivation, 
and GR binding to GREs within the cell nucleus (Schmidt, Holsboer, & Spengler, 2001). 
However, there is a dearth of research assessing the effects of beta-blockade on 
corticosteroid receptor function. To date, one study has assessed the effects of drugs 
commonly used to treat CHD on GR protein levels, and one of the drugs included was 
the beta-blocker metoprolol. Measuring GR protein levels gives an indication of GR gene 
function. Eighty hospitalised CHD patients were enrolled in the study. Twenty of these 
patients received metoprolol (50mg/day) and GR protein levels in lymphocytes were 
measured before and one month after administration of the drug (Ji, Guo, Yan, Li, & Lu, 
2010). Results indicated that those taking metoprolol had increased GR protein levels 
following one month of treatment, compared with baseline levels. This result provides 
support for modulation of the corticosteroid receptors by beta-blockade. However, much 
more work is needed, particularly in healthy volunteers where the drug effects cannot be 
ascribed to symptom remission. Examining both the effects of beta-blockade on basal 
corticosteroid receptor sensitivity and on how the receptors respond to acute stress would 
provide information on how suppression of the SNS brings about increases in HPA axis 
function.  
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6.6 Literature review: SSRIs and corticosteroid receptor sensitivity 
As mentioned previously, depression is known to be characterised by dysregulation of 
the HPA axis. One explanation of this dysregulation is an imbalance in both GR and MR 
sensitivity. There is evidence to suggest that SSRIs directly modulate corticosteroid 
receptor sensitivity. This may be one of the mechanisms through which SSRIs serve to 
‘normalise’ HPA axis activity (Anacker, Zunszain, Carvalho, & Pariante, 2011). The 
effects of SSRIs on both corticosteroid receptor function and sensitivity have been 
examined in both murine and human studies.  
 6.6.1 Murine studies 
Pariante and colleagues examined the effects of 24-hour co-incubation of LMCAT 
murine cells with dexamethasone and the SSRIs paroxetine, citalopram, and fluoxetine 
on GR function (Pariante et al., 2001; Pariante, Kim, Makoff, & Kerwin, 2003). GR 
function was measured by looking at rates of GR-mediated gene transcription. 
Citalopram, paroxetine, and fluoxetine, were all found to enhance GR function in this cell 
line. They also found that SSRIs increased GR function by inhibiting the LMCAT cell 
membrane steroid transporter (a protein, like p-glycoprotein, that expels glucocorticoids 
from cells). This idea was later disproven when Mason and colleagues showed that the 
effects of the tricyclic antidepressant desipramine on glucocorticoid accumulation did not 
differ between wild-type and p-glycoprotein knockout mice (Mason, Thomas, Lightman, 
& Pariante, 2011). 
Lai and colleagues assessed the effects of four-day incubation with fluoxetine on GR and 
MR mRNA expression in rat hippocampal cells (Lai et al., 2003). In line with Pariante’s 
findings, fluoxetine significantly increased GR mRNA expression. However, MR mRNA 
expression was unaffected. The authors suggest this shows that GR and MR are 
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differentially regulated by short-term exposure to increased serotonin levels. 
Interestingly, nine-day incubation with fluoxetine brought about a decrease in MR mRNA 
expression in rat hippocampal cells (Yau, Noble, Hibberd, & Seckl, 2001). However, this 
differential regulation in GR and MR function seems to even out following 14-day 
treatment with SSRIs. In rat hippocampal cells, 14-day incubation with paroxetine 
brought about increases in GR mRNA expression (Okugawa et al., 1999), and incubation 
with citalopram for the same time period also brought about increases in MR mRNA 
expression (Seckl & Fink, 1992). This indicates that longer-term incubation with SSRIs 
brings about increased GR and MR function. 
 6.6.2 Human in vitro studies 
The effects of fluoxetine on GR function has been measured in the lymphocytes of healthy 
volunteers (Okuyama-Tamura, Mikuni, & Kojima, 2003). In this study GR function was 
measured by looking at the rate of translocation of the GR into the cell nuclei. Following 
one hour incubation, fluoxetine induced rapid translocation of the GR into the cell nuclei, 
meaning this SSRI enhanced GR function. Carvalho and colleagues investigated the 
effects of a number of different types of antidepressants on GR sensitivity in whole blood 
drawn from healthy volunteers (Carvalho, Garner, Dew, Fazakerley, & Pariante, 2010). 
GR sensitivity was measured using dexamethasone inhibition of LPS-stimulated IL-6 
production in whole blood. Whole blood was co-incubated for 24 hours with 
dexamethasone and two different tricyclic antidepressants, one serotonin and 
norepinephrine reuptake inhibitor (SNRI) and two SSRIs (sertraline and paroxetine). The 
results indicated that all the antidepressant types brought about reduced GR sensitivity. 
This finding is in disagreement with previous research which indicates that 
antidepressants seem to increase GR function in murine and human in vitro studies.  
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 6.6.3 Human in vivo studies 
As mentioned in Section 2.9.2 of this thesis, the DST is the most widely used method to 
measure GR-mediated negative feedback of the HPA axis in humans in vivo (Rohleder, 
Wolf, & Kirschbaum, 2003). The dexamethasone/CRH (dex/CRH) test is another version 
of the DST which is said to be more specific, and have more utility when it comes to 
diagnosing mood disorders (Watson, Gallagher, Smith, Ferrier, & Young, 2006). The 
dex/CRH test is essentially a DST followed by a CRH infusion which is supposed to 
induce the release of ACTH from the pituitary. Like the DST, the dex/CRH test is 
considered an indirect way to measure corticosteroid receptor sensitivity as 
dexamethasone administration will modulate the HPA axis via interaction with the 
corticosteroid receptors. Some argue that the dex/CRH test can detect subtle changes in 
HPA axis function that the DST cannot (Watson et al., 2006). However, others claim that 
the dex/CRH test simply measures GR-mediated negative feedback of the HPA axis at 
both the level of the adrenal and the pituitary glands (Pariante & Miller, 2001). 
Studies that have investigated the effects of antidepressants on glucocorticoid sensitivity 
in vivo have almost exclusively used the dex/CRH test. The majority of studies have been 
carried out in depressed patients. Nickel and colleagues provided six weeks treatment 
with paroxetine to 22 depressed men and women (Nickel et al., 2003). These patients 
underwent the dex/CRH test at baseline and at the end of the treatment period. Paroxetine 
administration resulted in decreases in ACTH and cortisol levels following the dex/CRH 
tests indicating SSRI-induced increases in GR sensitivity. In a similar study, 20 depressed 
patients underwent the dex/CRH test following one week of receiving placebo, and after 
two, four, and 16 weeks of receiving treatment with citalopram (40mg/day) (Nikisch et 
al., 2005). There was a time-dependent reduction in the ACTH and cortisol responses to 
the test over the 16-week treatment period indicating an increase in corticosteroid receptor 
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sensitivity. Moreover, the magnitude of the decrease in cortisol responsivity (increase in 
receptor sensitivity) at four weeks was significantly associated with a reduction in 
depressive symptoms at 16 weeks.  
Bschor and colleagues gave 30 patients with depression four weeks SSRI therapy with 
citalopram (20-40mg/day) (Bschor et al., 2012). The patients underwent the dex/CRH test 
before and after treatment. Citalopram reduced the amount of ACTH released following 
the dex/CRH test indicating increased GR sensitivity. Cortisol levels remained 
unaffected. This implies that citalopram effects took place at the pituitary, but not the 
adrenal, level of the HPA axis. Reductions in ACTH and cortisol responses to the 
dex/CRH test have also been observed in 30 female patients with borderline personality 
disorder receiving 12-week treatment with fluvoxamine (150mg/day) (Rinne et al., 2003). 
Interestingly, those who had a history of sustained childhood abuse showed the strongest 
reduction in responses, and they also had the lowest GR sensitivity at baseline. This 
indicates that SSRI treatment increased GR sensitivity in these patients, particularly in 
those who had experienced chronic stress in early life.  
However, some studies have reported contradictory results in depressed patients. In a 
recent study, 28 patients with major depression received five weeks treatment with 
escitalopram (10mg/day) (Sarubin, Nothdurfter, Schmotz, et al., 2014). The dex/CRH test 
was carried out at baseline, and after one and five weeks of treatment with the SSRI. 
Interestingly, escitalopram led to an increase in cortisol responses to the dex/CRH test 
after week one, whereas levels of suppression at baseline and five weeks were 
comparable. What this implies is that treatment with escitalopram brought about a 
transient decrease in GR sensitivity, but overall had no significant long-term effect. An 
observational study has also reported decreased GR sensitivity in SSRI users. Manthey 
and colleagues examined cross-sectional associations between SSRI use and responses to 
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the DST in 1526 patients from the Netherlands Study of Depression and Anxiety 
(Manthey et al., 2011). Compared to non-users (n=1068), those who used SSRIs (n=309) 
had decreased cortisol suppression after dexamethasone ingestion. This implies that they 
had reduced GR sensitivity. The authors controlled for a number of relevant factors 
including duration of SSRI use, and severity of depression. They posit that treatment 
resistance, a factor they did not consider in their analysis, may explain their incongruous 
result. Treatment resistance has been associated with impaired responses to 
glucocorticoid suppression tests (Juruena et al., 2009). 
The effects of SSRIs on glucocorticoid sensitivity have also been examined using healthy 
samples. Carpenter and colleagues administered six weeks treatment with either sertraline 
(100mg/day) or placebo to 22 healthy men and women (Carpenter et al., 2011). 
Participants underwent the dex/CRH test at baseline and following the treatment period. 
The results showed that those who received sertraline had increased cortisol levels 
following the dex/CRH test compared with placebo. This implies that SSRI treatment in 
healthy people led to a decrease in GR sensitivity, leading to impaired feedback inhibition 
of the HPA axis. Pariante and colleagues examined the effects of shorter-term 
administration of SSRIs in healthy volunteers (Pariante et al., 2004). Eight healthy men 
and women were given four days administration of citalopram (20mg/day). Participants 
underwent the PST at baseline and after the four days treatment. Citalopram increased 
cortisol suppression by prednisolone indicating that this SSRI brought about increased 
corticosteroid receptor sensitivity (prednisolone binds to both the GR and MR). However, 
this increase in suppression was only observed in the morning, and not in the early or late 
afternoon, implying that the diurnal rhythm of HPA axis activity (regulated by the MR) 
may be an influencing factor here.  
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 6.6.4 Summary 
In murine samples it appears that SSRIs bring about increases in corticosteroid receptor 
function. Similarly, in vitro examination of GR function in human lymphocytes reveals 
that SSRIs increase the rate of translocation of the GR into the cell nuclei. However, GR 
sensitivity, measured using in vitro glucocorticoid sensitivity assays, appears to be 
decreased in human whole blood incubated with antidepressants. Directly measuring GR 
function (translocation of receptors into cell nuclei) is different to assessing sensitivity 
using glucocorticoid sensitivity assays as they provide only a proxy measure of biological 
receptor ‘function’. This may be a reason for the discrepancy in results.  
Within depressed patients, the research suggests that SSRI treatment does bring about 
increases in GR receptor sensitivity as measured by the dex/CRH test. In one case the 
magnitude of the increase in sensitivity was associated with symptom improvement. 
These results are in support of the notion that SSRIs may help to ameliorate symptoms of 
depression by ‘normalising’ dysregulated HPA axis function. Two studies reported 
decreases in receptor sensitivity in depressed patients (Manthey et al., 2011; Sarubin, 
Nothdurfter, Schmotz, et al., 2014). However, Manthey and colleague’s study did not 
adopt an experimental design meaning a number of factors could not be controlled for. In 
Sarubin and colleague’s study, the participants were also randomised to undergo a yoga 
intervention (Sarubin, Nothdurfter, Schüle, et al., 2014). Yoga is known to affect cortisol 
levels (Field, 2011), and this factor was not adjusted for in this study meaning the yoga 
intervention could have influenced how the SSRIs interacted with the HPA axis.  
To date, only two studies have assessed the effect of SSRIs on corticosteroid receptor 
sensitivity in healthy people, eliciting mixed results. Long-term treatment was found to 
decrease GR sensitivity whereas short-term treatment was found to increase both GR and 
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MR sensitivity in the morning only. Due to the difference in treatment durations, and the 
use of different suppression tests (dex/CRH versus PST), it is difficult to draw 
conclusions from the results of these studies. More work is needed examining the effects 
of SSRIs on corticosteroid receptor function in healthy individuals. Additionally, 
examining the effects of SSRIs on how corticosteroid receptors sensitivity changes in 
response to acute stress may shed light on how SSRIs affect cortisol stress reactivity. 
6.7 Corticosteroid receptor sensitivity: Aims and hypotheses 
The aim of this study was to assess the effects of seven-day administration of beta-
blockers and SSRIs on corticosteroid receptor sensitivity both before and after acute 
psychosocial stress in the laboratory using data from the Stress Pathways Study. As 
outlined in Chapter 2, chronic stress and depression are associated with alterations in 
corticosteroid receptor sensitivity. This implies that stress-related HPA axis dysregulation 
is brought about via diminished sensitivity of these receptors. Examining how beta-
blockers and SSRIs might alter pre-stress baseline receptor sensitivity, and how these 
drugs affect receptor sensitivity responses to acute stress, may provide more information 
about how stress-related HPA axis dysregulation comes about.  
Placebo 
Acute receptor reactivity: Earlier in this thesis I outlined the both human and animal 
studies carried out to date examining the effects of acute psychosocial stress in the 
laboratory on corticosteroid receptor sensitivity (See Chapter 2, Table 2.2). The results of 
these studies suggest that the effects of acute stress on GR sensitivity vary according to 
sex, age, BMI, and health status. Overall, there is a lack of studies investigating the effects 
of acute stress on GR and MR sensitivity, and the observed effects of covariates are yet 
to be replicated. Due to the variability of results from these studies, and the lack of studies 
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examining the effects of acute stress on the MR, in this study I will examine the effects 
of acute psychosocial stress on both GR and MR sensitivity in unmedicated healthy 
volunteers who have received placebo. Based on the findings of human and murine 
studies outlined in Chapter 2 (Section 2.10.2) and based on the findings from previous 
work carried out by our group (Carvalho et al., 2015) I hypothesise that acute stress 
will lead to a decrease in corticosteroid receptor sensitivity in young unmedicated 
healthy volunteers.   
Beta-blockers 
Baseline receptor sensitivity: As beta-blockade induced increases in GR protein levels in 
CHD patients (Ji et al., 2010), this suggests that beta-blockers increase GR sensitivity. 
However, the effects of beta-blockers on GR sensitivity directly are not known. To date 
there have been no studies assessing the effects of beta-blockers on MR sensitivity. I 
hypothesise that baseline GR and MR sensitivity will be increased in healthy 
volunteers receiving beta-blockers compared with placebo.  
Acute stress receptor sensitivity: In Section 6.4 I hypothesise that seven-day treatment 
with propranolol will bring about increased cortisol stress reactivity in the laboratory. I 
therefore hypothesise that seven-day treatment with propranolol will bring about 
enhanced changes in GR and MR sensitivity in response to acute stress compared 
with placebo.  
SSRIs 
Baseline receptor sensitivity: Although results from healthy volunteers have been mixed, 
the results from murine models and depressed patients seem to suggest that SSRI 
administration brings about increased GR sensitivity. The results regarding the MR are a 
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little more mixed, but the results of Pariante and colleague’s (2004) study suggest that 
short-term SSRI administration increases both GR and MR sensitivity, albeit in the 
morning. Therefore, I hypothesise that seven-day treatment with escitalopram will 
bring about increases in baseline GR and MR sensitivity compared with placebo.  
Acute stress receptor sensitivity: In Section 6.4 I hypothesise that seven-day treatment 
with escitalopram will bring about increased cortisol stress reactivity in the laboratory. 
Therefore, I hypothesise that seven-day treatment with escitalopram will bring 
about enhanced changes in GR and MR sensitivity in response to acute stress 
compared with placebo.  
It should be noted that I had no hypotheses concerning differences between propranolol 
and escitalopram. The study was analysed as two parallel comparisons with placebo, 
rather than contrasting the two active medication conditions.  
Sex 
Sex has not been considered in the studies assessing the effects of beta-blockers and 
SSRIs on corticosteroid receptor functions in humans. However, as I am examining the 
effects of how sex influences the effects of the study medications on cortisol stress 
reactivity, I will also explore how sex influences the medication effects on baseline and 
stress-related corticosteroid receptor sensitivity. Sex differences in how the corticosteroid 
receptors respond to acute stress have been previously reported (Rohleder et al., 2001). 
6.8 Biological measures 
Data from the Stress Pathways Study were used to test the hypotheses of this study. To 
reiterate, participants were randomised to receive seven-day administration of either 
propranolol (80mg/day), escitalopram (10mg/day), or placebo. Following this, they 
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underwent acute psychosocial stress testing in the laboratory. Saliva and blood samples 
were taken throughout the session for the measurement of cortisol and corticosteroid 
receptor sensitivity respectively. A detailed account of the methodology is provided in 
Chapter 4 of this thesis.  
 6.8.1 Calculation of cortisol parameters in the laboratory 
A detailed description of the cortisol sampling procedure is provided in Chapter 4, Section 
4.4.4 and Section 4.4.7. To reiterate, during the laboratory stress testing session, one 
saliva sample was taken prior to the stress protocol to allow measurement of baseline 
cortisol levels (25 minutes after cannulation). A sample was then taken immediately post-
stress, and at 10, 20, 45, and 75 minutes post-stress to measure cortisol stress reactivity. 
Cortisol values for each time-point were calculated as well as the overall cortisol AUC in 
the laboratory (post-stress – 75 minute sample). The cortisol AUC was calculated with 
respect to ground (Pruessner et al., 2003). Although 91 participants provided complete 
samples during the laboratory session, not all time-points were included for each 
participant. Participants were excluded from the analysis if any cortisol value in the 
laboratory exceeded 50 nmol/L. Therefore, at baseline five values were removed, post-
stress two values were removed, at 10m post-stress three values were removed, at 20m 
post-stress and 45m post-stress one value was removed, and at 75m post-stress four values 
were removed. Cortisol AUC was calculated only for those who provided six usable 
saliva samples. Therefore, after the removal of outliers from the sample, cortisol AUC 
was calculated for 85 participants. Different sample sizes for each cortisol time-point are 
detailed in Table 6.4.  
Counter to expectations, cortisol levels decreased following the acute stress protocol in 
every experimental condition (see Figure 6.6, Section 6.10.4). The possible reasons for 
200 
 
this will be discussed in Section 6.11.6. Therefore, I categorised the participants according 
to whether or not they responded to the stress protocol.  In accordance with Hamer et al. 
(2010), participants were considered responders if an increase of ≥1 nmol/L cortisol was 
detected immediately after the stress protocol, 10 minutes, or 20 minutes post-stress 
relative to baseline. The number of responders in each medication group is provided in 
Table 6.4.  
 6.8.2 Corticosteroid receptor sensitivity 
Reagents 
RPMI 1640 medium (Sigma), 500ml, sterile, R8758; foetal calf serum (Gibco 10270); 
penicillin/streptomycin (Sigma), 500ml, sterile, P4458; LPS (Sigma), 10mg, L2630; 
dexamethasone (Sigma), D4902; prednisolone (Sigma), P-6004. 
Protocol 
Corticosteroid receptor sensitivity was measured using an in vitro glucocorticoid 
sensitivity assay (see Figure 6.1). Sensitivity was assessed by measuring dexamethasone 
(GR) and prednisolone (MR) suppression of LPS-induced IL-6 production in whole 
blood. Whole blood was diluted ten-fold using RPMI 1640 medium supplemented with 
10% foetal calf serum, 100IU/ml penicillin, and 100mg/ml streptomycin. LPS and either 
dexamethasone or prednisolone were added into each well of two 48-well FALCON cell 
culture plates. The following concentrations of dexamethasone and prednisolone were 
used: 0M, 5.4 x 10-6M, 1.8 x 10-6M, 5.4 x 10-7M, 1.8 x 10-7M, and 5.4 x 10-8M. 
Subsequently, 540ml of diluted blood was added to each well. Samples were incubated 
for 24 hours in a humidified atmosphere containing 5% CO2. After incubation, plates 
were centrifuged (1000 x g, 4°C, 10mins) and the cell culture supernatant was carefully 
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collected. The samples were then stored at -80°C before being analysed for IL-6 
production.  
IL-6 production analysis was carried out using a commercially available Luminex 
technology kit for IL-6 from Bio-RAD®. The inter- and intra-assay coefficient of 
variation (CV) for IL-6 analysis was 13.3% and 7% respectively, and the detection limit 
was 2.6 pg/ml. Dexamethasone suppression of IL-6 production was assessed using the 
following concentrations: 0M, 5.4 x 10-6M, 1.8 x 10-6M, 5.4 x 10-7M, 1.8 x 10-7M, and 
5.4 x 10-8M dexamethasone. Prednisolone suppression of IL-6 production was assessed 
using the following concentrations: 0M, 5.4 x 10-6M, 1.8 x 10-6M, 5.4 x 10-7M, and 1.8 x 
10-7M prednisolone. IL-6 suppression by 5.4 x 10-8M prednisolone was not assessed as 
prednisolone had a higher IC50 and 5.4 x 10
-8M of prednisolone is not associated with any 
biological function.  
The glucocorticoid sensitivity assay 
1. Whole blood was diluted with 
RPMI, foetal calf serum, and 
penicillin-streptomycin 
2. LPS was added all wells of a 48 
well plate. Either dexamethasone 
(GR) or prednisolone (MR) were 
added in varying concentrations 
to 40 wells. 
3. Whole blood from all four time-
points was then added to each 
well (in duplicate) 
4. The plate was incubated for 24 
hours 
5. Supernatant was collected and 
analysed for IL-6  
 
Figure 6.1.  The glucocorticoid sensitivity assay 
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Glucocorticoid suppression of IL-6 was calculated by considering LPS-stimulated levels 
of IL-6 in the absence of either dexamethasone or prednisolone as 100%. Percentage 
inhibition of IL-6 by the glucocorticoids was then calculated using the following 
equation:  
(
LPS-induced IL-6 levels in the presence of glucocorticoids
LPS-induced IL-6 levels in the absence of glucocorticoids
× 100) = % 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 
Percentage inhibition for each concentration of dexamethasone and prednisolone was 
then entered into GraphPad Prism (GraphPad Software Inc., San Diego, CA, USA) in 
order to calculate the log inhibitory concentration 50% (IC50) values of the dose-response 
curve of dexamethasone and prednisolone suppression of IL-6 production at each time-
point. The IC50 is the measure of how effective a substance is at inhibiting a specific 
biological function. It represents the concentration of substance or drug required to bring 
about 50% inhibition in vitro. Figure 6.2 provides an example of how the IC50 is 
calculated. Log IC50 values are inversely proportional to glucocorticoid sensitivity. 
Higher log IC50 values indicate that more dexamethasone or prednisolone was required 
to suppress IL-6 production by 50%, and this implies that GR and/or MR sensitivity is 
decreased. 
6.8.3 Cardiovascular measures 
A detailed description of the cardiovascular data measured in the stress laboratory is 
provided in Chapter 4, Section 4.4.7. To reiterate, all participants were attached to a 
Finometer® PRO in order to measure BP, heart rate, and cardiac output continuously 
during the laboratory session. All cardiovascular measures were averaged into mean 
readings taken from five-minute intervals. There was a five-minute baseline interval (pre- 
stress), as well as two five-minute recovery period intervals (+40-45m, and +70-75m). 
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Cardiovascular measures during the stress protocol were averaged across tasks. Cardiac 
index (L/min/m2) was calculated by dividing cardiac output (L/min) by the body surface 
area (m2).  
6.9 Statistical analyses 
Kolmogorov-Smirnov tests were performed to test for normality of the distribution in 
measures of cortisol, corticosteroid receptor sensitivity (IC50 values), and cardiovascular 
measures in the laboratory. These normality tests revealed that all corticosteroid receptor 
sensitivity and cardiovascular measures were normally distributed (all p values > 0.05). 
However, all measures of salivary cortisol in the laboratory were not normally distributed. 
Log transformation (base 10) normalised the distributions. 
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As in Chapter 5, the data were analysed using two parallel statistical analyses: propranolol 
versus placebo, and escitalopram versus placebo. Two-way ANOVAs and chi-square 
tests were used to compare the three study medication groups on all demographic 
characteristics. Where possible, sex was included as a between-person factor alongside 
experimental condition. Paired t-tests were used to assess differences between subjective 
stress ratings at rest and following the acute stress protocol in the overall sample. One-
way ANOVAs were used to assess the effects of the study medications on subjective 
stress ratings at rest, and ANCOVAs were used to assess the effects of the study 
medications on subjective stress ratings following the stress protocol, adjusting for rest 
ratings.  
All biological stress measures in the laboratory were analysed using two separate pairwise 
analyses; propranolol versus placebo, and escitalopram versus placebo. Repeated 
measures ANOVAs were used to examine stress-related changes over time in cortisol, 
corticosteroid receptor sensitivity, and cardiovascular measures. Paired t-tests were used 
to explore significant within-subject contrasts. Where necessary, differences between the 
two experimental conditions in biological stress parameters at each time-point were 
analysed using two-way ANOVAs, with experimental condition and sex being included 
as the main fixed factors. Logistic regression was used to assess the effects of 
experimental condition on the cortisol responder category. Where there were significant 
differences between experimental conditions on any of the demographic characteristics, 
repeated measures ANCOVAs were run where the demographic variable of interest was 
included as a covariate. Pearson’s R correlations were used in exploratory analysis to 
ascertain what factors were associated with pre-stress salivary cortisol levels in the 
laboratory. 
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The significance level was set to p < 0.05 for all analyses, with precise p values reported 
for all test results. All statistical analyses were performed using SPSS version 22.0 (SPSS 
Inc., Chicago, Illinois, USA). 
6.10 Results 
 6.10.1 Participants 
As mentioned previously, 91 participants provided saliva samples for cortisol 
measurement in the laboratory. Blood used for the measurement of corticosteroid receptor 
sensitivity was drawn successfully from 85 participants, and cardiovascular measures 
were gathered from 90 participants. Participants with at least one of these biological 
measures (cortisol, receptor sensitivity, or cardiovascular measures) were included in the 
main sample of this study (n = 91). Of the 91 participants in this main sample, 30 were 
taking escitalopram, 31 were taking propranolol, and 30 received placebo. Table 6.1 
summarises the characteristics of the participants in each experimental condition. The 
sample had an age range of 18-48 years (M = 22.8, SD = 4.8), were almost two-thirds 
women (63.7%), and were mostly normal weight (78.0% BMI<25). Over half of the 
sample were white (58.2%) and the majority of participants had a high SES based upon 
parental education (80.2%). Smokers comprised 16.5% of the sample. Baseline scores 
(measured on Day 1 of the study) on the BDI-II ranged from 0-31 indicating the presence 
of severe depressive symptoms in some participants. Frequency analysis revealed that 
four participants had BDI-II scores greater than 19 suggesting the presence of clinical 
depression. Baseline scores on the HADS ranged from 0-15 indicating anxiety in some 
participants. Nine participants had scores of 11 or greater, suggesting the presence of 
clinical anxiety in these individuals. Sensitivity analyses were carried out with these 
participants removed (n = 12; propranolol n = 7, escitalopram n = 1, placebo n = 4). 
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Exclusion of these participants did not affect results obtained. Scores on the PSS ranged 
from 2-32 indicating a good level of variability in perceived stress within the sample.  
The propranolol group did not differ significantly from the placebo group in terms of age 
(F(1, 57) = 1.82, p = 0.18), sex (χ2 = 0.36, df = 1, p = 0.85), BMI (F(1, 57) = 0.90, p = 
0.30), smoking status (χ2 = 0.13, df = 1, p = 0.72), ethnicity (χ2 = 3.28, df = 1, p = 0.51), 
or SES (χ2 = 0.77, df = 1, p = 0.68). Amongst female participants there was no difference 
between the propranolol and placebo group in terms of hormonal contraception use (χ2 = 
1.12, df = 1, p = 0.29). The propranolol and placebo groups also did not differ in time of 
study session (morning versus afternoon) (χ2=0.11, df = 1, p = 0.92), or in the arm used 
for cannulation (dominant versus non-dominant) (χ2=0.25, df = 1, p = 0.62). Groups also 
did not differ significantly in baseline depression scores (F(1, 57) = 0.06, p = 0.81), 
anxiety scores (F(1, 57) = 0.01, p = 0.93), positive affect (F(1, 57) = 0.49, p = 0.49), or 
perceived stress (F(1, 57) = 0.17, p = 0.68).  
The escitalopram group did not differ significantly from the placebo group in terms of 
age (F(1, 56) = 1.14, p = 0.75). However, there was a significant interaction between 
experimental group and sex with respect to age (F(1, 56) = 5.29, p = 0.03). There was a 
significant difference in age between the escitalopram and placebo group in men (F(1, 
21) = 4.94, p = 0.037) but not in women (p = 0.16). Men in the escitalopram group were 
slightly younger (M = 20.1 years, SD = 1.6) than men in the placebo group (M = 22.4 
years, SD = 3.5). The escitalopram group did not differ from the placebo group in terms 
of sex (χ2 = 1.76, df = 1, p = 0.18), BMI (F(1, 56) = 1.26, p =0.74), smoking status (χ2 = 
2.78, df = 1, p = 0.10), ethnicity (χ2 = 1.03, df = 1, p = 0.91), or SES (χ2 = 0.32, df = 1, p 
= 0.85). Amongst female participants there was no difference in hormonal contraception 
use (χ2 = 2.65, df = 1, p = 0.10). The escitalopram and placebo groups also did not differ 
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in time of study session (χ2 = 0.00, df = 1, p = 1.00), or in the arm used for cannulation 
(χ2 = 0.32, df = 1, p = 0.57). Groups also did not differ in baseline depression scores (F(1, 
56) = 6.86, p =0.66), anxiety scores (F(1, 56) = 2.86, p =0.63), positive affect (F(1, 56) = 
15.0, p =0.47), or perceived stress (F(1, 56) = 1.19, p =0.28). 
I also investigated the effects of the study medications on changes in stress-related 
psychological factors on Day 7 of administration. Paired t-tests revealed that there was 
no significant change in depression scores (p = 0.76), anxiety scores (p = 0.78), or positive 
affect (p = 0.29) over the seven day study period in the placebo group. There was also no 
significant change in anxiety scores (p = 0.57) or positive affect (p = 0.22) in the 
propranolol group. However, propranolol appeared to bring about a significant decrease 
in depression scores (t(30) = 2.62, p = 0.014). In the escitalopram group there were no 
changes in depression (p = 0.95) or anxiety (p = 0.10) scores, but there was a significant 
decrease in positive affect (t(29) = 2.37, p = 0.025). Exploratory analysis revealed that 
those who reported experiencing adverse effects within the escitalopram group had lower 
levels of positive affect (M = 28.7, SD = 8.1) on Day 7 compared to those who had not 
reported experiencing adverse effects (M = 35.4, SD = 7.3) (t(28) = 2.35, p = 0.028). This 
suggests that the lowering of positive affect in the escitalopram group was related to 
experiencing adverse effects.  
6.10.2 Subjective stress ratings 
In the overall sample, the stress protocol used in the current study brought about a 
significant increase in subjective stress ratings (t(90) = -15.8, p <0.001). Prior to the stress 
protocol, the mean subjective stress rating of the sample was 1.81 (SD = 0.99). This 
increased to 4.04 (SD = 0.10) following acute stress. There was no difference between 
the propranolol group or the placebo group in terms of subjective stress ratings at rest 
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Table 6.1. Demographic characteristics of the sample (n = 91)  
 
Propranolol (n=31) 
 
Escitalopram (n=30) 
 
Placebo (n=30) 
 
Propranolol vs. placebo  
 
Escitalopram vs. placebo  
 
Characteristic Mean ± SD or N(%) Mean ± SD or N(%) Mean ± SD or N(%) 
Group  
p value 
Group*sex  
p value 
Group  
p value 
Group*sex  
p value 
Age (years) 24.56.4 22.13.9 22.23.1 0.183 0.504 0.751 0.025 
Female 21(67.7) 16(53.3) 21(70.0) 0.849 - 0.184 - 
BMI (kg/m2)  22.62.5 23.34.3 23.34.1 0.346 0.498 0.795 0.283 
Smoker 4(12.9) 8(26.7) 3(10.0) 0.722 - 0.095 - 
Ethnicity (White) 21(67.7) 17(56.7) 15(50.0) 0.511 - 0.905 - 
SES (n=93)    0.681 - 0.854 - 
         Low 5(16.1) 3(10.0) 3(10.0) - - - - 
        Medium 3(9.7) 1(3.3) 2(6.7) - - - - 
        High 23(74.2) 25(83.3) 25(83.3) - - - - 
Hormonal Contraception  (n=58) 7(33.3) 7(43.8) 4(19.0) 0.292 - 0.103 - 
Depressive symptoms  baseline 7.166.65  5.606.54 6.104.99 0.814 0.526 0.658 0.492 
Depressive symptoms follow-up 5.134.96 5.675.19 6.206.98 0.385 0.485 0.901 0.573 
Anxiety symptoms baseline 5.104.20 4.702.87 5.404.04 0.926 0.689 0.633 0.812 
Anxiety symptoms follow-up 4.814.17 3.902.87 5.604.39 0.522 0.979 0.088 0.320 
Positive Affect baseline 33.16.1 35.55.8 35.04.9 0.489 0.131 0.470 0.146 
Positive affect follow-up 33.96.1 32.78.2 34.16.0 0.712 0.184 0.789 0.063 
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Table 6.1 continued 
 
Propranolol (n=31) 
 
Escitalopram (n=30) 
 
Placebo (n=30) 
 
Propranolol vs. placebo  
 
Escitalopram vs. placebo  
 
Characteristic Mean ± SD or N(%) Mean ± SD or N(%) Mean ± SD or N(%) 
Group  
p value 
Group*sex  
p value 
Group  
p value 
Group*sex  
p value 
Perceived stress 14.56.9 12.95.5 15.17.3 0.377 0.719 0.280 0.415 
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(F(1, 57) = 0.93, p = 0.34), or following the stress protocol (F(1, 56) = 0.95, p = 0.34) 
(Table 6.2). There was also no difference between the escitalopram group and the placebo 
group in subjective stress ratings at rest (F(1, 56) = 0.67, p = 0.42), or following the stress 
protocol (F(1, 56) = 0.04, p = 0.85) (Table 6.2). 
6.10.3 Cardiovascular measures 
Overall sample  
In the overall sample, repeated measures ANOVA revealed a significant main effect of 
time on heart rate levels across the testing session (F(1, 87) = 129.6, p < 0.001) (see Figure 
6.3). Pairwise comparisons revealed that heart rate during stress was significantly higher 
than baseline heart rate (p < 0.001). Heart rate values during stress were also significantly 
higher than post-stress heart rates at 45 minutes (p < 0.001) and 75 minutes (p < 0.001).  
There was a significant main effect of time on systolic blood pressure (SBP) levels across 
the testing session in the overall sample (F(1, 87) = 101.9, p < 0.001). Pairwise 
comparisons showed that SBP values during stress were significantly higher than baseline 
levels (p < 0.001), and levels at 45 minutes (p < 0.001) and 75 minutes (p < 0.001) post-
stress.   
There was a significant main effect of time on diastolic blood pressure (DBP) levels 
across the testing session in the overall sample (F(1, 87) = 146.1, p < 0.001). DBP values 
during stress were significantly elevated compared to baseline (p < 0.001), and 45 (p < 
0.001) and 75 minutes (p < 0.001) post-stress.  
There was a main effect of time on measures of cardiac index across the testing session 
in the overall sample (F(1, 87) = 56.8, p < 0.001). Cardiac index values during stress were 
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Table 6.2. Subjective stress ratings at baseline, post-stress, and 20 minutes after stress 
 
Propranolol (n=31) 
 
Escitalopram (n=30) 
 
Placebo (n=30) 
 
Propranolol vs. placebo  
 
Escitalopram vs. placebo  
 
Characteristic Mean ± SD  Mean ± SD  Mean ± SD  
Group  
p value 
Group*sex  
p value 
Group  
p value 
Group*sex  
p value 
Baseline subjective stress 1.680.80 1.731.05 2.031.10 0.340 0.319 0.417 0.093 
Post-task subjective stress 3.800.98 4.190.98 4.130.98 0.335 0.812 0.846 0.364 
Recovery subjective stress 1.650.80 1.800.99 1.970.99 0.321 0.491 0.723 0.153 
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Figure 6.3. Heart rate (A), SBP (B), DBP (C), and cardiac index (D) values across the testing session in the 
overall sample. Error bars represent SEM.  
 
significantly elevated compared to baseline values (p < 0.001), cardiac index values at 45 
minutes (p < 0.001) and 75 minutes (p < 0.001) post-stress. 
These cardiovascular results indicate that the tasks did induce substantial blood pressure 
and heart rate responses in the overall sample. SBP increased around 18%, DBP by 24%, 
and heart rate by 11% during the stress protocol across experimental conditions. There 
was complete recovery to baseline levels in heart rate and cardiac index, while SBP and 
DBP remained somewhat elevated during the post-stress recovery period.  
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Table 6.3. Mean values on cardiovascular measures in the laboratory in each experimental condition  
 Propranolol 
(n=31) 
 
Escitalopram 
(n=30) 
 
Placebo (n=30) 
 
Propranolol vs. placebo  
 
Escitalopram vs. placebo  
 
Cardiovascular Measure Mean ± SD  Mean ± SD  Mean ± SD  
Group  
p value 
Group*sex  
p value 
Group  
p value 
Group*sex  
p value 
        Heart rate baseline (bpm)(n=90) 61.2±6.8 68.7±6.7 70.2±8.7 <0.001* 0.422 0.714 0.726 
Mean difference±SE -9.0±2.0 -1.5±2.0      
        Heart rate stress (bpm)(n=90) 66.6±9.1 78.1±8.9 78.3±9.3 <0.001* 0.372 0.817 0.850 
Mean difference±SE -11.7±2.4 -0.2±2.4      
        Heart rate 45m post-stress (bpm)(n=89) 60.5±7.4 66.3±6.8 69.3±8.9 0.001* 0.375 0.330 0.506 
Mean difference±SE -8.8±2.1 -3.0±2.1      
        Heart rate 75m post-stress (bpm) (n=89) 60.6±7.4 67.4±6.3 69.5±9.1 0.001* 0.198 0.710 0.123 
Mean difference±SE -8.9±2.2 -2.1±2.1      
        SBP baseline (mmHg)(n=90) 104.9±9.5 109.6±10.5 108.2±10.8 0.064 0.077 0.909 0.825 
Mean difference±SE -3.3±2.6 1.4±2.8      
        SBP stress (mmHg)(n=90) 124.8±11.9 129.9±13.6 127.7±13.7 0.266 0.420 0.776 0.702 
Mean difference±SE -2.9±3.3 2.2±3.6      
        SBP 45m post-stress (mmHg)(n=89) 112.2±14.2 119.9±15.9 111.3±15.8 0.690 0.096 0.167 0.351 
Mean difference±SE 0.9±3.9 8.6±4.2      
        SBP 75m post-stress (mmHg)(n=89) 112.9±13.5 123.1±13.1 117.8±11.8 0.142 0.754 0.194 0.655 
Mean difference±SE -4.9±3.3 5.3±3.3      
bpm = beats per minute; mmHg = millimetre of mercury. Mean difference is calculated by subtracting placebo values from each experimental condition. The SE of the mean difference was 
calculated as the square root of the sum of the squares of the SE for each group 
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Table 6.3. continued 
 Propranolol 
(n=31) 
 
Escitalopram 
(n=30) 
 
Placebo (n=30) 
 
Propranolol vs. placebo  
 
Escitalopram vs. placebo  
 
Cardiovascular Measure Mean ± SD  Mean ± SD  Mean ± SD  
Group  
p value 
Group*sex  
p value 
Group  
p value 
Group*sex  
p value 
        DBP baseline (mmHg)(n=90) 63.5±8.6 68.5±5.5 66.9±8.9 0.051 0.121 0.661 0.546 
Mean difference±SE -3.4±2.3 1.6±1.9      
        DBP stress (mmHg)(n=90) 80.2±9.0 83.6±6.4 82.7±13.6 0.228 0.259 0.973 0.702 
Mean difference±SE -2.5±2.9 0.9±2.8      
        DBP 45m post-stress (mmHg)(n=89) 69.6±11.2 76.5±9.2 71.1±11.0 0.253 0.082 0.168 0.332 
Mean difference±SE -1.5±2.9 5.4±2.7      
        DBP 75m post-stress (mmHg)(n=89) 70.6±10.3 78.3±7.5 75.7±12.0 0.081 0.675 0.429 0.985 
Mean difference±SE -5.1±2.9 2.6±2.6      
        Cardiac index baseline (L/min/m2)(n=90) 2.60±0.48 3.08±0.48 2.94±0.71 0.133 0.170 0.244 0.346 
Mean difference±SE -0.34±0.16 0.14±0.16      
        Cardiac index stress (L/min/m2)(n=90) 2.97±0.72 3.78±0.64 3.38±1.06 0.341 0.063 0.027* 0.149 
Mean difference±SE -0.41±0.24 0.4±0.23      
        CI 45m post-stress (L/min/m2)(n=89) 2.54±0.47 3.01±0.45 2.76±0.74 0.423 0.221 0.093 0.475 
Mean difference±SE -0.22±0.16 0.25±0.16      
        CI 75m post-stress (L/min/m2)(n=89) 2.56±0.49 3.13±0.49 2.78±0.69 0.479 0.094 0.010* 0.068 
Mean difference±SE -0.22±0.16 0.35±0.16      
bpm = beats per minute; mmHg = millimetre of mercury. Mean difference is calculated by subtracting placebo values from each experimental condition. The SE of the mean difference was 
calculated as the square root of the sum of the squares of the SE for each group 
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Propranolol versus placebo 
There was a significant main effect of experimental condition on heart rate across the 
testing session (F(1, 56) = 16.0, p <0.001). The propranolol group had significantly lower 
measures of heart rate at baseline (F(1, 56) = 14.8, p <0.001), during stress (F(1, 56) = 
17.7, p <0.001), 45 minutes after stress (F(1, 56) = 12.7, p = 0.001), and 75 minutes after 
stress (F(1, 56) = 12.0, p = 0.001), compared with the placebo group (see Figure 6.4). 
Mean heart rate values for each experimental condition are provided in Table 6.3. There 
were no significant effects of sex on any of the heart rate measures (all p values > 0.05). 
This indicates that propranolol was biologically active in these participants as heart rate 
was significantly reduced in this experimental condition at all time-points.  
 
 
The propranolol group and the placebo group did not differ significantly in SBP, DBP, or 
cardiac index values at any time-point (all p values > 0.05, see Table 6.3). There was also 
no main or interactive effect of sex on these cardiovascular parameters at any time-point 
(all p values > 0.05, see Table 6.3). 
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Figure 6.4. Mean heart rate values across the session in the propranolol 
(pink line) and placebo (grey line) groups. Error bars represent SEM.  
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Escitalopram versus placebo 
The escitalopram and placebo groups did not differ significantly on any measure of heart 
rate, SBP, or DBP, throughout the testing session (all p values > 0.05, see Table 6.3). 
There was also no main or interactive effect of sex on heart rate, SBP, or DBP values at 
any time-point (all p values > 0.05). There was no significant difference between 
experimental conditions on cardiac index at baseline and 45 minutes after stress (all p 
values > 0.05). However, the escitalopram group had a higher cardiac index during stress 
compared to those who had taken placebo (F(1, 55) = 5.13, p = 0.027) (see Figure 6.5).  
This was also the case 75 minutes after stress (F(1, 54) = 7.22, p = 0.010). There were no 
significant main interactive effects of sex on any of the cardiac index measures (all p 
values > 0.05). Cardiac index is calculated by multiplying heart rate by stroke volume. 
As cardiac index was elevated during stress and 75 minutes post-stress in the escitalopram 
condition this indicates that escitalopram increased stroke volume during stress, seeing 
as heart rate was not affected. 
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Figure 6.5. Mean cardiac index values across the session in the escitalopram 
(blue line) and placebo (grey line) groups. Error bars represent SEM.  
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Taken together, these cardiovascular results indicate that both propranolol and 
escitalopram were biologically active in these participants as both medications altered 
heart rate and cardiac index respectively.  
6.10.4 Cortisol stress reactivity 
Overall sample 
In the overall sample, there was a significant linear main effect of time on cortisol levels 
across the testing session (F(1, 82) = 84.3, p < 0.001). Pairwise comparisons revealed that 
there was a significant difference in cortisol levels between each time-point (p values 
range from < 0.001 – 0.027). However, looking to the mean values indicated that contrary 
to expectation cortisol levels steadily decreased from baseline values irrespective of the 
acute stress protocol (see Figure 6.6). 
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Figure 6.6. Mean cortisol values (not log-transformed) at each time-point 
across the testing session in the overall sample. Error bars represent SEM.  
218 
 
Table 6.4. Mean (raw) cortisol values across the laboratory session in each experimental condition (p values from analyses with log transformed cortisol values). 
 Propranolol 
(n=31) 
 
Escitalopram 
(n=30) 
 
Placebo (n=30) 
 
Propranolol vs. 
placebo  
 
Escitalopram vs. 
placebo  
 
Cortisol stress reactivity (raw scores) Mean ± SD or N(%) Mean ± SD or N(%) Mean ± SD or N(%) 
Group  
p value 
Group*sex  
p value 
Group  
p value 
Group*sex  
p value 
        Baseline cortisol (nmol/L)(n=86) 18.0±12.1 17.7±10.9 15.4±10.0 0.255 0.763 0.597 0.279 
Mean difference±SE 2.6±2.9 2.3±2.7      
        Post-stress cortisol (nmol/L)(n=89) 13.5±7.5 14.9±8.3 13.9±6.7 0.642 0.322 0.630 0.239 
Mean difference±SE -0.4±2.3 1.0±2.0      
        Cortisol 10m post-stress (nmol/L)(n=88) 12.4±6.7 12.0±5.6 13.9±9.1 0.845 0.619 0.235 0.433 
Mean difference±SE -1.5±2.3 -1.9±2.1      
        Cortisol 20m post-stress (nmol/L)(n=90) 11.4±4.9 11.1±5.7 12.6±7.0 0.540 0.413 0.140 0.399 
Mean difference±SE -1.2±2.31 -1.5±1.84      
        Cortisol 45m post-stress (nmol/L)(n=90) 9.63±3.52 9.27±4.59 9.38±4.31 0.214 0.319 0.642 0.756 
Mean difference±SE 0.25±1.60 -0.11±1.46      
        Cortisol 75m post-stress (nmol/L)(n=87) 8.87±2.96 8.68±4.21 8.78±3.95 0.194 0.578 0.990 0.704 
Mean difference±SE 0.09±1.05 -0.10±1.09      
        Cortisol AUC (nmol/L)(n=85) 833.7±342.4 774.3±367.1 818.2±384.6 0.798 0.871 0.479 0.293 
Mean difference±SE 15.5±95.6 -43.9±100.5      
        Cortisol responders (n=86) 4(12.9) 7(23.3) 10(33.3) 0.084† - 0.359† - 
nmol = nanomole. Mean difference is calculated by subtracting placebo values from each experimental condition. The SE of the mean difference was calculated as the square root of the 
sum of the squares of the SE for each group. 
†p value for logistic regression 
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Propranolol versus placebo 
Repeated measures ANOVA revealed no significant main effect of drug (p = 0.98) or 
time x drug interaction (p = 0.21) on cortisol stress reactivity. The propranolol and 
placebo groups did not differ significantly on baseline levels of cortisol, post-stress levels 
of cortisol, or levels of cortisol at 10, 20, 45, and 75 minutes after stress (all p values > 
0.05, see Table 6.4). Additionally, there was no difference between groups on overall 
cortisol output in the laboratory (AUC) (p = 0.80). There was no interactive effect of sex 
on cortisol levels across the session (all p values > 0.05). Logistic regression was used to 
test associations between drug type and whether participants were cortisol responders or 
non-responders. There was no association between experimental condition and cortisol 
response (p = 0.08). 
Escitalopram versus placebo 
Repeated measures ANOVA revealed a significant time x drug quadratic effect (F(1, 52) 
= 4.49, p = 0.039) which indicates that the slope of change in cortisol across the testing 
session differed across experimental conditions (see Figure 6.7). Paired t-tests were used 
to explore this effect further. In the escitalopram group, baseline cortisol values were 
significantly higher than values during stress (p = 0.001), and at 10 (p < 0.001), 20 (p 
<0.001), 45 (p <0.001), and 75 minutes (p <0.001) post-stress. In the placebo group, 
baseline cortisol values did not differ significantly from values during stress (p = 0.90), 
values 10 minutes (p = 0.59), or values 20 minutes post-stress (p = 0.23). Cortisol values 
at 45 (p <0.001) and 75 minutes (p =0.001) post-stress were significantly lower than 
baseline values in the placebo group. In the escitalopram group, cortisol values during 
stress were significantly higher than values at 10 (p = 0.004), 20 (p <0.001), 45 (p < 
0.001), and 75 (p < 0.001) minutes post-stress. In the placebo group, cortisol values during 
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stress did not differ from values 10 minutes post-stress (p = 0.37). Values at 20 (p = 
0.012), 45 (p < 0.001), and 75 minutes (p < 0.001) were significantly lower than stress 
values in the placebo group. What these results show is that decreases in cortisol values 
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Figure 6.7. Mean cortisol values (not log-transformed) at each time-point across the 
testing session in the propranolol (pink line), escitalopram (blue line), and placebo 
(grey line) groups. Error bars represent SEM.  
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across the testing session were more pronounced in the escitalopram group indicating a 
blunting of the cortisol stress response in this group.   
In sum, although the stress tasks did not elicit an increase in cortisol in any of the 
experimental conditions, a steeper slope of decline was present in those taking 
escitalopram. Propranolol did not significantly affect cortisol values across the testing 
session.  
 6.10.5 Corticosteroid receptor sensitivity 
Overall sample 
In the overall sample, there was a significant main effect of time on LPS-stimulated IL-6 
release across the testing session (F(1, 77) = 20.2, p < 0.001) (see Table 6.5 for LPS-
stimulated IL-6 values). Pairwise comparisons revealed that IL-6 release post-stress, and 
at 45 and 75 minutes after stress was significantly higher than baseline IL-6 release (all p 
values <0.001). This indicates that the stress protocol brought about changes in immune 
function. There was also a significant main effect of time on dexamethasone suppression 
of LPS-induced IL-6 release in the overall sample (F(1, 77) = 6.82, p = 0.001). Compared 
to baseline, GR sensitivity significantly decreased immediately following stress (p < 
0.001), at 45 minutes post-stress (p < 0.001), and at 75 minutes post-stress (p = 0.003). 
There was a significant main effect of time on prednisolone suppression of LPS-induced 
IL-6 release (F(1, 77) = 13.3, p < 0.001). Results indicate that MR sensitivity also 
decreased significantly immediately post-stress (p = 0.011), at 45 minutes (p = 0.001), 
and at 75 minutes post stress (p < 0.001).   
Together, these results show that the stress protocol brought about changes in immune 
function, and GR and MR sensitivity in the overall sample.  
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Placebo group 
As mentioned in Chapter 2, one of the main aims of this study was to examine the effects 
of acute psychosocial stress on both GR and MR function in healthy medication-free 
volunteers. Within the placebo group, repeated measures ANOVA showed a significant 
quadratic effect of time on dexamethasone IC50 values across the testing session (F(1, 22) 
= 5.37, p = 0.030). Individual pairwise comparisons revealed that compared to baseline, 
GR sensitivity decreased immediately post-stress (p = 0.007), and remained decreased at 
45 minutes post-stress (p = 0.045), but had returned towards baseline levels by 75 minutes 
(p = 0.54 in comparison with baseline) post-stress (see Figure 6.8).  
 
 
There was also a significant linear effect of time on prednisolone IC50 values across the 
testing session (F(1, 22) = 5.06, p = 0.035) (see Figure 6.9). As can be seen, receptor 
sensitivity decreased across the session, with individual pairwise comparisons showing a 
significant difference between prednisolone IC50 values at baseline and at 75 minutes 
after stress (p = 0.010).  
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Figure 6.8. Mean log IC50 values for dexamethasone in the placebo 
group. Error bars represent SEM.  
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There was no main or interactive effect of sex on dexamethasone or prednisolone IC50 
values across the testing session in the placebo group.  
 
 
In sum, within unmedicated healthy volunteers, acute stress brought about a transient 
decrease in GR sensitivity that had normalised to baseline levels by 75 minutes post-
stress. Acute stress also brought about a decrease in MR sensitivity that was more 
sustained and most pronounced at 75 minutes post-stress.   
Propranolol versus placebo 
Repeated measures ANOVA revealed that the propranolol and placebo conditions did not 
differ significantly on measures of LPS induced IL-6 production across the testing session 
(p = 0.25). Similarly, the propranolol and the placebo group did not differ significantly 
on measures of GR sensitivity (dexamethasone IC50) across the testing session (p = 0.35) 
(see Figure 6.10). Although the groups did not differ significantly, there appears to be a 
different pattern of change in GR sensitivity in each group (see Figure 6.10). This is 
supported by the significant linear effect of time on dexamethasone IC50 values across the 
testing session in the propranolol group (F(1, 27) = 4.61, p = 0.041) in contrast with the 
-7.35
-7.3
-7.25
-7.2
-7.15
-7.1
-7.05
-7
Baseline Pre-stress 45 min 75 min
P
re
d
n
is
o
lo
n
e 
lo
g 
IC
5
0
 (M
o
la
r)
Figure 6.9. Mean log IC50 values for prednisolone in the placebo group. Error 
bars represent SEM.  
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Table 6.5. Raw IL-6 values (LPS) and mean log IC50 values (dexamethasone and prednisolone) across the laboratory session in each experimental condition  
 Propranolol 
(n=31) 
 
Escitalopram 
(n=30) 
 
Placebo (n=30) 
 
Propranolol vs. placebo  
 
Escitalopram vs. placebo  
 
Corticosteroid receptor sensitivity Mean ± SD  Mean ± SD  Mean ± SD  
Group  
p value 
Group*sex  
p value 
Group  
p value 
Group*sex  
p value 
LPS only        
        Baseline (ng/ml)(n=85) 1710.3918.5 1820.31291.8 1581.5616.5 0.761 0.537 0.531 0.674 
        Post-stress(ng/ml)(n=80) 2040.01029.1 2044.21102.4 1956.3832.6 0.997 0.411 0.964 0.926 
        45min (ng/ml)(n=84) 2018.1994.5 2122.71289.6 1871.3821.6 0.743 0.605 0.549 0.694 
        75min (ng/ml (n=79) 2074.91106.3 2024.31268.2 1810.4782.0 0.494 0.490 0.667 0.819 
Dexamethasone        
        Baseline log IC50 (M)(n=85) -8.170.26 -8.150.19 -8.180.17 0.435 0.112 0.284 0.250 
        Post-stress log IC50 (M)(n=80) -8.120.25 -8.080.20 -8.110.18 0.960 0.761 0.484 0.576 
        45min log IC50 (M)(n=84) -8.070.23 -8.040.18 -8.080.25 0.698 0.780 0.282 0.080 
        75min log IC50 (M)(n=79) -8.080.24 -7.980.35 -8.190.31 0.189 0.932 0.058 0.758 
Prednisolone        
        Baseline log IC50 (M)(n=85) -7.260.25 -7.290.18 -7.240.23 0.745 0.178 0.747 0.296 
        Post-stress log IC50 (M)(n=80) -7.220.27 -7.240.21 -7.190.28 0.639 0.969 0.642 0.696 
        45min log IC50 (M)(n=84) -7.180.27 -7.210.24 -7.160.28 0.895 0.994 0.686 0.307 
        75min log IC50 (M)(n=79) -7.150.27 -7.070.32 -7.160.20 0.966 0.850 0.367 0.554 
IC50 = inhibitory concentration 50%; ng/ml = nanogram/milliliter; M = molar concentration 
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significant quadratic effect of time on dexamethasone IC50 values across the testing 
session in the placebo group (F(1, 22) = 5.37, p = 0.030). 
The propranolol and placebo group did not differ significantly in MR sensitivity 
(prednisolone IC50) across the testing session (p = 0.81) (see Figure 6.11). There was no 
main or interactive effect of sex on GR or MR sensitivity (all p values > 0.05).  
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Figure 6.10. Mean dexamethasone log IC50 values in the propranolol (pink 
line) and placebo (grey line) groups. Error bars represent SEM.   
Figure 6.11. Mean prednisolone log IC50 values in the propranolol (pink line) 
and placebo (grey line) groups. Error bars represent SEM.   
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Over all time points, GR sensitivity was lower in the escitalopram group. Additionally, 
the escitalopram group exhibited a marked decrease in GR sensitivity 75 minutes post-
stress, whereas the receptor sensitivity of the placebo group returned towards baseline. 
Escitalopram versus placebo 
The escitalopram and placebo conditions did not differ significantly on measures of LPS 
induced IL-6 production across the testing session (p = 0.40). There was a main effect of 
drug on GR sensitivity across the testing session (F(1, 45) = 4.18, p = 0.048) indicating 
that overall the groups differed in GR sensitivity across the testing session (mean values 
provided in Table 6.5, see Figure 6.12). Compared with placebo, GR sensitivity was 
reduced in the escitalopram group. Moreover, at 75 minutes post-stress there was a 
marked decrease in GR sensitivity in the escitalopram group, whereas GR sensitivity 
returned towards baseline levels in the placebo group. This difference reached borderline 
significance (F(1, 46) = 3.79, p = 0.058). In order to further explore this difference I 
created change scores by subtracting baseline log IC50 values from log IC50 values at 75 
minutes. An independent samples t-test revealed a significant difference between 
conditions (t(48) = -2.02, p = 0.049) indicating a more pronounced change in the 
escitalopram group (M = 0.17, SD  = 0.29) compared with the placebo group (M = 0.01, 
SD = 0.29). The escitalopram and placebo conditions did not differ significantly on MR 
sensitivity (prednisolone IC50) across the testing session (p = 0.83) (see Figure 6.13); 
instead, both groups showed a progressive reduction in MR sensitivity across samples. 
There was no main or interactive effect of sex on GR or MR sensitivity (all p values > 
0.05).  
To summarise, these results show that propranolol did not bring about any significant 
changes in stress-related GR and MR sensitivity compared with placebo. Although not 
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statistically significant, examining Figure 6.10 indicates that the propranolol group 
experienced a linear decrease in GR sensitivity after stress compared to the quadratic 
pattern seen in the placebo group. Compared with the placebo group, escitalopram 
brought about significant changes in GR sensitivity that were observed throughout the 
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Figure 6.12. Mean dexamethasone log IC50 values in the escitalopram (blue 
line) and placebo (grey line) groups. Error bars represent SEM.   
Figure 6.13. Mean prednisolone log IC50 values in the escitalopram (blue 
line) and placebo (grey line) groups. Error bars represent SEM.   
*p = 0.058 
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session. Over all time points, GR sensitivity was lower in the escitalopram group. 
Additionally, the escitalopram group exhibited a marked decrease in GR sensitivity 75 
minutes post-stress, whereas the receptor sensitivity of the placebo group returned 
towards baseline.  
 6.10.6 Sensitivity Analyses 
Counter to expectation, cortisol values exhibited a distinct decline across the testing 
session, without any experimental condition exhibiting a cortisol stress response. 
Therefore, I ran some exploratory analysis examining factors that might explain the 
unusually high baseline cortisol values in participants. In the current study pre-stress 
cortisol values were measured from saliva collected 25 minutes after cannulation. 
Therefore, it is possible that the number of cannulation attempts was associated with 
baseline cortisol levels. However, there was no significant correlation between these 
factors (r = 0.47, p = 0.08). Nevertheless, since the correlation was quite high, I created a 
binary variable in order to compare participants who experienced one cannulation attempt 
with those who experienced two or three attempts. An independent t-test revealed no 
significant difference between groups (p = 0.51).  
Cortisol levels at baseline may also have been elevated due to anticipatory stress. 
Therefore, I examined associations between pre-stress subjective stress and anxiety 
levels. There was no association between baseline cortisol levels and responses to the 
item ‘How stressed do you feel?’ (p = 0.63). However, there was significant negative 
correlation between baseline cortisol levels and responses to the item ‘How relaxed do 
you feel?’ (r = -0.32, p = 0.003). There was also a significant correlation between pre-
stress cortisol values and baseline scores on the HADS anxiety subscale (r = 0.28, p = 
0.009).  
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6.11 Discussion 
 6.11.1 Aims and hypotheses 
The aim of this study was to assess the effects of seven-day administration of beta-
blockers and SSRIs on cortisol secretion in response to acute psychosocial stress in the 
laboratory in healthy volunteers. This study also aimed to assess the effects of these drugs 
on baseline corticosteroid receptor sensitivity and corticosteroid receptor responses to 
acute psychosocial stress. I also sought to examine the effects of acute psychosocial stress 
on both GR and MR sensitivity in unmedicated participants.  
In terms of cortisol stress reactivity, I hypothesised that both seven-day treatment with 
propranolol and escitalopram would enhance cortisol stress reactivity and that sex would 
be an influential factor on the effects of the medications. In the placebo group, I 
hypothesised that acute stress would lead to a decrease in both GR and MR sensitivity. 
Moreover, I hypothesised that both propranolol and escitalopram would enhance these 
changes in GR and MR sensitivity in response to acute stress. Regarding baseline GR and 
MR sensitivity, I hypothesised that both propranolol and escitalopram would increase 
sensitivity. I also posited that sex would be an influential factor on the stress and 
medication effects on receptor sensitivity. The results of this study provided limited 
support for these hypotheses. 
 6.11.2 Summary of results 
Following the acute stress protocol there were significant increases in subjective stress 
ratings in the overall sample. During the stress tasks there were also significant increases 
in cardiovascular responses. Heart rate, SBP, DBP, and cardiac index all increased in 
response to the stress tasks in the overall sample. What this indicates is that the stress 
protocol used in the current study was successful in eliciting a subjective and a biological 
230 
 
stress response. Moreover, propranolol was found to decrease baseline heart rate and 
stress-related heart rate compared to placebo indicating that beta-blockade had been 
successfully achieved. Similarly, escitalopram also exerted effects on cardiac index 
during and at 75 minutes after stress indicating that this SSRI was also biologically active. 
Propranolol brought about significant decreases in depression scores and escitalopram 
brought about significant decreases in positive affect. Exploratory analysis revealed that 
the decrease in positive affect was likely due to experiencing adverse effects over the 
seven days.  
In terms of cortisol stress reactivity, in the overall sample there was a significant effect 
of stress on cortisol values over the testing session. However, counter to expectations, 
cortisol values declined steadily throughout the session. I will discuss possible 
explanations for this pattern of results later in the Discussion section. Propranolol did not 
have an effect on cortisol stress reactivity. In the escitalopram group there was a steeper 
slope of change over the testing session, which is in disagreement with the study 
hypothesis. Instead of the interrupted decrease in cortisol across the session seen in the 
placebo group in response to tasks (Figure 6.7), the escitalopram group showed a 
continuous decline over time.  
In the overall sample LPS-induced IL-6 release was increased following the stress 
protocol. This suggests that the stress protocol led to an increase in immune activity. The 
stress protocol also elicited changes in GR and MR sensitivity in the overall sample. 
Within the placebo group, I hypothesised that acute stress would bring about decreases in 
both GR and MR sensitivity. In support of this hypothesis, there was a transient decrease 
in GR sensitivity after stress that had normalised to baseline values by 75 minutes post-
stress. Acute stress brought about a linear decrease in MR sensitivity in unmedicated 
healthy volunteers that was sustained at 75 minutes post-stress.  
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There was no effect of propranolol on baseline or stress-related changes in GR and MR 
sensitivity. Compared to the placebo group, escitalopram brought about significant 
changes in GR sensitivity that were observed throughout the session. Over all time points, 
GR sensitivity was lower in the escitalopram group.  Additionally, 75 minutes after the 
stress protocol, the escitalopram group exhibited a marked decrease in GR sensitivity 
whereas GR sensitivity in the placebo group had returned towards baseline. I 
hypothesised that SSRI administration would result in enhanced changes in GR 
sensitivity in response to acute stress. This prolonged decrease in sensitivity suggests that 
escitalopram is serving to enhance the GR decrease in response to stress thereby providing 
support for this hypothesis. There was no effect of escitalopram on MR sensitivity at 75 
minutes post-stress.  
6.11.3 Stress-related changes in cardiovascular measures 
In the current study propranolol decreased heart rate at all time-points and did not affect 
blood pressure or cardiac index. These findings are in line with the results of a review of 
59 studies which summarised that beta-blockade significantly reduces heart rate, but not 
blood pressure following acute psychosocial stress (Mills & Dimsdale, 1991). These 
result are also similar to those of von Känel and colleagues who found that five-day 
administration of propranolol (80mg/day) to healthy volunteers also did not bring about 
alterations in blood pressure after an acute stress paradigm (von Känel, Kudielka, 
Helfricht, et al., 2008).  
I also found that the escitalopram group had increased cardiac index immediately 
following stress, and at 75 minutes after stress, compared to the placebo group. To 
reiterate, cardiac index is a measure of cardiac output that takes the body surface area into 
account thus relating cardiovascular performance to the size of the person. Cardiac output 
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is calculated by multiplying heart rate by stroke volume. As heart rate was unaffected by 
escitalopram in the current study, the changes in cardiac output were likely driven by 
alterations in stroke volume. SSRI use within the Multi-Ethnic Study of Atherosclerosis 
has been associated with increased right ventricular stroke volume in those free of CVD 
(Ventetuolo et al., 2012). However, Straneva-Meuse and colleagues found that depressed 
patients taking the SSRI paroxetine had reduced cardiac output after acute stress 
compared to healthy controls (Straneva-Meuse et al., 2004). This implies that health 
status plays a role in SSRI effects on cardiac output.  
 6.11.4 Cortisol stress reactivity 
In the current study, propranolol had no effect on cortisol stress reactivity. This is in line 
with the results of Kudielka and colleagues who found that five-day treatment with 
propranolol (80mg/day) had no effect on pre-stress cortisol levels or cortisol stress 
reactivity in healthy men and women (Kudielka et al., 2007). Null cortisol findings in 20 
healthy men undergoing a bungee jump who had received three-day administration of 
propranolol (40mg/day) also corroborate the findings of the current study (van Westerloo 
et al., 2011). Similarly, in agreement with our findings, acute doses of propranolol have 
been found to have no effect on cortisol stress reactivity (Benschop et al., 1996; Dreifus 
et al., 2014; Uusitupa et al., 1982). Taken together, our results and the results of these 
previous studies do not provide support for the supposed inverse association between the 
HPA axis and the SAM system. In the Introduction of this chapter (Section 6.2.3) I 
highlight the fact that acute beta-blockade only affects cortisol stress responsivity in all-
male samples, and that this might be the reason for the null findings reported by Kudielka 
and colleagues (2007) who used a sample comprised of men and women. In the current 
study sex did not influence propranolol effects on cortisol stress reactivity providing no 
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evidence for the role of sex in the interaction between beta-adrenergic receptors and 
cortisol stress reactivity. 
Escitalopram resulted in a steeper slope of change across the session compared with 
placebo. This finding is in disagreement with previous studies that have found that longer-
term SSRI administration increases cortisol stress reactivity in healthy volunteers 
(Kotlyar et al., 2013; Ljung et al., 2001). However, the results of the current study are in 
line with those of Straneva-Meuse and colleagues (2004) who found that depressed 
patients receiving SSRIs had blunted cortisol stress reactivity compared to controls. This 
was unexpected considering the sample in the current study comprised healthy volunteers. 
The results of the current study indicate that seven-day administration of SSRIs results in 
down-regulation of stress-related HPA axis function. In the studies cited above using 
healthy volunteers, SSRIs were administered for one month (Kotlyar et al., 2013) and six 
months (Ljung et al., 2001). Perhaps in the current study seven-day treatment brought 
about a transient blunting of the cortisol stress response that would correct itself with 
longer-term administration. 
6.11.5 Stress-related changes in corticosteroid receptor sensitivity in healthy 
unmedicated volunteers 
In healthy unmedicated volunteers acute stress brought about a significant decrease in GR 
sensitivity immediately after stress, and at 45 minutes after stress, with GR sensitivity 
returning to baseline levels by 75 minutes. A number of previous studies have found that 
acute stress brings about decreases in GR sensitivity in both murine and human models. 
Acute SRO exposure in mice has been found to bring about reduced GR sensitivity 
(Sheridan et al., 2000; Stark et al., 2001). SRO exposure has also reduced GR mRNA 
expression in mice (Quan et al., 2001). In humans, acute exercise paradigms have also 
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been found to bring about transient reductions in GR sensitivity (DeRijk et al., 1996; 
Smits et al., 1998). Similar to this study, acute psychosocial stress in the laboratory has 
brought about transient decreases in GR sensitivity in young women (Rohleder et al., 
2001), healthy older men (Rohleder et al., 2002), and healthy older men and women 
(Carvalho et al., 2015). However, acute stress in the laboratory has been found to bring 
about increases in GR sensitivity in healthy young men (Rohleder et al., 2001), healthy 
older men who had received a testosterone injection (Rohleder et al., 2002), and healthy 
young women on the oral contraceptive pill (Rohleder et al., 2003).  
In the placebo group, acute stress also brought about a decrease in MR sensitivity which 
became significant at 75 minutes post-stress. Decreased MR sensitivity following acute 
stress has been reported in healthy older adults (Carvalho et al., 2015). However, in 
Carvalho and colleague’s sample, this decrease was transient and MR sensitivity had 
returned to baseline levels by 75 minutes post-stress.  
To reiterate, in the current study I found that GR sensitivity transiently decreased 
following acute stress in the placebo group, but returned to normal baseline levels by 75 
minutes post-stress. MR sensitivity also decreased following acute stress in this group 
and this linear decrease became even more pronounced at 75 minutes post-stress.  
It is plausible that this transient decrease in GR sensitivity after stress may serve to 
temporarily prevent cortisol from exerting its anti-inflammatory effects. This would allow 
the immune system to mount its inflammatory response to stress. This adaptive 
inflammatory immune response serves to protect against injury and infection potentially 
brought about by the ‘stressor’ (Segerstrom & Miller, 2004). Seventy-five minutes after 
stress, GR sensitivity returned to pre-stress levels. Restored GR sensitivity might then 
allow cortisol to exert its regulatory function, shutting down the inflammatory response 
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in order to prevent tissue damage. Furthermore, cortisol itself is known to downregulate 
corticosteroid receptor function (Bamberger et al., 1996). Therefore, this stress-induced 
decrease in GR sensitivity might be an adaptive function preventing tissue damage from 
overexposure to cortisol, which may over time become maladaptive. However, the results 
of the current study provide little evidence for this hypothesis seeing as the transient 
decrease in GR sensitivity occurred alongside a steady decrease in cortisol levels.  
This is the first study to report a linear decrease in MR sensitivity following acute stress. 
The decrease in MR sensitivity was most pronounced at 75 minutes post-stress. By this 
time GR sensitivity had returned to pre-stress levels. As mentioned previously, the GR 
and the MR both work in concert to regulate the cortisol and inflammatory stress 
response. It is possible that the prolonged decrease in MR sensitivity at 75 minutes 
facilitated the return of GR sensitivity to baseline levels. More research is needed to 
confirm this. 
6.11.6 Stress-related changes in corticosteroid receptor sensitivity in those 
receiving propranolol 
Propranolol had no effects on baseline corticosteroid receptor sensitivity or stress-related 
changes in sensitivity. This finding is at odds with those of Ji and colleagues who found 
that treatment with metoprolol increased GR protein levels in CHD patients (Ji et al., 
2010). However, these findings are not easily comparable as GR protein levels provide a 
measure of the number of GR whereas the in vitro glucocorticoid sensitivity assay carried 
out in the current study provides a measure of GR function. Furthermore, Ji and 
colleagues (2010) examined effects in a CHD patient sample and therefore the changes 
in GR protein levels may have been related to symptom remission. The null findings in 
the current study are in line with a murine study which found that propranolol had no 
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effect on GR mRNA levels in rat hippocampal cells (Lai et al., 2003). Together, the lack 
of effect of beta-blockade on cortisol stress reactivity and corticosteroid receptor 
sensitivity in the present study provide no support for the notion that there is an inverse 
relationship between the SAM system and the HPA axis, i.e. blocking the beta-adrenergic 
receptors does not affect cortisol stress responsivity via modulation of the corticosteroid 
receptors. There was no effect of propranolol on baseline or stress-related changes in GR 
and MR sensitivity.  
6.11.7 Stress-related changes in corticosteroid receptor sensitivity in those 
receiving escitalopram 
Escitalopram brought about significant changes in GR sensitivity that were observed 
throughout the session. Compared with placebo, GR sensitivity was lower in the 
escitalopram group over all time points. Furthermore, 75 minutes after acute stress, the 
escitalopram group exhibited a prolonged marked decrease in GR sensitivity compared 
to the placebo group where GR sensitivity had returned towards baseline levels. To date, 
no one has examined the effects of SSRI treatment on corticosteroid receptor responses 
to stress. However, this finding is in line with previous studies which have found that 
SSRI administration brings about decreased receptor sensitivity. The only previous study 
to also measure GR sensitivity using LPS-stimulation of IL-6 production in whole blood 
found that 24-hour treatment with various SSRIs brought about a reduction in GR 
sensitivity in healthy volunteers (Carvalho et al., 2010). In healthy adults six-week SSRI 
treatment has been found impair feedback inhibition of the HPA axis, which is considered 
a proxy for GR sensitivity (Carpenter et al., 2011). This is in agreement with the findings 
of the current study where the overall and prolonged decrease in GR sensitivity indicates 
a protracted reduction in stress-related HPA axis feedback in those taking SSRIs. Also in 
line with the findings of the current study were results reported by Sarubin and colleagues 
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(2014) who found that 10mg escitalopram per day for one week brought about a transient 
decrease in glucocorticoid sensitivity in depressed patients, implying a decrease in GR 
sensitivity.  
Seven day administration of escitalopram altered both stress-related cortisol secretion and 
corticosteroid receptor sensitivity. Compared to placebo, the slope of decline in the 
ecitalopram group was steeper. Due to the linear decrease in cortisol secretion seen in all 
experimental conditions over the testing, this steepening is difficult to interpret. However, 
this pattern of cortisol stress reactivity in the escitalopram group suggests a blunting of 
the cortisol stress response. Escitalopram administration also resulted in an enhanced and 
prolonged decrease in GR sensitivity following acute stress compared to placebo. This 
decrease could be considered to be an enhancement of stress-related changes in GR 
function brought about by SSRI use. As well as influencing the onset of the cortisol stress 
response, the GR is also responsible for the magnitude of the cortisol stress response (de 
Kloet, 1998). Therefore, this decrease in GR sensitivity might be accountable for the 
blunting of the cortisol stress response in the escitalopram group.  
A possible mechanism through which SSRIs may have decreased stress-related GR 
sensitivity is through inhibition of the nuclear transcription factor NF-κB. NF-κB is an 
important transcription factor that plays a crucial role in mediating the production of pro-
inflammatory cytokines such as IL-6 and TNF-α (McKay & Cidlowski, 1999). Stress 
activates NF-κB, which translocates to the nucleus where it binds to its response elements 
leading to the stress-related production of pro-inflammatory cytokines (Pace et al., 2007). 
Acute psychosocial stress in the laboratory has been found to increase levels of NF-κB in 
healthy volunteers (Bierhaus et al., 2003).   
238 
 
NF-κB is known to interact with the GR (McKay & Cidlowski, 1999) and has been shown 
to inhibit GR function (Pace et al., 2007). This increase in NF-κB after stress and the 
subsequent inhibition of GR function likely facilitates the mounting of the inflammatory 
stress response. In this sense, stress-related increases in NF-κB might be seen as adaptive. 
However, over time, prolonged exposure to stress might lead to sustained increases in 
both NF-κB and inflammation. In fact, high levels of of NF-κB have been found in stress-
related diseases such as diabetes and depression (Bierhaus et al., 2001; Miklowitz et al., 
2016), and there is evidence to suggest a role for NF-κB in inflammatory heart disease 
(Bangert et al., 2016). 
SSRIs have been found to reduce both NF-κB activity (Daniele, Da Pozzo, Zappelli, & 
Martini, 2015; Roumestan et al., 2007) and levels of inflammatory cytokines 
(Strawbridge et al., 2015). In the current study it is possible that administration of 
escitalopram resulted in a reduction in the NF-κB and inflammatory stress response 
leading to enhanced GR function, i.e. an enhanced and prolonged decrease in GR 
sensitivity in response to stress. NF-κB activity was not measured in this study so this 
suggestion is speculative. Future work is needed to examine the simultaneous effects of 
SSRIs on stress-related NF-κB activity and GR function. 
One of the mechanisms that might explain the prolonged decrease in GR function in the 
escitalopram group is increased nuclear translocation of the GR at 75 minutes post-stress. 
In line with this timing, GR nuclear translocation rates have been shown to peak 
approximately one hour after exposure to corticosterone (Nishi, Tanaka, Matsuda, 
Sunaguchi, & Kawata, 2004). However, in the current study cortisol did not increase 
following the acute stress paradigm in the escitalopram group meaning that if the 
pronounced decrease in GR sensitivity following stress was due to increased rates of 
nuclear translocation, this was caused by a cortisol-independent mechanism (such as 
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alterations in NF- κB activity). SSRIs and TCAs have been found to enhance GR nuclear 
translocation in the absence of any steroids in vitro (Okuyama-Tamura et al., 2003; 
Pariante, Pearce, Pisell, Owens, & Miller, 1997) meaning that escitalopram may have 
caused enhanced stress-related GR nuclear translocation in the current study in the 
absence of an increase in cortisol. However, as we did not measure the rate of nuclear 
translocation in the current study, we cannot confirm this was the case.   
These changes in stress-related cortisol secretion and GR sensitivity might be one of the 
ways in which SSRIs exert their therapeutic effects. Perhaps altering the way in which 
the body responds to stressful situations is one of the ways in which antidepressants serve 
to ameliorate symptoms of depression. Future research should seek to measure how long 
these alterations in GR sensitivity are sustained for following stress.  
 6.11.8 Cortisol stress reactivity: Lack of response 
In the current study there was a lack of effect of acute stress on cortisol secretion. There 
are a number of possible explanations for why this occurred. Firstly, the stress protocol 
used in the current study may not have been sufficient to bring about a biological stress 
response in the overall sample. However, subjective stress ratings, cardiovascular 
measures, and changes in corticosteroid receptor sensitivity suggest that the participants 
experienced both a psychological and a biological response to the stress protocol. It is 
possible that the stress protocol was not sufficient to elicit changes in HPA axis function. 
In a large meta-analysis of 208 laboratory studies, psychological stress paradigms overall 
were found to induce cortisol increases (Dickerson & Kemeny, 2004). However, the 
stress effects varied widely across studies with a number of studies reporting no changes 
in cortisol (ibid).  
240 
 
Although previously in this thesis I mentioned that there are generally high correlations 
between salivary cortisol levels and levels of unbound cortisol in plasma and serum 
(Section 4.4.7), there is evidence to suggest that this might not necessarily be the case 
during and after stress. Some study participants have been found to have an absent or 
blunted cortisol stress response in saliva, with marked cortisol increases in plasma 
(Kirschbaum & Hellhammer, 2000). As cortisol was measured in saliva in the current 
study it may be that the cortisol stress response was missed due to failure to measure 
cortisol in plasma.  
Due to the unusually high levels of pre-stress cortisol in the current study it is more 
probable that anticipatory effects of attending the laboratory session masked the effects 
of the stress protocol. The baseline cortisol value was calculated from saliva collected 25 
minutes after venepuncture. Venepuncture is thought to elicit a rise in cortisol levels 
(Kirschbaum & Hellhammer, 1989). The 25 minute rest period may not have been 
sufficient time for cortisol levels to return to unstressed levels. However, exploratory 
analysis revealed no significant association between venepuncture attempts and pre-stress 
cortisol levels.  
On recruitment to the study, all participants were aware that during the laboratory session 
they would undergo a battery of ‘challenging mental tasks’ while regularly providing 
biological samples. It is possible that participants were anxious or nervous prior to 
attending the laboratory session. Exploratory analysis showed that high baseline cortisol 
values were associated with lower levels of subjective feelings of relaxation, and higher 
levels of baseline anxiety. This indicates that feelings of nervousness or anxiety affected 
baseline cortisol levels. Perhaps to tackle this future studies should alter the language used 
during the study recruitment process. Omitting terms or phrases such as ‘stress’ or 
241 
 
‘challenging mental tasks’ could have reduced anxiety levels at the beginning of the 
laboratory session.   
 6.11.9 Strengths and limitations 
A strength of the current study is that it was a randomised placebo-controlled double blind 
trial. We used a parallel group design meaning that participants receiving placebo acted 
as the control comparison for both experimental medications. Adopting a parallel groups 
design allowed us to avoid problems relating to order and carry-over effects to do with 
study medications. It also meant that participants were unable to become habituated to 
the stress protocol. The three groups did not differ significantly on demographic or stress-
related factors. However, as we did not adopt a crossover design where participants act 
as their own placebo comparison, it is possible that the experimental groups were 
unbalanced on some covariates that were not measured in the study. For example, we did 
not assess menstrual cycle phase in female participants. Menstrual cycle phase has been 
shown to affect cortisol responses to acute stress (Kirschbaum et al., 1999), although the 
evidence is mixed (Kirschbaum, Klauer, Filipp, & Hellhammer, 1995).  
This study had a retention rate of 87.5% with 91 participants providing usable stress-
related cardiovascular, cortisol, or corticosteroid receptor data. However, the sample sizes 
for individual analyses were less than this (see Table 6.3, 6.4, and 6.5). It is possible that 
this study was underpowered to detect certain effects of the medications. Additionally, 
our sample was composed mostly of young healthy university students from high 
socioeconomic backgrounds. Therefore the results of this study may not be readily 
generalizable to other groups.  
The lack of effect of propranolol observed in the current study may be related to issues 
surrounding the study medications. Propranolol elicited the expected changes on stress-
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related cardiovascular function. This implies that the medication did have a biological 
effect. However, it is possible that the dosage used, and the treatment duration, were not 
sufficient to induce changes in the HPA axis, or the corticosteroid receptors. Previously, 
five day administration of 80mg propranolol per day (Kudielka et al., 2007) and three day 
administration of 120mg per day (van Westerloo et al., 2011) did not affect cortisol stress 
reactivity in healthy volunteers. This suggests that beta-blocker dosage was probably not 
an issue in the current study. In terms of treatment duration, propranolol is a rapidly 
metabolised drug that exerts its effects rapidly (Leahey et al., 1980). Therefore, it is 
difficult to say whether increasing the treatment duration in the current study would have 
affected the propranolol group. Furthermore, as mentioned in Section 5.8.6, propranolol 
may not have been the most appropriate probe to use to assess the effects of sympathetic 
activation on HPA axis function as this drug is known to act as an antagonist of the 
serotonin receptors 5-HT1A and 5-HT1B. The use of a cleaner probe such as metoprolol 
may have elicited different results.  
Although escitalopram did bring about changes in cortisol stress reactivity and stress-
related corticosteroid receptor sensitivity it is possible that increasing the study treatment 
duration might have made these changes more pronounced. Many SSRIs take at least two 
weeks to elicit any beneficial response from depressed patients (Kasper et al., 2006). 
However, escitalopram has been shown to be the most fast-acting SSRI on the market 
exerting clinically meaningful effects within seven days (Burke et al., 2002; Montgomery 
et al., 2001; Nierenberg et al., 2007). Nevertheless, future research should seek to extend 
the duration of administration of escitalopram in healthy individuals to explore whether 
the effects on the HPA axis and its receptors are more pronounced.  
It is possible that some participants did not adhere to the study protocol and missed doses 
of medications on certain days. There is also no guarantee that participants took the drugs 
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at the same time every day with food as directed. Therefore, there may have been some 
variability between participants in the current study regarding the bioavailability of the 
medications. However, pill counts were performed in order to ensure adherence to the 
protocol and changes in cardiovascular parameters across the medication groups indicated 
that the participants did take the medications as required. Nevertheless, future studies 
should measure blood concentrations of pharmacological probes in order to measure the 
bioavailability of the drug and confirm adherence.  
The stress protocol used in the current study elicited changes in subjective stress levels, 
cardiovascular parameters, and corticosteroid receptor sensitivity. Therefore the lack of 
stress-related effects on cortisol stress reactivity in the current study is likely not related 
to the stress protocol used. Issues with the measurement of cortisol may partly explain 
the null findings. As mentioned previously, there can be discrepancies between levels of 
salivary and plasma levels of cortisol during and after stress. Therefore, the stress protocol 
may have brought about increases in plasma but not salivary cortisol in the current study, 
although this is unlikely. ACTH, but not cortisol, levels also may have been altered by 
the stress protocol in the current study. Failure to measure ACTH in the current study 
means that we could not assess these effects at the level of the pituitary. Future studies 
should endeavour to measure both plasma levels of cortisol and ACTH. 
In terms of corticosteroid receptor sensitivity, performing glucocorticoid sensitivity 
assays in whole blood rather than in isolated PBMCs may have affected results obtained. 
It is preferable to carry out these tests in isolated lymphocytes or monocytes as analysis 
in whole blood means that individual differences in cell population ratios are not being 
taken into account. For example, in studies looking at the effects of exercise on GR 
sensitivity in healthy volunteers, the glucocorticoid sensitivity assay carried out in whole 
blood shows that sensitivity decreases in response to exercise (DeRijk et al., 1996; Smits 
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et al., 1998) whereas the assay carried out in isolated PBMCs shows that sensitivity 
increases in response to exercise (Duclos et al., 1999; Fragala et al., 2011). Future studies 
using in vitro glucocorticoid sensitivity assays to examine receptor sensitivity should 
carry out these tests in isolated PBMCs. Moreover, these assays only provide a proxy 
measure of GR and MR sensitivity. In the current study we measured glucocorticoid 
suppression of LPS-induced IL-6 release meaning we did not examine all the wider 
effects of glucocorticoids. Perhaps it would have been useful to directly measure receptor 
mRNA levels, or measure the rate of translocation of the corticosteroid receptors into the 
cell nuclei using Western blot analysis or a DNA binding ELISA for activated 
corticosteroid receptors. Future studies should try to measure both receptor levels and 
sensitivity in order to gain a more in depth understanding of what is occurring at the 
cellular level.  
In the current study, pre-stress cortisol levels were high and steadily declined across the 
testing session despite participants undergoing a modified version of the TSST. 
Exploratory analysis indicated that this was probably due to high levels of anticipatory 
stress. This may be due to the language that was used in the recruitment material. As 
mentioned earlier, future studies should avoid using certain terminologies that might 
make participants anxious or nervous about attending the laboratory session.  
A further limitation of the current study is that there were 12 participants who had high 
depression and/or anxiety scores. Prior to recruitment, participants were asked if they had 
ever received a clinical diagnosis of any psychiatric disorder. As a result, those 
participants who had never received a clinical diagnosis of anxiety or depression, but who 
did meet the depression/anxiety cut-offs on self-report measures were recruited into the 
study. Future studies should screen participants using brief measures of depression and 
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anxiety prior to recruitment into the study to ensure that the sample is comprised of 
healthy volunteers free of mental illness.  
One additional limitation of this study was the use of multiple comparisons. Within each 
comparison group, the effects of experimental condition on a number of cortisol related 
parameters (stress-related secretion, changes in GR and MR sensitivity) were measured 
simultaneously. This means that the probability of observing a significant result due to 
chance may have been increased. The use of Bonferroni or Sidak corrections could have 
been applied to deal with multiple comparisons within the repeated measures analyses. 
However, these corrections have a tendency to be too conservative (Narum, 2006) which 
may have been problematic for results, particularly when dealing with minute changes at 
the cell receptor level. Nevertheless, this issue should be borne in mind when interpreting 
results.  
 6.11.10 Conclusion 
To conclude, the results of this study showed that acute stress brings about decreases in 
corticosteroid receptor sensitivity that likely occur to facilitate the inflammatory stress 
response. This seems to occur independently of stress-related changes in cortisol 
secretion, which did not follow the expected pattern. Seven-day administration of SSRIs 
brought about a steeper slope of decline in the cortisol stress response and also enhanced 
and prolonged the stress-induced decrease in GR sensitivity. These changes might be 
brought about through alterations in cellular pathways known to influence inflammation. 
Altering the biological stress response using SSRIs might have implications for stress-
related diseases such as depression and CVD. Future work is needed to confirm these 
findings and also delineate in more detail the possible mechanisms involved. 
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Chapter 7  
Discussion 
 
7.1 Overview  
There is evidence to suggest that dysregulation of the HPA axis might be one of the 
biological pathways linking psychosocial stress with CVD. This PhD consisted of three 
studies that aimed to assess the role of HPA axis dysregulation in CVD, and to examine 
potential biological pathways that might be involved in basal and stress-related HPA axis 
dysregulation. Two different methods of investigation were used in this thesis to 
investigate these aims. Firstly, an observational clinical cohort study was used to assess 
the role of HPA axis dysregulation in patients with advanced CVD. Secondly, an RCT 
where healthy volunteers were randomised to receive different pharmacological probes 
was used to examine the role of certain biological pathways in basal and stress-related 
HPA axis function.  
A body of evidence has highlighted the role of psychosocial stress in CVD and provided 
evidence for the role of the HPA axis in the stress-CVD link. However, gaps in the 
understanding remain which this PhD sought to address, particularly concerning the 
clinical relevance of HPA axis dysregulation in CVD, and the biological mechanisms 
through which psychosocial stress might cause this dysregulation. 
In Study 1 (presented in Chapter 3) I examined the utility of pre-surgical diurnal cortisol 
rhythm in predicting the occurrence of post-surgical death and/or MACE in patients 
undergoing CABG surgery. In Study 2 (presented in Chapter 5) I examined the effects of 
six-day administration of beta-blockers and SSRIs on diurnal cortisol secretion in healthy 
volunteers. This was in order to find out more about what mechanisms and biological 
systems are involved in dysregulation of diurnal HPA axis functioning. In Study 3 
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(presented in Chapter 6) I examined the effects of seven-day administration of these same 
medications on cortisol stress reactivity and basal and stress-related changes in 
corticosteroid receptor sensitivity. Moreover, I examined the effects of acute stress on 
both GR and MR sensitivity in unmedicated healthy volunteers as there is a relative dearth 
of research in this area. In this Discussion chapter the hypotheses and findings of the three 
studies presented in this thesis will be briefly summarised and the contribution of these 
studies to the literature will be highlighted. Implications of the results, limitations of this 
thesis, and ideas for future research will also be discussed.  
7.2 Main findings  
 7.2.1 Study 1: Diurnal cortisol rhythm and adverse clinical outcomes in patients  
                    with advanced CVD: The ARCS Study 
In Study 1 (presented in Chapter 3) I examined the relationship between pre-surgical 
diurnal cortisol and adverse post-surgical outcomes in patients with advanced CHD 
undergoing CABG surgery. There is growing evidence (provided in Chapter 2) that the 
HPA axis plays a role in the progression of CVD. A number of studies have provided 
evidence for associations between single measures of plasma or serum cortisol and 
mortality or risk of future cardiac events in CVD (Güder et al., 2007; Jutla, Yuyun, Quinn, 
& Ng, 2014; Reynolds et al., 2010; Yamaji et al., 2009). However, the directions of these 
associations are mixed. In Chapter 3 I argue that this is because the diurnal nature of 
cortisol secretion is not being taken into account. One important large-scale study has 
shown an association between flatter cortisol slopes and increased risk of cardiovascular 
death in 4,047 originally healthy civil servants from the Whitehall II cohort (Kumari, 
Shipley, Stafford, & Kivimaki, 2011).  
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To date, no published studies have examined the role of diurnal HPA axis function in the 
prognosis of those who already have advanced CVD. In order to address this gap in the 
literature I measured several indices of diurnal cortisol secretion in 250 patients 
undergoing CABG surgery approximately 30 days prior to the procedure. I also collected 
data on long-term clinical outcomes (death/MACE) for these patients up to approximately 
2-3 years after surgery. I hypothesised that a flatter diurnal cortisol slope pre-surgery 
would be associated with higher rates of adverse cardiac events and mortality in the years 
following revascularisation, but not CAR or cortisol AUC. I also hypothesised that poorer 
psychosocial stress profiles (high depressive symptoms, high anxiety symptoms, more 
stressful life events, low social support) would be cross-sectionally associated with a 
flatter cortisol rhythms. 
As hypothesised, the results showed that patients with flatter pre-surgical cortisol slopes 
were at increased risk of experiencing death and/or MACE in the years following CABG 
surgery. The results showed that lower cortisol on waking and higher evening cortisol 
were also associated with increased risk of adverse clinical outcomes. This suggests that 
alterations in morning and evening levels were driving the association between slope and 
adverse outcomes. In agreement with the hypotheses, neither the CAR nor the cortisol 
AUC were associated with adverse clinical outcomes in these patients. Contrary to 
expectation, there were no robust cross-sectional associations between the psychosocial 
stress measures and cortisol slope. 
This was the first study that examined the association between diurnal cortisol rhythm 
and prognosis in patients with CVD. The findings of this study add to a small but 
important body of work that show that flatter cortisol slopes also have prognostic value 
in other serious illnesses such as breast. lung, ovarian cancer, and renal cell carcinoma 
(Cohen et al., 2012; Schrepf et al., 2015; Sephton et al., 2013; Sephton, Sapolsky, 
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Kraemer, & Spiegel, 2000). Flatter cortisol slopes have also been observed in CHD 
patients compared to controls (Nijm et al., 2007). The association I report in this thesis 
implies variation of cortisol rhythm within patients who have CVD, which suggests that 
HPA axis dysregulation might worsen with disease progression. Furthermore, Kumari 
and colleagues found that alterations in evening cortisol drove the association between 
cortisol slope and cardiovascular mortality in originally healthy subjects, whereas I report 
that alterations in both morning and evening cortisol levels drive the association observed 
in the current study. This indicates that HPA axis dysregulation has progressed further in 
people with advanced CVD, again suggesting that dysregulation might worsen with 
disease progression. It is noteworthy that flatter slopes are also indicative of disease 
progression in other physical illnesses (Cohen et al., 2012; Schrepf et al., 2015; Sephton 
et al., 2013, 2000) meaning that these effects are not specific to CVD.  
Counter to expectation I found no association between flatter cortisol slopes and any of 
the psychosocial stress variables. This implies that at this stage of advanced CHD, cortisol 
dysregulation might be driven more by physiological factors associated with the disease 
rather than psychosocial factors. The lack of association might also be due to our sample 
being a relatively unstressed sample. Psychosocial stress factors might not have been 
measured comprehensively or accurately. For example, in Chapter 1 I assert that life 
events, which were included as the main stress measure in the ARCS Study, might not 
provide a meaningful assessment of chronic stress levels. 
Further limitations of this study also relate to the sample in that it was comprised largely 
of white males and thus the results cannot be readily generalised to other groups. A 
detailed discussion of the limitations of this study is provided in Chapter 3. However, it 
is important to reiterate here that the sample of this study was relatively small with only 
19 adverse events occurring in the follow-up period. Therefore, statistical power was 
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limited and only a small number of covariates could be included in analyses. It is also 
important to mention that these results do not provide direct evidence of a causal 
association between cortisol slope and adverse outcomes in these patients as there may 
have been other unmeasured factors influencing diurnal cortisol rhythms and increasing 
risk of adverse outcomes.  
The findings of this study need to be corroborated by further research with larger, more 
varied samples, and longer follow-up periods. Despite these considerations and others 
outlined in more detail in Chapter 3, the findings of Study 1 of this thesis are novel and 
have significantly added to the literature providing support for the role of HPA axis 
dysregulation in CVD prognosis.  
 7.2.2 Study 2: The effect of pharmacological blockade on diurnal cortisol  
                    secretion in healthy volunteers 
In Study 2 (presented in Chapter 5) I sought to build on the findings presented in Chapter 
3 by examining the effects of beta-blockade and SSRIs on diurnal cortisol secretion in 
healthy volunteers using data from the Stress Pathways Study described in Chapter 4. 
Using these pharmacological probes might tell us more about the mechanisms and 
different biological pathways involved in dysregulation of diurnal HPA axis functioning. 
There is a body of work that suggests that acute and longer-term administration of beta-
blockers affects cortisol secretion. More specifically, SNS suppression by beta-blockade 
seems to enhance HPA axis activation. However, to date, no one has examined the effects 
of beta-blockade on diurnal cortisol parameters. On the other hand, a number of studies 
have examined the effects of SSRIs on diurnal cortisol secretion and these studies have 
shown that long-term treatment with SSRIs does alter diurnal cortisol rhythm. However, 
all studies to date have been carried out in depressed patients meaning we cannot 
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distinguish whether the observed effects are due to symptom remission of direct 
biological effects on HPA axis function. 
In order to address these gaps in the literature, I examined the effects of six-day 
administration of beta-blockers and SSRIs on diurnal cortisol parameters in 94 healthy 
volunteers. Although no study to date has examined effects of beta-blockade on diurnal 
cortisol secretion, I hypothesised that beta-blockers would increase secretion leading to 
more enhanced CAR and cortisol AUC, and flatter cortisol slopes. Based on previous 
research in depressed patients, I hypothesised that SSRIs would reduce cortisol AUC and 
reduce the CAR. In line with these reductions I also hypothesised that SSRIs would 
steepen slopes. I also sought to examine how sex influences the effects of the medications. 
The results presented in Chapter 5 provide limited support for the hypotheses. There was 
no effect of beta-blockade on any diurnal cortisol parameter. Similarly, SSRI 
administration did not affect cortisol AUC or the CAR. However, women taking SSRIs 
had significantly steeper cortisol slopes over the day compared to those taking placebo. 
These changes in HPA axis occurred independently of any change in mood which 
suggests that the observed results were due to direct biological effects of SSRIs on HPA 
axis function. Mechanistically, these results provide support for the notion that the 
serotonergic system exerts substantial effects on the HPA axis, potentially via 
desensitisation of the 5-HT1A receptor. These results also provide evidence in support of 
the idea that SSRIs may directly exert effects on the HPA axis via modulation of the 
corticosteroid receptors (this issue was investigated in Study 3 presented in Chapter 6). 
The observed sex difference found in Study 2 is interesting and implies that oestrogen 
plays a role in how SSRIs affect the HPA axis.  
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Flatter cortisol slopes are characteristic of depression (Doane et al., 2013; Jarcho, Slavich, 
Tylova-Stein, Wolkowitz, & Burke, 2013; Sjögren, Leanderson, & Kristenson, 2006). 
The steeper cortisol rhythm brought about by brief SSRI treatment in women in Study 2 
of this thesis implies that this might be one of the mechanisms through which these 
medications exert their therapeutic effect. Perhaps SSRIs might be a plausible therapeutic 
intervention for female CHD patients with flatter cortisol slopes. SSRI treatment has been 
associated with reduced mortality in CVD patients (Taylor, Youngblood, Catellier, et al., 
2005). 
There are a number of possible reasons why SSRI administration did not bring about 
alterations in other cortisol parameters. Health status appears to be an influential factor 
on results in that SSRI effects on HPA axis function seem to be more pronounced in 
depressed patients. Dosage may also be an issue and treatment duration might also be an 
issue for both the SSRI and beta-blocker group. This and other limitations are dealt with 
in detail in Chapter 5. Future research is needed to replicate the results of this study.  
Despite methodological limitations, the findings of Study 2 are novel. It is the first time 
that the effects of beta-blockade on diurnal cortisol secretion have been measured. It is 
also the first time that the effects of SSRIs on several diurnal cortisol parameters have 
been measured in healthy people. These findings add to those of Study 1 as they indicate 
that SSRIs modulate diurnal cortisol slope – a cortisol parameter that is associated with 
worse prognosis in CVD.  
 7.2.3 Study 3: The effect of pharmacological blockade on cortisol stress  
                    reactivity and corticosteroid receptor sensitivity in healthy volunteers 
In Study 3 (presented in Chapter 6) I sought to extend existing knowledge on stress-
related HPA axis function by examining the effects of seven-day administration of beta-
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blockers and SSRIs on cortisol stress reactivity and stress-related corticosteroid receptor 
function. Furthermore, I examined the effects of these medications on basal corticosteroid 
receptor function. I also examined the effects of acute stress on GR and MR sensitivity in 
unmedicated healthy volunteers in order to garner more information on how these 
receptors respond to stress. Together with the results from Study 2, these results were 
intended to provide insight into the biological mechanisms involved in stress-related 
dysregulation of the HPA Axis, which is known to be a factor in CVD risk and prognosis. 
There is a body of work that suggest that suppression of the SNS via beta-blockade 
enhances HPA axis stress reactivity. The main effectors of the SAM system, epinephrine 
and norepinephrine, have been shown to affect GR function and beta-blockade has also 
been shown to increase GR protein levels in CHD patients (Ji, Guo, Yan, Li, & Lu, 2010; 
Schmidt, Holsboer, & Spengler, 2001). However, to date no published study has assessed 
the effects of beta-blockade on corticosteroid receptor function in healthy people, or on 
acute stress-related changes in corticosteroid receptor sensitivity. Studies assessing the 
effects of SSRI administration on cortisol stress reactivity are scarce but the evidence 
suggests that this drug might enhance the cortisol stress response (Jezová & Duncko, 
2002; Ljung et al., 2001). SSRIs are known to modulate corticosteroid receptor sensitivity 
(see Section 6.6) but, to date, no study has assessed the effects of SSRI administration on 
stress-related changes in corticosteroid receptor sensitivity.  
Study 3 sought to address these gaps in the literature using data from the Stress Pathways 
Study described in Chapter 4. Firstly I examined the effects of acute stress on 
corticosteroid receptor sensitivity in unmedicated healthy volunteers. I hypothesised that 
acute stress would lead to a decrease in GR and MR sensitivity. I then assessed the effects 
of beta-blockade and SSRI administration on cortisol stress reactivity and baseline and 
stress-related corticosteroid receptor sensitivity. I hypothesised that beta-blockade would 
254 
 
bring about increased cortisol stress reactivity. Based on Ji and colleagues (2010) work I 
hypothesised that beta-blockade would increase basal GR sensitivity. I also hypothesised 
that stress-related changes in GR and MR sensitivity would be enhanced in the volunteers 
receiving beta-blockers. I hypothesised that SSRIs would bring about increased cortisol 
stress reactivity. I also hypothesised that SSRI treatment would increase baseline GR and 
MR sensitivity and enhance stress-related changes in GR and MR sensitivity compared 
to placebo.  
The results of Study 3 provided limited support for the hypotheses. In the placebo group, 
acute stress brought about decreases in both GR and MR sensitivity as hypothesised. 
There was a transient decrease in GR sensitivity which had returned towards baseline by 
75 minutes post-stress. Acute stress brought about a linear decrease in MR sensitivity 
which was most pronounced at 75 minutes post-stress. Propranolol had no significant 
effects on cortisol stress reactivity or corticosteroid receptor sensitivity. However, 
escitalopram administration resulted in a blunted cortisol stress response and a more 
enhanced and prolonged decrease in GR sensitivity throughout the stress testing session 
compared to placebo.   
As discussed in Chapter 6, the transient decrease in GR sensitivity after acute stress in the 
placebo group is likely an adaptive function preventing tissue damage from overexposure 
to glucocorticoids while allowing the immune system to mount its inflammatory response 
to stress. The prolonged linear decrease in MR sensitivity following stress might serve to 
facilitate the return of GR sensitivity towards baseline levels. More work is needed to 
confirm this. Seven-day treatment with escitalopram enhanced this decrease in GR 
sensitivity across the testing session and also prolonged it. Additionally cortisol stress 
reactivity was blunted in those receiving escitalopram. It is possible that this enhanced 
decrease in GR sensitivity was accountable for the blunting of the cortisol stress response 
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in this group seeing as the GR is responsible for the magnitude of the cortisol stress 
response (de Kloet, 1998). Mechanistically, SSRI administration might have altered 
stress-related GR sensitivity through altering levels of the transcription factor NF-κB 
which is known to play a role in the inflammatory stress response. This is described in 
detail in Section 6.11.7 of Chapter 6. The prolonged decrease in GR sensitivity brought 
about by SSRIs might be associated with alterations in nuclear translocation rates. Future 
research should aim to measure stress-related changes in levels of NF-κB and rates of 
nuclear translocation alongside changes in GR sensitivity in order to shed more light on 
the mechanisms involved. Although replication is needed, these results suggest that 
SSRIs alter HPA axis and corticosteroid receptor stress reactivity indicating that changing 
the way in which the body responds to stressful situations might be one of the ways in 
which antidepressants serve to ameliorate symptoms of depression. 
There are a number of methodological issues which may have affected the results 
obtained. A detailed account of these is provided in Chapter 6. Measurement of cortisol 
and corticosteroid receptor sensitivity may have been problematic, and also the sample 
contained participants who had high scores on measures of depression and/or anxiety. 
Suggestions for improvement in future research were provided in Chapter 6 and will also 
be provided later in this chapter.  
Despite the methodological shortcomings, the findings of Study 3 are novel. To date, the 
effects of acute stress on both GR and MR sensitivity in healthy younger volunteers had 
yet to be examined. Additionally, no published study had examined the effects of beta-
blockers or SSRIs on stress related changes in corticosteroid receptor sensitivity. 
Although the results of this study provided limited support for the hypotheses, the results 
are still novel and will be discussed in detail later in the Discussion.  
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7.3 Overall summary of findings and implications 
Firstly, this PhD has provided support for the clinical relevance of HPA axis 
dysregulation in advanced CVD by showing that flatter cortisol slopes were associated 
with adverse outcomes in the years following CABG surgery. The results of this PhD also 
indicate that changes in central neurotransmitter function brought about by SSRIs affect 
HPA axis function. Augmenting levels of serotonin resulted in a steepening of the cortisol 
slope in women. This may have therapeutic implications for both depression and CVD. 
Results from this PhD also show that in unmedicated individuals, acute stress brings about 
a decreases in GR and MR sensitivity. Augmenting levels of serotonin with SSRIs 
appears to have implications for cortisol levels and GR sensitivity after acute stress 
providing further evidence for the role of central neurotransmitters in HPA axis function. 
However, this study provided no evidence for the involvement of the peripheral nervous 
system in HPA axis function.  
 7.3.1 Study 1: Implications 
The findings from Study 1 provide support for the clinical relevance of HPA axis function 
in CVD. HPA axis dysregulation was associated with poorer outcomes in CVD patients 
undergoing coronary revascularisation. Diurnal cortisol profiles can be obtained without 
difficulty because the measures are non-invasive and samples are stable for several days. 
Measuring diurnal cortisol rhythm in CVD patients may help to identify those at risk of 
adverse events or death allowing additional support and care to be provided. However, 
replication of the findings of Study 1 is required in order to confirm the clinical utility of 
measuring diurnal HPA axis function in CVD. Ideas for future research will be provided 
in Section 7.5.1.  
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Flattening of the diurnal cortisol slope is seen in CHD patients compared to healthy 
controls (Nijm et al., 2007) and in this study flattening of the cortisol slope was associated 
with adverse outcomes within a CHD patient group. This begs the question could 
modifying cortisol be beneficial for people with CVD? One intervention that has been 
used to modify cortisol secretion in patient cohorts is physical activity (Collomp et al., 
2016). To date, studies have assessed the effects of both aerobic exercise and yoga on 
cortisol secretion in a number of patient groups. In breast cancer, a six month 
cardiovascular and diet intervention led to increases in morning cortisol levels, and 
decreases in depressive symptoms in 90 overweight patients (Saxton et al., 2014). 
However, it is difficult to ascertain whether it was the physical activity or the dietary 
intervention that was responsible for this change in cortisol secretion. Furthermore, the 
authors did not report whether or not patients experienced weight-loss – a factor that is 
known to affect HPA axis function (Seimon, Hostland, Silveira, Gibson, & Sainsbury, 
2013).  
Exercise has also been shown to alter cortisol secretion in the metabolic syndrome. Corey 
and colleagues randomised 136 people with the metabolic syndrome to undergo a 
stretching (n = 64) or a yoga (n = 72) intervention for six months (Corey et al., 2014). 
Salivary cortisol was measured at four time-points over three days at baseline and at the 
end of the intervention. Following the intervention, the stretching group had decreased 
waking and bedtime cortisol levels and increased GR sensitivity as assessed by the DST 
compared to those receiving the yoga intervention. Exploratory analysis revealed that 
these decreases were driven by an increase in social support experienced by the stretching 
group. Unfortunately, the authors do not report whether any of the symptoms of the 
metabolic syndrome were reduced or associated with changes in HPA axis function. 
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Yoga has also been found to affect cortisol secretion in patient groups. Vadiraja and 
colleagues randomly enrolled 88 breast cancer patients to either a six-week yoga 
programme (n=44) or brief therapy while undergoing radiotherapy (Vadiraja et al., 2009). 
After six weeks, those enrolled on the yoga programme had decreased depression and 
anxiety symptoms, decreased PSS scores, and increased morning cortisol levels. In a 
small RCT, 18 breast cancer patients were randomly assigned to attend yoga classes for 
90 minutes twice weekly (n=9) or to a wait-list control group (Banasik, Williams, 
Haberman, Blank, & Bendel, 2011). After the yoga course, the patients reported better 
emotional well-being, lower fatigue, and lower morning and 5pm cortisol levels. 
However, this study was limited by a small sample of 18 which may have affected results. 
Aside from cancer patients, the effects of yoga on cortisol changes in depression have 
been examined. Woolery and colleagues randomised 28 young volunteers with mild 
levels of depression to undergo a five-week yoga program or be enrolled into a wait-list 
control group (Woolery, Myers, Sternlieb, & Zeltzer, 2004). Compared with controls, 
those who underwent the yoga intervention had lower depression and anxiety scores 
following the five-week program, and also had higher levels of morning cortisol.  
Overall, the evidence suggests that exercise and yoga can alter diurnal cortisol secretion 
in patient groups. However, the evidence largely comes from small sample sizes, and it 
is difficult to tease apart exactly how these physical activities might modulate HPA axis 
function. A number of factors might be relevant, such as weight loss, social support, and 
improvements in sleep brought about by the physical activity (Chen et al., 2009). 
Moreover, the relaxation element of yoga may be what is driving the alterations in cortisol 
secretion rather than the physical activity itself. To date, the effects of exercise or yoga 
on diurnal HPA axis function in CVD patients has yet to be examined. Based on evidence 
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from cancer and depression, the use of physical activity to alter HPA axis function in 
patient groups is an interesting prospect.  
In recent years a large study has been carried out by Blumenthal and colleagues intending 
to examine the effects of stress management training on changes in biomarkers (including 
cortisol) in patients enrolled in traditional exercise-based cardiac rehabilitation 
(Blumenthal et al., 2010). Recent results from the ENHANCED trial indicate that patients 
who received the stress management training alongside the traditional cardiac 
rehabilitation experienced significant reductions in psychosocial stress measures 
(depression, anxiety, PSS) and markers of inflammation (CRP) (Blumenthal et al., 2016). 
However, results pertaining to cortisol have not yet been reported.  
Another way of moderating HPA axis function in CVD is through pharmacological 
treatment. Results from Study 2 of this PhD provide limited evidence that serotonergic 
antidepressants may have clinical utility in altering HPA axis function in females. This 
will be discussed in the next section.      
 7.3.2 Study 2: Implications 
Results from this PhD indicated that changes in central neurotransmitter function affected 
HPA axis function. Pharmacologically increasing levels of serotonin resulted in a 
steepening of the cortisol slope in women after six days. These changes in HPA axis 
function occurred independently of any alterations in mood indicating that they were a 
result of direct biological effects. This implies that increasing the bioavailability of 
serotonin alters the diurnal rhythm of the HPA axis. As well as increasing levels of 
serotonin, SSRIs are thought to exert anti-inflammatory effects which might have 
implications for HPA axis functioning (Walker, 2013). Nonetheless, these results provide 
further evidence that the CNS and HPA axis are functionally related. It is possible that 
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stress-related dysregulation of the HPA axis could be down to alterations in the CNS 
particularly related to serotonin. Chronic stress and depression are known to be associated 
with decreased levels of brain serotonin and increased levels of cortisol (Cowen, 2002; 
Tafet et al., 2001). The serotonergic system and the HPA axis are reciprocally linked 
(Porter, Gallagher, Watson, & Young, 2004) and altering levels of one has implications 
for levels of the other. In this PhD I have provided further evidence for this reciprocal 
association as SSRI administration in women brought about steeper cortisol slopes. 
However, there was no change in cortisol AUC showing that the diurnal rhythm was 
altered rather than overall cortisol levels.  
These results suggest that the steeper cortisol rhythm observed in women taking SSRIs 
may be one of the mechanisms through which these drugs exert their therapeutic effects. 
Furthermore, these results also suggest that SSRIs may be particularly valuable for female 
CHD patients with flattened diurnal cortisol slopes. As mentioned before in this thesis, 
depression is prevalent and persistent in CHD patients (Thombs et al., 2006) and many 
patients with comborbid CHD and depression take SSRIs (Shapiro, 2015). A number of 
studies have assessed the effects of SSRI use in CHD patients who are depressed. In a 
recent systematic review of 40 studies assessing associations between antidepressant use 
and CHD, the authors concluded that SSRIs (compared to other types of serotonergic 
antidepressants) are cardio-protective in nature (Nezafati, Vojdanparast, & Nezafati, 
2015). They posit that SSRIs may exert these protective effects by promoting optimal 
platelet activity, thus preventing the development of atherosclerotic plaques and thrombi 
(ibid). Within CHD patients with depression, SSRI use has also been found to be 
associated with lower risk of death and recurrent cardiac events in the 29 months 
following an MI (Taylor et al., 2005). Conversely, antidepressant use in CHD has been 
associated with increased mortality (Brouwers et al., 2016; Hansen et al., 2016). 
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However, these studies failed to take antidepressant type into account. In Study 1 of this 
PhD I provided evidence for an association between flattened cortisol slopes and adverse 
clinical outcomes in patients with advanced CHD. It is possible that direct effects of 
SSRIs on diurnal cortisol slope might be a pathway through which SSRIs exert their 
supposed protective effects in CHD patients with depression. However, I have only 
shown this association in healthy women. Replication of these findings in larger studies 
is required before any conclusions can be drawn. Ideas for future research will be 
provided in Section 7.5.  
 7.3.3 Study 3: Implications 
Results from this PhD indicate that in unmedicated healthy volunteers acute stress brings 
about decreases in both GR and MR sensitivity. The decrease in GR appears to be 
transient returning towards baseline levels just a little over an hour after the stressor. It is 
possible that this transient decrease is an adaptive function allowing the immune system 
to mount its inflammatory response to stress by reducing the inhibitory effects of cortisol. 
Although adaptive, this stress-related decrease in corticosteroid receptors might signpost 
what happens in chronic stress. In Chapter 2 I outlined a number of studies that have 
shown that baseline GR sensitivity is decreased in those experiencing chronic stress 
including depression (Bauer et al., 2000; Bellingrath, Rohleder, & Kudielka, 2013; Calfa 
et al., 2003; Jarcho et al., 2013; Miller, Cohen, & Kim, 2002; Sauer et al., 1995; Wirtz et 
al., 2003). In some cases reduced GR sensitivity was associated with higher levels of 
circulating IL-6 and CRP (Jarcho et al., 2013; Wirtz et al., 2003). Although decreased 
corticosteroid receptor function following acute stress might be adaptive in healthy, 
unstressed individuals, it is possible that exposure to chronic stress results in a long-term 
reduction in GR sensitivity leading to a pro-inflammatory state. These changes in 
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corticosteroid receptor sensitivity therefore have implications for the aetiology of stress-
related inflammatory disorders such as CVD.  
In some of the studies cited above examining associations between chronic stress and 
basal GR sensitivity, decreased sensitivity was associated with flatter diurnal cortisol 
slopes (Jarcho et al., 2013; Miller et al., 2002). In Study 2 (Chapter 5), we found that six 
day SSRI administration resulted in steeper diurnal cortisol slopes in female participants. 
In the Discussion of that chapter I posited that the steeper slope seen in these women 
might be a result of increased sensitivity of the corticosteroid receptors. However, the 
results from Study 3 provided no support for this. This implies that SSRI-induced changes 
in diurnal cortisol slope occurred independently of alterations in basal corticosteroid 
receptor function. It is possible that changes in the serotonin receptors might be involved 
here seeing as escitalopram has been shown to desensitise the 5-HT1A receptor which 
could lead to changes in cortisol levels (Zhong, Haddjeri, & Sánchez, 2012). However, 
there is a body of evidence outlined in Section 6.6 of this thesis suggesting that SSRI 
administration modulates basal corticosteroid receptor function. Therefore, more research 
is required in order to delineate the associations between SSRI induced changes in diurnal 
cortisol secretion and basal corticosteroid receptor function.  
As well as showing that acute stress brings about a transient decrease in GR sensitivity, 
the results of this PhD also show that seven-day administration of escitalopram enhanced 
and prolonged this desensitisation of the GR. In Chapter 6 I argued that this might be one 
of the mechanisms through which SSRIs exert their therapeutic effects. This might seem 
counterintuitive seeing as decreased basal GR sensitivity has been associated with chronic 
stress and depression. However, in the current study we are reporting SSRI-induced 
alterations in stress-related GR sensitivity which is distinct from basal GR function. 
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SSRIs enhance and prolong the response which could be adaptive preventing tissue 
damage from overexposure to glucocorticoids (Bamberger, Schulte, & Chrousos, 1996).  
What these results indicate is that increasing levels of serotonin results in a more 
pronounced GR desensitisation following stress. Altering how the body responds to 
stressful situations might be one of the ways in which antidepressants exert their 
therapeutic effects in depression. As mentioned previously a recent review of 40 studies 
concluded that SSRIs are cardio-protective in nature via promoting optimal platelet 
activity (Nezafati et al., 2015). Perhaps this cardio-protective effect is also exerted via 
modulation of the stress response at the level of the GR.  
7.4 Methodological issues and limitations 
The results presented in this thesis have to be interpreted with their limitations borne in 
mind. The short-comings of each individual study were provided at the end of each 
chapter. Therefore, in this section, only the most important limitations and issues will be 
discussed 
 7.4.1 The study samples 
In this PhD two study samples were used. The sample from Study 1 was taken from the 
ARCS Study carried out by the Psychobiology Group at UCL. This sample comprised 
250 men and women with advanced heart disease undergoing CABG surgery. In Study 2 
and 3 the samples were taken from the Stress Pathways Study. These samples comprised 
94 and 91 healthy volunteers respectively who were randomised to receive either beta-
blockers or SSRIs for one week and then undergo acute psychosocial stress testing in the 
laboratory. In Study 1, one advantage of the sample used was that they were all 
undergoing CABG surgery. What this indicates is that all patients in the sample had 
received a diagnosis of CVD that was advanced enough to warrant coronary 
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revascularisation. In Study 2 and 3, an advantage of the sample was that each participant 
had to meet strict inclusion criteria (see Section 4.4.3) in order to take part in the study.  
However, these participant samples were not without their limitations. The ARCS sample 
was largely comprised of white men of European origin recruited from a single hospital 
in South London (St. George’s University hospital, Tooting). This hospital is located in 
an ethnically diverse area of South West London, with approximately 22% of the borough 
stating their ethnicity as non-white (Wandsworth Council, 2011). In Study 1, 12.4% of 
the sample were non-white. Ethnicity is known to be a factor that affects long-term 
recovery after CABG surgery (Deb et al., 2016; Rumsfeld et al., 2002) with ethnic 
minorities being less likely to be invited to attend or enrol in cardiac rehabilitation 
programmes in the UK (Bethell, Lewin, & Dalal, 2009). This means the results of Study 
1 may not be readily generalizable to other groups. Additionally, the sample appeared to 
be fairly well-adjusted in terms of psychosocial stress factors. Depression and anxiety 
symptoms were relatively low in this patient group. Only 8.5% of the sample met the 
criteria for moderate depressive symptoms, and 15.4% met the criteria for high anxiety 
levels. These rates are lower than those presented in the literature which states that about 
30% of CHD patients undergoing CABG surgery have mild-to-moderate depressive 
symptoms (Ravven, Bader, Azar, & Rudolph, 2013)  and about 38.7% suffer from an 
anxiety disorder (Gallagher & McKinley, 2009). Additionally, this sample also had on 
average experienced only one stressful life event in the previous six months and had high 
levels of social support. Therefore, it may have been that the cross-sectional associations 
between psychosocial stress factors and diurnal cortisol profiles were too weak to detect 
seeing as at the time of collection the sample was relatively unstressed.  
The Stress Pathways Study sample was largely comprised of healthy young students from 
high socioeconomic backgrounds. Therefore the results might not be generalizable to 
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other groups, or to clinical groups with depression or CVD. Furthermore, a number of 
participants in each sample group had high depression and anxiety symptoms. Prior to 
recruitment, participants were asked whether they had ever received a clinical diagnosis 
of a psychiatric disorder, but were not screened using measures of depression and anxiety. 
To account for this, in both Study 2 and Study 3 sensitivity analyses were performed 
excluding these participants from the main analyses. This did not have major 
repercussions for the results of Study 2 or Study 3. Future studies should screen 
participants using brief measures of depression and anxiety prior to recruitment into the 
study to ensure that the sample is comprised of healthy volunteers free of mental illness. 
The recruitment strategies used may have introduced bias into the studies. The sample 
from Study 1 was recruited from pre-surgical assessment clinics. Potential participants 
were approached in the waiting room prior to their appointment to see if they wished to 
enrol on the study. Many participants who refused to participate were either not interested 
in the study or were too stressed or anxious to take part. This means that patients that may 
have been most relevant to the hypotheses of Study 1 were not recruited. Additionally, 
the fact that recruitment was limited to one hospital within one London borough means 
we only had access to patients from similar areas of London. This, as outlined above, had 
issues for the representativeness of the study sample. 
The sample used in Study 2 and 3 was recruited in and around UCL campus via email 
and poster advertisements. This resulted in a sample largely comprised of students. The 
study advertisement specified that people would have a cannula inserted for blood 
sampling, would have to take medications for a week, and would have to undergo some 
‘challenging mental tasks’ in the laboratory. Many prospective participants may have 
found this study daunting and therefore chose not to participate. This means the sample 
was only comprised of those that may not have felt unnerved or anxious by the protocol. 
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However, baseline cortisol levels from Study 3 suggest that the sample was anxious prior 
to the laboratory testing session. Nevertheless, the daunting protocol meant the study 
sample was probably not representative of the broader student body at UCL.  
 7.4.2 The HPA axis: Measurement issues 
In Study 1 and Study 2, diurnal cortisol secretion was measured using seven saliva 
samples taken over the course of one weekday. This means that in both samples diurnal 
rhythm may have been affected by situational factors, rather than long-term factors. 
Diurnal cortisol secretion is primarily affected by trait rather than situational factors on a 
weekday as most people have established weekday routines (Hellhammer et al., 2007). 
However, the sample from Study 2 (chapter 5) was comprised mostly of university 
students. Students are likely to have a routine that is quite variable across weekdays 
meaning that it might have been preferable to take measures over the course of several 
days. In fact, diurnal cortisol parameters measured over the course of three days have 
shown considerable day-to-day fluctuation with little evidence for stable trait-like 
influences (Ross, Murphy, Adam, Chen, & Miller, 2014). The sample from Study 1 
(chapter 3) was comprised of mostly older, retired CVD patients and their habits may be 
less variable across days meaning that a single day could be more representative than in 
younger people. Even so, it would have been preferable to measure diurnal cortisol 
secretion over several days in both the ARCS and the Stress Pathways Study. In both 
studies it was decided to measure diurnal cortisol secretion over the course of one day 
only in order to minimise participant burden and therefore facilitate recruitment.  
In Studies 1, 2, and 3 cortisol was measured in saliva. Cortisol can be measured in a 
number of biological specimens including saliva, blood, urine, and hair. Cortisol was 
measured in saliva for a number of reasons. Saliva-sampling is a non-invasive, relatively 
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inexpensive way to measure cortisol and allows for ambulatory assessment in naturalistic 
setting where participants are collecting their own samples. Salivary cortisol also provides 
a reliable measure of unbound, biologically active cortisol. There are generally high 
correlations between salivary cortisol levels and levels of unbound plasma cortisol 
(Hellhammer, Wüst, & Kudielka, 2009). Therefore, we chose to measure cortisol in saliva 
to reduce participant burden, and to ensure that ambulatory measures were consistent with 
laboratory measures. Measurement of diurnal cortisol parameters also required the use of 
salivary cortisol as repeat blood samples across the day would be impractical and would 
likely affect cortisol levels. However, it is worth mentioning that during times of stress 
plasma cortisol can rise with no change at the salivary level (Kirschbaum & Hellhammer, 
2000). Similarly, stress can also elicit changes in ACTH but not cortisol (Cacioppo et al., 
1995; Malarkey, Kiecolt-Glaser, Pearl, & Glaser, 1994; van der Pompe, Antoni, & 
Heijnen, 1996). This is of particular relevance to Study 3 as not measuring plasma cortisol 
or ACTH levels means that stress effects in the laboratory may have been missed.  
In Study 3 corticosteroid sensitivity at several time-points was measured using 
glucocorticoid sensitivity assays. Specifically, GR and MR sensitivity was measured by 
dexamethasone and prednisolone suppression of LPS induced IL-6 levels in whole blood. 
This assay provides a proxy measure of GR and MR sensitivity. Whole blood allowed for 
the rapid measurement of peripheral glucocorticoid sensitivity. For this reason the assay 
was carried out in whole blood in the Stress Pathways Study. However, measurement in 
isolated monocytes or lymphocytes would have allowed for a more focused measure of 
IL-6 suppression. This is because certain leukocyte subsets produce more inflammatory 
cytokines than others. For example, monocytes are the main source of LPS-stimulated 
pro-inflammatory cytokines such as IL-6 (Berczi, 1998). Additionally, only IL-6 
suppression was measured to facilitate brevity in the Stress Pathways Study. Measuring 
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only a single outcome which is known to be affected by glucocorticoids (i.e. IL-6) does 
not allow for examination of the wider effects of glucocorticoids. The results of Study 3 
should be interpreted with these issues borne in mind.  
 7.4.3 The study medications 
Data from the Stress Pathways Study were used in Study 2 and Study 3. As mentioned in 
Chapter 4, the Stress Pathways Study was primarily designed to assess the effects of 
pharmacological probes on inflammatory responses to acute stress. SSRIs and beta-
blockers were chosen mainly for their relevance to inflammation. My PhD sought to use 
this study as an opportunity to assess the effects of these pharmacological probes on HPA 
axis function. One of the main roles of the HPA axis is inhibition of the stress-related 
release of inflammatory cytokines (Kaltsas, Zannas, & Chrousos, 2012) meaning that the 
anti-inflammatory actions of SSRIs and beta-blockers may be related to alterations in 
HPA axis function. Literature which has provided evidence for the effects of beta-
blockers and SSRIs on HPA axis function has been described in both Chapter 5 and 6. 
However, these drug types may not have been the ideal choices for garnering information 
about the biological mechanisms underlying stress-related changes in HPA axis function. 
Many studies described in Chapter 5 and 6 report null findings and in this PhD beta-
blockade had no significant effects on HPA axis function. Reasons for this (e.g. dosage, 
treatment duration) are provided in the Discussion sections of each chapter. However, it 
could be that alternative pharmacological probes would have provided more information 
about HPA axis dysregulation. Suggested alternatives are provided in Section 7.6.1. 
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7.5 Suggestions for future research 
Specific suggestions for future research have been provided in the Discussion section of 
each study. In this section I will outline more general ideas for future work in the area of 
stress-related HPA axis dysregulation.  
 7.5.1 The clinical utility of HPA axis dysregulation in CVD 
Study 1 provided evidence for the clinical utility of measuring diurnal cortisol secretion, 
in that flatter cortisol slopes predicted adverse long-term outcomes in patients undergoing 
CABG surgery. Firstly, this study needs replication in a larger, more representative 
sample, recruited across several hospital sites. More psychosocial stress measures should 
be included also in order to fully explore associations between stress and HPA axis 
dysregulation in CHD. Additionally, diurnal cortisol secretion could be measured over 
several days to minimise the influence of situational factors.  
In Chapter 3 I posit that HPA dysregulation of diurnal HPA axis function may worsen 
with CVD progression and that a more pronounced flattening of the cortisol slope might 
be associated with greater disease severity. In breast cancer patients, it has been shown 
that patients with more severe metastatic spread showed a tendency towards flatter 
cortisol slopes across the day (Abercrombie et al., 2004). Future research could seek to 
characterise diurnal cortisol profiles in CHD patients according to disease severity. 
Examining associations between cortisol profiles and long-term outcomes in these patient 
subgroups could also be interesting. This may allow for further investigation into the 
clinical utility of measuring diurnal cortisol secretion in CHD patients. Additionally, 
psychosocial factors that are associated with HPA axis dysregulation could also be 
measured in these patient subgroups. Examining basal corticosteroid receptor sensitivity 
in these patients might also be useful.  
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Study 1 examined associations between diurnal cortisol secretion and long-term outcomes 
in those with advanced CHD that required CABG surgery. Future research should also 
seek to assess associations between diurnal cortisol secretion and long-term outcomes in 
other CVD patients, such as those who have heart failure, or who have had a stroke or an 
MI. Measuring cortisol concentrations in the hair of these patients would provide a 
retrospective indicator of average cortisol exposure over the previous months (Stalder & 
Kirschbaum, 2012) thus allowing for a pre-event measure of cortisol. Retrospectively 
measuring psychosocial stress factors in these patients would allow for associations 
between pre-event levels of stress and exposure to cortisol to be examined. Hair cortisol 
levels have been found to associate with measures of chronic stress, depression, and 
anxiety (Herane Vives et al., 2015; Russell, Koren, Rieder, & Van Uum, 2012; 
Staufenbiel, Penninx, Spijker, Elzinga, & van Rossum, 2013). 
 7.5.2 Alternative pharmacological probes 
In Study 2 and Study 3 the effects of beta-blockers and SSRIs on diurnal cortisol 
secretion, cortisol stress reactivity, and corticosteroid receptor sensitivity were assessed 
in healthy volunteers. In Study 2, six-day SSRI administration resulted in steeper cortisol 
slopes in women. In Study 3, seven-day SSRI treatment resulted in an enhanced GR 
response (decrease in sensitivity) to acute stress in the laboratory. It is possible that 
increasing the SSRI treatment duration may have resulted in more pronounced changes 
in HPA axis function in both studies.  However, asking healthy volunteers to take 
serotonergic antidepressants for a considerable period may have ethical implications 
(Uher et al., 2009). One way in which future research could be carried out examining the 
effects of increasing the bioavailability of serotonin on HPA axis function in healthy 
volunteers is through the use of 5-hydroxytryptophan (5-HTP) (Turner, Loftis, & 
Blackwell, 2006). 5-HTP is an amino acid and is the immediate biological precursor of 
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serotonin. It is essentially a nutritional supplement that has been used in the treatment of 
depression and anxiety for over 30 years (Birdsall, 1998; Iovieno, Dalton, Fava, & 
Mischoulon, 2011). There has not been much work examining the effects of 5-HTP on 
cortisol but preliminary work suggests it modulates cortisol secretion (Meltzer & Maes, 
1994; Schruers, van Diest, Nicolson, & Griez, 2002). This nutritional supplement may 
allow us to examine the effects of longer-term changes of serotonergic function on diurnal 
and stress-related HPA axis function. 
As mentioned previously, SSRIs and beta-blockers were chosen as the pharmacological 
probes for the Stress Pathways Study mainly due to their relevance to inflammation. 
These probes may not have been the most appropriate choices for garnering information 
about the biological mechanisms underlying stress-related changes in HPA axis function. 
There are a number of medications that might be better suited to examining these 
mechanisms. Firstly, examining drugs that are known to directly modulate the HPA axis 
would be useful to gain knowledge about basal and stress-related function. Metyrapone 
is a cortisol synthesis inhibitor used in the treatment of adrenal insufficiency. Inhibition 
of cortisol with metyrapone reduces baseline cortisol levels and also reduces cortisol 
stress reactivity (Broadley et al., 2005). Reducing the cortisol stress response 
pharmacologically would likely have consequences for how GR and MR sensitivity 
changes in response to stress. Administration of metyrapone might tell us a little more 
about why corticosteroid receptor sensitivity decreases in response to acute stress. 
However, it has been found to elicit adverse effects in many people (Ducat et al., 2013). 
Mifepristone is a GR antagonist meaning that it inhibits the binding of GR agonists (such 
as cortisol) to the GR. It is known to increase numbers of GR rapidly thus restoring 
‘normal’ HPA axis negative feedback. Therefore, mifepristone has been used in the 
treatment of depression and other neuropsychiatric disorders (DeBattista & Belanoff, 
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2006; Maric & Adzic, 2013). Examining how rapidly increasing GR numbers affects 
diurnal cortisol secretion and cortisol stress reactivity in the laboratory might tell us more 
about the role of the GR in HPA axis dysregulation. Mifepristone is well-tolerated with 
few side effects. However, it is used as a form of emergency contraception which may 
have reproductive implications for women taking it (von Hertzen et al., 2002).  
It may also be useful to examine the effects of medications that are frequently prescribed 
to CVD patients that are known to have effects on HPA axis function also. Angiotensin-
converting-enzyme (ACE) inhibitors are used to treat hypertension and heart failure. They 
decrease vasoconstriction and a number of hormones that play role in blood pressure (e.g. 
aldosterone, vasopressin). In murine models, ACE inhibitors have been found to attenuate 
HPA axis reactivity to a CRH injection (Raasch et al., 2006). A SNP in the ACE gene 
had also been associated with both depression and hypercortisolism (Baghai et al., 2006). 
Administering ACE inhibitors to healthy volunteers might tell us more about cortisol 
stress reactivity and stress-related GR and MR sensitivity.  
Calcium channel blockers are also frequently prescribed to CVD patients for the treatment 
of hypertension. These drugs reduce hypertension by disrupting the movement of calcium 
ions through calcium channels. In a placebo-controlled study, seven-day administration 
of calcium channel blockers decreased serum cortisol levels in 12 hypertensive men 
(Beer, Jakubowicz, Beer, & Nestler, 1993). One month treatment with calcium channel 
blockers increased GR protein levels in 20 hospitalised patients with CHD (Ji et al., 2010). 
Therefore, calcium channel blockers might also be a potential pharmacological probe for 
use in future research assessing the biological pathways underlying stress-related HPA 
axis dysregulation.  
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 7.5.3 The role of arginine vasopressin 
Arginine vasopressin (AVP) is a hormone produced in the paraventricular nucleus of the 
hypothalamus which regulates osmotic homeostasis and blood pressure. AVP also works 
synergistically with CRH in the modulation of stress-related ACTH secretion (Rivier & 
Vale, 1983). AVP levels are responsive to changes in plasma levels of glucocorticoids 
and are under feedback inhibition by glucocorticoids making AVP part of the HPA axis 
feedback loop (Aguilera & Rabadan-Diehl, 2000). AVP levels are responsive to stress. 
Acute stress has been found to lead to increases in AVP levels and basal circulating AVP 
levels are increased in chronic stress (Aguilera, Subburaju, Young, & Chen, 2008).  
AVP can be difficult to measure due to its small size and short half-life. Often, copeptin 
is measured as a surrogate marker for AVP. Copeptin is a byproduct of AVP production. 
It is easier to measure as it is a more stable peptide with a longer half-life than AVP. 
Copeptin levels have been found to correspond with individual stress levels. Katan and 
colleagues examined cortisol and copeptin at three stress levels – unstressed healthy 
controls, hospitalised medical patients with moderate stress, and surgical patients 30 
minutes after extubation with maximal stress (Katan et al., 2008). They found that cortisol 
levels were significantly higher in the maximally stress surgical patients compared to the 
medical patients and healthy controls. Copeptin was significantly higher in the medical 
patients compared to the healthy controls, and even higher in the maximally stressed 
surgical patients. Furthermore, levels of cortisol and copeptin were highly correlated in 
all groups. This shows that copeptin, as an AVP surrogate marker, is a novel indicator of 
stress that might even be more sensitive to individual stress levels than cortisol.  
AVP has also been linked to the emotional stress response. In a recent study, 166 men 
and women underwent the TSST (Moons, Way, & Taylor, 2014). Those with 
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polymorphisms in the AVP receptor gene (AVPR1A) had higher levels of post-stress 
AVP and also reported more post-stress anger than non-carriers of the polymorphism.  
AVP also appears to play a role in CVD (Yalta, Yalta, Sivri, & Yetkin, 2013). Increased 
copeptin levels have been found to be associated with poor prognosis in patients with 
CHD. Khan and colleagues examined copeptin levels in 980 men and women who had 
been admitted to hospital with an MI. They found that increased copeptin levels were 
associated with future readmittance to hospital and mortality in the 60 day period 
following an MI (Khan et al., 2007). In a sample of 2700 CHD patients undergoing 
coronary angiography, von Haehling and colleagues found that initial increases in 
copeptin levels were associated with increased risk of all-cause and cardiovascular 
mortality, stroke, and reoccurrence of MI in the following three months (von Haehling et 
al., 2012).  
AVP also seems to be associated with clinical factors associated with the development of 
CVD. Higher levels of circulating copeptin have been cross-sectionally associated with 
prevalent diabetes mellitus and insulin resistance in a large Swedish cohort of 4747 men 
and women (Enhörning et al., 2010). Copeptin levels were also predictive of new onset 
diabetes over 12 years of follow-up. In this same cohort of patients, higher levels of 
copeptin were associated with hypertension, abdominal obesity, obesity, higher 
circulating levels of CRP, and the metabolic syndrome (Enhörning et al., 2011).  
Together, this research suggests that AVP plays a role in stress, and also plays a role in 
CVD development and prognosis. Therefore, it is possible that AVP may be a HPA axis 
hormone involved in the link between stress and CVD. To date, very little research has 
examined the effects of psychosocial stress on AVP and more work is needed on the role 
of AVP in the development of CVD. Future research should seek to clarify the role of 
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AVP in both chronic stress and CVD in order to further our understanding of HPA axis 
involvement in the stress-CVD link.  
7.6 Final conclusion 
 This PhD aimed to assess the role of HPA axis dysregulation in CVD, and to examine 
potential biological pathways that might be involved in HPA axis dysregulation through 
the use of two pharmacological probes: beta-blockers and SSRIs. To conclude, the results 
of this PhD provide evidence for the clinical relevance of HPA axis dysregulation in CVD 
by showing that flatter cortisol slopes were associated with adverse outcomes in the years 
following coronary revascularisation. Augmenting levels of serotonin using SSRIs 
appeared to steepen diurnal cortisol slopes in women, which may have therapeutic 
implications for both depression and CVD. This finding provided further evidence for the 
functional relationship between central neurotransmission and HPA axis function. 
At the cellular level, this PhD showed that acute stress brought about decreases in both 
GR and MR sensitivity that are likely adaptive in nature. Augmenting levels of serotonin 
with SSRIs appeared to enhance and prolong stress-related decreases in GR sensitivity, 
while blunting the cortisol stress response. This finding also provided further evidence 
for the role of central neurotransmitters in HPA axis function. SSRI-induced alterations 
in the biological stress response might have implications for stress-related diseases such 
as CVD.  
Together this body of work provides support for the notion that alterations in HPA axis 
function play a role in CVD and that the serotonergic system likely plays a role in stress-
related dysregulation of the HPA axis. Future work should seek to replicate these findings 
and describe in more detail the possible mechanisms involved through the use of different 
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pharmacological probes and more detailed measurement of other biological factors of 
relevance.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
277 
 
References 
Abercrombie, H. C., Giese-Davis, J., Sephton, S., Epel, E. S., Turner-Cobb, J. M., & 
Spiegel, D. (2004). Flattened cortisol rhythms in metastatic breast cancer patients. 
Psychoneuroendocrinology, 29(8), 1082–1092.  
Adam, E. K., & Kumari, M. (2009). Assessing salivary cortisol in large-scale, 
epidemiological research. Psychoneuroendocrinology, 34(10), 1423–1436.  
Agbedia, O. O., Varma, V. R., Seplaki, C. L., Seeman, T. E., Fried, L. P., Li, L., … & 
Carlson, M. C. (2011). Blunted diurnal decline of cortisol among older adults with 
low socioeconomic status. Annals of the New York Academy of Sciences, 1231, 
56–64.  
Aguilera, G., & Rabadan-Diehl, C. (2000). Vasopressinergic regulation of the 
hypothalamic-pituitary-adrenal axis: Implications for stress adaptation. 
Regulatory Peptides, 96(1), 23-29. 
Aguilera, G., Subburaju, S., Young, S., & Chen, J. (2008). The parvocellular 
vasopressinergic system and responsiveness of the hyporhalamic-pituitary-
adrenal axis during chronic stress. Progress in Brain Research, 170, 29-39. 
Ahmed, A. H., Calvird, M., Gordon, R. D., Taylor, P. J., Ward, G., Pimenta, E., … & 
Stowasser, M. (2011). Effects of two selective serotonin reuptake inhibitor 
antidepressants, sertraline and escitalopram, on aldosterone/renin ratio in 
normotensive depressed male patients. The Journal of Clinical Endocrinology and 
Metabolism, 96(4), 1039–1045.  
Ahmed, A. H., Gordon, R. D., Taylor, P., Ward, G., Pimenta, E., & Stowasser, M. (2010). 
Effect of atenolol on aldosterone/renin ratio calculated by both plasma Renin 
activity and direct Renin concentration in healthy male volunteers. The Journal of 
Clinical Endocrinology and Metabolism, 95(7), 3201–3206.  
Ahrens, T., Frankhauser, P., Lederbogen, F., & Deuschle, M. (2007). Effect of single-
dose sertraline on the hypothalamus-pituitary-adrenal system, autonomic nervous 
system, and platelet function. Journal of Clinical Psychopharmacology, 27(6), 
602–606.  
Alhurani, A. S., Dekker, R., Tovar, E., Bailey, A., Lennie, T. A., Randall, D. C., & Moser, 
D. K. (2014). Examination of the potential association of stress with morbidity 
and mortality outcomes in patient with heart failure. SAGE Open Medicine, 2, 
2050312114552093.  
278 
 
Allegra, J. R., Mostashari, F., Rothman, M. J., Milano, M. P., & Cochrane, D. G. (2005). 
Cardiac events in New Jersey after the September 11, 2001, terrorist attack. 
Journal of Urban Health, 82(3), 358–363. 
Anacker, C., Zunszain, P. A., Carvalho, L. A., & Pariante, C. M. (2011). The 
glucocorticoid receptor: Pivot of depression and of antidepressant treatment? 
Psychoneuroendocrinology, 36(3), 415–425.  
Andersen, I., Diderichsen, F., Kornerup, H., Prescott, E., & Rod, N. H. (2011). Major life 
events and the risk of ischaemic heart disease: Does accumulation increase the 
risk? International Journal of Epidemiology, 40(4), 904–913.  
Andrews, J., D’Aguiar, C., & Pruessner, J. C. (2012). The combined 
dexamethasone/TSST paradigm--a new method for psychoneuroendocrinology. 
PloS One, 7(6), e38994.  
Andrews, J., & Pruessner, J. C. (2013). The combined propranolol/TSST paradigm--a 
new method for psychoneuroendocrinology. PloS One, 8(2), e57567.  
Angermann, C. E., Gelbrich, G., Störk, S., Gunold, H., Edelmann, F., Wachter, R., … & 
Blankenberg, S. (2016). Effect of escitalopram on all-cause mortality and 
hospitalization in patients with heart failure and depression: The MOOD-HF 
randomized clinical trial. JAMA, 315(24), 2683–2693.  
Arce, E., Simmons, A. N., Lovero, K. L., Stein, M. B., & Paulus, M. P. (2008). 
Escitalopram effects on insula and amygdala BOLD activation during emotional 
processing. Psychopharmacology, 196(4), 661–672.  
Arnold, S. V., Smolderen, K. G., Buchanan, D. M., Li, Y., & Spertus, J. A. (2012). 
Perceived stress in myocardial infarction: long-term mortality and health status 
outcomes. Journal of the American College of Cardiology, 60(18), 1756–1763. 
Aronson, D., & Burger, A. J. (2001). Effect of beta-blockade on autonomic modulation 
of heart rate and neurohormonal profile in decompensated heart failure. Annals of 
Noninvasive Electrocardiology, 6(2), 98–106.  
Attenburrow, M. J., Mitter, P. R., Whale, R., Terao, T., & Cowen, P. J. (2001). Low-dose 
citalopram as a 5-HT neuroendocrine probe. Psychopharmacology, 155(3), 323–
326. 
Avitsur, R., Stark, J. L., Dhabhar, F. S., Padgett, D. A., & Sheridan, J. F. (2002). Social 
disruption-induced glucocorticoid resistance: kinetics and site specificity. Journal 
of Neuroimmunology, 124(1), 54–61. 
279 
 
Badrick, E., Kirschbaum, C., & Kumari, M. (2007). The relationship between smoking 
status and cortisol secretion. The Journal of Clinical Endocrinology & 
Metabolism, 92(3), 819–824.  
Baghai, T. C., Binder, E. B., Schule, C., Salyakina, D., Eser, D., Lucae, S., … & Bondy, 
B. (2006). Polymorphisms in the angiotensin-converting enzyme gene are 
associated with unipolar depression, ACE activity and hypercortisolism. 
Molecular Psychiatry, 11(11), 1003–1015.  
Bamberger, C. M., Schulte, H. M., & Chrousos, G. P. (1996). Molecular determinants of 
glucocorticoid receptor function and tissue sensitivity to glucocorticoids. 
Endocrine Reviews, 17(3), 245–261.  
Banasik, J., Williams, H., Haberman, M., Blank, S. E., & Bendel, R. (2011). Effect of 
Iyengar yoga practice on fatigue and diurnal salivary cortisol concentration in 
breast cancer survivors. Journal of the American Academy of Nurse Practitioners, 
23(3), 135–142.  
Bangert, A., Andrassy, M., Müller, A.-M., Bockstahler, M., Fischer, A., Volz, C. H., … 
& Kaya, Z. (2016). Critical role of RAGE and HMGB1 in inflammatory heart 
disease. Proceedings of the National Academy of Sciences of the United States of 
America, 113(2), E155-164.  
Barth, J., Schneider, S., & von Känel, R. (2010). Lack of social support in the etiology 
and the prognosis of coronary heart disease: A systematic review and meta-
analysis. Psychosomatic Medicine, 72(3), 229–238. 
Barth, J., Schumacher, M., & Herrmann-Lingen, C. (2004). Depression as a risk factor 
for mortality in patients with coronary heart disease: A meta-analysis. 
Psychosomatic Medicine, 66(6), 802–813. 
Barugh, A. J., Gray, P., Shenkin, S. D., MacLullich, A. M. J., & Mead, G. E. (2014). 
Cortisol levels and the severity and outcomes of acute stroke: A systematic 
review. Journal of Neurology, 261(3), 533–545.  
Batelaan, N. M., Seldenrijk, A., Bot, M., van Balkom, A. J. L. M., & Penninx, B. W. J. 
H. (2016). Anxiety and new onset of cardiovascular disease: Critical review and 
meta-analysis. The British Journal of Psychiatry: The Journal of Mental Science, 
208(3), 223–231.  
Bauer, M. E., Perks, P., Lightman, S. L., & Shanks, N. (2001). Restraint stress is 
associated with changes in glucocorticoid immunoregulation. Physiology & 
Behavior, 73(4), 525–532. 
280 
 
Bauer, M. E., Vedhara, K., Perks, P., Wilcock, G. K., Lightman, S. L., & Shanks, N. 
(2000). Chronic stress in caregivers of dementia patients is associated with 
reduced lymphocyte sensitivity to glucocorticoids. Journal of Neuroimmunology, 
103(1), 84–92. 
Beck, A. T., Steer, R. A., & Brown, G. K. (1996). Beck depression inventory-II. San 
Antonio. Retrieved from 
http://www.homeworkmarket.com/sites/default/files/q5/22/11/becks_depression.
docx 
Beck, A. T., Steer, R. A., & Carbin, M. G. (1988). Psychometric properties of the Beck 
Depression Inventory: Twenty-five years of evaluation. Clinical Psychology 
Review, 8(1), 77–100. 
Beer, N. A., Jakubowicz, D. J., Beer, R. M., & Nestler, J. E. (1993). The calcium channel 
blocker amlodipine raises serum dehydroepiandrosterone sulfate and 
androstenedione, but lowers serum cortisol, in insulin-resistant obese and 
hypertensive men. The Journal of Clinical Endocrinology and Metabolism, 76(6), 
1464–1469.  
Bellingrath, S., Rohleder, N., & Kudielka, B. M. (2013). Effort–reward-imbalance in 
healthy teachers is associated with higher LPS-stimulated production and lower 
glucocorticoid sensitivity of interleukin-6 in vitro. Biological Psychology, 92(2), 
403–409.  
Benschop, R. J., Jacobs, R., Sommer, B., Schürmeyer, T. H., Raab, J. R., Schmidt, R. E., 
& Schedlowski, M. (1996). Modulation of the immunologic response to acute 
stress in humans by beta-blockade or benzodiazepines. The FASEB Journal, 
10(4), 517–524. 
Benschop, R. J., Nieuwenhuis, E. E., Tromp, E. A., Godaert, G. L., Ballieux, R. E., & 
Doornen, L. J. van. (1994). Effects of beta-adrenergic blockade on immunologic 
and cardiovascular changes induced by mental stress. Circulation, 89(2), 762–
769.  
Berardelli, R., Margarito, E., Ghiggia, F., Picu, A., Balbo, M., Bonelli, L., … & Arvat, E. 
(2010). Neuroendocrine effects of citalopram, a selective serotonin re-uptake 
inhibitor, during lifespan in humans. Journal of Endocrinological Investigation, 
33(9), 657–662.  
Berczi, I. (1998). Neurohormonal host defense in endotoxin shock. Annals of the New 
York Academy of Sciences, 840, 787–802. 
281 
 
Bethell, H., Lewin, R., & Dalal, H. (2009). Cardiac rehabilitation in the United Kingdom. 
Heart, 95(4), 271–275.  
Bethin, K. E., Vogt, S. K., & Muglia, L. J. (2000). Interleukin-6 is an essential, 
corticotropin-releasing hormone-independent stimulator of the adrenal axis 
during immune system activation. Proceedings of the National Academy of 
Sciences of the United States of America, 97(16), 9317–9322. 
Bhagwagar, Z., Hafizi, S., & Cowen, P. J. (2002). Acute citalopram administration 
produces correlated increases in plasma and salivary cortisol. 
Psychopharmacology, 163(1), 118–120.  
Bhagwagar, Z., Hafizi, S., & Cowen, P. J. (2005). Increased salivary cortisol after waking 
in depression. Psychopharmacology, 182(1), 54–57.  
Bhattacharyya, M. R., Molloy, G. J., & Steptoe, A. (2008). Depression is associated with 
flatter cortisol rhythms in patients with coronary artery disease. Journal of 
Psychosomatic Research, 65(2), 107–113.  
Bierer, L. M., Bader, H. N., Daskalakis, N. P., Lehrner, A. L., Makotkine, I., Seckl, J. R., 
& Yehuda, R. (2014). Elevation of 11β-hydroxysteroid dehydrogenase type 2 
activity in Holocaust survivor offspring: Evidence for an intergenerational effect 
of maternal trauma exposure. Psychoneuroendocrinology, 48, 1–10.  
Bierhaus, A., Schiekofer, S., Schwaninger, M., Andrassy, M., Humpert, P. M., Chen, J., 
… & Nawroth, P. P. (2001). Diabetes-associated sustained activation of the 
transcription factor nuclear factor-kappaB. Diabetes, 50(12), 2792–2808. 
Bierhaus, A., Wolf, J., Andrassy, M., Rohleder, N., Humpert, P. M., Petrov, D., … & 
Nawroth, P. P. (2003). A mechanism converting psychosocial stress into 
mononuclear cell activation. Proceedings of the National Academy of Sciences, 
100(4), 1920–1925. 
Birdsall, T. C. (1998). 5-Hydroxytryptophan: a clinically-effective serotonin precursor. 
Alternative Medicine Review: A Journal of Clinical Therapeutic, 3(4), 271–280. 
Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002). The validity of the 
Hospital Anxiety and Depression Scale: An updated literature review. Journal of 
Psychosomatic Research, 52(2), 69–77.  
Blumenthal, J. A., Sherwood, A., Smith, P. J., Watkins, L., Mabe, S., Kraus, W. E., … & 
Hinderliter, A. (2016). Enhancing cardiac rehabilitation with stress management 
training: A randomized, clinical efficacy trial. Circulation, 133(14), 1341–1350.  
282 
 
Blumenthal, J. A., Wang, J. T., Babyak, M., Watkins, L., Kraus, W., Miller, P., … & 
Sherwood, A. (2010). Enhancing standard cardiac rehabilitation with stress 
management training: Background, methods, and design for the enhanced study. 
Journal of Cardiopulmonary Rehabilitation and Prevention, 30(2), 77–84.  
Bomhof-Roordink, H., Seldenrijk, A., van Hout, H. P. J., van Marwijk, H. W. J., Diamant, 
M., & Penninx, B. W. J. H. (2015). Associations between life stress and 
subclinical cardiovascular disease are partly mediated by depressive and anxiety 
symptoms. Journal of Psychosomatic Research, 78(4), 332–339.  
Booij, S. H., Bos, E. H., Bouwmans, M. E. J., van Faassen, M., Kema, I. P., Oldehinkel, 
A. J., & de Jonge, P. (2015). Cortisol and α-amylase secretion patterns between 
and within depressed and non-depressed individuals. PloS One, 10(7), e0131002.  
Booij, S. H., Bouma, E. M., de Jonge, P., Ormel, J., & Oldehinkel, A. J. (2013). 
Chronicity of depressive problems and the cortisol response to psychosocial stress 
in adolescents: The TRAILS study. Psychoneuroendocrinology, 38(5), 659–666. 
Bower, J. E., Ganz, P. A., Dickerson, S. S., Petersen, L., Aziz, N., & Fahey, J. L. (2005). 
Diurnal cortisol rhythm and fatigue in breast cancer survivors. 
Psychoneuroendocrinology, 30(1), 92–100.  
Broadley, A. J. M., Korszun, A., Abdelaal, E., Moskvina, V., Jones, C. J. H., Nash, G. B., 
… & Frenneaux, M. P. (2005). Inhibition of cortisol production with metyrapone 
prevents mental stress-induced endothelial dysfunction and baroreflex 
impairment. Journal of the American College of Cardiology, 46(2), 344–350.  
Brotman, D. J., Golden, S. H., & Wittstein, I. S. (2007). The cardiovascular toll of stress. 
The Lancet, 370(9592), 1089–1100.  
Brouwers, C., Christensen, S. B., Damen, N. L., Denollet, J., Torp-Pedersen, C., Gislason, 
G. H., & Pedersen, S. S. (2016). Antidepressant use and risk for mortality in 
121,252 heart failure patients with or without a diagnosis of clinical depression. 
International Journal of Cardiology, 203, 867–873.  
Brown, D. L. (1999). Disparate effects of the 1989 Loma Prieta and 1994 Northridge 
earthquakes on hospital admissions for acute myocardial infarction: Importance 
of superimposition of triggers. American Heart Journal, 137(5), 830–836. 
Bruehl, H., Rueger, M., Dziobek, I., Sweat, V., Tirsi, A., Javier, E., … & Convit, A. 
(2007). Hypothalamic-pituitary-adrenal axis dysregulation and memory 
impairments in type 2 diabetes. The Journal of Clinical Endocrinology & 
Metabolism, 92(7), 2439–2445. 
283 
 
Bschor, T., Ising, M., Erbe, S., Winkelmann, P., Ritter, D., Uhr, M., & Lewitzka, U. 
(2012). Impact of citalopram on the HPA system. A study of the combined 
DEX/CRH test in 30 unipolar depressed patients. Journal of Psychiatric 
Research, 46(1), 111–117.  
Buckley, T., Hoo, S. Y. S., Fethney, J., Shaw, E., Hanson, P. S., & Tofler, G. H. (2015). 
Triggering of acute coronary occlusion by episodes of anger. European Heart 
Journal: Acute Cardiovascular Care, 4(6), 493–498.  
Bui, E., Orr, S. P., Jacoby, R. J., Keshaviah, A., LeBlanc, N. J., Milad, M. R., … & Simon, 
N. M. (2013). Two weeks of pretreatment with escitalopram facilitates extinction 
learning in healthy individuals. Human Psychopharmacology, 28(5), 447–456.  
Bunevicius, A., Gintauskiene, V., Podlipskyte, A., Zaliunas, R., Brozaitiene, J., Prange, 
A. J., & Bunevicius, R. (2012). Fatigue in patients with coronary artery disease: 
association with thyroid axis hormones and cortisol. Psychosomatic Medicine, 
74(8), 848–853.  
Burke, H. M., Davis, M. C., Otte, C., & Mohr, D. C. (2005). Depression and cortisol 
responses to psychological stress: A meta-analysis. Psychoneuroendocrinology, 
30(9), 846–856.  
Burke, W. J., Gergel, I., & Bose, A. (2002). Fixed-dose trial of the single isomer SSRI 
Escitalopram in depressed outpatients. Journal of Clinical Psychiatry, 63(4), 331–
336.  
Burnsides, C., Corry, J., Alexander, J., Balint, C., Cosmar, D., Phillips, G., & Marketon, 
J. I. W. (2012). Ex vivo stimulation of whole blood as a means to determine 
glucocorticoid sensitivity. Journal of Inflammation Research, 5, 89–97.  
Cacioppo, J. T., Malarkey, W. B., Kiecolt-Glaser, J. K., Uchino, B. N., Sgoutas-Emch, S. 
A., Sheridan, J. F., … & Glaser, R. (1995). Heterogeneity in neuroendocrine and 
immune responses to brief psychological stressors as a function of autonomic 
cardiac activation. Psychosomatic Medicine, 57(2), 154–164. 
Calfa, G., Kademian, S., Ceschin, D., Vega, G., Rabinovich, G. A., & Volosin, M. (2003). 
Characterization and functional significance of glucocorticoid receptors in 
patients with major depression: Modulation by antidepressant treatment. 
Psychoneuroendocrinology, 28(5), 687–701.  
Capistrant, B. D., Moon, J. R., Berkman, L. F., & Glymour, M. M. (2012). Current and 
long-term spousal caregiving and onset of cardiovascular disease. Journal of 
Epidemiology and Community Health, 66(10), 951–956.  
284 
 
Carey, I. M., Shah, S. M., DeWilde, S., Harris, T., Victor, C. R., & Cook, D. G. (2014). 
Increased risk of acute cardiovascular events after partner bereavement: A 
matched cohort study. JAMA Internal Medicine, 174(4), 598–605.  
Carlsson, A. C., Starrin, B., Gigante, B., Leander, K., Hellenius, M.-L., & de Faire, U. 
(2014). Financial stress in late adulthood and diverse risks of incident 
cardiovascular disease and all-cause mortality in women and men. BMC Public 
Health, 14, 17.  
Carpenter, L. L., Carvalho, J. P., Tyrka, A. R., Wier, L. M., Mello, A. F., Mello, M. F., 
… & Price, L. H. (2007). Decreased adrenocorticotropic hormone and cortisol 
responses to stress in healthy adults reporting significant childhood maltreatment. 
Biological Psychiatry, 62(10), 1080–1087. 
Carpenter, L. L., Shattuck, T. T., Tyrka, A. R., Geracioti, T. D., & Price, L. H. (2010). 
Effect of childhood physical abuse on cortisol stress response. 
Psychopharmacology, 214(1), 367–375.  
Carpenter, L. L., Tyrka, A. R., Lee, J. K., Tracy, A. P., Wilkinson, C. W., & Price, L. H. 
(2011). A placebo-controlled study of sertraline’s effect on cortisol response to 
the dexamethasone/corticotropin-releasing hormone test in healthy adults. 
Psychopharmacology, 218(2), 371–379.  
Carpenter, T., Grecian, S., & Reynolds, R. (2015). Sex differences in early life 
programming of the hypothalamic-pituitary-adrenal axis in humans suggest 
increased vulnerability in females. Psychoneuroendocrinology, 61, 32.  
Carroll, D., Ebrahim, S., Tilling, K., Macleod, J., & Smith, G. D. (2002). Admissions for 
myocardial infarction and World Cup football: Database survey. BMJ, 325(7378), 
1439–1442.  
Carvalho, L. A., Garner, B. A., Dew, T., Fazakerley, H., & Pariante, C. M. (2010). 
Antidepressants, but not antipsychotics, modulate GR function in human whole 
blood: An insight into molecular mechanisms. European 
Neuropsychopharmacology, 20(6), 379–387.  
Carvalho, L. A., & Pariante, C. M. (2008). In vitro modulation of the glucocorticoid 
receptor by antidepressants. Stress, 11(6), 411–424.  
Carvalho, L. A., Urbanova, L., Hamer, M., Hackett, R. A., Lazzarino, A. I., & Steptoe, 
A. (2015). Blunted glucocorticoid and mineralocorticoid sensitivity to stress in 
people with diabetes. Psychoneuroendocrinology, 51, 209–218.  
285 
 
Celano, C. M., Millstein, R. A., Bedoya, C. A., Healy, B. C., Roest, A. M., & Huffman, 
J. C. (2015). Association between anxiety and mortality in patients with coronary 
artery disease: A meta-analysis. American Heart Journal, 170(6), 1105–1115.  
Centre for Economics and Business Research. (2014). The economic cost of 
cardiovascular disease from 2014-2020 in six European economies. Retrieved 
from 
http://www.sanita24.ilsole24ore.com/pdf2010/Sanita2/_Oggetti_Correlati/Docu
menti/Dibattiti-e-Idee/3Cebr%20-
%20The%20economic%20cost%20of%20cardiovascular%20disease%20from%
202014-2020%20in%20six%20European%20economies.pdf?uuid=AbV1x4QK 
Champaneri, S., Xu, X., Carnethon, M. R., Bertoni, A. G., Seeman, T., DeSantis, A. S., 
… & Golden, S. H. (2013). Diurnal salivary cortisol is associated with body mass 
index and waist circumference: The Multiethnic Study of Atherosclerosis. Obesity 
(Silver Spring, Md.), 21(1), E56-63.  
Chen, K. M., Chen, M. H., Chao, H. C., Hung, H. M., Lin, H. S., & Li, C. H. (2009). 
Sleep quality, depression state, and health status of older adults after silver yoga 
exercises: Cluster randomized trial. International Journal of Nursing Studies, 
46(2), 154–163.  
Chi, J. S., Poole, W. K., Kandefer, S. C., & Kloner, R. A. (2003). Cardiovascular mortality 
in New York City after September 11, 2001. The American Journal of Cardiology, 
92(7), 857–861. 
Chi, J. S., Speakman, M. T., Poole, W. K., Kandefer, S. C., & Kloner, R. A. (2003). 
Hospital admissions for cardiac events in New York City after September 11, 
2001. The American Journal of Cardiology, 92(1), 61–63. 
Chida, Y., & Hamer, M. (2008). Chronic psychosocial factors and acute physiological 
responses to laboratory-induced stress in healthy populations: a quantitative 
review of 30 years of investigations. Psychological Bulletin, 134(6), 829–885.  
Chida, Y., & Steptoe, A. (2009). Cortisol awakening response and psychosocial factors: 
a systematic review and meta-analysis. Biological Psychology, 80(3), 265–278.  
Chriguer, R. S., Elias, L. L. K., da Silva, I. M., Vieira, J. G. H., Moreira, A. C., & de 
Castro, M. (2005). Glucocorticoid sensitivity in young healthy individuals: in 
vitro and in vivo studies. The Journal of Clinical Endocrinology and Metabolism, 
90(11), 5978–5984.  
286 
 
Clow, A., Thorn, L., Evans, P., & Hucklebridge, F. (2004). The awakening cortisol 
response: Methodological issues and significance. Stress, 7(1), 29–37.  
Cohen, L., Cole, S. W., Sood, A. K., Prinsloo, S., Kirschbaum, C., Arevalo, J. M. G., … 
& Pisters, L. (2012). Depressive symptoms and cortisol rhythmicity predict 
survival in patients with renal cell carcinoma: Role of inflammatory signalling. 
PLoS ONE, 7(8), e42324.  
Cohen, S., Janicki-Deverts, D., Doyle, W. J., Miller, G. E., Frank, E., Rabin, B. S., & 
Turner, R. B. (2012). Chronic stress, glucocorticoid receptor resistance, 
inflammation, and disease risk. Proceedings of the National Academy of Sciences, 
109(16), 5995–5999.  
Cohen, S., Kamarck, T., & Mermelstein, R. (1983). A global measure of perceived stress. 
Journal of Health and Social Behavior, 24(4), 385–396.  
Collomp, K., Baillot, A., Forget, H., Coquerel, A., Rieth, N., & Vibarel-Rebot, N. (2016). 
Altered diurnal pattern of steroid hormones in relation to various behaviors, 
external factors and pathologies: A review. Physiology & Behavior, 164(Pt A), 
68–85.  
Corey, S. M., Epel, E., Schembri, M., Pawlowsky, S. B., Cole, R. J., Araneta, M. R. G., 
… & Kanaya, A. M. (2014). Effect of restorative yoga vs. stretching on diurnal 
cortisol dynamics and psychosocial outcomes in individuals with the metabolic 
syndrome: The PRYSMS randomized controlled trial. 
Psychoneuroendocrinology, 49, 260–271.  
Cowen, P. J. (2002). Cortisol, serotonin and depression: All stressed out? The British 
Journal of Psychiatry, 180(2), 99–100.  
Crawford, J. R., & Henry, J. D. (2004). The Positive and Negative Affect Schedule 
(PANAS): Construct validity, measurement properties and normative data in a 
large non-clinical sample. British Journal of Clinical Psychology, 43(3), 245–265.  
Critchley, J. A., & Capewell, S. (2003). Mortality risk reduction associated with smoking 
cessation in patients with coronary heart disease: A systematic review. JAMA, 
290(1), 86–97. 
Cropley, M., Rydstedt, L. W., Devereux, J. J., & Middleton, B. (2015). The relationship 
between work-related rumination and evening and morning salivary cortisol 
secretion. Stress and Health: Journal of the International Society for the 
Investigation of Stress, 31(2), 150–157.  
287 
 
Damoiseaux, V. A., Proost, J. H., Jiawan, V. C. R., & Melgert, B. N. (2014). Sex 
Differences in the pharmacokinetics of antidepressants: Influence of female sex 
hormones and oral contraceptives. Clinical Pharmacokinetics, 53(6), 509–519.  
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., … 
& Gudnason, V. (2004). C-reactive protein and other circulating markers of 
inflammation in the prediction of coronary heart disease. New England Journal of 
Medicine, 350(14), 1387–1397.  
Daniele, S., Da Pozzo, E., Zappelli, E., & Martini, C. (2015). Trazodone treatment 
protects neuronal-like cells from inflammatory insult by inhibiting NF-κB, p38 
and JNK. Cellular Signalling, 27(8), 1609–1629.  
Dart, A. M., Lewis, M. J., Groom, G. V., Meek, E. M., & Henderson, A. H. (1981). The 
effect of chronic propranolol treatment on overnight plasma levels of anterior 
pituitary and related hormones. British Journal of Clinical Pharmacology, 12(6), 
849–853. 
Davids, E., & Lesch, K. P. (1996). The 5-HT1A receptor: A new effective principle in 
psychopharmacologic therapy? Forschritte der Neurologie-Psychiatrie, 64(11), 
460-472. 
de Kloet, E. R. (1998). Brain corticosteroid receptor balance in health and disease. 
Endocrine Reviews, 19(3), 269–301.  
de Kloet, E. R., DeRijk, R. H., & Meijer, O. C. (2007). Therapy insight: Is there an 
imbalanced response of mineralocorticoid and glucocorticoid receptors in 
depression? Nature Clinical Practice Endocrinology & Metabolism, 3(2), 168–
179.  
de Miranda Azevedo, R., Roest, A. M., Hoen, P. W., & de Jonge, P. (2014). 
Cognitive/affective and somatic/affective symptoms of depression in patients 
with heart disease and their association with cardiovascular prognosis: A meta-
analysis. Psychological Medicine, 44(13), 2689–2703.  
de Rooij, S. R. (2013). Blunted cardiovascular and cortisol reactivity to acute 
psychological stress: A summary of results from the Dutch Famine Birth Cohort 
Study. International Journal of Psychophysiology, 90(1), 21–27. 
Deb, S., Tu, J. V., Austin, P. C., Ko, D. T., Rocha, R., Mazer, C. D., … & Fremes, S. E. 
(2016). Impact of South Asian ethnicity on long-term outcomes after coronary 
artery bypass grafting surgery: A large population-based propensity matched 
study. Journal of the American Heart Association, 5(7), e003941.  
288 
 
DeBattista, C., & Belanoff, J. (2006). The use of mifepristone in the treatment of 
neuropsychiatric disorders. Trends in Endocrinology & Metabolism, 17(3), 117–
121.  
Dedovic, K., & Ngiam, J. (2015). The cortisol awakening response and major depression: 
examining the evidence. Neuropsychiatr Dis Treat, 11, 1181–9. 
Dekker, M. J. H. J., Koper, J. W., van Aken, M. O., Pols, H. a. P., Hofman, A., de Jong, 
F. H., … & Tiemeier, H. (2008). Salivary cortisol is related to atherosclerosis of 
carotid arteries. The Journal of Clinical Endocrinology and Metabolism, 93(10), 
3741–3747.  
DeRijk, R. H., Petrides, J., Deuster, P., Gold, P. W., & Sternberg, E. M. (1996). Changes 
in corticosteroid sensitivity of peripheral blood lymphocytes after strenuous 
exercise in humans. The Journal of Clinical Endocrinology & Metabolism, 81(1), 
228–235. 
DeRijk, R. H., Wüst, S., Meijer, O. C., Zennaro, M.-C., Federenko, I. S., Hellhammer, D. 
H., …& de Kloet, E. R. de. (2006). A common polymorphism in the 
mineralocorticoid receptor modulates stress responsiveness. Journal of Clinical 
Endocrinology & Metabolism, 91(12), 5083–5089.  
DeSantis, A. S., Adam, E. K., Mendelsohn, K. A., & Doane, L. D. (2010). Concordance 
between self-reported and objective wakeup times in ambulatory salivary cortisol 
research. International Journal of Behavioral Medicine, 17(1), 74–78. 
Deuschle, M., Hamann, B., Meichel, C., Krumm, B., Lederbogen, F., Kniest, A., … & 
Heuser, I. (2003). Antidepressive treatment with amitriptyline and paroxetine: 
effects on saliva cortisol concentrations. Journal of Clinical 
Psychopharmacology, 23(2), 201–205. 
Dhar, A. K., & Barton, D. A. (2016). Depression and the link with cardiovascular disease. 
Molecular Psychiatry, 33.  
Dickerson, S. S., & Kemeny, M. E. (2004). Acute stressors and cortisol responses: A 
theoretical integration and synthesis of laboratory research. Psychological 
Bulletin, 130(3), 355–391.  
Dienes, K. A., Hazel, N. A., & Hammen, C. L. (2013). Cortisol secretion in depressed, 
and at-risk adults. Psychoneuroendocrinology, 38(6), 927–940.  
Diez Roux, A. V., Ranjit, N., Powell, L., Jackson, S., Lewis, T. T., Shea, S., & Wu, C. 
(2006). Psychosocial factors and coronary calcium in adults without clinical 
cardiovascular disease. Annals of Internal Medicine, 144(11), 822–831.  
289 
 
Dimsdale, J. E. (2008). Psychological stress and cardiovascular disease. Journal of the 
American College of Cardiology, 51(13), 1237–1246.  
Doane, L. D., Mineka, S., Zinbarg, R. E., Craske, M., Griffith, J. W., & Adam, E. K. 
(2013). Are flatter diurnal cortisol rhythms associated with major depression and 
anxiety disorders in late adolescence? The role of life stress and daily negative 
emotion. Development and Psychopathology, 25(3), 629–642.  
Dockray, S., Bhattacharyya, M. R., Molloy, G. J., & Steptoe, A. (2008). The cortisol 
awakening response in relation to objective and subjective measures of waking in 
the morning. Psychoneuroendocrinology, 33(1), 77–82.  
Dozois, D. J., Dobson, K. S., & Ahnberg, J. L. (1998). A psychometric evaluation of the 
Beck Depression Inventory–II. Psychological Assessment, 10(2), 83. 
Dreifus, L., Engler, H., & Kissler, J. (2014). Retrieval-induced forgetting under 
psychosocial stress: No reduction by delayed stress and beta-adrenergic blockade. 
Neurobiology of Learning and Memory, 110, 35–46.  
Duan, H., Yuan, Y., Zhang, L., Qin, S., Zhang, K., Buchanan, T. W., & Wu, J. (2013). 
Chronic stress exposure decreases the cortisol awakening response in healthy 
young men. Stress, 16(6), 630–637. 
Ducat, E., Ray, B., Bart, G., Umemura, Y., Varon, J., Ho, A., & Kreek, M. J. (2013). Mu-
opioid receptor A118G polymorphism in healthy volunteers affects 
hypothalamic–pituitary–adrenal axis adrenocorticotropic hormone stress response 
to metyrapone. Addiction Biology, 18(2), 325–331.  
Duclos, M., Minkhar, M., Sarrieau, A., Bonnemaison, D., Manier, G., & Mormede, P. 
(1999). Reversibility of endurance training-induced changes on glucocorticoid 
sensitivity of monocytes by an acute exercise. Clinical Endocrinology, 51(6), 
749–756. 
Dziurkowska, E., Wesolowski, M., & Dziurkowski, M. (2013). Salivary cortisol in 
women with major depressive disorder under selective serotonin reuptake 
inhibitors therapy. Archives of Women’s Mental Health, 16(2), 139–147.  
Ebrecht, M., Buske-Kirschbaum, A., Hellhammer, D., Kern, S., Rohleder, N., Walker, 
B., & Kirschbaum, C. (2000). Tissue specificity of glucocorticoid sensitivity in 
healthy adults. The Journal of Clinical Endocrinology and Metabolism, 85(10), 
3733–3739.  
290 
 
Eller, N. H., Netterstrøm, B., & Allerup, P. (2005). Progression in intima media thickness-
the significance of hormonal biomarkers of chronic stress. 
Psychoneuroendocrinology, 30(8), 715–723.  
Eller, N. H., Netterstrøm, B., Gyntelberg, F., Kristensen, T. S., Nielsen, F., Steptoe, A., 
& Theorell, T. (2009). Work-related psychosocial factors and the development of 
ischemic heart disease: a systematic review. Cardiology in Review, 17(2), 83–97.  
Eller, N. H., Netterstrøm, B., & Hansen, A. M. (2001). Cortisol in urine and saliva: 
relations to the intima media thickness. Atherosclerosis, 159(1), 175–185. 
Elliott, W. J. (2001). Cyclic and circadian variations in cardiovascular events. American 
Journal of Hypertension, 14(S6), 291S–295S.  
Elzinga, B. M., Roelofs, K., Tollenaar, M. S., Bakvis, P., van Pelt, J., & Spinhoven, P. 
(2008). Diminished cortisol responses to psychosocial stress associated with 
lifetime adverse events: A study among healthy young subjects. 
Psychoneuroendocrinology, 33(2), 227–237.  
Emdin, C. A., Odutayo, A., Wong, C. X., Tran, J., Hsiao, A. J., & Hunn, B. H. M. (2016). 
Meta-analysis of anxiety as a risk factor for cardiovascular disease. The American 
Journal of Cardiology.  
Emptoz-Bonneton, A., Crave, J. C., LeJeune, H., Brébant, C., & Pugeat, M. (1997). 
Corticosteroid-binding globulin synthesis regulation by cytokines and 
glucocorticoids in human hepatoblastoma-derived (HepG2) cells. The Journal of 
Clinical Endocrinology and Metabolism, 82(11), 3758–3762.  
Enhörning, S., Struck, J., Wirfält, E., Hedblad, B., Morgenthaler, N. G., & Melander, O. 
(2011). Plasma copeptin, a unifying factor behind the metabolic syndrome. The 
Journal of Clinical Endocrinology & Metabolism, 96(7), 1065-1072. 
Enhörning, S., Wang, T. J., Nilsson, P. M., Almgren, P., Hedblad, B., Berglund, G., … 
& Groop, L. (2010). Plasma copeptin and the risk of diabetes mellitus. 
Circulation, 121(19), 2102 – 2108.  
Everson-Rose, S. A., & Lewis, T. T. (2005). Psychosocial factors and cardiovascular 
diseases. Annual Review of Public Health, 26(1), 469–500.  
Feng, J., Lenihanx, D. J., Johnson, M. M., Karri, V., & Reddy, C. V. R. (2006). Cardiac 
sequelae in Brooklyn after the September 11 terrorist attacks. Clinical Cardiology, 
29(1), 13–17.  
Field, T. (2011). Yoga clinical research review. Complementary Therapies in Clinical 
Practice, 17(1), 1–8.  
291 
 
Fishta, A., & Backé, E.-M. (2015). Psychosocial stress at work and cardiovascular 
diseases: An overview of systematic reviews. International Archives of 
Occupational and Environmental Health, 88(8), 997–1014.  
Fragala, M. S., Kraemer, W. J., Mastro, A. M., Denegar, C. R., Volek, J. S., Kupchak, B. 
R., … & Maresh, C. M. (2011). Glucocorticoid receptor expression on human b 
cells in response to acute heavy resistance exercise. Neuroimmunomodulation, 
18(3), 156–164.  
Frazer, A., & Benmansour, S. (2002). Delayed pharmacological effects of 
antidepressants. Molecular Psychiatry, 7(s1), S23–S28.  
Gallagher, R., & McKinley, S. (2009). Anxiety, depression and perceived control in 
patients having coronary artery bypass grafts. Journal of Advanced Nursing, 
65(11), 2386–2396.  
Gallo, L. C., Roesch, S. C., Fortmann, A. L., Carnethon, M. R., Penedo, F. J., Perreira, 
K., … & Isasi, C. R. (2014). Associations of chronic stress burden, perceived 
stress, and traumatic stress with cardiovascular disease prevalence and risk factors 
in the Hispanic Community Health Study/Study of Latinos Sociocultural 
Ancillary Study. Psychosomatic Medicine, 76(6), 468–475.  
Gan, Y., Gong, Y., Tong, X., Sun, H., Cong, Y., Dong, X., … & Lu, Z. (2014). Depression 
and the risk of coronary heart disease: A meta-analysis of prospective cohort 
studies. BMC Psychiatry, 14, 371.  
Garcia-Leal, C., Del-Ben, C. M., Leal, F. M., Graeff, F. G., & Guimarães, F. S. (2010). 
Escitalopram prolonged fear induced by simulated public speaking and released 
hypothalamic-pituitary-adrenal axis activation. Journal of Psychopharmacology, 
24(5), 683–694.  
Gartland, N., O’Connor, D. B., Lawton, R., & Bristow, M. (2014). Exploring day-to-day 
dynamics of daily stressor appraisals, physical symptoms and the cortisol 
awakening response. Psychoneuroendocrinology, 50, 130–138.  
Gehi A, Haas D, Pipkin S, & Whooley MA. (2005). Depression and medication adherence 
in outpatients with coronary heart disease: Findings from the Heart and Soul 
study. Archives of Internal Medicine, 165(21), 2508–2513.  
Georgiades, A., Janszky, I., Blom, M., László, K. D., & Ahnve, S. (2009). Financial strain 
predicts recurrent events among women with coronary artery disease. 
International Journal of Cardiology, 135(2), 175–183. 
292 
 
Gibbison, B., Spiga, F., Walker, J. J., Russell, G. M., Stevenson, K., Kershaw, Y., … & 
Lightman, S. L. (2015). Dynamic pituitary-adrenal interactions in response to 
cardiac surgery. Critical Care Medicine, 43(4), 791–800.  
Girod, J. P., & Brotman, D. J. (2004). Does altered glucocorticoid homeostasis increase 
cardiovascular risk? Cardiovascular Research, 64(2), 217–226.  
Glassman, A. H., & Shapiro, P. A. (1998). Depression and the course of coronary artery 
disease. American Journal of Psychiatry, 155(1), 4–11.  
Glazer, K. M., Emery, C. F., Frid, D. J., & Banyasz, R. E. (2002). Psychological 
predictors of adherence and outcomes among patients in cardiac rehabilitation. 
Journal of Cardiopulmonary Rehabilitation and Prevention, 22(1), 40–46. 
Goel, N., & Bale, T. L. (2010). Sex differences in the serotonergic influence on the 
hypothalamic-pituitary-adrenal stress axis. Endocrinology, 151(4), 1784–1794.  
Goel, N., Workman, J. L., Lee, T. T., Innala, L., & Viau, V. (2014). Sex differences in 
the HPA axis. Comprehensive Physiology.  
Goldberg, D. (1992). General health questionnaire (GHQ-12). Windsor, UK: Nfer-
Nelson. 
Golding, M., Kotlyar, M., Carson, S. W., Hoyler, S., Lazarus, C., Davidson, C., … & 
Garbutt, J. C. (2005). Effects of paroxetine on cardiovascular response to mental 
stress in subjects with a history of coronary artery disease and no psychiatric 
diagnoses. Psychopharmacology, 182(3), 321–326.  
Goldman-Mellor, S., Hamer, M., & Steptoe, A. (2012). Early-life stress and recurrent 
psychological distress over the lifecourse predict divergent cortisol reactivity 
patterns in adulthood. Psychoneuroendocrinology, 37(11), 1755–1768.  
Golub, M. S., Tuck, M. L., & Fittingoff, D. B. (1981). Effect of propranolol therapy on 
aldosterone responses to angiotensin II and adrenocorticotropic hormone in 
essential hypertension. Clinical Science, 61(1), 107–110. 
Gomeni, R., Bianchetti, G., Sega, R., & Morselli, P. L. (1977). Pharmacokinetics of 
propranolol in normal healthy volunteers. Journal of Pharmacokinetics and 
Biopharmaceutics, 5(3), 183–192.  
Gonzalez, A., Jenkins, J. M., Steiner, M., & Fleming, A. S. (2009). The relation between 
early life adversity, cortisol awakening response and diurnal salivary cortisol 
levels in postpartum women. Psychoneuroendocrinology, 34(1), 76–86. 
Gorre, F., & Vandekerckhove, H. (2010). Beta-blockers: focus on mechanism of action. 
Which beta-blocker, when and why? Acta Cardiologica, 65(5), 565–570.  
293 
 
Granger, D. A., Hibel, L. C., Fortunato, C. K., & Kapelewski, C. H. (2009). Medication 
effects on salivary cortisol: Tactics and strategy to minimize impact in 
behavioural and developmental science. Psychoneuroendocrinology, 34(10), 
1437–1448. 
Gudbjörnsdóttir, S., Fowelin, J., Elam, M., Attvall, S., Bengtsson, B. A., Mårin, P., & 
Lönnroth, P. (1997). The effect of metoprolol treatment on insulin sensitivity and 
diurnal plasma hormone levels in hypertensive subjects. European Journal of 
Clinical Investigation, 27(1), 29–35. 
Güder, G., Bauersachs, J., Frantz, S., Weismann, D., Allolio, B., Ertl, G., … & Störk, S. 
(2007). Complementary and incremental mortality risk prediction by cortisol and 
aldosterone in chronic heart failure. Circulation, 115(13), 1754–1761.  
Gullestad, L., Dolva, L. O., Kjeldsen, S. E., Eide, I., & Kjekshus, J. (1989). Effect of beta-
adrenergic blockade on hormonal responses during continuous and intermittent 
exercise. Cardiovascular Drugs and Therapy, 3(1), 63–71. 
Hackett, R. A., Steptoe, A., & Kumari, M. (2014). Association of diurnal patterns in 
salivary cortisol with type 2 diabetes in the Whitehall II Study. The Journal of 
Clinical Endocrinology & Metabolism, 99(12), 4625–4631.  
Hajat, A., Diez-Roux, A. V., Sánchez, B. N., Holvoet, P., Lima, J. A., Merkin, S. S., … 
& Wu, M. (2013). Examining the association between salivary cortisol levels and 
subclinical measures of atherosclerosis: The Multi-Ethnic Study of 
Atherosclerosis. Psychoneuroendocrinology, 38(7), 1036–1046.  
Haley, W. E., Roth, D. L., Howard, G., & Safford, M. M. (2010). Caregiving strain and 
estimated risk for stroke and coronary heart disease among spouse caregivers 
differential effects by race and sex. Stroke, 41(2), 331–336.  
Hamer, M., Endrighi, R., Venuraju, S. M., Lahiri, A., & Steptoe, A. (2012). Cortisol 
responses to mental stress and the progression of coronary artery calcification in 
healthy men and women. PLoS ONE, 7(2), e31356.  
Hamer, M., Molloy, G. J., & Stamatakis, E. (2008). Psychological distress as a risk factor 
for cardiovascular events: Pathophysiological and behavioral mechanisms. 
Journal of the American College of Cardiology, 52(25), 2156–2162.  
Hamer, M., O’Donnell, K., Lahiri, A., & Steptoe, A. (2010). Salivary cortisol responses 
to mental stress are associated with coronary artery calcification in healthy men 
and women. European Heart Journal, 31(4), 424–429.  
294 
 
Hamer, M., & Steptoe, A. (2012). Cortisol responses to mental stress and incident 
hypertension in healthy men and women. The Journal of Clinical Endocrinology 
and Metabolism, 97(1), E29-34.  
Hannestad, J., DellaGioia, N., & Bloch, M. (2011). The effect of antidepressant 
medication treatment on serum levels of inflammatory cytokines: A meta-
analysis. Neuropsychopharmacology, 36(12), 2452–2459.  
Hansen, R. A., Khodneva, Y., Glasser, S. P., Qian, J., Redmond, N., & Safford, M. M. 
(2016). Antidepressant medication use and its association with cardiovascular 
disease and all-cause mortality in the reasons for geographic and racial differences 
in stroke (REGARDS) Study. Annals of Pharmacotherapy, 50(4), 253–261.  
Hanson, C. S., Outhred, T., Brunoni, A. R., Malhi, G. S., & Kemp, A. H. (2013). The 
impact of escitalopram on vagally mediated cardiovascular function to stress and 
the moderating effects of vigorous physical activity: A randomized controlled 
treatment study in healthy participants. Frontiers in Physiology, 4, 259.  
Hansson, G. K., & Hermansson, A. (2011). The immune system in atherosclerosis. Nature 
Immunology, 12(3), 204–212. 
Hansson, G. K., & Libby, P. (2006). The immune response in atherosclerosis: A double-
edged sword. Nature Reviews Immunology, 6(7), 508–519. 
Hare, D. L., Toukhsati, S. R., Johansson, P., & Jaarsma, T. (2014). Depression and 
cardiovascular disease: A clinical review. European Heart Journal, 35(21), 1365–
1372.  
Harmer, C. J., Bhagwagar, Z., Shelley, N., & Cowen, P. J. (2003). Contrasting effects of 
citalopram and reboxetine on waking salivary cortisol. Psychopharmacology, 
167(1), 112–114.  
Hawken, E. R., Owen, J. A., Hudson, R. W., & Delva, N. J. (2009). Specific effects of 
escitalopram on neuroendocrine response. Psychopharmacology, 207(1), 27–34.  
Hawken, E. R., Owen, J. A., Van Vugt, D., & Delva, N. J. (2006). Effects of oral racemic 
citalopram on neuroendocrine responses. Progress in Neuro-
Psychopharmacology & Biological Psychiatry, 30(4), 694–700.  
Heaney, J. L., Phillips, A. C., & Carroll, D. (2010). Ageing, depression, anxiety, social 
support and the diurnal rhythm and awakening response of salivary cortisol. 
International Journal of Psychophysiology, 78(3), 201–208. 
295 
 
Heim, C., Ehlert, U., & Hellhammer, D. H. (2000). The potential role of hypocortisolism 
in the pathophysiology of stress-related bodily disorders. 
Psychoneuroendocrinology, 25(1), 1–35. 
Hellhammer, D. H., Wüst, S., & Kudielka, B. M. (2009). Salivary cortisol as a biomarker 
in stress research. Psychoneuroendocrinology, 34(2), 163–171.  
Hellhammer, J., Fries, E., Schweisthal, O. W., Schlotz, W., Stone, A. A., & Hagemann, 
D. (2007). Several daily measurements are necessary to reliably assess the cortisol 
rise after awakening: State and trait components. Psychoneuroendocrinology, 
32(1), 80–86.  
Henning, J., & Netter, P. (2002). Oral application of citalopram (20 mg) and its usefulness 
for neuroendocrine challenge tests. The International Journal of 
Neuropsychopharmacology/Official Scientific Journal of the Collegium 
Internationale Neuropsychopharmacologicum (CINP), 5(1), 67–71. 
Herane Vives, A., De Angel, V., Papadopoulos, A., Strawbridge, R., Wise, T., Young, A. 
H., … & Cleare, A. J. (2015). The relationship between cortisol, stress and 
psychiatric illness: New insights using hair analysis. Journal of Psychiatric 
Research, 70, 38–49.  
Hernandez, M. E., Mendieta, D., Pérez-Tapia, M., Bojalil, R., Estrada-Garcia, I., Estrada-
Parra, S., & Pavón, L. (2013). Effect of selective serotonin reuptake inhibitors and 
immunomodulator on cytokines levels: An alternative therapy for patients with 
major depressive disorder. Clinical & Developmental Immunology, 2013, 267871.  
Heuser, I., Deuschle, M., Weber, B., Stalla, G. K., & Holsboer, F. (2000). Increased 
activity of the hypothalamus-pituitary-adrenal system after treatment with the 
mineralocorticoid receptor antagonist spironolactone. 
Psychoneuroendocrinology, 25(5), 513–518. 
Hewitt, P. L., Flett, G. L., & Mosher, S. W. (1992). The Perceived Stress Scale: Factor 
structure and relation to depression symptoms in a psychiatric sample. Journal of 
Psychopathology and Behavioral Assessment, 14(3), 247–257.  
Hibel, L. C., Granger, D. A., Cicchetti, D., & Rogosch, F. (2007). Salivary biomarker 
levels and diurnal variation: Associations with medications prescribed to control 
children’s problem behavior. Child Development, 78(3), 927–937.  
Hibel, L. C., Mercado, E., & Trumbell, J. M. (2012). Parenting stressors and morning 
cortisol in a sample of working mothers. Journal of Family Psychology, 26(5), 
738–746.  
296 
 
Hinkelmann, K., Moritz, S., Botzenhardt, J., Muhtz, C., Wiedemann, K., Kellner, M., & 
Otte, C. (2012). Changes in cortisol secretion during antidepressive treatment and 
cognitive improvement in patients with major depression: A longitudinal study. 
Psychoneuroendocrinology, 37(5), 685–692.  
Hirschfeld, R. M. A. (2001). the comorbidity of major depression and anxiety disorders: 
recognition and management in primary care. Primary Care Companion to The 
Journal of Clinical Psychiatry, 3(6), 244–254. 
Hjemdahl, P., Rosengren, A., & Steptoe, A. (2011). Stress and Cardiovascular Disease. 
Springer. 
Holman, E., Silver, R., Poulin, M., Andersen, J., Gil-Rivas, V., & McIntosh, D. N. (2008). 
Terrorism, acute stress, and cardiovascular health: A 3-year national study 
following the September 11th attacks. Archives of General Psychiatry, 65(1), 73–
80.  
Holt-Lunstad, J., Smith, T. B., & Layton, J. B. (2010). Social relationships and mortality 
risk: A meta-analytic review. PLoS Med, 7(7), e1000316.  
Hoyer, D., Clarke, D. E., Fozard, J. R., Hartig, P. R., Martin, G. R., Mylecharane, E. J., 
… & Humphrey, P. P. (1994). International Union of Pharmacology classification 
of receptors for 5-hydroxytryptamine (serotonin). Pharmacological Reviews, 
46(2), 157-203. 
Hoyt, L. T., Craske, M. G., Mineka, S., & Adam, E. K. (2015). Positive and negative 
affect and arousal: Cross-sectional and longitudinal associations with adolescent 
cortisol diurnal rhythms. Psychosomatic Medicine, 77(4), 392–401.  
Hsiao, F.-H., Yang, T.-T., Ho, R. T. H., Jow, G.-M., Ng, S.-M., Chan, C. L. W., … & 
Wang, K.-C. (2010). The self-perceived symptom distress and health-related 
conditions associated with morning to evening diurnal cortisol patterns in 
outpatients with major depressive disorder. Psychoneuroendocrinology, 35(4), 
503–515.  
Hulme, P. A., French, J. A., & Agrawal, S. (2011). Changes in diurnal salivary cortisol 
levels in response to an acute stressor in healthy young adults. Journal of the 
American Psychiatric Nurses Association, 17(5), 339–349.  
Inder, W. J., Prickett, T. C., Mulder, R. T., Donald, R. A., & Joyce, P. R. (2001). 
Reduction in basal afternoon plasma ACTH during early treatment of depression 
with fluoxetine. Psychopharmacology, 156(1), 73–78. 
297 
 
Iovieno, N., Dalton, E. D., Fava, M., & Mischoulon, D. (2011). Second-tier natural 
antidepressants: Review and critique. Journal of Affective Disorders, 130(3), 343–
357.  
Iso, H., Date, C., Yamamoto, A., Toyoshima, H., Tanabe, N., Kikuchi, S., … & Group, 
J. S. (2002). Perceived mental stress and mortality from cardiovascular disease 
among Japanese men and women the Japan Collaborative Cohort study for 
evaluation of cancer risk sponsored by Monbusho (JACC Study). Circulation, 
106(10), 1229–1236.  
Jarcho, M. R., Slavich, G. M., Tylova-Stein, H., Wolkowitz, O. M., & Burke, H. M. 
(2013). Dysregulated diurnal cortisol pattern is associated with glucocorticoid 
resistance in women with major depressive disorder. Biological Psychology, 
93(1), 150–158.  
Jazayeri, S., Keshavarz, S. A., Tehrani-Doost, M., Djalali, M., Hosseini, M., Amini, H., 
… & Djazayery, A. (2010). Effects of eicosapentaenoic acid and fluoxetine on 
plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in 
patients with major depressive disorder. Psychiatry Research, 178(1), 112–115.  
Jenkins, N. P., Keevil, B. G., Hutchinson, I. V., & Brooks, N. H. (2002). Beta-blockers 
are associated with lower C-reactive protein concentrations in patients with 
coronary artery disease. The American Journal of Medicine, 112(4), 269–274.  
Jezová, D., & Duncko, R. (2002). Enhancement of stress-induced pituitary hormone 
release and cardiovascular activation by antidepressant treatment in healthy men. 
Journal of Psychopharmacology, 16(3), 235–240. 
Jezová, D., Vigas, M., Klimes, I., & Jurcovicová, J. (1983). Adenopituitary hormone 
response to exercise combined with propranolol infusion in man. Endocrinologia 
Experimentalis, 17(2), 91–98. 
Ji, H., Guo, W. Z., Yan, Z. H., Li, D., & Lu, C. L. (2010). Influence of drug treatment on 
glucocorticoid receptor levels in patients with coronary heart disease. Chinese 
Medical Journal, 123(13), 1685–1689. 
Jiang, W., Velazquez,  E.J., Kuchibhatla, M., Samad, Z., Boyle, S. H., Kuhn, C., … & 
O’Connor, C. (2013). Effect of escitalopram on mental stress–induced myocardial 
ischemia: Results of the remit trial. JAMA, 309(20), 2139–2149.  
Jokinen, J., & Nordström, P. (2009). HPA axis hyperactivity and cardiovascular mortality 
in mood disorder inpatients. Journal of Affective Disorders, 116(1–2), 88–92.  
298 
 
Juruena, M. F., Pariante, C. M., Papadopoulos, A. S., Poon, L., Lightman, S., & Cleare, 
A. J. (2009). Prednisolone suppression test in depression: Prospective study of the 
role of HPA axis dysfunction in treatment resistance. The British Journal of 
Psychiatry: The Journal of Mental Science, 194(4), 342–349.  
Jutla, S. K., Yuyun, M. F., Quinn, P. A., & Ng, L. L. (2014). Plasma cortisol and prognosis 
of patients with acute myocardial infarction. Journal of Cardiovascular Medicine, 
15(1), 33–41.  
Kaltsas, G., Zannas, A. S., & Chrousos, G. P. (2012). Hypothalamic–pituitary–adrenal 
axis and cardiovascular disease. In P. Hjemdahl, A. Steptoe, & A. Rosengren 
(Eds.), Stress and Cardiovascular Disease (pp. 71–87). Springer London.  
Kam, J. C., Szefler, S. J., Surs, W., Sher, E. R., & Leung, D. Y. (1993). Combination IL-
2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to 
glucocorticoids. The Journal of Immunology, 151(7), 3460–3466. 
Karasek, R. A., & Theorell, T. (1990). Healthy Work. New York: Basic Books. 
Kasper, S., Spadone, C., Verpillat, P., & Angst, J. (2006). Onset of action of escitalopram 
compared with other antidepressants: results of a pooled analysis. International 
Clinical Psychopharmacology, 21(2), 105–110. 
Katan, M., Morgenthaler, N., Widmer, I., Puder, J. J., Konig, C., Muller, B., & Christ-
Crain, M. (2008). Copeptin, a stable peptide derived from the vasopressin 
precursoe, correlates with the individual stress level. Neuroendocrinology Letters, 
29(3), 341-346. 
Kauffman, R. P., Castracane, V. D., White, D. L., Baldock, S. D., & Owens, R. (2005). 
Impact of the selective serotonin reuptake inhibitor citalopram on insulin 
sensitivity, leptin and basal cortisol secretion in depressed and non-depressed 
euglycemic women of reproductive age. Gynecological Endocrinology: The 
Official Journal of the International Society of Gynecological Endocrinology, 
21(3), 129–137.  
Keeshin, B. R., Strawn, J. R., Out, D., Granger, D. A., & Putnam, F. W. (2014). Cortisol 
awakening response in adolescents with acute sexual abuse related posttraumatic 
stress disorder. Depression and Anxiety, 31(2), 107–114. 
Kershaw, K. N., Brenes, G. A., Charles, L. E., Coday, M., Daviglus, M. L., Denburg, N. 
L., … & Horn, L. V. (2014). Associations of stressful life events and social strain 
with incident cardiovascular disease in the Women’s Health Initiative. Journal of 
the American Heart Association, 3(3), e000687.  
299 
 
Kershaw, K. N., Roux, A. V. D., Bertoni, A., Carnethon, M. R., Everson-Rose, S. A., & 
Liu, K. (2015). Associations of chronic individual-level and neighbourhood-level 
stressors with incident coronary heart disease: The Multi-Ethnic Study of 
Atherosclerosis. Journal of Epidemiology and Community Health, 69(2), 136–
141.  
Khan, A., Brodhead, A. E., Schwartz, K. A., Kolts, R. L., & Brown, W. A. (2005). Sex 
differences in antidepressant response in recent antidepressant clinical trials. 
Journal of Clinical Psychopharmacology, 25(4), 318–324. 
Khan, S. Q., Dhillon, O. S., O’Brien, R. J., Struck, J., Quinn, P. A., Morgenthaler, N. G., 
… & Ng, L. L. (2007). C-terminal provasopressin (copeptin) as a novel and 
prognostic marker in acute myocardial infarction Leicester acute myocardial 
infarction peptide (LAMP) study. Circulation, 115(16), 2103-2110. 
Khan, S., Liberzon, I., & Abelson, J. L. (2004). Effects of propranolol on symptom and 
endocrine responses to pentagastrin. Psychoneuroendocrinology, 29(9), 1163–
1171.  
Kidd, T., Poole, L., Leigh, E., Ronaldson, A., Jahangiri, M., & Steptoe, A. (2014). 
Attachment anxiety predicts IL-6 and length of hospital stay in coronary artery 
bypass graft surgery (CABG) patients. Journal of Psychosomatic Research, 77(2), 
155–157. 
Kidd, T., Poole, L., Leigh, E., Ronaldson, A., Jahangiri, M., & Steptoe, A. (2016). Health-
related personal control predicts depression symptoms and quality of life but not 
health behaviour following coronary artery bypass graft surgery. Journal of 
Behavioral Medicine, 39(1), 120–127. 
Kidd, T., Poole, L., Ronaldson, A., Leigh, E., Jahangiri, M., & Steptoe, A. (2016). 
Attachment anxiety predicts depression and anxiety symptoms following 
coronary artery bypass graft surgery. British Journal of Health Psychology 21, 
796-811.  
Kim, C., Redberg, R. F., Pavlic, T., & Eagle, K. A. (2007). A systematic review of gender 
differences in mortality after coronary artery bypass graft surgery and 
percutaneous coronary interventions. Clinical Cardiology, 30(10), 491-495. 
Kirkup, W., & Merrick, D. W. (2003). A matter of life and death: Population mortality 
and football results. Journal of Epidemiology and Community Health, 57(6), 429–
432.  
300 
 
Kirschbaum, C., & Hellhammer, D. H. (1989). Salivary cortisol in psychobiological 
research: An overview. Neuropsychobiology, 22(3), 150–169. 
Kirschbaum, C., & Hellhammer, D. H. (2000). Salivary cortisol. Encyclopedia of Stress, 
3(379–383).  
Kirschbaum, C., Klauer, T., Filipp, S. H., & Hellhammer, D. H. (1995). Sex-specific 
effects of social support on cortisol and subjective responses to acute 
psychological stress. Psychosomatic Medicine, 57(1), 23–31. 
Kirschbaum, C., Kudielka, B. M., Gaab, J., Schommer, N. C., & Hellhammer, D. H. 
(1999). Impact of gender, menstrual cycle phase, and oral contraceptives on the 
activity of the hypothalamus-pituitary-adrenal axis. Psychosomatic Medicine, 
61(2), 154–162. 
Kirschbaum, C., Pirke, K. M., & Hellhammer, D. H. (1993). The “Trier Social Stress 
Test”–a tool for investigating psychobiological stress responses in a laboratory 
setting. Neuropsychobiology, 28(1–2), 76–81. 
Kivimäki, M., Jokela, M., Nyberg, S. T., Singh-Manoux, A., Fransson, E. I., Alfredsson, 
L., … & Clays, E. (2015). Long working hours and risk of coronary heart disease 
and stroke: A systematic review and meta-analysis of published and unpublished 
data for 603,838 individuals. Lancet, 386(10005), 1739–1746.  
Kivimäki, M., & Kawachi, I. (2015). Work stress as a risk factor for cardiovascular 
disease. Current Cardiology Reports, 17(9), 1–9. 
Kizildere, S., Glück, T., Zietz, B., Schölmerich, J., & Straub, R. H. (2003). During a 
corticotropin-releasing hormone test in healthy subjects, administration of a beta-
adrenergic antagonist induced secretion of cortisol and dehydroepiandrosterone 
sulfate and inhibited secretion of ACTH. European Journal of Endocrinology, 
148(1), 45–53. 
Kloner, R. A., McDonald, S., Leeka, J., & Poole, W. K. (2009). Comparison of total and 
cardiovascular death rates in the same city during a losing versus winning super 
bowl championship. The American Journal of Cardiology, 103(12), 1647–1650.  
Knorr, U., Vinberg, M., Gether, U., Winkel, P., Gluud, C., Wetterslev, J., & Kessing, L. 
V. (2012). The effect of escitalopram versus placebo on perceived stress and 
salivary cortisol in healthy first-degree relatives of patients with depression-A 
randomised trial. Psychiatry Research, 200(2–3), 354–360.  
301 
 
Knorr, U., Vinberg, M., Kessing, L. V., & Wetterslev, J. (2010). Salivary cortisol in 
depressed patients versus control persons: A systematic review and meta-analysis. 
Psychoneuroendocrinology, 35(9), 1275–1286.  
Kojima, H., Terao, T., Iwakawa, M., Soya, A., Inoue, N., Shiraishi, Y., … & Nakamura, 
J. (2003). Paroxetine as a 5-HT neuroendocrine probe. Psychopharmacology, 
167(1), 97–102.  
Koss, K. J., Mliner, S. B., Donzella, B., & Gunnar, M. R. (2016). Early adversity, 
hypocortisolism, and behavior problems at school entry: A study of 
internationally adopted children. Psychoneuroendocrinology, 66, 31–38.  
Kotlyar, M., al’Absi, M., Thuras, P., Vuchetich, J. P., Adson, D. E., Nowack, A. L., & 
Hatsukami, D. K. (2013). Effect of paroxetine on physiological response to stress 
and smoking. Psychosomatic Medicine, 75(3), 236–243.  
Kristenson, M., Lassvik, C., Bergdahl, B., Kucinskiène, Z., Aizieniène, L., Bo, Z., … & 
Olsson, A. G. (2000). Ultrasound determined carotid and femoral atherosclerosis 
in Lithuanian and Swedish men: The LiVicordia study. Atherosclerosis, 151(2), 
501–508. 
Kristenson, M., Orth-Gomér, K., Kucinskienë, Z., Bergdahl, B., Calkauskas, H., 
Balinkyniene, I., & Olsson, A. G. (1998). Attenuated cortisol response to a 
standardized stress test in Lithuanian versus Swedish men: the LiVicordia study. 
International Journal of Behavioral Medicine, 5(1), 17–30.  
Kudielka, B. M., Fischer, J. E., Metzenthin, P., Helfricht, S., Preckel, D., & von 
K&auml;nel, R. (2007). No effect of 5-day treatment with acetylsalicylic acid 
(aspirin) or the beta-blocker propranolol (inderal) on free cortisol responses to 
acute psychosocial stress: A randomized double-blind, placebo-controlled study. 
Neuropsychobiology, 56(2–3), 159–166.  
Kuepper, Y., Bausch, S., Iffland, J., Reuter, M., & Hennig, J. (2006). S-Citalopram in 
neuroendocrine challenge-tests: Serotonergic responsivity in healthy male and 
female human participants. Psychoneuroendocrinology, 31(10), 1200–1207.  
Kumari, M., Badrick, E., Chandola, T., Adam, E. K., Stafford, M., Marmot, M. G., … & 
Kivimaki, M. (2009). Cortisol secretion and fatigue: associations in a community 
based cohort. Psychoneuroendocrinology, 34(10), 1476–1485.  
Kumari, M., Shipley, M., Stafford, M., & Kivimaki, M. (2011). Association of diurnal 
patterns in salivary cortisol with all-cause and cardiovascular mortality: Findings 
302 
 
from the Whitehall II Study. The Journal of Clinical Endocrinology & 
Metabolism, 96(5), 1478–1485. 
Kumsta, R., Entringer, S., Hellhammer, D. H., & Wüst, S. (2007). Cortisol and ACTH 
responses to psychosocial stress are modulated by corticosteroid binding globulin 
levels. Psychoneuroendocrinology, 32(8–10), 1153–1157.  
Kunz-Ebrecht, S. R., Mohamed-Ali, V., Feldman, P. J., Kirschbaum, C., & Steptoe, A. 
(2003). Cortisol responses to mild psychological stress are inversely associated 
with proinflammatory cytokines. Brain, Behavior, and Immunity, 17(5), 373–383. 
Kuper, H., Marmot, M., & Hemingway, H. (2005). Systematic review of prospective 
cohort studies of psychosocial factors in the aetiology and prognosis of coronary 
heart disease. Coronary Heart Disease Epidemiology: From Aetiology to Public 
Health. Oxford University Press, Oxford, 363–413. 
Lai, M., McCormick, J. A., Chapman, K. E., Kelly, P. A. T., Seckl, J. R., & Yau, J. L. W. 
(2003). Differential regulation of corticosteroid receptors by monoamine 
neurotransmitters and antidepressant drugs in primary hippocampal culture. 
Neuroscience, 118(4), 975–984. 
Lanfumey, L., Mongeau, R., Cohen-Salmon, C., & Hamon, M. (2008). Corticosteroid–
serotonin interactions in the neurobiological mechanisms of stress-related 
disorders. Neuroscience & Biobehavioral Reviews, 32(6), 1174–1184. 
Lazzarino, A. I., Hamer, M., Stamatakis, E., & Steptoe, A. (2013). Low socioeconomic 
status and psychological distress as synergistic predictors of mortality from stroke 
and coronary heart disease. Psychosomatic Medicine, 75(3), 311–316.  
Leahey, W. J., Neill, J. D., Varma, M. P. S., & Shanks, R. G. (1980). Comparison of the 
efficacy and pharmacokinetics of conventional propranolol and a long acting 
preparation of propranolol. British Journal of Clinical Pharmacology, 9(1), 33–
40. 
Lee, S., Colditz, G. A., Berkman, L. F., & Kawachi, I. (2003). Caregiving and risk of 
coronary heart disease in U.S. women: A prospective study. American Journal of 
Preventive Medicine, 24(2), 113–119.  
Lenze, E. J., Mantella, R. C., Shi, P., Goate, A. M., Nowotny, P., Butters, M. A., … & 
Rollman, B. L. (2011). Elevated cortisol in older adults with generalized anxiety 
disorder is reduced by treatment: A placebo-controlled evaluation of escitalopram. 
The American Journal of Geriatric Psychiatry, 19(5), 482–490.  
303 
 
Leor, J., & Kloner, R. A. (1996). The Northridge earthquake as a trigger for acute 
myocardial infarction. The American Journal of Cardiology, 77(14), 1230–1232. 
Leor, J., Poole, W. K., & Kloner, R. A. (1996). Sudden cardiac death triggered by an 
earthquake. New England Journal of Medicine, 334(7), 413–419.  
Leung, D. Y. M., Hamid, Q., Vottero, A., Szefler, S. J., Surs, W., Minshall, E., … & 
Klemm, D. J. (1997). Association of glucocorticoid insensitivity with increased 
expression of glucocorticoid receptor β. The Journal of Experimental Medicine, 
186(9), 1567–1574. 
Lewis, J. G., Bagley, C. J., Elder, P. A., Bachmann, A. W., & Torpy, D. J. (2005). Plasma 
free cortisol fraction reflects levels of functioning corticosteroid-binding globulin. 
Clinica Chimica Acta, 359(1–2), 189–194.  
Lewis, M. J., Groom, G. V., Barber, R., & Henderson, A. H. (1981). The effects of 
propranolol and acebutolol on the overnight plasma levels of anterior pituitary and 
related hormones. British Journal of Clinical Pharmacology, 12(5), 737–742. 
Li, J., Zhang, M., Loerbroks, A., Angerer, P., & Siegrist, J. (2014). Work stress and the 
risk of recurrent coronary heart disease events: A systematic review and meta-
analysis. International Journal of Occupational Medicine and Environmental 
Health, 1–12.  
Liao, J., Brunner, E. J., & Kumari, M. (2013). Is there an association between work stress 
and diurnal cortisol patterns? Findings from the Whitehall II Study. PLOS ONE, 
8(12), e81020.  
Libby, P., Ridker, P. M., & Hansson, G. K. (2011). Progress and challenges in translating 
the biology of atherosclerosis. Nature, 473(7347), 317–325.  
Liedholm, H., Wåhlin-Boll, E., & Melander, A. (1990). Mechanisms and variations in the 
food effect on propranolol bioavailability. European Journal of Clinical 
Pharmacology, 38(5), 469–475. 
Ljung, T., Ahlberg, A. C., Holm, G., Friberg, P., Andersson, B., Eriksson, E., & 
Björntorp, P. (2001). Treatment of abdominally obese men with a serotonin 
reuptake inhibitor: A pilot study. Journal of Internal Medicine, 250(3), 219–224. 
Lopez-Duran, N. L., McGinnis, E., Kuhlman, K., Geiss, E., Vargas, I., & Mayer, S. 
(2015). HPA-axis stress reactivity in youth depression: Evidence of impaired 
regulatory processes in depressed boys. Stress, 18(5), 545–553. 
304 
 
Lotrich, F. E., Bies, R., Muldoon, M. F., Manuck, S. B., Smith, G. S., & Pollock, B. G. 
(2005). Neuroendocrine response to intravenous citalopram in healthy control 
subjects: pharmacokinetic influences. Psychopharmacology, 178(2–3), 268–275.  
Lu, S., Gao, W., Huang, M., Li, L., & Xu, Y. (2016). In search of the HPA axis activity 
in unipolar depression patients with childhood trauma: Combined cortisol 
awakening response and dexamethasone suppression test. Journal of Psychiatric 
Research, 78, 24–30.  
Lu, S., Gao, W., Wei, Z., Wu, W., Liao, M., Ding, Y., … & Li, L. (2013). Reduced 
cingulate gyrus volume associated with enhanced cortisol awakening response in 
young healthy adults reporting childhood trauma. PloS One, 8(7), e69350.  
Macdonald, I. A., Bennett, T., Brown, A. M., Wilcox, R. G., & Skene, A. M. (1984). The 
effects of acute or chronic ingestion of propranolol or metoprolol on the metabolic 
and hormonal responses to prolonged, submaximal exercise in hypertensive men. 
British Journal of Clinical Pharmacology, 17(3), 283–293. 
Maheu, F. S., Joober, R., & Lupien, S. J. (2005). Declarative memory after stress in 
humans: Differential involvement of the β-adrenergic and corticosteroid systems. 
The Journal of Clinical Endocrinology & Metabolism, 90(3), 1697–1704. 
Maina, G., Bovenzi, M., Palmas, A., & Filon, F. L. (2009). Associations between two job 
stress models and measures of salivary cortisol. International Archives of 
Occupational and Environmental Health, 82(9), 1141–1150.  
Maina, G., Palmas, A., & Filon, F. L. (2007). Relationship between self-reported mental 
stressors at the workplace and salivary cortisol. International Archives of 
Occupational and Environmental Health, 81(4), 391–400.  
Malarkey, W. B., Kiecolt-Glaser, J. K., Pearl, D., & Glaser, R. (1994). Hostile behavior 
during marital conflict alters pituitary and adrenal hormones. Psychosomatic 
Medicine, 56(1), 41–51. 
Manenschijn, L., Van Den Akker, E. L., Lamberts, S. W., & Van Rossum, E. F. (2009). 
Clinical features associated with glucocorticoid receptor polymorphisms. Annals 
of the New York Academy of Sciences, 1179(1), 179–198. 
Mannie, Z. N., Harmer, C. J., & Cowen, P. J. (2007). Increased waking salivary cortisol 
levels in young people at familial risk of depression. American Journal of 
Psychiatry, 164(4), 617–621. 
305 
 
Manthey, L., Leeds, C., Giltay, E. J., van Veen, T., Vreeburg, S. A., Penninx, B. W. J. H., 
& Zitman, F. G. (2011). Antidepressant use and salivary cortisol in depressive and 
anxiety disorders. European Neuropsychopharmacology, 21(9), 691–699.  
Marchand, A., Durand, P., Juster, R.-P., & Lupien, S. J. (2014). Workers’ psychological 
distress, depression, and burnout symptoms: associations with diurnal cortisol 
profiles. Scandinavian Journal of Work, Environment & Health, 40(3), 305–314.  
Maric, N. P., & Adzic, M. (2013). Pharmacological modulation of HPA axis in depression 
- new avenues for potential therapeutic benefits. Psychiatria Danubina, 25(3), 
299–305. 
März, P., Cheng, J.-G., Gadient, R. A., Patterson, P. H., Stoyan, T., Otten, U., & Rose-
John, S. (1998). Sympathetic neurons can produce and respond to interleukin 6. 
Proceedings of the National Academy of Sciences of the United States of America, 
95(6), 3251–3256. 
Mason, B. L., Thomas, S. A., Lightman, S. L., & Pariante, C. M. (2011). Desipramine 
treatment has minimal effects on the brain accumulation of glucocorticoids in P-
gp-deficient and wild-type mice. Psychoneuroendocrinology, 36(9), 1351–1360.  
Matthews, K., Schwartz, J., Cohen, S., & Seeman, T. (2006). Diurnal cortisol decline is 
related to coronary calcification: CARDIA study. Psychosomatic Medicine, 68(5), 
657–661.  
Mattos, P., Franco, V. A., Noel, F., Segenreich, D., & Gonçalves, J. C. (2006). Usefulness 
of serotoninergic challenge with oral citalopram. Revista Brasileira De 
Psiquiatria, 28(3), 203–205. 
McEwen, B. S. (1998). Protective and damaging effects of stress mediators. New England 
Journal of Medicine, 338(3), 171–179.  
McEwen, B. S. (2000). The neurobiology of stress: from serendipity to clinical relevance. 
Brain Research, 886(1–2), 172–189.  
McEwen, B. S. (2007). Physiology and neurobiology of stress and adaptation: Central 
role of the brain. Physiological Reviews, 87(3), 873–904.  
McEwen, B. S. (2008). Central effects of stress hormones in health and disease: 
Understanding the protective and damaging effects of stress and stress mediators. 
European Journal of Pharmacology, 583(2–3), 174–185.  
McEwen, B. S., & Wingfield, J. C. (2003). The concept of allostasis in biology and 
biomedicine. Hormones and Behavior, 43(1), 2–15. 
306 
 
McEwen, B. S., & Wingfield, J. C. (2010). What is in a name? Integrating homeostasis, 
allostasis and stress. Hormones and Behavior, 57(2), 105–111.  
McGill, H. C., McMahan, C. A., Zieske, A. W., Tracy, R. E., Malcom, G. T., Herderick, 
E. E., … & Pathological Determinants of Atherosclerosis in Youth (PDAY) 
Research Group. (2000). Association of coronary heart disease risk factors with 
microscopic qualities of coronary atherosclerosis in youth. Circulation, 102(4), 
374–379.  
McKay, L. I., & Cidlowski, J. A. (1999). Molecular control of immune/inflammatory 
responses: interactions between nuclear factor-kappa B and steroid receptor-
signaling pathways. Endocrine Reviews, 20(4), 435–459.  
McLachlan, K., Rasmussen, C., Oberlander, T. F., Loock, C., Pei, J., Andrew, G., … & 
Weinberg, J. (2016). Dysregulation of the cortisol diurnal rhythm following 
prenatal alcohol exposure and early life adversity. Alcohol, 53, 9–18.  
Meijer, A., Conradi, H. J., Bos, E. H., Thombs, B. D., van Melle, J. P., & de Jonge, P. 
(2011). Prognostic association of depression following myocardial infarction with 
mortality and cardiovascular events: a meta-analysis of 25 years of research. 
General Hospital Psychiatry, 33(3), 203–216. 
Meisel, S. R., Kutz, I., Dayan, K. I., Pauzner, H., Chetboun, I., Arbel, Y., & David, D. 
(1991). Effect of Iraqi missile war on incidence of acute myocardial infarction and 
sudden death in Israeli civilians. Lancet (London, England), 338(8768), 660–661. 
Meltzer, H. Y., & Maes, M. (1994). Effect of pindolol on the L-5-HTP-induced increase 
in plasma prolactin and cortisol concentrations in man. Psychopharmacology, 
114(4), 635–643. 
Meltzer, H. Y. (1994). Effects of buspirone on plasma prolactin and cortisol levels in 
major depressed and normal subjects. Biological Psychiatry, 35(5), 316–323. 
Menke, A., Arloth, J., Gerber, M., Rex-Haffner, M., Uhr, M., Holsboer, F., … & Beck, 
J. (2014). Dexamethasone stimulated gene expression in peripheral blood 
indicates glucocorticoid-receptor hypersensitivity in job-related exhaustion. 
Psychoneuroendocrinology, 44, 35–46.  
Merswolken, M., Deter, H. C., Siebenhuener, S., Orth-Gomér, K., & Weber, C. S. (2013). 
Anxiety as predictor of the cortisol awakening response in patients with coronary 
heart disease. International Journal of Behavioral Medicine, 20(3), 461–467.  
307 
 
Messerli-Bürgy, N., Molloy, G. J., Wikman, A., Perkins-Porras, L., Randall, G., & 
Steptoe, A. (2012). Cortisol levels and history of depression in acute coronary 
syndrome patients. Psychological Medicine, 42(9), 1815–1823.  
Miklowitz, D. J., Portnoff, L. C., Armstrong, C. C., Keenan-Miller, D., Breen, E. C., 
Muscatell, K. A., … & Irwin, M. R. (2016). Inflammatory cytokines and nuclear 
factor-kappa B activation in adolescents with bipolar and major depressive 
disorders. Psychiatry Research, 241, 315–322.  
Miller, G. E., Chen, E., & Zhou, E. S. (2007). If it goes up, must it come down? Chronic 
stress and the hypothalamic-pituitary-adrenocortical axis in humans. 
Psychological Bulletin, 133(1), 25. 
Miller, G. E., Cohen, S., & Kim, A. (2002). Chronic psychological stress and the 
regulation of pro-inflammatory cytokines: A glucocorticoid-resistance model. 
Health Psychology, 21(6), 531–541.  
Miller, G. E., Murphy, M. L. M., Cashman, R., Ma, R., Ma, J., Arevalo, J. M. G., … & 
Cole, S. W. (2014). Greater inflammatory activity and blunted glucocorticoid 
signaling in monocytes of chronically stressed caregivers. Brain, Behavior, and 
Immunity, 41, 191–199.  
Mills, P. J., & Dimsdale, J. E. (1991). Cardiovascular reactivity to psychosocial stressors: 
A review of the effects of beta-blockade. Psychosomatics, 32(2), 209–220. 
Mitchell, P. H., Powell, L., Blumenthal, J., Norten, J., Ironson, G., Pitula, C. R., … & 
Berkman, L. F. (2003). A short social support measure for patients recovering 
from myocardial infarction: The ENRICHD Social Support Inventory. Journal of 
Cardiopulmonary Rehabilitation, 23(6), 398–403. 
Montgomery, S. A., Loft, H., Sánchez, C., Reines, E. H., & Papp, M. (2001). 
Escitalopram (S-enantiomer of citalopram): Clinical efficacy and onset of action 
predicted from a rat model. Pharmacology & Toxicology, 88(5), 282–286.  
Moons, W. G., Way, B. M., & Taylor, S. E. (2014). Oxytocin and vasopressin receptor 
polymorphisms interact with circulating neuropeptides to predict human 
emotional reactions to stress. Emotion, 14(3), 562. 
Mostofsky, E., Penner, E. A., & Mittleman, M. A. (2014). Outbursts of anger as a trigger 
of acute cardiovascular events: A systematic review and meta-analysis. European 
Heart Journal, ehu033.  
Mück-Seler, D., Pivac, N., Sagud, M., Jakovljević, M., & Mihaljević-Peles, A. (2002). 
The effects of paroxetine and tianeptine on peripheral biochemical markers in 
308 
 
major depression. Progress in Neuro-Psychopharmacology & Biological 
Psychiatry, 26(7–8), 1235–1243. 
Nadeem, H. S., Attenburrow, M. J., & Cowen, P. J. (2004). Comparison of the effects of 
citalopram and escitalopram on 5-HT-mediated neuroendocrine responses. 
Neuropsychopharmacology, 29(9), 1699–1703.  
Nakagawa, I., Nakamura, K., Oyama, M., Yamazaki, O., Ishigami, K., Tsuchiya, Y., & 
Yamamoto, M. (2009). Long-term effects of the Niigata-Chuetsu earthquake in 
Japan on acute myocardial infarction mortality: An analysis of death certificate 
data. Heart, 95(24), 2009–2013.  
Narum, S. R. (2006). Beyond Bonferroni: Less conservative analyses for conservation 
genetics. Conservation Genetics, 7(5), 783-787. 
Neylon, A., Canniffe, C., Anand, S., Kreatsoulas, C., Blake, G. J., Sugrue, D., & 
McGorrian, C. (2013). A global perspective on psychosocial risk factors for 
cardiovascular disease. Progress in Cardiovascular Diseases, 55(6), 574–581.  
Nezafati, M. H., Vojdanparast, M., & Nezafati, P. (2015). Antidepressants and 
cardiovascular adverse events: A narrative review. ARYA Atherosclerosis, 11(5), 
295–304. 
Nguyen, L. P., Omoluabi, O., Parra, S., Frieske, J. M., Clement, C., Ammar-Aouchiche, 
Z., … & Tuvim, M. J. (2008). Chronic exposure to beta-blockers attenuates 
inflammation and mucin content in a murine asthma model. American Journal of 
Respiratory Cell and Molecular Biology, 38(3), 256–262. 
Nicholson, A., Kuper, H., & Hemingway, H. (2006). Depression as an aetiologic and 
prognostic factor in coronary heart disease: A meta-analysis of 6362 events 
among 146 538 participants in 54 observational studies. European Heart Journal, 
27(23), 2763–2774.  
Nickel, T., Sonntag, A., Schill, J., Zobel, A. W., Ackl, N., Brunnauer, A., … & Holsboer, 
F. (2003). Clinical and neurobiological effects of tianeptine and paroxetine in 
major depression. Journal of Clinical Psychopharmacology, 23(2), 155–168. 
Nicolson, N. A., & van Diest, R. (2000). Salivary cortisol patterns in vital exhaustion. 
Journal of Psychosomatic Research, 49(5), 335–342. 
Nielsen, N. R., Kristensen, T. S., Prescott, E., Larsen, K. S., Schnohr, P., & Grønbaek, 
M. (2006). Perceived stress and risk of ischemic heart disease: causation or bias? 
Epidemiology, 17(4), 391–397.  
309 
 
Nierenberg, A. A., Greist, J. H., Mallinckrodt, C. H., Prakash, A., Sambunaris, A., 
Tollefson, G. D., & Wohlreich, M. M. (2007). Duloxetine versus escitalopram and 
placebo in the treatment of patients with major depressive disorder: onset of 
antidepressant action, a non-inferiority study. Current Medical Research and 
Opinion, 23(2), 401-416. 
Niiyama, M., Tanaka, F., Nakajima, S., Itoh, T., Matsumoto, T., Kawakami, M., … & 
Sakata, K. (2014). Population-based incidence of sudden cardiac and unexpected 
death before and after the 2011 earthquake and tsunami in Iwate, northeast Japan. 
Journal of the American Heart Association, 3(3), e000798. 
Nijm, J., & Jonasson, L. (2009). Inflammation and cortisol response in coronary artery 
disease. Annals of Medicine, 41(3), 224–233.  
Nijm, J., Kristenson, M., Olsson, A. G., & Jonasson, L. (2007). Impaired cortisol response 
to acute stressors in patients with coronary disease. Implications for inflammatory 
activity. Journal of Internal Medicine, 262(3), 375–384.  
Nikisch, G., Mathé, A. A., Czernik, A., Thiele, J., Bohner, J., Eap, C. B., … & Baumann, 
P. (2005). Long-term citalopram administration reduces responsiveness of HPA 
axis in patients with major depression: Relationship with S-citalopram 
concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. 
Psychopharmacology, 181(4), 751–760.  
Nishi, M., Tanaka, M., Matsuda, K., Sunaguchi, M., & Kawata, M. (2004). Visualization 
of glucocorticoid receptor and mineralocorticoid receptor interactions in living 
cells with gfp-based fluorescence resonance energy transfer. The Journal of 
Neuroscience, 24(21), 4918–4927.  
Nonell, A., Kerk, S., Lederbogen, F., Kopf, D., Hamann, B., Lewicka, S., & Deuschle, 
M. (2004). No major effect of orciprenaline and propranolol upon ACTH-induced 
cortisol secretion. Experimental and Clinical Endocrinology & Diabetes, 112(1), 
59–61.  
Nozaki, E., Nakamura, A., Abe, A., Kagaya, Y., Kohzu, K., Sato, K., … & Seki, H. 
(2013). Occurrence of cardiovascular events after the 2011 Great East Japan 
Earthquake and tsunami disaster. International Heart Journal, 54(5), 247–253. 
Oakley, R. H., & Cidlowski, J. A. (2013). The biology of the glucocorticoid receptor: 
New signaling mechanisms in health and disease. The Journal of Allergy and 
Clinical Immunology, 132(5), 1033–1044.  
310 
 
Oberbeck, R., Schürmeyer, T. H., Jacobs, R., Benschop, R. J., Sommer, B., Schmidt, R. 
E., & Schedlowski, M. (1998). Effects of b-adrenoceptor-blockade on stress-
induced adrenocorticotrophin release in humans. European Journal of Applied 
Physiology and Occupational Physiology, 77(6), 523–526. 
O’Flaherty, M., Buchan, I., & Capewell, S. (2013). Contributions of treatment and 
lifestyle to declining CVD mortality: Why have CVD mortality rates declined so 
much since the 1960s? Heart, 99(3), 159–162.  
Ohtsuka, T., Hamada, M., Hiasa, G., Sasaki, O., Suzuki, M., Hara, Y., … & Hiwada, K. 
(2001). Effect of beta-blockers on circulating levels of inflammatory and anti-
inflammatory cytokines in patients with dilated cardiomyopathy. Journal of the 
American College of Cardiology, 37(2), 412–417. 
Okugawa, G., Omori, K., Suzukawa, J., Fujiseki, Y., Kinoshita, T., & Inagaki, C. (1999). 
Long-term treatment with antidepressants increases glucocorticoid receptor 
binding and gene expression in cultured rat hippocampal neurones. Journal of 
Neuroendocrinology, 11(11), 887–895. 
Okun, M. L., Krafty, R. T., Buysse, D. J., Monk, T. H., Reynolds, C. F., Begley, A., & 
Hall, M. (2010). What constitutes too long of a delay? Determining the cortisol 
awakening response (CAR) using self-report and PSG-assessed wake time. 
Psychoneuroendocrinology, 35(3), 460–468. 
Okuyama-Tamura, M., Mikuni, M., & Kojima, I. (2003). Modulation of the human 
glucocorticoid receptor function by antidepressive compounds. Neuroscience 
Letters, 342(3), 206–210. 
Olivier, J. D. A., Blom, T., Arentsen, T., & Homberg, J. R. (2011). The age-dependent 
effects of selective serotonin reuptake inhibitors in humans and rodents: A review. 
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35(6), 1400-
1408. 
Oosterholt, B. G., Maes, J. H. R., Van der Linden, D., Verbraak, M. J. P. M., & Kompier, 
M. A. J. (2015). Burnout and cortisol: Evidence for a lower cortisol awakening 
response in both clinical and non-clinical burnout. Journal of Psychosomatic 
Research, 78(5), 445–451.  
Orth-Gomér K, Wamala SP, Horsten M, Schenck-Gustafsson K, Schneiderman N, & 
Mittleman MA. (2000). Marital stress worsens prognosis in women with coronary 
heart disease: The Stockholm female coronary risk study. JAMA, 284(23), 3008–
3014.  
311 
 
Owens, M. J., & Nemeroff, C. B. (1994). Role of serotonin in the pathophysiology of 
depression: Focus on the serotonin transporter. Clinical Chemistry, 40(2), 288–
295. 
Pacak, K. (2000). Stressor-specific activation of the hypothalamic-pituitary 
adrenocortical axis. Physiological Research, 49, S11–S18. 
Pacak, K., Palkovits, M., Kopin, I. J., & Goldstein, D. S. (1995). Stress-induced 
norepinephrine release in the hypothalamic paraventricular nucleus and pituitary-
adrenocortical and sympathoadrenal activity: In vivo microdialysis studies. 
Frontiers in Neuroendocrinology, 16(2), 89–150. 
Pace, T. W. W., Hu, F., & Miller, A. H. (2007). Cytokine-effects on glucocorticoid 
receptor function: Relevance to glucocorticoid resistance and the pathophysiology 
and treatment of major depression. Brain, Behavior, and Immunity, 21(1), 9–19.  
Panagiotakopoulos, L., & Neigh, G. N. (2014). Development of the HPA axis: Where and 
when do sex differences manifest? Frontiers in Neuroendocrinology, 35(3), 285–
302.  
Pariante, C. M., Alhaj, H. A., Arulnathan, V. E., Gallagher, P., Hanson, A., Massey, E., 
& McAllister-Williams, R. H. (2012). Central glucocorticoid receptor-mediated 
effects of the antidepressant, citalopram, in humans: A study using EEG and 
cognitive testing. Psychoneuroendocrinology, 37(5), 618–628.  
Pariante, C. M., Kim, R. B., Makoff, A., & Kerwin, R. W. (2003). Antidepressant 
fluoxetine enhances glucocorticoid receptor function in vitro by modulating 
membrane steroid transporters. British Journal of Pharmacology, 139(6), 1111–
1118.  
Pariante, C. M., & Lightman, S. L. (2008). The HPA axis in major depression: classical 
theories and new developments. Trends in Neurosciences, 31(9), 464–468.  
Pariante, C. M., Makoff, A., Lovestone, S., Feroli, S., Heyden, A., Miller, A. H., & 
Kerwin, R. W. (2001). Antidepressants enhance glucocorticoid receptor function 
in vitro by modulating the membrane steroid transporters. British Journal of 
Pharmacology, 134(6), 1335–1343.  
Pariante, C. M., & Miller, A. H. (2001). Glucocorticoid receptors in major depression: 
relevance to pathophysiology and treatment. Biological Psychiatry, 49(5), 391–
404. 
312 
 
Pariante, C. M., Papadopoulos, A. S., Poon, L., Checkley, S. A., English, J., Kerwin, R. 
W., & Lightman, S. (2002). A novel prednisolone suppression test for the 
hypothalamic-pituitary-adrenal axis. Biological Psychiatry, 51(11), 922–930. 
Pariante, C. M., Papadopoulos, A. S., Poon, L., Cleare, A. J., Checkley, S. A., English, 
J., … & Lightman, S. (2004). Four days of citalopram increase suppression of 
cortisol secretion by prednisolone in healthy volunteers. Psychopharmacology, 
177(1–2), 200–206.  
Pariante, C. M., Pearce, B. D., Pisell, T. L., Owens, M. J., & Miller, A. H. (1997). Steroid-
independent translocation of the glucocorticoid receptor by the antidepressant 
desipramine. Molecular Pharmacology, 52(4), 571–581. 
Pariante, C. M., Thomas, S. A., Lovestone, S., Makoff, A., & Kerwin, R. W. (2004). Do 
antidepressants regulate how cortisol affects the brain? 
Psychoneuroendocrinology, 29(4), 423–447.  
Park, E. J., Lee, J. H., Jeong, D. C., Han, S. I., & Jeon, Y. W. (2015). Natural killer cell 
activity in patients with major depressive disorder treated with escitalopram. 
International Immunopharmacology, 28(1), 409–413.  
Peckett, A. J., Wright, D. C., & Riddell, M. C. (2011). The effects of glucocorticoids on 
adipose tissue lipid metabolism. Metabolism: Clinical and Experimental, 60(11), 
1500–1510.  
Pejtersen, J. H., Burr, H., Hannerz, H., Fishta, A., & Hurwitz Eller, N. (2015). Update on 
work-related psychosocial factors and the development of ischemic heart disease: 
A systematic review. Cardiology in Review, 23(2), 94–98.  
Peters, M. N., Moscona, J. C., Katz, M. J., Deandrade, K. B., Quevedo, H. C., Tiwari, S., 
… & Irimpen, A. M. (2014). Natural disasters and myocardial infarction: the six 
years after Hurricane Katrina. Mayo Clinic Proceedings, 89(4), 472–477.  
Petrovsky, N., McNair, P., & Harrison, L. C. (1998). Diurnal rhythms of pro-
inflammatory cytokines: Regulation by plasma cortisol and therapeutic 
implications. Cytokine, 10(4), 307–312.  
Piazza, J. R., Charles, S. T., Stawski, R. S., & Almeida, D. M. (2013). Age and the 
association between negative affective states and diurnal cortisol. Psychology and 
Aging, 28(1), 47–56.  
Pitchot, W., Wauthy, J., Legros, J.-J., & Ansseau, M. (2004). Hormonal and temperature 
responses to flesinoxan in normal volunteers: an antagonist study. European 
Neuropsychopharmacology, 14(2), 151–155.  
313 
 
Poole, L., Kidd, T., Leigh, E., Ronaldson, A., Jahangiri, M., & Steptoe, A. (2014a). 
Depression, C-reactive protein and length of post-operative hospital stay in 
coronary artery bypass graft surgery patients. Brain, Behavior, and Immunity, 37, 
115–121. 
Poole, L., Kidd, T., Leigh, E., Ronaldson, A., Jahangiri, M., & Steptoe, A. (2014b). 
Preoperative sleep complaints are associated with poor physical recovery in the 
months following cardiac surgery. Annals of Behavioral Medicine, 47(3), 347–
357. 
Poole, L., Kidd, T., Leigh, E., Ronaldson, A., Jahangiri, M., & Steptoe, A. (2015). 
Psychological distress and intensive care unit stay after cardiac surgery: The role 
of illness concern. Health Psychology, 34(3), 283. 
Poole, L., Kidd, T., Ronaldson, A., Leigh, E., Jahangiri, M., & Steptoe, A. (2016). 
Depression 12-months after coronary artery bypass graft is predicted by cortisol 
slope over the day. Psychoneuroendocrinology, 71, 155-158.  
Poole, L., Leigh, E., Kidd, T., Ronaldson, A., Jahangiri, M., & Steptoe, A. (2014). The 
combined association of depression and socioeconomic status with length of post-
operative hospital stay following coronary artery bypass graft surgery: Data from 
a prospective cohort study. Journal of Psychosomatic Research, 76(1), 34–40. 
Poole, L., Ronaldson, A., Kidd, T., Leigh, E., Jahangiri, M., & Steptoe, A. (2016). Pre-
operative cognitive functioning and inflammatory and neuroendocrine responses 
to cardiac surgery. Annals of Behavioral Medicine, 1–9. 
Popp, D. A., Tse, T. F., Shah, S. D., Clutter, W. E., & Cryer, P. E. (1984). Oral propranolol 
and metoprolol both impair glucose recovery from insulin-induced hypoglycemia 
in insulin-dependent diabetes mellitus. Diabetes Care, 7(3), 243–247.  
Porter, R. J., Gallagher, P., Watson, S., & Young, A. H. (2004). Corticosteroid-serotonin 
interactions in depression: A review of the human evidence. 
Psychopharmacology, 173(1–2), 1–17.  
Pruessner, J. C., Kirschbaum, C., Meinlschmid, G., & Hellhammer, D. H. (2003). Two 
formulas for computation of the area under the curve represent measures of total 
hormone concentration versus time-dependent change. 
Psychoneuroendocrinology, 28(7), 916–931.  
Quan, N., Avitsur, R., Stark, J. L., He, L., Shah, M., Caligiuri, M., … & Sheridan, J. F. 
(2001). Social stress increases the susceptibility to endotoxic shock. Journal of 
Neuroimmunology, 115(1), 36–45. 
314 
 
Quax, R. A., Manenschijn, L., Koper, J. W., Hazes, J. M., Lamberts, S. W. J., van 
Rossum, E. F. C., & Feelders, R. A. (2013). Glucocorticoid sensitivity in health 
and disease. Nature Reviews. Endocrinology, 9(11), 670–686.  
Raasch, W., Wittmershaus, C., Dendorfer, A., Voges, I., Pahlke, F., Dodt, C., … & 
Jöhren, O. (2006). Angiotensin II inhibition reduces stress sensitivity of 
hypothalamo-pituitary-adrenal axis in spontaneously hypertensive rats. 
Endocrinology, 147(7), 3539–3546.  
Raetz, C. R. H., & Whitfield, C. (2002). Lipopolysaccharide endotoxins. Annual Review 
of Biochemistry, 71, 635–700.  
Rao, D. N. (2007). The clinical pharmacokinetics of escitalopram. Clinical 
Pharmacokinetics, 46(4), 281–290.  
Ravven, S., Bader, C., Azar, A., & Rudolph, J. L. (2013). Depressive symptoms after 
CABG surgery: A meta-analysis. Harvard Review of Psychiatry, 21(2), 59–69.  
Reynolds, R. M., Walker, B. R., Haw, S., Newby, D. E., Mackay, D. F., Cobbe, S. M., … 
& Pell, J. P. (2010). Low serum cortisol predicts early death after acute myocardial 
infarction. Critical Care Medicine, 38(3), 973–975.  
Rhebergen, D., Korten, N. C. M., Penninx, B. W. J. H., Stek, M. L., van der Mast, R. C., 
Oude Voshaar, R., & Comijs, H. C. (2015). Hypothalamic-pituitary-adrenal axis 
activity in older persons with and without a depressive disorder. 
Psychoneuroendocrinology, 51, 341–350.  
Rich, T., Innominato, P. F., Boerner, J., Mormont, M. C., Iacobelli, S., Baron, B., … & 
Lévi, F. (2005). Elevated serum cytokines correlated with altered behavior, serum 
cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with 
metastatic colorectal cancer. Clinical Cancer Research, 11(5), 1757–1764.  
Richardson, S., Shaffer, J. A., Falzon, L., Krupka, D., Davidson, K. W., & Edmondson, 
D. (2012). Meta-analysis of perceived stress and its association with incident 
coronary heart disease. The American Journal of Cardiology, 110(12), 1711–
1716. 
Rinne, T., de Kloet, E. R., Wouters, L., Goekoop, J. G., de Rijk, R. H., & van den Brink, 
W. (2003). Fluvoxamine reduces responsiveness of HPA axis in adult female BPD 
patients with a history of sustained childhood abuse. Neuropsychopharmacology, 
28(1), 126–132.  
315 
 
Ripley, T. L., & Saseen, J. J. (2014). β-blockers: A review of their pharmacological and 
physiological diversity in hypertension. The Annals of Pharmacotherapy, 48(6), 
723–733.  
Rivier, C., & Vale, W. (1983). Modulation of stress-induced ACTH release by 
corticotropin-releasing factor, catecholamines and vasopressin. Nature, 305, 325-
327. 
Roberti, J. W., Harrington, L. N., & Storch, E. A. (2006). Further psychometric support 
for the 10-item version of the perceived stress scale. Journal of College 
Counseling, 9(2), 135–147.  
Roberts, S. B., Bonnici, D. M., Mackinnon, A. J., & Worcester, M. C. (2001). 
Psychometric evaluation of the Hospital Anxiety and Depression Scale (HADS) 
among female cardiac patients. British Journal of Health Psychology, 6(4), 373–
383.  
Rod, N. H., Kristensen, T. S., Diderichsen, F., Prescott, E., Jensen, G. B., & Hansen, Å. 
M. (2010). Cortisol, estrogens and risk of ischaemic heart disease, cancer and all-
cause mortality in postmenopausal women: a prospective cohort study. 
International Journal of Epidemiology, 39, 530-538.  
Roepke, S. K., Allison, M., Von Känel, R., Mausbach, B. T., Chattillion, E. A., Harmell, 
A. L., … & Grant, I. (2012). Relationship between chronic stress and carotid 
intima-media thickness (IMT) in elderly Alzheimer’s disease caregivers. Stress, 
15(2), 121–129.  
Roest, A. M., Martens, E. J., de Jonge, P., & Denollet, J. (2010). Anxiety and risk of 
incident coronary heart disease: A meta-analysis. Journal of the American College 
of Cardiology, 56(1), 38–46.  
Roest, A. M., Martens, E. J., Denollet, J., & de Jonge, P. (2010). Prognostic association 
of anxiety post myocardial infarction with mortality and new cardiac events: A 
meta-analysis. Psychosomatic Medicine, 72(6), 563–569.  
Roest, A. M., Zuidersma, M., & Jonge, P. de. (2012). Myocardial infarction and 
generalised anxiety disorder: 10-year follow-up. The British Journal of 
Psychiatry, 200(4), 324–329.  
Rohleder, N., Kudielka, B. M., Hellhammer, D. H., Wolf, J. M., & Kirschbaum, C. 
(2002). Age and sex steroid-related changes in glucocorticoid sensitivity of pro-
inflammatory cytokine production after psychosocial stress. Journal of 
Neuroimmunology, 126(1), 69–77. 
316 
 
Rohleder, N., Schommer, N. C., Hellhammer, D. H., Engel, R., & Kirschbaum, C. (2001). 
Sex differences in glucocorticoid sensitivity of proinflammatory cytokine 
production after psychosocial stress. Psychosomatic Medicine, 63(6), 966–972. 
Rohleder, N., Wolf, J. M., & Kirschbaum, C. (2003). Glucocorticoid sensitivity in 
humans-interindividual differences and acute stress effects. Stress: The 
International Journal on the Biology of Stress, 6(3), 207–222.  
Rohleder, N., Wolf, J. M., Piel, M., & Kirschbaum, C. (2003). Impact of oral 
contraceptive use on glucocorticoid sensitivity of pro-inflammatory cytokine 
production after psychosocial stress. Psychoneuroendocrinology, 28(3), 261–273.  
Ronaldson, A., Kidd, T., Poole, L., Leigh, E., Jahangiri, M., & Steptoe, A. (2015). Diurnal 
cortisol rhythm is associated with adverse cardiac events and mortality in 
coronary artery bypass patients. The Journal of Clinical Endocrinology and 
Metabolism, 100(10), 3676–3682.  
Ronaldson, A., Poole, L., Kidd, T., Leigh, E., Jahangiri, M., & Steptoe, A. (2014). 
Optimism measured pre-operatively is associated with reduced pain intensity and 
physical symptom reporting after coronary artery bypass graft surgery. Journal of 
Psychosomatic Research, 77(4), 278–282. 
Roques, F., Michel, P., Goldstone, A. R., & Nashef, S. A. M. (2003). The logistic 
euroscore. European Heart Journal, 24(9), 882–882. 
Rosen, R. C., Kostis, J. B., & Jekelis, A. W. (1988). Beta-blocker effects on sexual 
function in normal males. Archives of Sexual Behavior, 17(3), 241–255. 
Ross, K. M., Murphy, M. L. M., Adam, E. K., Chen, E., & Miller, G. E. (2014). How 
stable are diurnal cortisol activity indices in healthy individuals? Evidence from 
three multi-wave studies. Psychoneuroendocrinology, 39, 184–193.  
Rota, E., Broda, R., Cangemi, L., Migliaretti, G., Paccotti, P., Rosso, C., … & Portaleone, 
P. (2005). Neuroendocrine (HPA axis) and clinical correlates during fluvoxamine 
and amitriptyline treatment. Psychiatry Research, 133(2–3), 281–284.  
Roumestan, C., Michel, A., Bichon, F., Portet, K., Detoc, M., Henriquet, C., … & 
Mathieu, M. (2007). Anti-inflammatory properties of desipramine and fluoxetine. 
Respiratory Research, 8, 35.  
Rudolph, K. E., Sánchez, B. N., Stuart, E. A., Greenberg, B., Fujishiro, K., Wand, G. S., 
… & Golden, S. H. (2016). Job strain and the cortisol diurnal cycle in MESA: 
Accounting for between- and within-day variability. American Journal of 
Epidemiology, 183(5), 497–506.  
317 
 
Ruhé, H. G., Khoenkhoen, S. J., Ottenhof, K. W., Koeter, M. W., Mocking, R. J. T., & 
Schene, A. H. (2015). Longitudinal effects of the SSRI paroxetine on salivary 
cortisol in Major Depressive Disorder. Psychoneuroendocrinology, 52, 261–271.  
Rumsfeld, J. S., Plomondon, M. E., Peterson, E. D., Shlipak, M. G., Maynard, C., 
Grunwald, G. K., … & Shroyer, A. L. W. (2002). The impact of ethnicity on 
outcomes following coronary artery bypass graft surgery in the Veterans Health 
Administration. Journal of the American College of Cardiology, 40(10), 1786–
1793. 
Russ, T. C., Stamatakis, E., Hamer, M., Starr, J. M., Kivimäki, M., & Batty, G. D. (2012). 
Association between psychological distress and mortality: Individual participant 
pooled analysis of 10 prospective cohort studies. The BMJ, 345, e4933.  
Russell, E., Koren, G., Rieder, M., & Van Uum, S. (2012). Hair cortisol as a biological 
marker of chronic stress: Current status, future directions and unanswered 
questions. Psychoneuroendocrinology, 37(5), 589–601.  
Saban, K. L., Mathews, H. L., Bryant, F. B., O’Brien, T. E., & Janusek, L. W. (2012). 
Depressive symptoms and diurnal salivary cortisol patterns among female 
caregivers of stroke survivors. Biological Research for Nursing, 14(4), 396–404.  
Sagud, M., Pivac, N., Mück-Seler, D., Jakovljević, M., Mihaljević-Peles, A., & Korsić, 
M. (2002). Effects of sertraline treatment on plasma cortisol, prolactin and thyroid 
hormones in female depressed patients. Neuropsychobiology, 45(3), 139–143.  
Sarubin, N., Nothdurfter, C., Schmotz, C., Wimmer, A.-M., Trummer, J., Lieb, M., … 
Schüle, C. (2014). Impact on cortisol and antidepressant efficacy of quetiapine 
and escitalopram in depression. Psychoneuroendocrinology, 39, 141–151.  
Sarubin, N., Nothdurfter, C., Schüle, C., Lieb, M., Uhr, M., Born, C., … Baghai, T. C. 
(2014). The influence of Hatha yoga as an add-on treatment in major depression 
on hypothalamic–pituitary–adrenal-axis activity: A randomized trial. Journal of 
Psychiatric Research, 53, 76–83.  
Sauer, J., Polack, E., Wikinski, S., Holsboer, F., Stalla, G. K., & Arzt, E. (1995). The 
glucocorticoid sensitivity of lymphocytes changes according to the activity of the 
hypothalamic-pituitary-adrenocortical system. Psychoneuroendocrinology, 
20(3), 269–280.  
Saxton, J. M., Scott, E. J., Daley, A. J., Woodroofe, M. N., Mutrie, N., Crank, H., … & 
Coleman, R. E. (2014). Effects of an exercise and hypocaloric healthy eating 
intervention on indices of psychological health status, hypothalamic-pituitary-
318 
 
adrenal axis regulation and immune function after early-stage breast cancer: a 
randomised controlled trial. Breast Cancer Research, 16, R39.  
Schmidt, P., Holsboer, F., & Spengler, D. (2001). β2-adrenergic receptors potentiate 
glucocorticoid receptor transactivation via G proteinβγ -subunits and the 
phosphoinositide 3-kinase pathway. Molecular Endocrinology, 15(4), 553–564.  
Schrepf, A., Thaker, P. H., Goodheart, M. J., Bender, D., Slavich, G. M., Dahmoush, L., 
… & Lutgendorf, S. K. (2015). Diurnal cortisol and survival in epithelial ovarian 
cancer. Psychoneuroendocrinology, 53, 256–267.  
Schruers, K., van Diest, R., Nicolson, N., & Griez, E. (2002). L-5-hydroxytryptophan 
induced increase in salivary cortisol in panic disorder patients and healthy 
volunteers. Psychopharmacology, 161(4), 365–369.  
Schulz, R., & Beach, S. R. (1999). Caregiving as a risk factor for mortality: The Caregiver 
Health Effects Study. JAMA, 282(23), 2215–2219. 
Seckl, J. R., & Fink, G. (1992). Antidepressants increase glucocorticoid and 
mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. 
Neuroendocrinology, 55(6), 621–626. 
Segerstrom, S. C., & Miller, G. E. (2004). Psychological stress and the human immune 
system: a meta-analytic study of 30 years of inquiry. Psychological Bulletin, 
130(4), 601–630.  
Seifritz, E., Baumann, P., Müller, M. J., Annen, O., Amey, M., Hemmeter, U., … & 
Holsboer-Trachsler, E. (1996). Neuroendocrine effects of a 20-mg citalopram 
infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT 
function probe. Neuropsychopharmacology, 14(4), 253–263.  
Seimon, R. V., Hostland, N., Silveira, S. L., Gibson, A. A., & Sainsbury, A. (2013). 
Effects of energy restriction on activity of the hypothalamo-pituitary-adrenal axis 
in obese humans and rodents: Implications for diet-induced changes in body 
composition. Hormone Molecular Biology and Clinical Investigation, 15(2), 71–
80.  
Seldenrijk, A., Vogelzangs, N., Batelaan, N. M., Wieman, I., van Schaik, D. J. F., & 
Penninx, B. J. W. H. (2015). Depression, anxiety and 6-year risk of cardiovascular 
disease. Journal of Psychosomatic Research, 78(2), 123–129.  
Sephton, S. E., Lush, E., Dedert, E. A., Floyd, A. R., Rebholz, W. N., Dhabhar, F. S., … 
& Salmon, P. (2013). Diurnal cortisol rhythm as a predictor of lung cancer 
survival. Brain, Behavior, and Immunity, 30, S163–S170.  
319 
 
Sephton, S. E., Sapolsky, R. M., Kraemer, H. C., & Spiegel, D. (2000). Diurnal cortisol 
rhythm as a predictor of breast cancer survival. Journal of the National Cancer 
Institute, 92(12), 994–1000.  
Shapiro, P. A. (2015). Management of depression after myocardial infarction. Current 
Cardiology Reports, 17(10), 1–9.  
Sheridan, J. F., Stark, J. L., Avitsur, R., & Padgett, D. A. (2000). Social disruption, 
immunity, and susceptibility to viral infection: role of glucocorticoid insensitivity 
and NGF. Annals of the New York Academy of Sciences, 917(1), 894–905. 
Shibasaki, M., Wilson, T. E., Bundgaard-Nielsen, M., Seifert, T., Secher, N. H., & 
Crandall, C. G. (2011). Modelflow underestimates cardiac output in heat-stressed 
individuals. American Journal of Physiology - Regulatory, Integrative and 
Comparative Physiology, 300(2), R486–R491.  
Šimečková, M., Janskỳ, L., Lesna, I., Vybiral, S., & Šrámek, P. (2000). Role of beta 
adrenoceptors in metabolic and cardiovascular responses of cold exposed humans. 
Journal of Thermal Biology, 25(6), 437–442. 
Sjögren, E., Leanderson, P., & Kristenson, M. (2006). Diurnal saliva cortisol levels and 
relations to psychosocial factors in a population sample of middle-aged Swedish 
men and women. International Journal of Behavioral Medicine, 13(3), 193–200.  
Sjörs, A., Ljung, T., & Jonsdottir, I. H. (2014). Diurnal salivary cortisol in relation to 
perceived stress at home and at work in healthy men and women. Biological 
Psychology, 99, 193–197.  
Smits, H. H., Grünberg, K., Derijk, R. H., Sterk, P. J., & Hiemstra, P. S. (1998). Cytokine 
release and its modulation by dexamethasone in whole blood following exercise. 
Clinical and Experimental Immunology, 111(2), 463. 
Smolderen, K. G., Strait, K. M., Dreyer, R. P., D’Onofrio, G., Zhou, S., Lichtman, J. H., 
… & Spertus, J. A. (2015). Depressive symptoms in younger women and men 
with acute myocardial infarction: insights from the VIRGO study. Journal of the 
American Heart Association, 4(4).  
Smolina, K., Wright, F. L., Rayner, M., & Goldacre, M. J. (2012). Determinants of the 
decline in mortality from acute myocardial infarction in England between 2002 
and 2010: Linked national database study. BMJ, 344, d8059. 
Snaith, R. P. (2003). The Hospital Anxiety and Depression Scale. Health and Quality of 
Life Outcomes, 1, 29.  
320 
 
Spiga, F., Walker, J. J., Terry, J. R., & Lightman, S. L. (2014). HPA axis-rhythms. 
Comprehensive Physiology, 4(3), 1273–1298.  
Stahl, S. M. (1998). Mechanism of action of serotonin selective reuptake inhibitors: 
Serotonin receptors and pathways mediate therapeutic effects and side effects. 
Journal of Affective Disorders, 51(3), 215–235.  
Stalder, T., & Kirschbaum, C. (2012). Analysis of cortisol in hair – State of the art and 
future directions. Brain, Behavior, and Immunity, 26(7), 1019–1029.  
Stalder, T., Kirschbaum, C., Kudielka, B. M., Adam, E. K., Pruessner, J. C., Wüst, S., … 
& Clow, A. (2016). Assessment of the cortisol awakening response: Expert 
consensus guidelines. Psychoneuroendocrinology, 63, 414–432.  
Stark, J. L., Avitsur, R., Padgett, D. A., Campbell, K. A., Beck, F. M., & Sheridan, J. F. 
(2001). Social stress induces glucocorticoid resistance in macrophages. American 
Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 
280(6), R1799–R1805. 
Statistics and census information | Wandsworth Council. Retrieved September 21, 2016, 
from 
http://www.wandsworth.gov.uk/info/200088/statistics_and_census_information 
Staufenbiel, S. M., Penninx, B. W. J. H., Spijker, A. T., Elzinga, B. M., & van Rossum, 
E. F. C. (2013). Hair cortisol, stress exposure, and mental health in humans: A 
systematic review. Psychoneuroendocrinology, 38(8), 1220–1235.  
Stawski, R. S., Cichy, K. E., Piazza, J. R., & Almeida, D. M. (2013). Associations among 
daily stressors and salivary cortisol: Findings from the National Study of Daily 
Experiences. Psychoneuroendocrinology, 38(11), 2654–2665.  
Steptoe, A., & Brydon, L. (2009). Emotional triggering of cardiac events. Neuroscience 
& Biobehavioral Reviews, 33(2), 63–70.  
Steptoe, A., Hamer, M., & Chida, Y. (2007). The effects of acute psychological stress on 
circulating inflammatory factors in humans: A review and meta-analysis. Brain, 
Behavior, and Immunity, 21(7), 901–912.  
Steptoe, A., & Kivimäki, M. (2012). Stress and cardiovascular disease. Nature Reviews. 
Cardiology, 9(6), 360–370.  
Steptoe, A., & Kivimäki, M. (2013). Stress and cardiovascular disease: an update on 
current knowledge. Annual Review of Public Health, 34, 337–354.  
321 
 
Steptoe, A., Poole, L., Ronaldson, A., Kidd, T., Leigh, E., & Jahangiri, M. (2015). 
Depression 1 year after CABG is predicted by acute inflammatory responses. 
Journal of the American College of Cardiology, 65(16), 1710–1711.  
Sterling, P., & Eyer, J. (1988). Allostasis: A new paradigm to explain arousal pathology. 
In S. Fisher & J. Reason (Eds.), Handbook of life stress, cognition and health (pp. 
629–649). Oxford, England: John Wiley & Sons. 
Stewart, J. C., Hawkins, M. A. W., Khambaty, T., Perkins, A. J., & Callahan, C. M. 
(2016). Depression and anxiety screens as predictors of 8-year incidence of 
myocardial infarction and stroke in primary care patients. Psychosomatic 
Medicine, 78(5), 593–601.  
Straneva-Meuse, P. A., Light, K. C., Allen, M. T., Golding, M., & Girdler, S. S. (2004). 
Bupropion and paroxetine differentially influence cardiovascular and 
neuroendocrine responses to stress in depressed patients. Journal of Affective 
Disorders, 79(1–3), 51–61.  
Strawbridge, R., Arnone, D., Danese, A., Papadopoulos, A., Herane Vives, A., & Cleare, 
A. J. (2015). Inflammation and clinical response to treatment in depression: A 
meta-analysis. European Neuropsychopharmacology: The Journal of the 
European College of Neuropsychopharmacology, 25(10), 1532–1543.  
Suzuki, A., Poon, L., Papadopoulos, A. S., Kumari, V., & Cleare, A. J. (2014). Long term 
effects of childhood trauma on cortisol stress reactivity in adulthood and 
relationship to the occurrence of depression. Psychoneuroendocrinology, 50, 
289–299.  
Suzuki, S., Sakamoto, S., Koide, M., Fujita, H., Sakuramoto, H., Kuroda, T., … & 
Matsuo, T. (1997). Hanshin-Awaji earthquake as a trigger for acute myocardial 
infarction. American Heart Journal, 134(5), 974–977. 
Swaminathan, R. V., Feldman, D. N., Pashun, R. A., Patil, R. K., Shah, T., Geleris, J. D., 
... & Singh, H. S. (2016). Gender differences in in-hospital outcomes after 
coronary artery bypass grafting. The American Journal of Cardiology, 118(3), 
362-368. 
Tafet, G. E., Idoyaga-Vargas, V. P., Abulafia, D. P., Calandria, J. M., Roffman, S. S., 
Chiovetta, A., & Shinitzky, M. (2001). Correlation between cortisol level and 
serotonin uptake in patients with chronic stress and depression. Cognitive, 
Affective, & Behavioral Neuroscience, 1(4), 388–393.  
322 
 
Taylor, C. B., Conrad, A., Wilhelm, F. H., Neri, E., DeLorenzo, A., Kramer, M. A., … & 
Kraemer, H. (2006). Psychophysiological and cortisol responses to psychological 
stress in depressed and nondepressed older men and women with elevated 
cardiovascular disease risk. Psychosomatic Medicine, 68(4), 538–546. 
Taylor C, Youngblood ME, Catellier D, & et al. (2005). Effects of antidepressant 
medication on morbidity and mortality in depressed patients after myocardial 
infarction. Archives of General Psychiatry, 62(7), 792–798.  
Thase, M. E., Entsuah, R., Cantillon, M., & Kornstein, S. G. (2005). Relative 
antidepressant efficacy of venlafaxine and SSRIs: Sex-age interactions. Journal 
of Women's Health, 14(7), 609-616. 
Thombs, B. D., Bass, E. B., Ford, D. E., Stewart, K. J., Tsilidis, K. K., Patel, U., … & 
Ziegelstein, R. C. (2006). Prevalence of depression in survivors of acute 
myocardial infarction. Journal of General Internal Medicine, 21(1), 30–38. 
Townsend, N., Bhatnagar, P., Wilkins, E., Wickramasinghe, K., & Rayner, M. (2015). 
Cardiovascular disease statistics, 2015. London: British Heart Foundation. 
Troxler, R. G., Sprague, E. A., Albanese, R. A., Fuchs, R., & Thompson, A. J. (1977). 
The association of elevated plasma cortisol and early atherosclerosis as 
demonstrated by coronary angiography. Atherosclerosis, 26(2), 151–162. 
Truelsen, T., Nielsen, N., Boysen, G., & Grønbaek, M. (2003). Self-reported stress and 
risk of stroke: The Copenhagen City Heart Study. Stroke; a Journal of Cerebral 
Circulation, 34(4), 856–862.  
Tsigos, C., & Chrousos, G. P. (2002). Hypothalamic–pituitary–adrenal axis, 
neuroendocrine factors and stress. Journal of Psychosomatic Research, 53(4), 
865–871. 
Tucker, P., Beebe, K. L., Burgin, C., Wyatt, D. B., Parker, D. E., Masters, B. K., & Nawar, 
O. (2004). Paroxetine treatment of depression with posttraumatic stress disorder: 
Effects on autonomic reactivity and cortisol secretion. Journal of Clinical 
Psychopharmacology, 24(2), 131–140. 
Tully, P. J., Cosh, S. M., & Baumeister, H. (2014). The anxious heart in whose mind? A 
systematic review and meta-regression of factors associated with anxiety disorder 
diagnosis, treatment and morbidity risk in coronary heart disease. Journal of 
Psychosomatic Research, 77(6), 439–448.  
323 
 
Tully, P. J., Cosh, S. M., & Baune, B. T. (2013). A review of the effects of worry and 
generalized anxiety disorder upon cardiovascular health and coronary heart 
disease. Psychology, Health & Medicine, 18(6), 627–644.  
Turner, E. H., Loftis, J. M., & Blackwell, A. D. (2006). Serotonin a la carte: 
Supplementation with the serotonin precursor 5-hydroxytryptophan. 
Pharmacology & Therapeutics, 109(3), 325–338.  
Uher, R., Farmer, A., Henigsberg, N., Rietschel, M., Mors, O., Maier, W., … & Aitchison, 
K. J. (2009). Adverse reactions to antidepressants. The British Journal of 
Psychiatry, 195(3), 202–210.  
Ulrich-Lai, Y. M., & Herman, J. P. (2009). Neural regulation of endocrine and autonomic 
stress responses. Nature Reviews Neuroscience, 10(6), 397–409.  
Uusitupa, M., Siitonen, O., Härkönen, M., Gordin, A., Aro, A., Hersio, K., … & 
Rauramaa, R. (1982). Metabolic and hormonal response to physical exercise 
during beta 1-selective and non-selective beta-blockade. Hormone and Metabolic 
Research, 14(11), 583–588.  
Vadiraja, H. S., Raghavendra, R. M., Nagarathna, R., Nagendra, H. R., Rekha, M., 
Vanitha, N., … & Kumar, V. (2009). Effects of a yoga program on cortisol rhythm 
and mood states in early breast cancer patients undergoing adjuvant radiotherapy: 
A randomized controlled trial. Integrative Cancer Therapies, 8(1), 37–46.  
Valtorta, N. K., Kanaan, M., Gilbody, S., Ronzi, S., & Hanratty, B. (2016). Loneliness 
and social isolation as risk factors for coronary heart disease and stroke: 
systematic review and meta-analysis of longitudinal observational studies. Heart, 
1-8.  
Van der Kooy, K., van Hout, H., Marwijk, H., Marten, H., Stehouwer, C., & Beekman, 
A. (2007). Depression and the risk for cardiovascular diseases: Systematic review 
and meta-analysis. International Journal of Geriatric Psychiatry, 22(7), 613–626.  
Van der Pompe, G., Antoni, M. H., & Heijnen, C. J. (1996). Elevated basal cortisol levels 
and attenuated ACTH and cortisol responses to a behavioral challenge in women 
with metastatic breast cancer. Psychoneuroendocrinology, 21(4), 361–374. 
Van Melle, J. P., De Jonge, P., Spijkerman, T. A., Tijssen, J. G., Ormel, J., Van 
Veldhuisen, D. J., … & Van Den Berg, M. P. (2004). Prognostic association of 
depression following myocardial infarction with mortality and cardiovascular 
events: A meta-analysis. Psychosomatic Medicine, 66(6), 814–822. 
324 
 
Van Westerloo, D. J., Choi, G., Löwenberg, E. C., Truijen, J., de Vos, A. F., Endert, E., 
… & van der Poll, T. (2011). Acute stress elicited by bungee jumping suppresses 
human innate immunity. Molecular Medicine, 17(3–4), 180–188.  
Veen, G., van Vliet, I. M., DeRijk, R. H., Giltay, E. J., van Pelt, J., & Zitman, F. G. (2011). 
Basal cortisol levels in relation to dimensions and DSM-IV categories of 
depression and anxiety. Psychiatry Research, 185(1–2), 121–128.  
Veldhuis, J. D., Sharma, A., & Roelfsema, F. (2013). Age-dependent and gender-
dependent regulation of hypothalamic-adrenocorticotropic-adrenal axis. 
Endocrinology and Metabolism Clinics of North America, 42(2), 201–225.  
Ventetuolo, C. E., Barr, R. G., Bluemke, D. A., Jain, A., Delaney, J. A. C., Hundley, W. 
G., … & Kawut, S. M. (2012). Selective serotonin reuptake inhibitor use is 
associated with right ventricular structure and function: The MESA-right ventricle 
study. PloS One, 7(2), e30480.  
Vickers, A. J. (2005). Parametric versus non-parametric statistics in the analysis of 
randomized trials with non-normally distributed data. BMC Medical Research 
Methodology, 5, 35.  
Viru, A., Viru, M., Karelson, K., Janson, T., Siim, K., Fischer, K., & Hackney, A. C. 
(2007). Adrenergic effects on adrenocortical cortisol response to incremental 
exercise to exhaustion. European Journal of Applied Physiology, 100(2), 241–
245.  
Vogelzangs, N., Beekman, A. T. F., Milaneschi, Y., Bandinelli, S., Ferrucci, L., & 
Penninx, B. W. J. H. (2010). Urinary cortisol and six-year risk of all-cause and 
cardiovascular mortality. The Journal of Clinical Endocrinology and Metabolism, 
95(11), 4959–4964.  
von Haehling, S., Papassotiriou, J., Morgenthaler, N. G., Hartmann, O., Doehner, W., 
Stellos, K., ... & Bigalke, B. (2012). Copeptin as a prognostic factor for major 
adverse cardiovascular events in patients with coronary artery disease. 
International Journal of Cardiology, 162(1), 27-32. 
von Hertzen, H., Piaggio, G., Peregoudov, A., Ding, J., Chen, J., Song, S., … & Apter, 
D. (2002). Low dose mifepristone and two regimens of levonorgestrel for 
emergency contraception: A WHO multicentre randomised trial. The Lancet, 
360(9348), 1803–1810.  
von Känel, R. (2012). Psychosocial stress and cardiovascular risk : Current opinion. Swiss 
Medical Weekly, 142, w13502.  
325 
 
von Känel, R., Dimsdale, J. E., Ancoli-Israel, S., Mills, P. J., Patterson, T. L., McKibbin, 
C. L., … & Grant, I. (2006). Poor sleep is associated with higher plasma 
proinflammatory cytokine interleukin-6 and procoagulant marker fibrin d-dimer 
in older caregivers of people with Alzheimer’s disease. Journal of the American 
Geriatrics Society, 54(3), 431–437.  
von Känel, R., Kudielka, B. M., Helfricht, S., Metzenthin, P., Preckel, D., Haeberli, A., 
… & Fischer, J. E. (2008). The effects of aspirin and nonselective beta blockade 
on the acute prothrombotic response to psychosocial stress in apparently healthy 
subjects. Journal of Cardiovascular Pharmacology, 51(3), 231–238.  
von Känel, R. von von, Kudielka, B. M., Metzenthin, P., Helfricht, S., Preckel, D., 
Haeberli, A., … & Fischer, J. E. (2008). Aspirin, but not propranolol, attenuates 
the acute stress-induced increase in circulating levels of interleukin-6: A 
randomized, double-blind, placebo-controlled study. Brain, Behavior, and 
Immunity, 22(2), 150–157.  
von Werne Baes, C., de Carvalho Tofoli, S. M., Martins, C. M. S., & Juruena, M. F. 
(2012). Assessment of the hypothalamic–pituitary–adrenal axis activity: 
Glucocorticoid receptor and mineralocorticoid receptor function in depression 
with early life stress – a systematic review. Acta Neuropsychiatrica, 24(1), 4–15.  
Vreeburg, S. A., Kruijtzer, B. P., van Pelt, J., van Dyck, R., DeRijk, R. H., Hoogendijk, 
W. J. G., … & Penninx, B. W. J. H. (2009). Associations between 
sociodemographic, sampling and health factors and various salivary cortisol 
indicators in a large sample without psychopathology. 
Psychoneuroendocrinology, 34(8), 1109–1120.  
Vythilingam, M., Vermetten, E., Anderson, G. M., Luckenbaugh, D., Anderson, E. R., 
Snow, J., … & Bremner, J. D. (2004). Hippocampal volume, memory, and cortisol 
status in major depressive disorder: Effects of treatment. Biological Psychiatry, 
56(2), 101–112. 
Walker, F. R. (2013). A critical review of the mechanism of action for the selective 
serotonin reuptake inhibitors: Do these drugs possess anti-inflammatory 
properties and how relevant is this in the treatment of depression? 
Neuropharmacology, 67, 304–317.  
Waller, C., Bauersachs, J., Hoppmann, U., Höch, J., Krause, S., Szabo, F., … & Gündel, 
H. (2016). Blunted cortisol stress response and depression-induced 
326 
 
hypocortisolism is related to inflammation in patients with CAD. Journal of the 
American College of Cardiology, 67(9), 1124–1126.  
Wang, Y. P., & Gorenstein, C. (2013). Psychometric properties of the Beck Depression 
Inventory-II: A comprehensive review. Revista Brasileira de Psiquiatria, 35(4), 
416–431.  
Wardenaar, K. J., Vreeburg, S. A., van Veen, T., Giltay, E. J., Veen, G., Penninx, B. W., 
& Zitman, F. G. (2011). Dimensions of depression and anxiety and the 
hypothalamo-pituitary-adrenal axis. Biological Psychiatry, 69(4), 366–373. 
Watson, D. (1988). Intraindividual and interindividual analyses of positive and negative 
affect: their relation to health complaints, perceived stress, and daily activities. 
Journal of Personality and Social Psychology, 54(6), 1020–1030. 
Watson, D., Clark, L. A., & Tellegen, A. (1988). Development and validation of brief 
measures of positive and negative affect: The PANAS scales. Journal of 
Personality and Social Psychology, 54(6), 1063–1070.  
Watson, D., Wiese, D., Vaidya, J., & Tellegen, A. (1999). The two general activation 
systems of affect: Structural findings, evolutionary considerations, and 
psychobiological evidence. Journal of Personality and Social Psychology, 76(5), 
820. 
Watson, S., Gallagher, P., Smith, M. S., Ferrier, I. N., & Young, A. H. (2006). The 
dex/CRH test-Is it better than the DST? Psychoneuroendocrinology, 31(7), 889–
894.  
Webster, J. C., Oakley, R. H., Jewell, C. M., & Cidlowski, J. A. (2001). Proinflammatory 
cytokines regulate human glucocorticoid receptor gene expression and lead to the 
accumulation of the dominant negative beta isoform: A mechanism for the 
generation of glucocorticoid resistance. Proceedings of the National Academy of 
Sciences of the United States of America, 98(12), 6865–6870.  
Wedekind, D., Sprute, A., Broocks, A., Hüther, G., Engel, K., Falkai, P., & Bandelow, B. 
(2008). Nocturnal urinary cortisol excretion over a randomized controlled trial 
with paroxetine vs. placebo combined with relaxation training or aerobic exercise 
in panic disorder. Current Pharmaceutical Design, 14(33), 3518–3524. 
Wellhoener, P., Born, J., Fehm, H. L., & Dodt, C. (2004). Elevated resting and exercise-
induced cortisol levels after mineralocorticoid receptor blockade with canrenoate 
in healthy humans. The Journal of Clinical Endocrinology and Metabolism, 
89(10), 5048–5052.  
327 
 
Wesseling, K. H., Jansen, J. R., Settels, J. J., & Schreuder, J. J. (1993). Computation of 
aortic flow from pressure in humans using a nonlinear, three-element model. 
Journal of Applied Physiology, 74(5), 2566–2573. 
Wetherell, M. A., Lovell, B., & Smith, M. A. (2015). The effects of an anticipated 
challenge on diurnal cortisol secretion. Stress, 18(1), 42–48.  
WHO. (2015). WHO Cardiovascular Diseases. Retrieved July 1, 2015, from 
http://www.who.int/mediacentre/factsheets/fs317/en/ 
Whorwood, C. B., Donovan, S. J., Wood, P. J., & Phillips, D. I. (2001). Regulation of 
glucocorticoid receptor alpha and beta isoforms and type I 11beta-hydroxysteroid 
dehydrogenase expression in human skeletal muscle cells: a key role in the 
pathogenesis of insulin resistance? The Journal of Clinical Endocrinology and 
Metabolism, 86(5), 2296–2308.  
Wilbert-Lampen, U., Leistner, D., Greven, S., Pohl, T., Sper, S., Völker, C., … & 
Steinbeck, G. (2008). Cardiovascular events during World Cup soccer. New 
England Journal of Medicine, 358(5), 475–483. 
Williams, C. L., Hayman, L. L., Daniels, S. R., Robinson, T. N., Steinberger, J., Paridon, 
S., & Bazzarre, T. (2002). Cardiovascular health in childhood a statement for 
health professionals from the committee on atherosclerosis, hypertension, and 
obesity in the young (AHOY) of the Council on Cardiovascular Disease in the 
Young, American Heart Association. Circulation, 106(1), 143–160.  
Williams, J. E., Mosley, T. H., Kop, W. J., Couper, D. J., Welch, V. L., & Rosamond, W. 
D. (2010). Vital exhaustion as a risk factor for adverse cardiac events (from the 
Atherosclerosis Risk In Communities [ARIC] study). The American Journal of 
Cardiology, 105(12), 1661–1665.  
Williams, R. B., Lane, J. D., Kuhn, C. M., Knopes, K., & Schanberg, S. M. (1988). Effects 
of propranolol on cardiovascular and neuroendocrine responses to mental 
arithmetic in type A men. Neuropsychopharmacology, 1(4), 337–340. 
Wirtz, P. H., Ehlert, U., Emini, L., & Suter, T. (2008). Higher body mass index (BMI) is 
associated with reduced glucocorticoid inhibition of inflammatory cytokine 
production following acute psychosocial stress in men. 
Psychoneuroendocrinology, 33(8), 1102–1110.  
Wirtz, P. H., Känel, R. von, Schnorpfeil, P., Ehlert, U., Frey, K., & Fischer, J. E. (2003). 
Reduced glucocorticoid sensitivity of monocyte interleukin-6 production in male 
328 
 
industrial employees who are vitally exhausted. Psychosomatic Medicine, 65(4), 
672–678.  
Wolfram, M., Bellingrath, S., & Kudielka, B. M. (2011). The cortisol awakening response 
(CAR) across the female menstrual cycle. Psychoneuroendocrinology, 36(6), 
905–912.  
Wong, M.-L., Kling, M. A., Munson, P. J., Listwak, S., Licinio, J., Prolo, P., … & Gold, 
P. W. (2000). Pronounced and sustained central hypernoradrenergic function in 
major depression with melancholic features: Relation to hypercortisolism and 
corticotropin-releasing hormone. Proceedings of the National Academy of 
Sciences of the United States of America, 97(1), 325–330. 
Woolery, A., Myers, H., Sternlieb, B., & Zeltzer, L. (2004). A yoga intervention for 
young adults with elevated symptoms of depression. Alternative Therapies in 
Health and Medicine, 10(2), 60–3. 
Xu, X., Bao, H., Strait, K., Spertus, J. A., Lichtman, J. H., D’Onofrio, G., … & Krumholz, 
H. M. (2015). Sex differences in perceived stress and early recovery in young and 
middle-aged patients with acute myocardial infarction. Circulation.  
Yalta, K., Yalta, T., Sivri, N., & Yetkin, E. (2013). Copeptin and cardiovascular disease: 
A review of a novel neurohormone. International Journal of Cardiology, 167(5), 
1750-1759. 
Yamaji, M., Tsutamoto, T., Kawahara, C., Nishiyama, K., Yamamoto, T., Fujii, M., & 
Horie, M. (2009). Serum cortisol as a useful predictor of cardiac events in patients 
with chronic heart failure the impact of oxidative stress. Circulation: Heart 
Failure, 2(6), 608–615.  
Yau, J. L., Noble, J., Hibberd, C., & Seckl, J. R. (2001). Short-term administration of 
fluoxetine and venlafaxine decreases corticosteroid receptor mRNA expression in 
the rat hippocampus. Neuroscience Letters, 306(3), 161–164. 
Young, E. A., Lopez, J. F., Murphy-Weinberg, V., Watson, S. J., & Akil, H. (2003). 
Mineralocorticoid receptor function in major depression. Archives of General 
Psychiatry, 60(1), 24–28. 
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., … & Lisheng, L. 
(2004). Effect of potentially modifiable risk factors associated with myocardial 
infarction in 52 countries (the INTERHEART study): Case-control study. The 
Lancet, 364(9438), 937–952.  
329 
 
Zhong, H., Haddjeri, N., & Sánchez, C. (2012). Escitalopram, an antidepressant with an 
allosteric effect at the serotonin transporter—a review of current understanding of 
its mechanism of action. Psychopharmacology, 219(1), 1–13. 
Zigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and depression scale. Acta 
Psychiatrica Scandinavica, 67(6), 361–370. 
Zilioli, S., Imami, L., & Slatcher, R. B. (2016). The impact of negative family-work 
spillover on diurnal cortisol. Health Psychology, 35(10), 1164-1167.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
330 
 
List of Publications 
1. Poole, L., Ronaldson, A., Kidd, T., Leigh, E., Jahangiri, M., & Steptoe, A. (2016). 
Pre-surgical depression and anxiety and recovery following coronary artery 
bypass graft surgery. Journal of Behavioral Medicine, 1-10. [Impact factor 2.959] 
2. Poole, L., Kidd, T., Ronaldson, A., Leigh, E., Jahangiri, M., & Steptoe, A. (2016). 
Depression 12-months after coronary artery bypass graft is predicted by cortisol 
slope over the day. Psychoneuroendocrinology, 71, 155-158. [Impact factor 
4.944] 
3. Jackowska, M., Ronaldson, A., Brown, J., & Steptoe, A. (2016). Biological and 
psychological correlates of self-reported and objective sleep measures. Journal of 
Psychosomatic Research, 84, 52-55. [Impact factor 3.268] 
4. Poole, l., Ronaldson, A., Kidd, T., Leigh, E., Jahangiri, M., & Steptoe, A. (2016). 
Pre-operative cognitive functioning and inflammatory and neuroendocrine 
responses to cardiac surgery. Annals of Behavioral Medicine, 1-9. [Impact factor 
4.200] 
5. Ronaldson, A., Gazali, A. M., Zalli, A., Kaiser, F., Thompson, S. J., Henderson, 
B., Steptoe, A., & Carvalho, L. (2016). Increased percentages of regulatory T cells 
are associated with inflammatory and neuroendocrine responses to acute 
psychological stress and poorer health status in older men and women. 
Psychopharmacology, 1-8. [Impact factor 3.875] 
6. Kidd, T., Poole, L., Ronaldson, A., Leigh, E., Jahangiri, M., & Steptoe, A. (2016). 
Attachment anxiety predicts depression and anxiety symptoms following 
coronary artery bypass graft surgery. British Journal of Health Psychology. 
[Impact factor 2.895] 
331 
 
7. Kidd, T., Poole, L., Leigh, E., Ronaldson, A., Jahangiri, M., & Steptoe, A. (2016). 
Health-related personal control predicts depression symptoms and quality of life 
but not health behaviour following coronary artery bypass graft surgery. Journal 
of Behavioral Medicine, 39(1), 120-127. [Impact factor 2.959] 
8. Ronaldson, A., Kidd, T., Poole, L., Leigh, E., Jahangiri, M., & Steptoe, A.  
(2015). Diurnal cortisol rhythm is associated with adverse cardiac events and 
mortality in coronary artery bypass patients. Journal of Clinical Endocrinology & 
Metabolism, 100(10), 3676-3682. [Impact factor 6.209] 
9. Ronaldson, A., Molloy, G. J., Wikman, A., Poole, L., Kaski, J. C., & Steptoe, A. 
(2015). Optimism and recovery after acute coronary syndrome: a clinical cohort 
study. Psychosomatic Medicine, 77(3), 311. [Impact factor 3.968] 
10. Steptoe, A., Poole, L., Ronaldson, A., Kidd, T., Leigh, E., & Jahangiri, M. (2015). 
Depression 1 year after CABG is predicted by acute inflammatory 
responses. Journal of the American College of Cardiology, 65(16), 1710-1711. 
[Impact factor 17.759] 
11. Jackowska, M., Brown, J., Ronaldson, A., & Steptoe, A. (2015). The impact of a 
brief gratitude intervention on subjective well-being, biology and sleep. Journal 
of Health Psychology, 1-11. [Impact factor 1.882] 
12. Poole, L., Kidd, T., Leigh, E., Ronaldson, A., Jahangiri, M., & Steptoe, A. (2015). 
Psychological distress and intensive care unit stay after cardiac surgery: The role 
of illness concern. Health Psychology, 34(3), 283. [Impact factor 3.611] 
13. Ronaldson, A., Poole, L., Kidd, T., Leigh, E., Jahangiri, M., & Steptoe, A. (2014). 
Optimism measured pre-operatively is associated with reduced pain intensity and 
physical symptom reporting after coronary artery bypass graft surgery. Journal of 
Psychosomatic Research, 77(4), 278-282. [Impact factor 3.268] 
332 
 
14. Poole, L., Kidd, T., Leigh, E., Ronaldson, A., Jahangiri, M., & Steptoe, A. (2014). 
Depression, C-reactive protein and length of post-operative hospital stay in 
coronary artery bypass graft surgery patients. Brain, Behavior, and Immunity, 37, 
115-121. [Impact factor 5.889] 
15. Poole, L., Leigh, E., Kidd, T., Ronaldson, A., Jahangiri, M., & Steptoe, A. (2014). 
The combined association of depression and socioeconomic status with length of 
post-operative hospital stay following coronary artery bypass graft surgery: Data 
from a prospective cohort study. Journal of Psychosomatic Research, 76(1), 34-
40. [Impact factor 3.268] 
16. Poole, L., Kidd, T., Leigh, E., Ronaldson, A., Jahangiri, M., & Steptoe, A. (2014). 
Preoperative sleep complaints are associated with poor physical recovery in the 
months following cardiac surgery. Annals of Behavioral Medicine, 47(3), 347-
357. [Impact factor 4.200] 
17. Kidd, T., Poole, L., Leigh, E., Ronaldson, A., Jahangiri, M., & Steptoe, A. (2014). 
Attachment anxiety predicts IL-6 and length of hospital stay in coronary artery 
bypass graft surgery (CABG) patients. Journal of Psychosomatic 
Research, 77(2), 155-157. [Impact factor 3.268] 
 
 
 
 
333 
 
Conference Presentations 
1. ‘The effects of escitalopram and propranolol on cardiovascular stress reactivity 
and recovery in healthy volunteers’. Poster presentation at the 74th annual meeting 
at the American Psychosomatic Society at Denver Colorado (March 2016). 
2. ‘Optimism and recovery following acute coronary syndrome’. Citation poster 
presentation at the 73rd annual meeting of the American Psychosomatic Society at 
Savannah, Georgia (March 2015). 
 
 
 
 
 
 
 
 
 
334 
 
Appendices 
 
Appendix A Example page form the cortisol sampling diary (ARCS Study) ..... 335 
Appendix B Stress Pathways Study participant information sheet ..................... 336 
Appendix C Stress Pathways Study consent form ................................................. 341 
Appendix D Baseline questionnaire – Stress Pathways Study ............................. 342 
Appendix E Follow-up questionnaire – Stress Pathways Study .......................... 353 
Appendix F Example page from the cortisol sampling diary  
  (Stress Pathways Study) ..................................................................... 358 
Appendix G Subjective stress and task impact questionnaires  
  (Stress Pathways Study) ..................................................................... 359 
 
 
  
 
 
 
 
 
 
 
 
335 
 
Appendix A: Example page form the cortisol sampling diary (ARCS Study) 
TUBE 1 : AS SOON AS YOU WAKE UP 
What is the time now? _______a.m. / p.m. 
What was the exact time you collected the sample? 
 
_______a.m. / p.m 
 
Was there a delay between waking up and       Yes           No 
collecting your first sample?  
If yes, how long?   ____ hrs & ____ mins  
In the last 30 minutes how much did you feel….. 
 Not at all   Very much 
In control 1 2 3 4 5 
Tired 1 2 3 4 5 
Happy  1 2 3 4 5 
Frustrated or angry 1 2 3 4 5 
Sad 1 2 3 4 5 
Stressed 1 2 3 4 5 
Pain 1 2 3 4 5 
If you talked with others, how pleasant was the interaction? 
 
Not applicable     1 2 3 4 5 
 
In the last 30 minutes, but before you collected your sample did you…. 
Brush your teeth No Yes 
Drink any tea, coffee or other caffeinated drinks No Yes 
Take any medicines No Yes 
Eat a meal No Yes 
Drink any alcohol No Yes 
Do any exercise? No Yes 
Smoke any cigarettes? No Yes 
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Appendix B: Stress Pathways Study participant information sheet 
THE STRESS PATHWAYS STUDY 
You are being invited to take part in a research study. It is up to you to decide whether to 
take part or not; choosing not to take part will not disadvantage you in any way. Before 
you decide to take part it is important for you to understand why the research is being 
done and what it will involve. Please take time to read the following information carefully 
and discuss it with others if you wish. Ask us if there is anything that is not clear or if you 
would like more information. If you do decide to take part you are still free to withdraw 
at any time and without giving a reason.   
What is the purpose of the study? 
Cardiovascular disease (CVD) is the leading cause of death in the UK. Effective 
prevention relies on the identification of those at risk. Psychological stress is a risk factor 
for CVD but research done so far has provided little information on how stress causes 
CVD. By studying biological responses to challenging tasks in the laboratory we can 
gather information about what biological pathways are most relevant in the stress-CVD 
link. Furthermore, by asking healthy volunteers to take certain medications that block 
biological pathways suspected to be involved we can then gain further insight into the 
stress-CVD link and may also identify suitable therapeutic interventions.  
Who can take part? 
Healthy men and women aged 18-65 years can take part in this study. However, there are 
some exclusion criteria, so please do read them carefully: 
Please do not take part in this study if any of the following apply to you: 
- If you are taking any medicines on a regular basis 
- If you have any haematological, pulmonary, liver, renal, gastrointestinal, heart,    
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            cerebrovascular, or psychiatric disease 
- If you have any history of thromboembolism 
- If you suffer from asthma and/or have any known allergies to the study   
            medication 
- If you are currently pregnant or breastfeeding 
- If you have low or high blood pressure 
 
What will I have to do if I decide to join the study? 
Day 1: You will be invited to an appointment at UCL (taking about 45 minutes) where 
you will fill out some questionnaires and have your body composition measured. At this 
appointment you will be given some bottles to take home which will be used to provide 
saliva samples in a non-invasive manner. You will also be given the study medication. 
You will either be given a 7-day supply of propranolol (a beta-blocker), escitalopram (a 
selective serotonin reuptake inhibitor), or placebo (an inert sugar pill). Because the 
researcher cannot know what medication you are given you won’t be able to find this out 
until all the study data has been collected. If you have any current infection (e.g. common 
cold, flu, etc.) your appointment will be postponed. 
Day 2: We will ask you to begin taking your study medication. You will be required to 
take one pill every morning for 7 days. While taking the medication we recommend that 
you do not take any other medication for any condition, any kind of herbal remedy, do 
any high-intensity physical activity, drive or operate machinery, and that you avoid 
excessive alcohol intake. 
Day 7: We will ask you to provide 7 saliva samples at home which involves putting a 
cotton dental swab in your mouth for a couple of minutes several times over the course 
of one day and then returning it to a special storage tube which we will provide. This is 
so that we can measure a chemical called cortisol that we believe is relevant to the stress-
CVD link. 
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Day 8: You will take your last pill on this morning and then be invited to an appointment 
at UCL which will take approximately 3 hours. At this appointment we will ask you to 
complete some questionnaires and, following this, we will fit your arm with a small 
butterfly needle which will remain in place for the duration of the testing session so we 
won’t have to stick you several times. We will then ask you to carry out some challenging 
mental tasks. During the testing session we will take further saliva samples and 4 sets of 
blood samples from the needle fitted in your arm. At the end of the session you will 
received a £50 honorarium as a token of our gratitude. 
Why do we take blood samples? 
We are taking your blood to check for different markers that we believe are relevant to 
the stress-CVD pathway. On each blood-draw we will take approximately 35ml (about 6 
teaspoons). This is about 140ml in total across the testing session, which is below a third 
of what is taken when you go to donate blood (470ml).  
What are the possible benefits of taking part? 
By taking part in this study you will receive a complete and accurate body composition 
report with information like waist-to-hip ratio, amount of body fat, amount of muscle, 
body mass index, etc. This can be interesting as many people are routinely unaware of 
their body composition and this objective report will allow you to evaluate this. You will 
also receive a final report when the research data has been analysed describing the results 
of the study. 
What are the possible disadvantages of taking part? 
It is possible that some of the questionnaire items may be sensitive in nature – if there are 
any items you do not wish to answer it is ok to skip them. It is unlikely but possible that 
the study medications may cause some adverse effects. Details of the possible side-effects 
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are detailed on the study medications information sheet provided. Over the week where 
you are taking the study medication  if any health problems become apparent that may 
require medical attention we will advise you to contact your GP so that you can seek 
medical advice as soon as possible. During the time you will be with us in the lab and 
blood is being taken, we will have a medically qualified professional who will be able to 
assist in the unlikely event anything happens to you. We realise that not everyone likes 
having blood samples taken, but this is a crucial part of the study. The procedure for 
obtaining the blood sample may cause a little discomfort or small bruising. Blood will be 
taken by a qualified research nurse and they will follow procedures and take appropriate 
precautions to minimise any discomfort.  
What if there is a problem? 
In the event of any health concerns that arise over the course of the study you will be 
asked to contact one of the researchers who can facilitate your withdrawal from the study 
without penalty if you so desire and invite you to consult your GP or mental health 
professional. Complaints: If you wish to complain about any aspect of the way you have 
been approached or treated as part of this study, you should initially contact the study 
researchers that will do their best to answer your questions. If you remain unhappy and 
wish to complain formally, please email the Chair of the UCL Committee for the Ethics 
of Non-NHS Human Research (gradschoolhead@ucl.ac.uk) or send a letter to The 
Graduate School, North Cloisters, Wilkins Building, UCL, Gower Street, London WC1E 
6BT) quoting reference: 5203/001. All communication will be dealt in strict confidence.  
Will my taking part be confidential?  
All results obtained will be strictly confidential and will only be used for medical research 
purposes. All personal information will be coded and kept separately to your name and 
address so that you cannot be recognised from it. All paper questionnaires will be kept in 
340 
 
locked filing cabinets, in locked offices, accessible only to members of the research team. 
In compliance with UCL regulations all data will be stored in this way for up to 10 years 
before being destroyed. You may withdraw your data from the project at any time up until 
it is used in the final report (January 2015). 
What will happen to the results of the research study? 
The results will be statistically analysed and findings subsequently published in scientific 
journals and presented at scientific meetings and conferences. You will not be identified 
in any publication.   
Contact for further information: 
If you have any questions or concerns please contact the research team (Amy Ronaldson, 
Livia Carvalho, Argita Zalli) at the Department of Epidemiology and Public Health, 
University College London, 1-19 Torrington Place, London, WC1E 6BT. Telephone: 020 
7679 1682; email: stresspathwaysstudy@gmail.com or a.ronaldson@ucl.ac.uk 
 
 
 
 
 
 
 
 
 
 
 
 
341 
 
Appendix C: Stress Pathways Study consent form 
Confidential: Volunteer Informed Consent Form 
THE STRESS PATHWAYS STUDY 
 
  
PATIENT IDENTIFICATION NUMBER: ____________________ 
 
PLEASE 
INITIAL BOX 
 
1. I confirm that I have read and understood the participant information 
sheet dated 06/12/2013 (Version 1.1) for the above study. I have had 
the opportunity to consider the information, ask questions and have 
had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason and without my legal 
rights being affected. 
 
3. I understand that I am required to have a butterfly needle inserted into 
my arm and have four rounds of blood samples taken during the course 
of the study. Tissue samples will be used only as described in the 
information sheet and samples will be destroyed after the study.  
 
4. I understand that I am required to provide saliva samples which 
will be used only as described in the information sheet.  
5. I understand I must not take part if I meet any of the exclusion criteria 
detailed in the information sheet dated 06/12/2013 (Version 1.1)  
6. I understand that I am being paid for my assistance in this research and 
that some of my personal details will be passed to UCL Finance for 
administration purposes. 
 
7. I understand that such information will be treated as strictly 
confidential and handled in accordance with the provisions of the Data 
Protection Act 1998. 
 
 
 
8. I agree to take part in the above study.  
 
 
 
Participant:..........................  Date:..................  Signature:............................... 
Researcher:.........................  Date:..................  Signature:............................... 
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Appendix D: Baseline questionnaire – Stress Pathways Study 
 
Thank you very much for agreeing to be involved in the Stress Pathways Study. We 
would like to get information about your health and lifestyle in order to interpret the 
biological response data we will collect in the study. We should be most grateful if you 
could take the time to complete this booklet during your first appointment at University 
College London. 
The answers to these questions will of course be kept strictly confidential. The 
information will be anonymised before being analysed, and it will not be possible to 
identify your responses from any reports or publications or from the database. None of 
the information will be made available to anyone else.  
Most of the questions can be answered by ticking the appropriate answer. 
For example: 
 ‘I am relaxed’ 
Strongly disagree 
Disagree 
Neither agree nor disagree 
Agree 
Strongly agree 
 
Other questions ask you to circle a number on a scale to indicate the extent to which 
you agree with a statement, the lowest number indicating complete disagreement and 
the highest indicating complete agreement. 
 
For example: 
 
 “Over the past two weeks I have been able to relax…” 
 
 
Please be sure to read the instructions to each section carefully. After you have 
completed the questionnaire please check through all the pages to make sure you 
haven’t missed any out.  
 
This questionnaire should take approximately 20 minutes to complete.  
Once again, thank you very much for your cooperation 
 
 0 1 2 3 4 5 6 7 8 9 10  
None of the 
time 
         All of the 
time 
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Section 1: About your personal details, education, and work history 
 
1. Today’s date:  ____ /____ /____  
 
2. Age: ______ 
 
3. Date of Birth:  ____ /____ /____ 
 
4. Sex:   Male   Female   
 
5. Marital status: 
 
Single   Married  Living as Married  Separated  
Divorced  Widowed  Other: (please specify) ____________ 
 
6. Which category do you feel best describes your ethnic origin? 
 
WHITE    
White British    
White Irish   
Other White background (Please specify) 
________________________ 
 
MIXED 
White and Black Caribbean 
White and Black African  
White and Asian 
Black and Asian 
Other mixed background (Please specify) 
________________________ 
 
CHINESE  
 
 
ASIAN or ASIAN BRITISH   
Indian   
Pakistani 
Bangladeshi 
Other Asian background (Please specify) 
________________________ 
 
BLACK or BLACK BRITISH 
Black Caribbean 
African 
Other Black background (Please 
specify)______________________ 
 
 
OTHER ETHNIC GROUP (Please 
specify)_____________________  
 
 
 
7. Country of birth: ________________________ 
 
 
8. What educational qualifications do you have? Tick all that apply. 
 
School Certificate            GCSEs /O-levels/CSEs  A-levels 
Undergraduate degree   Postgraduate degree  None  
Other: __________________________________________________________ 
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9. How would you best describe your current employment status? Please tick all that apply.   
 
Employed full-time     Employed part-time       Self-employed     Student 
Unemployed      Volunteer   Disabled           
 
 
10. If currently employed, what is your job title? 
 Job title: ______________________________________________________ 
11. What educational qualifications do your parents have? Tick highest that applies. 
Father 
School Certificate            GCSEs /O-levels/CSEs  A-levels 
Undergraduate degree  Postgraduate degree  None            
Don’t know 
Other: __________________________________________________________ 
Mother 
School Certificate            GCSEs /O-levels/CSEs  A-levels 
Undergraduate degree   Postgraduate degree  None           
Don’t know  
Other: __________________________________________________________ 
 
  Section 2: Your Health and Wellbeing 
 
12. Please read each group of statements carefully and then pick out the one 
statement in each group that best describes the way you have been feeling during the 
past week, including today.  
 
a) Sadness 
0   I do not feel sad 
1   I feel sad much of the time 
2   I am sad all the time 
3   I am so sad or unhappy that I can’t   
     stand it 
 
b) Pessimism 
0   I am not discouraged about my future 
1   I feel more discouraged about my  
     future than I used to be 
2   I do not expect things to work out for  
     me 
3   I feel my future is hopeless and will  
     only get worse 
 
c) Past Failure 
0   I do not feel like a failure 
1   I have failed more than I should have 
2   As I look back, I see a lot of failures 
3   I feel I am a total failure as a person 
 
d) Loss of Pleasure 
0   I get as much pleasure as I ever did  
     from the things I enjoy 
1   I don’t enjoy things as much as I used   
to 
2   I get very little pleasure from the 
things  
     I used to enjoy 
3   I can’t get any pleasure from the 
things I used to enjoy 
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e) Guilty Feelings 
0   I don’t feel particularly guilty  
1   I feel guilty over many things I have  
     done or should have done 
2   I feel quite guilty most of the time 
3   I feel guilty all of the time 
 
f) Punishment Feelings 
0   I don’t feel I am being punished 
1   I feel I may be punished 
2   I expect to be punished 
3   I feel I am being punished 
 
g) Self-Dislike 
0   I feel the same about myself as ever 
1   I have lost confidence in myself 
2   I am disappointed in myself 
3   I dislike myself 
 
h) Self-Criticalness 
0   I don’t criticise or blame myself more  
     than usual 
1   I am more critical of myself than I 
used  
     to be 
2   I criticise myself for all of my faults 
3   I blame myself for everything bad that  
     happens 
 
i) Suicidal Thoughts or Wishes 
0   I don’t have any thoughts of killing  
     myself 
1   I have thoughts of killing myself, but I  
     would not carry them out 
2   I would like to kill myself 
3   I would kill myself if I had the chance 
 
j) Crying 
0   I don’t cry any more than I used to 
1   I cry more than I used to 
2   I cry over every little thing 
3   I feel like crying, but I can’t 
 
 
k) Agitation 
0   I am no more restless or wound up     
     than usual 
1   I feel more restless or wound up than  
     usual 
2   I am so restless or agitated that it’s    
     hard to stay still 
3   I am so restless or agitated that I have     
     to keep moving or doing something 
 
l) Loss of Interest 
0   I have not lost interest in other people   
     or activities 
1   I am less interested in other people or  
     things than before 
2   I have lost most of my interest in 
other  
     people or things 
3   It’s hard to get interested in anything 
 
m) Indecisiveness 
0   I make decisions about as well as ever 
1   I find it more difficult to make  
    decisions than usual 
2   I have much greater difficulty in  
     making decisions than I used to 
3   I have trouble making any decisions 
 
n) Worthlessness 
0   I do not feel I am worthless 
1   I don’t consider myself as worthwhile  
     and useful as I used to 
2   I feel more worthless as compared to  
     other people 
3   I feel utterly worthless 
 
o) Loss of Energy 
0   I have as much energy as ever 
1   I have less energy than I used to have 
2   I don’t have enough energy to do very  
     much  
3   I don’t have enough energy to do  
     anything 
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p) Changes in Sleeping Pattern 
0    I have not experienced any change in  
      my sleeping pattern  
1a  I sleep somewhat more than usual 
1b  I sleep somewhat less than usual 
2a  I sleep a lot more than usual 
2b  I sleep a lot less than usual 
3a  I sleep most of the day 
3b  I wake up 1-2 hours early and can’t get  
      back to sleep 
 
q) Irritability 
0   I am no more irritable than usual 
1   I am more irritable than usual 
2   I am much more irritable than usual 
3   I am irritable all the time 
 
r) Changes in Appetite 
0   I have not experienced any change in my  
     appetite 
1a  My appetite is somewhat less than usual 
1b  My appetite is somewhat greater than 
usual 
2a  My appetite is much less than before 
2b  My appetite is much greater than usual 
3a  I have no appetite at all 
3b  I crave food all the time 
 
 
s) Concentration Difficulty 
0   I can concentrate as well as ever 
1   I can’t concentrate as well as usual 
2   It’s hard to keep my mind on anything  
     for very long 
3   I find I can’t concentrate on anything 
 
t) Tiredness or Fatigue 
0   I am no more tired or fatigued than  
     usual 
1   I get more tired or fatigued more easily  
     than usual 
2   I am too tired or fatigued to do a lot of  
     the things I used to do 
3   I am too tired or fatigued to do most of  
     the things I used to do 
 
u) Loss of Interest in Sex 
0   I have not noticed any recent changes in  
     my interest in sex 
1   I am less interested in sex than I used to  
     be 
2   I am much less interested in sex now 
3   I have lost interest in sex completely 
 
13. Tick the reply which comes closest to how you have been feeling in the past week:  
a) I feel tense or 'wound-up': 
Most of the time 
A lot of the time 
Time to time, occasionally 
Not at all 
 
b) I get a sort of frightened feeling as if 
something awful is about to happen: 
Very definitely and quite badly 
Yes, but not too badly 
A little, but it doesn’t worry me 
Not at all 
 
c) Worrying thoughts go through my mind: 
A great deal of the time 
A lot of the time 
From time to time but not too often 
Only occasionally 
 
d) I can sit at ease and feel relaxed: 
Definitely 
Usually 
Not often 
Not at all 
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 e) I get a sort of frightened feeling like 
'butterflies' in the stomach: 
Very often 
Quite often 
Occasionally 
Not at all 
 
f)  I feel restless as if I have to be on 
the move: 
Very much indeed 
Quite a lot 
Not very much 
Not at all 
 
g)  I get sudden feelings of panic: 
Very often indeed 
Quite often 
Not very often 
Not at all 
 
 
 
14.  The questions in this scale ask you about your feelings and thoughts during the 
past week.  
 
a)  In the last month, how often have you 
been upset because of something that 
happened unexpectedly? 
Never 
Almost never 
Sometimes 
Fairly often 
Very often 
 
b)  In the last month, how often have you 
felt that you were unable to control the 
important things in your life? 
Never 
Almost never 
Sometimes 
Fairly often 
Very often 
 
c)  In the last month, how often have you 
felt nervous and ‘stressed’? 
Never 
Almost never 
Sometimes 
Fairly often 
Very often 
 
d)  In the last month, how often have 
you felt confident about your ability to 
handle your personal problems? 
Never 
Almost never 
Sometimes 
Fairly often 
Very often 
 
e)  In the last month, how often have you 
felt that things were going your way? 
Never 
Almost never 
Sometimes 
Fairly often 
Very often 
 
f)  In the last month, how often have you 
found that you could not cope with all 
the things you had to do? 
Never 
Almost never 
Sometimes 
Fairly often 
Very often 
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15.  Please read each item and then circle the number which is most appropriate. 
Indicate to what extent you have felt this way during the past week:  
 
a) Interested 
1 
Never 
 
2 
 
3 
 
4 
 
 
5 
Always 
b) Excited 
1 
Never 
2 
 
3 
 
4 
 
 
5 
Always 
c) Strong 
1 
Never 
 
2 
 
3 
 
4 
 
 
5 
Always 
d) Enthusiastic 
1 
Never 
 
2 
 
3 
 
4 
 
 
5 
Always 
e) Proud 
1 
Never 
 
2 
 
3 
 
4 
 
 
5 
Always 
f) Alert 
1 
Never 
 
2 
 
3 
 
4 
 
 
5 
Always 
g) Inspired 
1 
Never 
 
2 
 
3 
 
4 
 
 
5 
Always 
h) Determined 
1 
Never 
 
2 
 
3 
 
4 
 
 
5 
Always 
g)  In the last month, how often have you 
been able to control irritations in your 
life? 
Never 
Almost never 
Sometimes 
Fairly often 
Very often 
 
h)  In the last month, how often have you 
felt that you were on top of things? 
Never 
Almost never 
Sometimes 
Fairly often 
Very often 
 
 
i)  In the last month, how often have you 
been angered because of things that 
were outside of your control? 
Never 
Almost never 
Sometimes 
Fairly often 
Very often 
 
j)  In the last month, how often have you 
felt difficulties were piling up so high 
that you could not overcome them? 
Never 
Almost never 
Sometimes 
Fairly often 
Very often 
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i) Attentive 
1 
Never 
 
2 
 
3 
 
4 
 
 
5 
Always 
j) Active 
1 
Never 
 
2 
 
3 
 
4 
 
 
5 
Always 
 
16. In the past week… 
  a) My sleep was restless… 
Not at all 
A little bit 
Somewhat 
Quite a bit 
Very much  
 
c)  My sleep was refreshing… 
Not at all 
A little bit 
Somewhat 
Quite a bit 
Very much  
 
d) I had difficulty falling asleep… 
Not at all 
A little bit 
Somewhat 
Quite a bit 
Very much  
 
e) I had trouble staying asleep 
Never 
Rarely 
Sometimes 
Often  
Always 
 
b) I was satisfied with my sleep… 
Not at all 
A little bit 
Somewhat 
Quite a bit 
Very much  
 
f) I had trouble sleeping… 
Not at all 
A little bit 
Somewhat 
Quite a bit 
Very much  
 
g) I got enough sleep 
Not at all 
A little bit 
Somewhat 
Quite a bit 
Very much  
 
h) My sleep quality was… 
Very poor 
Poor  
Fair 
Good 
Very good  
 
 
 
Section 3: Your Lifestyle 
 
About smoking… 
 
17.   Do you smoke cigarettes, cigars or pipes? Please specify.   
  Yes     No – Go to question 20    Type: _________________    
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If yes: 
 
18. How many per day do you smoke? ___________ 
 
19.  How long have you smoked for? __________years and ___________months  
 
20. If not a current smoker, did you smoke in the past?   
    Yes      No – Go to question 23 
 
If yes: 
 
21. When did you quit smoking? ________________________________________ 
 
22.    Are you currently taking nicotine replacement therapy?      Yes      No   
 
 
About drinking… 
 
23. Thinking of the last 7 days, how much of each of the following did you drink? (If it 
helps,    
       think back over each day to this time last week). If none, please enter 0.  
 
  
Mon Tues Wed Thurs Fri  Sat Sun 
a) Beer, lager, cider pints 
       
b) Wine glasses 
       
c) Martini, sherry, 
port 
glasses 
       
d) Spirits measures 
       
e) Other alcoholic 
drinks 
glasses        
    
24. In the last year how often have you had a hangover from drinking alcohol? Select one 
only. 
At least once a week 
 
 
2-3 times a month 
 
 
Once a month 
 
 
Less than once a month 
 
 
Not at all in the last year 
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About exercise… 
25. How often do you take part in sports or activities that are mildly energetic, 
moderately energetic or vigorous? See details below. 
Tick one answer for each question 
  Never 
or 
hardly 
ever 
About 
1-3 
times a 
month 
Once or 
twice a 
week 
3 times 
a week 
or more 
a. Mildly energetic (for example, walking, 
bicycle repair, playing darts, general 
housework) 
    
b. Moderately energetic (for example, 
scrubbing, dancing, golf, cycling, decorating, 
leisurely swimming) 
    
c. Vigorous (for example, running, hard 
swimming, tennis, squash, cycle racing) 
    
 
Please give the average number of hours per week you spend in such sports or activities 
d. Mildly energetic 
 
 
e. Moderately energetic 
 
 
f. Vigorous 
 
 
                    
26. Thinking about the days of the past week: 
On average, for how long did you walk outside your home/workplace? 
(If you did not walk, please enter ‘0’ in each box)  
 
 hours minutes 
On each weekday 
 
 
 
On each weekend day 
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On average for how long did you cycle? 
(If you did not cycle, please enter ‘0’ in each box) 
 
 hours minutes 
On each weekday 
 
 
 
On each weekend day 
 
 
 
 
 
_______________________________________________________________________ 
 
 
Thank you very much for taking the time to complete this 
questionnaire. 
 
Please remember to return it to the experimenter before you 
leave this testing session 
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Appendix E: Follow-up questionnaire – Stress Pathways Study 
1. Please read each group of statements carefully and then pick out the one statement in 
each group that best describes the way you have been feeling during the past week, 
including today.  
 
a) Sadness 
0   I do not feel sad 
1   I feel sad much of the time 
2   I am sad all the time 
3   I am so sad or unhappy that I can’t   
     stand it 
 
b) Pessimism 
0   I am not discouraged about my future 
1   I feel more discouraged about my  
     future than I used to be 
2   I do not expect things to work out for  
     me 
3   I feel my future is hopeless and will  
     only get worse 
 
c) Past Failure 
0   I do not feel like a failure 
1   I have failed more than I should have 
2   As I look back, I see a lot of failures 
3   I feel I am a total failure as a person 
 
d) Loss of Pleasure 
0   I get as much pleasure as I ever did  
     from the things I enjoy 
1   I don’t enjoy things as much as I used to 
2   I get very little pleasure from the things  
     I used to enjoy 
3   I can’t get any pleasure from the things  
     I used to enjoy 
 
e) Guilty Feelings 
0   I don’t feel particularly guilty  
1   I feel guilty over many things I have  
     done or should have done 
2   I feel quite guilty most of the time 
3   I feel guilty all of the time 
 
 
f) Punishment Feelings 
0   I don’t feel I am being punished 
1   I feel I may be punished 
2   I expect to be punished 
3   I feel I am being punished 
 
g) Self-Dislike 
0   I feel the same about myself as ever 
1   I have lost confidence in myself 
2   I am disappointed in myself 
3   I dislike myself 
 
h) Self-Criticalness 
0   I don’t criticise or blame myself more than  
     usual 
1   I am more critical of myself than I used to be 
2   I criticise myself for all of my faults 
3   I blame myself for everything bad that  
     happens 
 
i) Suicidal Thoughts or Wishes 
0   I don’t have any thoughts of killing myself 
1   I have thoughts of killing myself, but I  
     would not carry them out 
2   I would like to kill myself 
3   I would kill myself if I had the chance 
 
j) Crying 
0   I don’t cry any more than I used to 
1   I cry more than I used to 
2   I cry over every little thing 
3   I feel like crying, but I can’t 
 
k) Agitation 
0   I am no more restless or wound up than  
     usual 
1   I feel more restless or wound up than usual 
2   I am so restless or agitated that it’s hard  
     to stay still 
3   I am so restless or agitated that I have to  
     keep moving or doing something 
 
354 
 
 
l) Loss of Interest 
0   I have not lost interest in other people   
     or activities 
1   I am less interested in other people or  
     things than before 
2   I have lost most of my interest in other  
     people or things 
3   It’s hard to get interested in anything 
 
m) Indecisiveness 
0   I make decisions about as well as ever 
1   I find it more difficult to make decisions  
     than usual 
2   I have much greater difficulty in making  
     decisions than I used to 
3   I have trouble making any decisions 
 
n) Worthlessness 
0   I do not feel I am worthless 
1   I don’t consider myself as worthwhile  
     and useful as I used to 
2   I feel more worthless as compared to  
     other people 
3   I feel utterly worthless 
 
o) Loss of Energy 
0   I have as much energy as ever 
1   I have less energy than I used to have 
2   I don’t have enough energy to do very 
much  
3   I don’t have enough energy to do anything 
 
p) Changes in Sleeping Pattern 
0    I have not experienced any change in my    
      sleeping pattern  
1a  I sleep somewhat more than usual 
1b  I sleep somewhat less than usual 
2a  I sleep a lot more than usual 
2b  I sleep a lot less than usual 
3a  I sleep most of the day 
3b  I wake up 1-2 hours early and can’t get  
      back to sleep 
 
 
 
q) Irritability 
0   I am no more irritable than usual 
1   I am more irritable than usual 
2   I am much more irritable than usual 
3   I am irritable all the time 
 
r) Changes in Appetite 
0   I have not experienced any change in my  
     appetite 
1a  My appetite is somewhat less than usual 
1b  My appetite is somewhat greater than usual 
2a  My appetite is much less than before 
2b  My appetite is much greater than usual 
3a  I have no appetite at all 
3b  I crave food all the time 
 
s) Concentration Difficulty 
0   I can concentrate as well as ever 
1   I can’t concentrate as well as usual 
2   It’s hard to keep my mind on anything for  
     very long 
3   I find I can’t concentrate on anything 
 
t) Tiredness or Fatigue 
0   I am no more tired or fatigued than usual 
1   I get more tired or fatigued more easily than    
     usual 
2   I am too tired or fatigued to do a lot of the  
     things I used to do 
3   I am too tired or fatigued to do most of the  
     things I used to do 
 
u) Loss of Interest in Sex 
0   I have not noticed any recent changes in  
     my interest in sex 
1   I am less interested in sex than I used to be 
2   I am much less interested in sex now 
3   I have lost interest in sex completely 
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2. Tick the reply which comes closest to how you have been feeling in the last week, 
including today:  
a) I feel tense or ‘wound up’: 
Most of the time 
A lot of the time 
Time to time, occasionally 
Not at all 
 
b) I get a sort of frightened feeling as if  
something awful is about to happen: 
Very definitely and quite badly 
Yes, but not too badly 
A little, but it doesn’t worry me 
Not at all 
 
c) Worrying thoughts go through my mind: 
A great deal of the time 
A lot of the time 
From time to time but not too often 
Only occasionally 
 
d) I can sit at ease and feel relaxed: 
Definitely 
Usually 
Not often 
Not at all 
 
e) I get a sort of frightened feeling like 
‘butterflies’ in the stomach: 
Very often 
Quite often 
Occasionally 
Not at all 
 
f) I feel restless as if I have to be on the 
move: 
Very much indeed 
Quite a lot 
Not very much 
Not at all 
 
g) I get sudden feelings of panic: 
Very often indeed 
Quite often 
Not very often 
Not at all 
 
 
3. In the past week… 
  a) My sleep was restless… 
Not at all 
A little bit 
Somewhat 
Quite a bit 
Very much  
 
b) I was satisfied with my sleep… 
Not at all 
A little bit 
Somewhat 
Quite a bit 
Very much  
 
 
c)  My sleep was refreshing… 
Not at all 
A little bit 
Somewhat 
Quite a bit 
Very much  
 
d) I had difficulty falling asleep… 
Not at all 
A little bit 
Somewhat 
Quite a bit 
Very much 
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e) I had trouble staying asleep 
Never 
Rarely 
Sometimes 
Often  
Always 
 
f) I had trouble sleeping… 
Not at all 
A little bit 
Somewhat 
Quite a bit 
Very much  
   g) I got enough sleep 
Not at all 
A little bit 
Somewhat 
Quite a bit 
Very much  
 
h) My sleep quality was… 
Very poor 
Poor  
Fair 
Good 
Very good  
 
4. Please read each item and then circle the number which is most appropriate. Indicate 
to what extent you have felt this way during the past week:  
 
a) Interested 
1 
Never 
 
2 
 
3 
 
4 
 
 
5 
Always 
b) Excited 
1 
Never 
 
 
2 
 
3 
 
4 
 
 
5 
Always 
c) Strong 
1 
Never 
 
2 
 
3 
 
4 
 
 
5 
Always 
d) Enthusiastic 
1 
Never 
 
2 
 
3 
 
4 
 
 
5 
Always 
e) Proud 
1 
Never 
 
2 
 
3 
 
4 
 
 
5 
Always 
f) Alert 
1 
Never 
 
2 
 
3 
 
4 
 
 
5 
Always 
g) Inspired 
1 
Never 
 
2 
 
3 
 
4 
 
 
5 
Always 
h) Determined 
1 
Never 
 
2 
 
3 
 
4 
 
 
5 
Always 
i) Attentive 
1 
Never 
 
2 
 
3 
 
4 
 
 
5 
Always 
j) Active 
1 
Never 
 
2 
 
3 
 
4 
 
 
5 
Always 
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5. Did you have any significant symptoms or medical problems since the last study visit? 
 If your answer to this question is ‘yes’ please detail the symptoms/problems in the space provided below. 
    Yes    No  
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________ 
 
 
6. Would you say that any medical problem experienced in the last week was due to the study 
medication?  
If your answer to this question is ‘yes’ please provide us with the specific medical problem below.    
   Yes    No  
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________ 
 
 
7. If you can, please indicate below which medication you think you have been taking for the last 
7 days.  
Please also provide a reason for your answer in the space below. 
 
Escitalopram (antidepressant)      Propranolol (beta-blocker)      Placebo (inert)  
 
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________ 
 
 
Thank you very much for taking the time to complete this 
questionnaire. 
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Appendix F: Example page from the cortisol sampling diary (Stress Pathways Study) 
TUBE 1 : AS SOON AS YOU WAKE UP 
What is the time now? _______a.m. / p.m. 
What was the exact time you collected the sample? 
 
_______a.m. / p.m 
 
Was there a delay between waking up and       Yes           No 
collecting your first sample?  
If yes, how long?   ____ hrs & ____ mins  
In the last 30 minutes how much did you feel….. 
 Not at all   Very much 
In control 1 2 3 4 5 
Tired 1 2 3 4 5 
Happy  1 2 3 4 5 
Frustrated or angry 1 2 3 4 5 
Sad 1 2 3 4 5 
Stressed 1 2 3 4 5 
Pain 1 2 3 4 5 
If you talked with others, how pleasant was the interaction? 
 
Not applicable     1 2 3 4 5 
 
In the last 30 minutes, but before you collected your sample did you…. 
Brush your teeth No Yes 
Drink any tea, coffee or other caffeinated drinks No Yes 
Take any medicines No Yes 
Eat a meal No Yes 
Drink any alcohol No Yes 
Do any exercise? No Yes 
Smoke any cigarettes? No Yes 
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Appendix G: Subjective stress and task impact questionnaires 
The STRESS PATHWAYS Study 
 
Rest Questionnaire  
 
Please answer the following questions by circling the number that best 
describes the way you feel 
 
 
1. How relaxed do you feel at the moment? 
Not at all 
relaxed 
 
     
Very 
relaxed 
 
1 2 3 4 5 6 7 
 
2. How anxious do you feel at the moment? 
Not at all 
anxious 
 
     
Very 
anxious 
 
1 2 3 4 5 6 7 
 
3. How stressed do you feel at the moment? 
 
Not at all 
stressed 
 
     
Very 
stressed 
 
1 2 3 4 5 6 7 
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The STRESS PATHWAYS Study 
 
Task Impact Questionnaire  
 
Please answer the following questions by circling the number that best 
describes the way you felt during the task 
 
1. How difficult did you find the task? 
Not at all 
difficult 
 
     
Very 
difficult 
 
1 2 3 4 5 6 7 
 
2. How involved in the task did you feel? 
Not at all 
involved 
 
     
Very 
involved 
 
1 2 3 4 5 6 7 
 
3. How well do you think you performed the task? 
 
Not at all 
well 
 
     
Very well 
 
1 2 3 4 5 6 7 
 
4. How stressed did you feel during the task? 
 
Not at all 
stressed 
 
     
Very 
stressed 
 
1 2 3 4 5 6 7 
 
5. How much in control of the task did you feel? 
 
Not at all 
in control 
 
     
Very in 
control 
 
1 2 3 4 5 6 7 
 
6. How relaxed did you feel during the task? 
 
Not at all 
relaxed 
 
     
Very 
relaxed 
 
1 2 3 4 5 6 7 
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The STRESS PATHWAYS Study 
 
Recovery Questionnaire 
 
Please answer the following questions by circling the number that best 
describes the way you feel 
 
1. How relaxed do you feel at the moment? 
Not at all 
relaxed 
 
     
Very 
relaxed 
 
1 2 3 4 5 6 7 
 
2. How anxious do you feel at the moment? 
Not at all 
anxious 
 
     
Very 
anxious 
 
1 2 3 4 5 6 7 
 
3. How stressed do you feel at the moment? 
 
Not at all 
stressed 
 
     
Very 
stressed 
 
1 2 3 4 5 6 7 
 
